
<html lang="en"     class="pb-page"  data-request-id="5455238c-bb6a-494c-be40-bfa98b08d157"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-15;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01442;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection" /></meta><meta name="dc.Creator" content="Yameng  Pei" /></meta><meta name="dc.Creator" content="Chunting  Wang" /></meta><meta name="dc.Creator" content="S. Frank  Yan" /></meta><meta name="dc.Creator" content="Gang  Liu" /></meta><meta name="dc.Description" content="For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymera..." /></meta><meta name="Description" content="For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymera..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 21, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01442" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01442" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01442" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01442" /></link>
        
    
    

<title>Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01442" /></meta><meta property="og:title" content="Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0001.jpeg" /></meta><meta property="og:description" content="For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis. We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics. A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogues, inhibitors of viral ribonuclease H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products. Compounds that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and Toll-like receptor (TLR) agonists, are also discussed. In this Perspective, we hope to provide an overview, albeit by no means being comprehensive, for the recent development of novel therapeutic agents for the treatment of chronic HBV infection, which not only are able to sustainably suppress viral DNA but also aim to achieve functional cure warranted by HBsAg loss and ultimately lead to virus eradication and cure of hepatitis B." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01442"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01442">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01442&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01442&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01442&amp;href=/doi/10.1021/acs.jmedchem.6b01442" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6461-6479</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b00010" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.7b00781"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yameng++Pei">Yameng Pei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chunting++Wang">Chunting Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=S.+Frank++Yan">S. Frank Yan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Liu">Gang Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5549-5686" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Molecular Design and Chemical Biology, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai 201203, China</span></div><div class="corresp-info"><strong>*</strong>For G.L.: phone, +86 10 62797740; E-mail, <a href="/cdn-cgi/l/email-protection#f89f99969f94918dcacfb88c8b91969f908d99d69d9c8dd69b96"><span class="__cf_email__" data-cfemail="f196909f969d9884c3c6b18582989f96998490df949584df929f">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.F.Y.: phone, +86 21 29846888; E-mail, <a href="/cdn-cgi/l/email-protection#89faf0bbbeb1c9e7f0fca7ecedfc"><span class="__cf_email__" data-cfemail="502329626768103e29257e353425">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01442&amp;href=/doi/10.1021%2Facs.jmedchem.6b01442" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6461–6479</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 6, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 September 2016</li><li><span class="item_label"><b>Published</b> online</span>21 April 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 August 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01442" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01442</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6461%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYameng%2BPei%252C%2BChunting%2BWang%252C%2BS.%2BFrank%2BYan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D15%26contentID%3Dacs.jmedchem.6b01442%26title%3DPast%252C%2BCurrent%252C%2Band%2BFuture%2BDevelopments%2Bof%2BTherapeutic%2BAgents%2Bfor%2BTreatment%2Bof%2BChronic%2BHepatitis%2BB%2BVirus%2BInfection%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6479%26publicationDate%3DAugust%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01442"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4300</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">42</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01442" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yameng&quot;,&quot;last_name&quot;:&quot;Pei&quot;},{&quot;first_name&quot;:&quot;Chunting&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;S.&quot;,&quot;last_name&quot;:&quot;Frank Yan&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;6461-6479&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01442&quot;},&quot;abstract&quot;:&quot;For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis. We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics. A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogues, inhibitors of viral ribonuclease H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products. Compounds that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/p&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01442&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01442" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01442&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01442" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01442&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01442" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01442&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01442&amp;href=/doi/10.1021/acs.jmedchem.6b01442" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01442" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01442" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01442%26sid%3Dliteratum%253Aachs%26pmid%3D28383274%26genre%3Darticle%26aulast%3DPei%26date%3D2017%26atitle%3DPast%252C%2BCurrent%252C%2Band%2BFuture%2BDevelopments%2Bof%2BTherapeutic%2BAgents%2Bfor%2BTreatment%2Bof%2BChronic%2BHepatitis%2BB%2BVirus%2BInfection%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D15%26spage%3D6461%26epage%3D6479%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291125" title="Hepatitis">Hepatitis</a>,</li><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/jmcmar.2017.60.issue-15/20170810/jmcmar.2017.60.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogues (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis. We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics. A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogues, inhibitors of viral ribonuclease H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products. Compounds that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and Toll-like receptor (TLR) agonists, are also discussed. In this Perspective, we hope to provide an overview, albeit by no means being comprehensive, for the recent development of novel therapeutic agents for the treatment of chronic HBV infection, which not only are able to sustainably suppress viral DNA but also aim to achieve functional cure warranted by HBsAg loss and ultimately lead to virus eradication and cure of hepatitis B.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Epidemiology of Hepatitis B Virus Infection</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis B virus (HBV) infection remains a major health concern, with an estimated 350 million chronically infected patients worldwide, and it is particularly prevalent in Southeast Asia and sub-Sahara Africa.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Chronic infection develops in approximately 90% of patients who contract the virus during infancy, while it develops in 30–50% of children infected before the age of six years old.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> For healthy adults, however, less than 5% of those infected will develop the chronic disease. Furthermore, of the chronically infected adults, about 20–30% develop cirrhosis and/or liver cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Although HBV vaccines induce over 95% protective responses in humans nowadays, chronic HBV infection remains a major cause of cirrhosis, which ultimately leads to hepatocellular carcinoma (HCC). It is currently estimated that HBV infection and the associated liver diseases result in close to one million deaths every year worldwide.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a></div><div class="NLM_p last">HBV is known to primarily replicate within hepatocytes, while a steady low rate of virus replication was also found in the lymphatic system using the woodchuck hepatitis virus (WHV) animal model.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Hepatitis B virus does not cause any direct damage to the host liver cells; however, viral infection does induce a host immune response, which not only helps the host eliminate the virus but more importantly is responsible for the unwanted, detrimental inflammatory damages inflicted on the liver.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Long-term and repeated liver damages due to inflammation caused by chronic HBV infection can result in fibrosis, cirrhosis, and the eventual HCC.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Hepatitis B Virus Genome and Life Cycle</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22486" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22486" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Hepatitis B Virus Genome Structure</h3><div class="NLM_p last">HBV is a member of the hepadnaviridae family of viruses, having a 3.2-kb circular, partially double-stranded DNA genome containing four partially overlapping open reading frames (ORFs) that code for a total of seven viral proteins.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The precore gene codes for the nonstructural, secretory HBV e antigen (HBeAg), while the core gene on the same open reading frame codes for the HBV core antigen (HBcAg), which is the primary protein component of the viral nucleocapsid. The polymerase gene codes for the viral polymerase that includes the reverse transcriptase (RT) domain, the ribonuclease H (RNase H) domain, and the terminal protein (TP) domain. The HBV surface antigen (HBsAg) gene codes for three HBV surface proteins, namely the large (L), middle (M), and small (S) surface proteins, which are part of the virus lipid envelope. Those surface proteins are synthesized from different promoters and are implicated in viral attachment, maturation, secretion, and immunogenicity.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The X gene codes for the small regulatory HBV X protein (HBx), which is known to be a multifaceted protein involved in however yet unknown functions related to virus life cycle, virus–host interactions, and most importantly contributing to the etiology of HCC.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.2 Hepatitis B Virus Life Cycle</h3><div class="NLM_p"><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> depicts the HBV life cycle, from viral particle entry into the hepatocyte to the secretion of newly produced virus out of the infected liver cell. Of course, every step of the HBV life cycle could potentially be a target for disruption and thereby as a therapeutic target subject to pharmaceutical modulation as treatment of HBV infection. As shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, first, the infectious hepatitis B virus particles, referred as the Dane particles, bind to the hepatocyte through a reversible, nonspecific attachment to the cell surface heparan sulfate proteoglycans (HSPGs), together with the specific recognition of the preS1 domain of the viral surface protein HBsAg by the putative HBV receptor, sodium taurocholate cotransporting polypeptide (NTCP).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The viral particle then internalizes into the endosome through endocytosis, and the nucleocapsid is subsequently released into the cytoplasm. The HBV genomic material inside the nucleocapsid, the relaxed circular DNA (rcDNA), is then transported into the nucleus. Taking advantage of the host DNA repair machinery, the partially double-stranded viral rcDNA is repaired to form covalently closed circular DNA (cccDNA). Although cccDNA exists only in very small amounts within the infected hepatocyte, it is believed to be stable and serve as the master template for all viral transcription and viral protein production.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Specifically, cccDNA is known to generate four distinct viral transcripts, including the pregenomic RNA (pgRNA) and three subgenomic RNAs (preS1, preS2, and X RNAs), which are responsible to produce all seven viral proteins. Namely, the core protein (HBcAg) and viral polymerase are translated from pgRNA, while the secretory HBeAg is produced, subject to post-translational proteolysis, from the precore RNA that is only slightly longer upstream to the pgRNA. The regulatory HBx protein is produced from the X RNA, and the three HBsAg surface envelope proteins are translated from their respective subgenomic RNAs (L protein from preS1 RNA and M and S proteins from preS2 RNA). It is noted, however, that both host factors, such as CCAAT/enhancer-binding protein (C/EBP) and hepatocyte nuclear factors (HNFs), and viral proteins including HBcAg and HBx are involved in the HBV transcriptional regulation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hepatitis B virus life cycle. The infectious HBV Dane particles attach to the cell surface HSPGs and bind to the putative HBV receptor, NTCP. Following viral particle endocytosis, the nucleocapsid is released into the cytoplasm from the endosome. The HBV partially double-stranded genomic rcDNA is then transported into the nucleus and is repaired to form cccDNA. Four distinct viral transcripts including pgRNA and preS1, preS2, and X RNAs are generated from cccDNA, which are responsible to produce all seven viral proteins. Viral polymerase and pgRNA are encapsulated through self-assembly of HBcAg to form the nascent nucleocapsid, within which the second-generation viral DNA is synthesized by reverse transcription catalyzed by viral polymerase using pgRNA as the template. The mature, rcDNA-containing nascent HBV nucleocapsid is either able to re-enter the nucleus for recycling or ready for secretion. After possible post-translational modifications within the endoplasmic reticulum and/or Golgi apparatus, the enveloped, mature viral particles are secreted out of the infected hepatocyte. A great number of noninfectious SVPs, which completely lack a functional nucleocapsid but display large number of different HBsAg proteins, are also secreted out of the hepatocyte. Every step of the HBV life cycle could potentially be a therapeutic target for treatment of HBV infection. cccDNA, covalently closed circular DNA; HBcAg, hepatitis B virus core antigen; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HBx, hepatitis B virus X protein; HSPG, heparan sulfate proteoglycan; NTCP, sodium taurocholate cotransporting polypeptide; pgRNA, pregenomic RNA; rcDNA, relaxed circular DNA; SVP, subviral particle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Followed by viral transcription and translation initiated through HBV cccDNA, the pgRNA and viral polymerase are encapsulated through self-assembly of the core proteins in the cytoplasm, forming the nascent viral nucleocapsid. Within the nucleocapsid, the second-generation viral DNA is synthesized by reverse transcription catalyzed by viral polymerase using pgRNA as the template. Subsequently, the mature, rcDNA-containing nascent HBV nucleocapsids are either able to re-enter the nucleus for recycling or ready for secretion. After possible post-translational modifications within the endoplasmic reticulum (ER) and/or Golgi apparatus, the enveloped, mature viral particles are secreted out of the infected hepatocyte in the form of 42 nm spherical, infectious particles (the Dane particles).<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> It is noteworthy that significantly larger numbers of noninfectious particles, so-called subviral particles (SVPs), which completely lack a functional nucleocapsid, are also secreted out of the hepatocytes. They are usually 22 nm in diameter and are spheroidal or filamentous.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The number of SVPs is usually more than 100-fold greater than that of the infectious Dane particles in the bloodstream of infected individuals. In addition, though these SVPs are not infectious, they do nonetheless display large number of different HBsAg proteins on their surfaces, which could play important roles in the immune tolerance of HBV infection.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3 Therapeutic Approaches for Hepatitis B Virus Treatment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis B virus has seven viral proteins and a complex viral life cycle involving also host factors, which can potentially present us various opportunities for pharmaceutical intervention and thereby treatment of HBV infection. Significant progress has already been made in developing novel anti-HBV agents, some of which are already in clinical investigation (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In this Perspective, we hope to provide an overview of those new therapeutic approaches against HBV targeting the various steps in the hepatitis B virus life cycle.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selected Therapeutics in Clinical Development for Treatment of Chronic Hepatitis B Virus Infection</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">mechanism of action</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">clinical trial registry no.<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">myrcludex-B</td><td class="colsep0 rowsep0" align="left">entry inhibitor</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">NCT02888106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02637999</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tenofovir alafenamide fumarate (TAF, GS-7340)</td><td class="colsep0 rowsep0" align="left">viral polymerase RT inhibitor, NA</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="left">NCT02957994</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CMX-157</td><td class="colsep0 rowsep0" align="left">viral polymerase RT inhibitor, NA</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">NCT02710604</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">morphothiadin (GLS4)</td><td class="colsep0 rowsep0" align="left">nucleocapsid inhibitor</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">ChiCTR-IIR-16008284</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NVR 3-778</td><td class="colsep0 rowsep0" align="left">nucleocapsid inhibitor</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">NCT02112799</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02401737</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">REP 2139</td><td class="colsep0 rowsep0" align="left">nucleic acid polymer</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">NCT02565719</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vesatolimod (GS-9620)</td><td class="colsep0 rowsep0" align="left">TLR7 agonist</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">NCT01590641</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01590654</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARC-520</td><td class="colsep0 rowsep0" align="left">RNAi DPC</td><td class="colsep0 rowsep0" align="left">terminated</td><td class="colsep0 rowsep0" align="left">NCT02738008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARC-521</td><td class="colsep0 rowsep0" align="left">RNAi DPC</td><td class="colsep0 rowsep0" align="left">terminated</td><td class="colsep0 rowsep0" align="left">NCT02797522</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALN-HBV</td><td class="colsep0 rowsep0" align="left">RNAi GalNAc</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">NCT02826018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IONIS-HBVRx (GSK3228836)</td><td class="colsep0 rowsep0" align="left">antisense oligonucleotide</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">NCT02981602</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IONIS-HBVLRx (GSK3389404)</td><td class="colsep0 rowsep0" align="left">antisense oligonucleotide</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">NCT02647281</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">NCT number is a United States National Clinical Trial registry number; ChiCTR is a Chinese Clinical Trial Register identification number.</p></div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1 Viral Entry Inhibitors</h3><div class="NLM_p">Establishing a robust in vitro infection system for HBV has been extremely challenging, largely due to the poor understanding of the underlying molecular mechanism that governs the infection process, particularly the very first entry step that relies on the elusive HBV cellular receptor. Recently, a cellular transporter NTCP was found to play an indispensable role in HBV entry and infection.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> An interaction between the preS1 domain of the HBV surface L protein and NTCP was suggested.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition, it has also been found that the N-terminal region containing 75 amino acids of the preS1 domain of the L protein was essential for HBV and hepatitis D virus (HDV) infectivity.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> Interestingly, <b>1</b> (myrcludex-B), a myristoylated peptide consisting of 47 N-terminal amino acids of the preS1 domain of the HBV L protein, could inhibit HBV infection with a 50% inhibitory concentration (IC<sub>50</sub>) of 8 nM in an HBV-susceptible HepaRG cell line.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Susceptibility of both HepaRG cells and primary human hepatocytes (PHHs) to HBV was reduced when these cells were preincubated with <b>1</b> peptide even for a short period of time, suggesting that <b>1</b> might play a role in preventing HBV from infecting human hepatocytes by blocking HBV entry.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, using immunodeficient urokinase-type plasminogen activator (uPA) chimeric mouse models transplanted with either primary human hepatocytes or <i>Tupaia belangeri</i> (northern treeshrew) hepatocytes, <b>1</b> was shown to be able to block both HBV and woolly monkey hepatitis B virus (WMHBV) infection.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> It is noteworthy that <b>1</b> was now shown to be an inhibitor of NTCP.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Phase I clinical evaluation of <b>1</b> demonstrated an acceptable tolerability and safety profile in healthy volunteers, and a phase IIa clinical trial was recently completed in chronically infected HBV patients with promising results.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Most recently, <b>1</b> is being further investigated in phase IIb clinical trials (NCT02888106 and NCT02637999; NCT, National Clinical Trial).</div><div class="NLM_p">An additional number of NTCP inhibitors has been reported, such as <b>2</b> (cyclosporin A, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) and its derivatives,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> progesterone, propranolol, bosentan, oxysterols,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>3</b> (irbesartan, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref15 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref15 ref24 ref25">(15, 24, 25)</a> ezetimibe,<a onclick="showRef(event, 'ref15 ref26'); return false;" href="javascript:void(0);" class="ref ref15 ref26">(15, 26)</a> and ritonavir.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For example, <b>2</b>, which primarily targets cellular peptidyl prolyl <i>cis</i>/<i>trans</i>-isomerase (PPIase) and cyclophilins<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and inhibits membrane transportation,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> was also identified to be a novel NTCP inhibitor with an IC<sub>50</sub> value of <0.2 μM in the HepaRG cell line.<a onclick="showRef(event, 'ref21 ref22 ref30'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref30">(21, 22, 30)</a> In addition, the antihypertensive drug <b>3</b> was reported to interfere NTCP function and be able to inhibit HBeAg expression with an IC<sub>50</sub> of 3.3 μM in the HepG2.N9 cell line, an NTCP-overexpressing HepG2 cell line; moreover, it exhibited no obvious cytotoxicity up to 1000 μM in the same cell line.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a><b>4</b> [epigallocatechin-3-gallate (EGCG), <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>], a flavonoid isolated from green tea extract, was shown to block HBV entry into the differentiated HuS-E/2 cells (immortalized PHHs) by more than 80% at 50 μM and at the same time it had no observed effects on HBV replication and viral particle secretion.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In all, the recent discovery of the putative HBV receptor NTCP has presented a new opportunity for interrupting the very first step of the normal virus life cycle and a possible alternative avenue for treating HBV infection; however, no compounds of this mechanism of action have demonstrated clinical proof of concept with balanced antiviral efficacy and safety. It is likely, due to the nature of the mechanism, that a combination strategy involving not only the entry inhibitors must be applied to achieve meaningful efficacy in treating HBV infection.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative hepatitis B virus entry inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2 Viral Transcription Inhibitors</h3><div class="NLM_p">Targeting viral transcription, a rather upstream event in the HBV viral life cycle, could be a promising approach for treating HBV infection. Helioxanthin,<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> isolated mainly from the bulky coniferous tree <i>Taiwania cryptomerioides</i> Hayata and the root of <i>Heliopsis scabra</i> Dunal, is an arylnaphthalene lignan lactone. Its derivatives, such as <b>5</b> (8-1),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>6</b> (5-4-2),<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36-38)</a> and <b>7</b> (HE-145)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), have been synthesized and evaluated for anti-HBV activity in vitro. <b>5</b> not only suppressed DNA replication of the wild-type and lamivudine (3TC)-resistant virus strains but also inhibited HBV transcription and protein production. The IC<sub>50</sub> for suppressing extracellular HBV DNA and 50% cytotoxic concentration (CC<sub>50</sub>) of <b>5</b> were 0.08 and 9 μM, respectively, in the HepG2.2.15 cell line.<a onclick="showRef(event, 'ref35 ref39'); return false;" href="javascript:void(0);" class="ref ref35 ref39">(35, 39)</a> Additional mechanism studies based on the electrophoretic mobility-shift assays (EMSAs) indicated that <b>5</b> inhibited all HBV promoters by reducing the binding affinity of the precore/core promoter enhancer II region to HNF-4, HNF-3, and fetoprotein factor.<a onclick="showRef(event, 'ref35 ref39'); return false;" href="javascript:void(0);" class="ref ref35 ref39">(35, 39)</a> The anti-HBV activity of another helioxanthin derivative, <b>7</b>, was also evaluated in the HepG2.2.15 cell line with an IC<sub>50</sub> value of 1 μM and a CC<sub>50</sub> value of 6 μM.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a><b>7</b> selectively suppressed surface antigen promoter II and the core promoter of HBV and reduced the DNA binding activity of HNFs to specific cis elements of HBV core promoter, including peroxisome proliferator-activated receptors (PPARs), PPAR response elements (PPREs), fetoprotein transcription factor (FTF), and transcription factor Sp1.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> It is plausible that helioxanthin derivatives inhibit HBV gene expression and replication through modulation of the hepatocyte transcriptional machinery.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative helioxanthin analogues as HBV viral transcription inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although helioxanthin derivatives have shown appreciable antiviral activity against HBV, they also exhibit significant toxicity toward hepatocytes.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> It has been suggested that helioxanthin derivatives exert their anti-HBV activities via interfering with the functions of HNFs, which are otherwise indispensable for hepatocyte growth; this indicates probable mechanism-based toxicity. To successfully develop this class of compounds as a viable anti-HBV treatment, a delicate balance between their activity and toxicity must be carefully considered.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.3 Viral Polymerase Reverse Transcriptase Domain Inhibitors</h3><div class="NLM_p">The establishment of hepatoma cell lines integrated with HBV whole genome,<a onclick="showRef(event, 'ref14 ref40'); return false;" href="javascript:void(0);" class="ref ref14 ref40">(14, 40)</a> such as the HepG2.2.15 cell line, has greatly facilitated the research of the molecular mechanisms of HBV replication. For example, they played pivotal roles in the development of the nucleoside/nucleotide analogue (NA) anti-HBV drugs that target the viral polymerase RT domain, which remain to be the only approved class of small molecule drugs against HBV. This class now includes lamivudine, telbivudine, entecavir (ETV), adefovir dipivoxil (ADV), <b>8</b> [tenofovir disoproxil fumarate (TDF)],<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and the very recently approved <b>9</b> [tenofovir alafenamide fumarate (TAF), GS-7340, NCT02957994] (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). It is noted that ETV and TDF are the most commonly used drugs and are recommended as the first-line therapy based on their high potency and relatively low frequency of developing resistance.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Approved nucleoside/nucleotide analogue drugs for treatment of HBV and representative newly developed nucleoside/nucleotide compounds targeting HBV reserve transcriptase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interferon (IFN)-based therapies are the only other class of approved treatment for HBV, and great efforts have been undertaken to test the efficacy and safety of combination treatment with IFNs and NAs; unfortunately, there has still been little success demonstrating additional benefits of the combination regimen compared to single-agent treatment.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Discovery of novel NA derivatives against HBV is being continued in both academia and industry. The latest development of these new NA derivatives is summarized in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>. Among the approximately 150 NA derivatives examined by Takamatsu et al., <b>10</b> [4′-<i>C</i>-cyano-2-amino-2′-deoxyadenosine (CAdA)] and <b>11</b> [4′-<i>C</i>-cyano-2′-deoxyguanosine (CdG)] (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) exhibited similar potency compared to ETV; interestingly, <b>10</b> and <b>11</b> also inhibited an ETV-resistant HBV strain.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p last">Prodrug design is a proven approach for improving oral bioavailability and tissue targeting; this is indeed the case for tenofovir.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Various prodrug strategies have been applied to tenofovir. For example, by conjugating a lipid moiety to tenofovir, <b>12</b> (CMX-157) was identified (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), which showed a 50% effective concentration (EC<sub>50</sub>) of 1.6 μM in HepG2.2.15 cells and 0.49 μM in HepAD38 cells, nearly 5-fold more potent than tenofovir with similar cytotoxicity.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Indeed, phase II clinical trials are ongoing for <b>12</b> in HBV patients (NCT02710604). Another prodrug of tenofovir, <b>9</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), which had been in phase III clinical investigation for the treatment of both human immunodeficiency virus (HIV) and HBV infections, is now approved for treating chronic HBV infection.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> On the basis of this novel prodrug design, the dose of <b>9</b> (25 mg) is about one-tenth of that of <b>8</b> (300 mg) while maintaining similar efficacy and increased hepatocyte delivery; the safety profile of <b>9</b> is conceivably improved over <b>8</b> due to this grossly reduced dose.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.4 Inhibitors of Viral Polymerase Ribonuclease H Domain</h3><div class="NLM_p">The RNase H domain is a critical component of the viral polymerase and required for HBV DNA replication. However, the potential of RNase H domain, being a valid target for HBV treatment, was never seriously explored until the establishment of a low-throughput screen assay using recombinant HBV RNase H.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A small, focused library of HIV RNase H and integrase inhibitors was then screened, and 12 compounds were identified as hits.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, they include <b>13</b> (β-thujaplicinol) and its derivatives (<b>14</b>, <b>15</b>, <b>16</b>) and <b>17</b> [2-hydroxyisoquinoline-1,3(2<i>H</i>,4<i>H</i>)-diones] with IC<sub>50</sub> values against HBV RNase H in the μM range.<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50-52)</a> It should be noted that those compounds were also active against human RNase H and were only 100-fold less potent than the HBV RNase H. Obviously, selectivity issue needs to be addressed in order for this class of compounds to be viable treatment options for HBV.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative HBV viral polymerase RNase H domain inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.5 Targeting Viral Nucleocapsid Assembly</h3><div class="NLM_p">The icosahedral nucleocapsid core of HBV is composed of a single species of protein, the HBV core protein, which is believed to exist in the form of homodimers. During the self-assembling process, core protein homodimers interact with one another in a concerted manner through a still unknown mechanism to form the enclosed capsid. A productive capsid formation encapsulates the HBV pgRNA, together with HBV polymerase, to form the biologically competent HBV nucleocapsid in which reverse transcription and replication occur to generate the partially double-stranded HBV genomic DNA.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Clearly, nucleocapsid assembly is a critical step in the HBV life cycle, and targeting the core protein is a viable and novel approach for the treatment of HBV infection. In addition, the HBV core protein seems to be rather conserved and could present a higher barrier for drug resistance development.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Furthermore, it was reported that the core protein might play additional roles beyond being the structural protein for the nucleocapsid.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In recent years, significant attention has been paid to the discovery and development of compounds that target the nucleocapsid formation, and many capsid inhibitors or accelerators, some of which are already in advanced clinical development, have been generated by both industrial and academic laboratories (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div id="sec3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.5.1 Heteroaryldihydropyrimidine (HAP) Series</h4><div class="NLM_p">The HAP series of compounds is probably the first most studied class of compounds that disturb the assembly of the HBV nucleocapsid as a treatment option for HBV infection. Since the pioneering discovery of <b>18</b> (BAY 41-4109) by scientists at Bayer,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> significant efforts have been made to further optimize this lead compound and a number of representative analogues with in vitro anti-HBV activities are shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. It has been shown that <b>18</b> was not only able to inhibit HBV replication; in addition, HBcAg in the livers of the HBV transgenic mice was also significantly reduced after being treated with <b>18</b>, suggesting a completely different mechanism of action from that of NAs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Furthermore, Deres et al. demonstrated that <b>18</b> and its close analogues, <b>19</b> (BAY 38-7690) and <b>20</b> (BAY 39-5493) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>), disrupted capsid formation by destabilizing the HBV core protein.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Interestingly, additional in vitro study revealed that another HAP analogue, <b>21</b> (HAP1, <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>), which is very close to <b>18</b>, in fact increased the rate at which HBV core proteins assemble and thereby led to aberrant, nonfunctional capsid particles.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Heteroaryldihydropyrimidine (HAP) series of HBV viral nucleocapsid inhibitors. The IC<sub>50</sub> values are for suppression of HBV DNA in HepG2.2.15 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Active HAP analogues are shown to share a few common features for the specific substitutions around the HAP core. For example, an often halogen-substituted phenyl group is usually seen at the 4-position of the HAP core with <i>R</i> stereo configuration, at the 2-position a heterocycle is preferred, and an ester substitution is common at the 5-position. On the other hand, the structure–activity relationship (SAR) is sometimes steep. For instance, comparing <b>18</b> and <b>22</b> (Z060228) in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, the major difference is that a 3,5-difluoropyridin-2-yl group at the 2-position of <b>18</b> is replaced by a 2,3,4-trifluorophenyl group on <b>22</b>; however, the selectivity index (SI, CC<sub>50</sub>/IC<sub>50</sub>) is greatly improved from SI = 5 for <b>18</b> to SI = 106 for <b>22</b>.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">The 6-position on the HAP core seems to be an important area for optimization, which not only plays a role in the compound in vitro anti-HBV activity but also seems to impact the compound pharmacokinetic (PK) properties. For example, a documented, optimized HAP analogue, <b>23</b> (morphothiadin, GLS4) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>), has a morpholine group at the 6-position and it showed an IC<sub>50</sub> of 0.012 μM in a HepG2.2.15 cell line, 5-fold more potent than <b>18</b> with an IC<sub>50</sub> of 0.05 μM as well as claimed improved PK profile.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> It has been reported that <b>23</b> is now in clinical development (ChiCTR-IIR-16008284; ChiCTR, Chinese Clinical Trial Register) for treatment of HBV infection. Furthermore, the mode of interaction between <b>24</b> (NVR-010-001-E2, <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) and the core protein has been elucidated by the complex crystal structure, which enables structure-based design for further compound optimization.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Additional modifications to the 6-position, including cyclization of the 5- and 6-position substitutes, yielded much less active analogues such as <b>25</b> and <b>26</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63, 64)</a> A recently disclosed core modification at the 4-position produced the new 4-methyl HAP analogues, e.g., <b>27</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> By introducing the 4-methyl substitution, the metabolic stability of the HAP core is improved, and as exemplified by <b>27</b>, this compound exhibited high oral bioavailability and liver exposure.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div></div><div id="sec3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.5.2 Phenylpropenamide Series</h4><div class="NLM_p">The phenylpropenamide capsid inhibitors were discovered via a random library screening using the HepAD38 cell line, and the ensuing mechanistic studies showed that they disturb the HBV capsid assembly process.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The screening hit <b>28</b> (AT-61, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) was reported to inhibit HBV replication in various HBV cell lines, such as HepAD38, HepAD79, HepG2.2.15, and the transiently transfected HepG2 cells, with IC<sub>50</sub> values ranging from 0.6 to 5.7 μM.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The mode of action study revealed that <b>28</b> had no effects on the viral polymerase activity, indicating distinct mode of action from the NAs while it reduced the level of viral pgRNA and had little impact on the level of core protein.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Further modification yielded a reasonably well optimized compound <b>29</b> (AT-130, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) with improved potency of IC<sub>50</sub> of 0.13 μM and reduced toxicity in the HepAD38 cell line.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> It is noteworthy that both <b>28</b> and <b>29</b> inhibited wild-type and 3TC-resistant HBV strains in vitro.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative phenylpropenamide (<b>28</b>, <b>29</b>) and sulfamoylbenzamide (<b>30</b>, <b>31</b>) series of inhibitors targeting viral nucleocapsid assembly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Similar to <b>28</b>, <b>29</b> was also shown to disrupt the packaging of HBV pgRNA and core protein to form functional nucleocapsids;<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> specifically, <b>29</b> accelerated the assembly of the capsid, leading to morphologically normal albeit empty HBV capsid particles without pgRNA.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This is different from the HAP series of compounds, which usually causes aberrant, nonfunctional capsid particles. In addition, the HAP compounds seem to decrease the level of HBcAg, while this class of capsid inhibitors does not. Crystallographic studies further indicated that <b>29</b> binds to a quasiequivalent hydrophobic pocket at the core protein dimer–dimer interface, the same quasiequivalent binding pocket for the HAP compounds, causing tertiary and quaternary structural changes without disrupting the basic capsid structure.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72-74)</a> On the other hand, it needs to be pointed out that the strongest density for the HAP series was located in the pocket of the C-subunit, whereas the strongest density for <b>29</b> was in the B-subunit pocket, possibly explaining the difference between the two classes of compounds on a structural level given that those binding pockets are only quasiequivalent.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72-74)</a></div></div><div id="sec3_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.5.3 Sulfamoylbenzamide Series</h4><div class="NLM_p">Using a cell-based assay established from an immortalized mouse hepatocyte-derived stable cell line that supports a high level of HBV replication in a tetracycline-inducible manner, Campagna et al. discovered 36 compounds sharing a common sulfamoylbenzamide moiety from an in-house compound library screen.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The representative compounds of this class, <b>30</b> (DVR-01) and <b>31</b> (DVR-23), are shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Additional studies showed that <b>30</b> shared the same mechanism of action as the phenylpropenamide series of capsid inhibitors such as <b>29</b>.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p last">NVR 3-778 (<b>32</b>, structure not disclosed) is known to be a potent, orally bioavailable HBV capsid inhibitor, likely belonging to the sulfamoylbenzamide series based on the available patent publications,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> which presumably accelerates core protein assembly in an unproductive fashion, resulting in faulty, empty capsids. Preclinical studies showed that <b>32</b> was able to inhibit HBV replication in HepG2.2.15 cells with sub-μM EC<sub>50</sub> values<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and demonstrated efficacy in an HBV humanized mouse model.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In addition, <b>32</b> was shown to be active against all tested HBV genotypes (A through H) in vitro.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In phase I clinical trials (NCT02112799 and NCT02401737), <b>32</b> demonstrated reasonable safety and tolerability in both healthy volunteers and chronic HBV patients.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80, 81)</a></div></div><div id="sec3_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">3.5.4 Other HBV Capsid Modulators</h4><div class="NLM_p">From screening of a small focused library of compounds derived from leucamide A, <b>33</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) was identified to show weak inhibition of HBV DNA with IC<sub>50</sub> of 76.4 μM in HepG2.2.15 cells.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Further modification of this lead compound yielded <b>34</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) with much improved potency of IC<sub>50</sub> value of 0.14 μM. Furthermore, it was reported that <b>33</b> did not have activities against HBV polymerase at a concentration as high as 50 μM.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Meanwhile, another active derivative, <b>35</b> (NZ-4, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), with IC<sub>50</sub> of 1.33 μM in HepG2.2.15 cells was shown to disrupt binding of pgRNA with HBV core protein,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> suggesting capsid inhibiting mechanism of action of this class of compounds.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Distinct classes of HBV viral nucleocapsid modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of a structure-based virtual screen exercise using X-ray structure-derived HBV core protein dimer and hexamer structural models, Cho et al. identified <b>36</b> (BCM-599, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), an acetamide compound, with IC<sub>50</sub> of 0.88 μM and CC<sub>50</sub> of 144 μM in HepG2.2.15 cells.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> It was also shown that <b>36</b> decreased both intracellular and extracellular viral DNA levels without affecting the pgRNA level; moreover, interestingly, at the concentration of 0.88 μM, <b>36</b> reduced the intracellular capsid level by 51% while increased the amount of free core protein dimer by 5-fold.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">Wang et al. recently identified a group of pyridazinone derivatives, exemplified by <b>37</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), which was able to reduce the extracellular HBV DNA level with IC<sub>50</sub> of 1.5 μM and inhibit the intracellular capsid-associated HBV DNA level with IC<sub>50</sub> of 1.9 μM in HepG2.2.15 cells.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In addition, both 3TC and ETV double-resistant L180M/M204I mutant strain and ADV-resistant A181T/N236T mutant strain were susceptible to <b>37</b>, which was shown to disrupt functional nucleocapsid formation by producing empty, genome-free HBV capsids.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p last">Yet another new class of capsid assembly inhibitors, exemplified by <b>38</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), was shown to exhibit greater than 50% anti-HBV activity at approximately 10 μM in an in vitro fluorescence quenching assembly assay.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Zlotnick and colleagues also reported a new 2,4-diaminopyrimidine series (<b>39</b>, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) as capsid assembly enhancers.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> It is noteworthy that an increasing volume of patent publications is now available for various classes of HBV capsid modulators exhibiting great chemical diversity (e.g., <b>40</b> and <b>41</b> in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> Interestingly, no series has been shown to induce aberrant, nonfunctional capsid particles and decrease the amount of the HBV core protein similar to the first HAP series.</div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.6 Disturbing Interactions between Hepatitis B Virus Core and Surface Proteins</h3><div class="NLM_p">Hepatitis B virus is an enveloped virus, whose outer coat is comprised of both lipid membrane and variants of HBsAg surface proteins. Newly formed HBV nucleocapsids must be enveloped to produce mature viral particles that can be readily secreted out of the hepatocytes. During this budding process, the interaction between the core and surface proteins, albeit poorly understood, is believed to be critical. Asif-Ullah et al. established a modified biochemical enzyme-linked immunosorbent assay (ELISA) to screen for compounds that can inhibit the interaction between HBV core and surface proteins.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Five compounds were identified, among which <b>42</b> (KKJ00626) and <b>43</b> (KSJ0001) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) were shown to also inhibit HBV replication in transfected Huh7 cells.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compounds that disturb interactions between HBV core and surface proteins (<b>42</b>, <b>43</b>) and putative inhibitors of HBsAg secretion (<b>44</b>, <b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.7 Blocking Hepatitis B Virus Surface Antigen Secretion</h3><div class="NLM_p">HBsAg plays a significant role in the pathogenesis of HBV infection. For example, it has been indicated that HBsAg level is correlated with the intrahepatic HBV cccDNA level,<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91, 92)</a> and continuous production of HBsAg would signal a high level of intracellular cccDNA, the master template for all viral transcription and viral protein production. In addition, HBsAg was suggested to interact with plasmacytoid dendritic cells (pDCs) through their surface blood dendritic cell antigen 2 (BDCA-2) receptors and upregulate suppressor of cytokine signaling-1 (SOCS-1) expression, resulting in diminished IFN-α production,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> which could in part explain the fundamental role that HBsAg plays in HBV immune tolerance. Furthermore, for patients who, at the end of the treatment, have more than one log decrease of the HBsAg level or have ≤10 IU/mL HBsAg titer, a higher rate of HBsAg loss was observed after three years,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> again suggesting the significance of HBsAg in HBV infection. In fact, clearance of HBsAg, with or without seroconversion, is now generally considered as the “functional cure” for chronic hepatitis B.</div><div class="NLM_p last">Dougherty et al. screened a small library of 80288 synthetic compounds to detect the level of HBsAg secreted by HepG2.2.15 cells, and <b>44</b> (HBF-0259, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) was identified to inhibit HBsAg with an EC<sub>50</sub> of 11.3 μM and a CC<sub>50</sub> value of >50 μM in HepG2.2.15 cells.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> It was also shown that <b>44</b> had no effects on the secretion of HBeAg, α-1-acid glycoprotein, and α-1-antitrypsin but did impact the levels of secreted viral and subviral particles, suggesting possible specific inhibition of HBsAg secretion.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Extensive SAR studies have led to a more potent HBsAg secretion inhibitor, <b>45</b> (PBHBV-2-15, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), with a substantially reduced EC<sub>50</sub> of 1.4 μM and a minimum selectivity index of 36.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.8 Host Targeting Agents</h3><div class="NLM_p">Therapeutic agents that directly act on the HBV viral proteins have been at the center of the discovery effort for novel treatments of HBV. On the other hand, an increasing volume of evidence has indicated that the close interaction between HBV and the host is an indispensable component of the viral life cycle,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> together with the realization of the crucial role that the human immune system plays in the pathogenesis and disease prognosis of HBV infection.<a onclick="showRef(event, 'ref96 ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref96 ref97 ref98">(96-98)</a> Besides direct antiviral agents (DAAs), an alternative approach to treat HBV infection will be the application of host targeting agents (HTAs), which target the host proteins that may directly interact with the viral factors and/or are involved in the host immune response. For example, it was reported that heat shock protein 90 (Hsp90) facilitated HBV capsid formation and stabilization, and inhibition and/or down-regulation of Hsp90 decreased HBV production in HepG2.2.15 cells.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In this case, targeting Hsp90 could be explored as an alternative, new approach to treat HBV infection.</div><div id="sec3_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.8.1 Toll-like Receptor (TLR) Agonists</h4><div class="NLM_p">It was shown that the pattern recognition receptors (PRRs), such as TLRs, on the liver nonparenchymal cells, including Kupffer cells, stellate cells, and sinusoidal endothelial cells, could recognize HBV and initiate the host innate immune responses, resulting in cytokine production and subsequent suppression of viral infection.<a onclick="showRef(event, 'ref96 ref98 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref96 ref98 ref100 ref101 ref102">(96, 98, 100-102)</a> Indeed, several TLR agonists have been shown to suppress HBV replication both in vitro<a onclick="showRef(event, 'ref103 ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref103 ref104 ref105 ref106">(103-106)</a> and in vivo.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96, 97)</a> Particularly, a number of TLR7 agonists that induce type I IFNs by activating pDCs have been evaluated for their antiviral activities in both preclinical and clinical settings.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a></div><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>, <b>46</b> (vesatolimod, GS-9620) is a partially selective TLR7 agonist.<a onclick="showRef(event, 'ref109 ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref111">(109-111)</a> In an HEK293 cell-based assay, the EC<sub>50</sub> values of <b>46</b> for TLR7 and TLR8 were 0.29 and 9.0 μM, respectively.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> This level of selectivity between TLR7 and TLR8 activation corroborated with the difference between IFN-α induction (TLR7-driven) and tumor necrosis factor (TNF)-α induction (TLR8-driven) observed from a human peripheral blood mononuclear cell (hPBMC)-based assay.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Menne et al. also reported that <b>46</b> reduced serum viral DNA, cccDNA, and RNA in woodchucks chronically infected with WHV.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It was suggested that <b>46</b> might not induce a systemic IFN-α production due to its highly localized activation of TLR7, which may instead lead to activation of pDCs in gut-associated lymphoid tissues and/or the liver.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a><b>46</b> has been reported to demonstrate solid PK and safety profiles as well as efficacy signals in phase I clinical trials,<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115, 116)</a> and it has been in phase II clinical investigations for the treatment of chronic HBV infection (NCT01590641 and NCT01590654). Although no TLR7 agonists have been approved for HBV treatment, this mechanism of action represents an alternative, new approach by inducing broad, protective immunity against viral infection. Development of such compounds is currently of great interest to the pharmaceutical industry.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Distinct host targeting agents, cccDNA inhibitors, and nucleic acid polymer for treatment of HBV infection. <b>46</b>, TLR7 agonist; <b>47</b>, cIAP antagonists; <b>48</b>, Hsc70 inhibitor; <b>49</b>, Hsp90 inhibitor; <b>50</b> and <b>51</b>, putative cccDNA inhibitor; <b>53</b>, NAP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">When treated with polyinosinic:polycytidylic acid [poly(I:C)], an TLR3 agonist,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> both parenchymal and nonparenchymal liver cells produced IFN-β and inhibited the replication of HBV.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In addition, viral load reduction was observed in an HBV hydrodynamic mouse model when poly(I:C) was administered by intraperitoneal (IP) injection,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> suggesting potential application of TLR3 agonists as an anti-HBV treatment.</div></div><div id="sec3_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">3.8.2 Antagonizing Cellular Inhibitor of Apoptosis Proteins (cIAPs)</h4><div class="NLM_p last">Recent studies have shown that cIAP antagonists, such as <b>47</b> (birinapant, <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) and other second mitochondria-derived activator of caspases (SMAC) mimetics, are able to reduce the serum levels of HBV DNA and HBsAg and promote elimination of hepatocytes containing HBcAg in an HBV hydrodynamic mouse model.<a onclick="showRef(event, 'ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121">(119-121)</a> It is believed that those SMAC mimetics induce cell death in a TNF-mediated fashion, which does not intrinsically discriminate between infected or normal liver cells. This may raise significant safety concerns for this new class of compounds in treating chronic HBV patients, and careful clinical investigations will be required to understand the benefit and risk for application of SMAC mimetics in a chronic disease such as hepatitis B.</div></div><div id="sec3_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.8.3 Lymphotoxin (LT) β Receptor (LTβR) Agonists</h4><div class="NLM_p last">TNF-α was known to control HBV replication in a noncytopathic fashion.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Interestingly, activation of another signaling pathway within the TNF superfamily, the LTβ pathway, using either a superagonistic tetravalent bispecific LTβR antibody (BS1) or a bivalent agonistic anti-LTβR monoclonal antibody (CBE11), resulted in decreases in nearly all HBV viral markers, particularly cccDNA and HBeAg, with an EC<sub>50</sub> of 0.01 μg/mL in HBV infected differentiated HepaRG cells.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> It was proposed that the resultant upregulation of nuclear APOBEC3 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3) deaminases (A3Bs) from LTβR activation might be responsible for the antiviral activities.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Specifically, A3Bs were suggested to recognize and bind to HBV cccDNA possibly mediated by HBV core protein and subsequently to form apurinic/apyrimidinic (AP) sites within the cccDNA.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> These AP sites are then recognized by cellular AP endonucleases, eventually leading to cccDNA degradation and clearance of HBV. Because removal and/or silence of cccDNA is a necessary step for the ultimate eradication of HBV, LTβR agonists thereby represent an attractive approach for a potential cure of the disease; nonetheless, it is still in early discovery stage and significant efforts will be required for identifying a viable clinical candidate.</div></div><div id="sec3_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.8.4 Inhibitors of Heat Stress Cognate 70 (Hsc70) and Heat Shock Protein 90</h4><div class="NLM_p">Hsc70 has been shown to be a necessary host factor for the viral reverse transcription process in experiments using duck hepatitis B virus (DHBV) DNA polymerase.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124, 125)</a> In addition, RNA interference (RNAi)-based knockdown of Hsc70 could block HBV replication without obvious cytotoxicity,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> suggesting that Hsc70 could be a potential target for treating HBV infection. A selective Hsc70 inhibitor, <b>48</b> (oxymatrine) shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>, was found to suppress de novo synthesis of both the wild-type HBV strain and strains resistant to 3TC, ADV, and ETV, presumably through destabilization of Hsc70 mRNA.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In HepG2.2.15 cells, <b>48</b> exhibited an EC<sub>50</sub> of 0.031 mg/mL and a CC<sub>50</sub> of 3.12 mg/mL, with an SI of over 100.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><div class="NLM_p last">Hsp90 can interact with the viral reverse transcriptase to facilitate ribonucleoprotein (RNP) complex formation between the polymerase and an RNA ligand. Hu and Seeger showed that an Hsp90 monoclonal antibody could block RNP formation and small molecule antibiotics <b>49</b> (geldanamycin, <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) could also selectively inhibit Hsp90 function through directly blocking the interactions between Hsp90 and p23, resulting in both decreased RNP formation in vitro and RNA packaging in vivo.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> It is noteworthy that p23 is a ubiquitously expressed phosphoprotein required for Hsp90 function.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> In all, Hsc70 and Hsp90 inhibition might provide an alternative approach to overcome the drug resistance that is associated with the current NA treatment.</div></div><div id="sec3_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.8.5 Programmed Cell Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Inhibitors</h4><div class="NLM_p">Immune checkpoint inhibitors, best exemplified by three recently approved PD-1/PD-L1 blocking drugs (nivolumab, pembrolizumab, and atezolizumab),<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> as well as many similar compounds that are currently in clinical development, represent a novel therapeutic approach to treat diseases by actively modulating the immune system.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131, 132)</a> Although we have witnessed the tremendous success of those PD-1/PD-L1 inhibitors in treating many different cancers, this type of immune checkpoint inhibitors has not been widely applied in other diseases. Interestingly, blockage of PD-1/PD-L1 checkpoint resulted in restoration of exhausted CD8<sup>+</sup> T cell function in chronic lymphocytic choriomeningitis virus (LCMV) infection,<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> and this was also observed in the case of HIV infection,<a onclick="showRef(event, 'ref134 ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136">(134-136)</a> suggesting a possible application of PD-1/PD-L1 inhibition in treating viral infection.</div><div class="NLM_p last">It becomes increasingly clear that chronic HBV infection is also at least in part an immune disorder; for example, T cells, especially CD8<sup>+</sup> T cells, are the key contributor in control of HBV replication.<a onclick="showRef(event, 'ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref137 ref138">(137, 138)</a> On the other hand, chronic HBV infection often results in CD8<sup>+</sup> T cell exhaustion and is associated with upregulation of PD-1.<a onclick="showRef(event, 'ref133 ref139'); return false;" href="javascript:void(0);" class="ref ref133 ref139">(133, 139)</a> It is noteworthy that HBV NA treatment was shown to reduce PD-1 expression, presumably enhancing immunity against HBV.<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140, 141)</a> Possibly, a combination of NAs, PD-1/PD-L1 blockers, and/or other immunomodulatory agents could be a useful strategy in treating HBV infection. Indeed, in woodchucks that have been chronically infected with WHV, one such combination of a PD-L1 blocker with a therapeutic vaccine was shown to enhance virus-specific immunity.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> It should be noted, however, that safety evaluation needs to be carefully carried out for immunotherapies such as PD-1/PD-L1 inhibitors for chronic diseases such as HBV infection.</div></div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">3.9 Targeting cccDNA</h3><div class="NLM_p">HBV cccDNA is believed to be highly persistent within the infected hepatocyte, and, albeit in a minute amount, is the master template for all viral transcription and protein synthesis. Because of its central function in HBV life cycle, exceptionally long half-life, and sheer low copy number, cccDNA becomes the principal culprit of chronic HBV infection and the dominant factor that chronic infection is extremely difficult to clear.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Clearance of cccDNA would represent eradication of the virus and ultimate cure of hepatitis B. However, the underlying foundational biology of cccDNA dynamics is not clear, and it has been immensely challenging to discover therapeutic agents that can eliminate and/or silence cccDNA.</div><div class="NLM_p last">Using secreted HBeAg as a surrogate biomarker for cccDNA, Cai et al. screened a small compound library by employing an HepDE19 cell-based assay.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Two disubstituted sulfonamide (DSS) compounds (<b>50</b> and <b>51</b> in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) were identified to inhibit cccDNA production at low μM range.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In addition, those DSS compounds were shown to inhibit HBV cccDNA without affecting intracellular HBV rcDNA or viral polymerase activity; furthermore, <b>50</b> was also able to reduce DHBV cccDNA biosynthesis in primary duck hepatocytes (PDHs).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The mechanism of action of the DSS compounds is however yet to be elucidated. In addition, one ought to keep in mind that HBeAg is, for lack of a better choice, a surrogate biomarker of cccDNA, given the challenges to accurately measure the cellular HBV cccDNA.</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">3.10 RNA Interference and Antisense Therapies</h3><div id="sec3_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">3.10.1 RNA Interference Therapy and Delivery</h4><div class="NLM_p">RNA interference is an evolutionarily conserved mechanism to suppress specific genes through neutralization of targeted mRNA molecules, which has immense potential as a therapeutics for targeted inhibition of disease relevance with high specificity and potency at the mRNA level.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> However, significant challenges related to for example cell and tissue delivery and toxicity have prevented RNAi therapeutics from becoming an otherwise much broader clinical application.<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145, 146)</a> Recent technological advancement in delivery and chemical conjugation of large molecules, such as lipid-based nanoparticles, <i>N</i>-acetylgalactosamine (GalNAc) conjugates, and dynamic polyconjugates (DPCs), has led an resurgence of RNAi-based therapies in clinical trials.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147, 148)</a></div><div class="NLM_p last">Multiple attempts have been made for using RNAi to treat HBV infection; although no drugs have been approved to date, some of the candidates are in advanced clinical evaluations.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148, 149)</a> For example, <b>52</b> (ARC-520, structure not disclosed), which is based on a proprietary DPC delivery technology, was in phase II clinical trial for chronic HBV infection.<a onclick="showRef(event, 'ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152">(150-152)</a> In preclinical animal studies, <b>52</b> significantly decreased HBV DNA, HBsAg, and HBeAg in chimpanzees, hydrodynamic injection HBV mice, and HBV transgenic mice.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152, 153)</a> However, <b>52</b> was very recently discontinued (NCT02738008), together with ARC-521 (structure not disclosed) (NCT02797522) and ARC-ATT (structure not disclosed), all of which used the same DPC-based technology, citing potential toxicity liabilities associated with the delivery vehicle. ALN-HBV (structure not disclosed) is another investigational RNAi drug that is based on the GalNAc conjugate delivery approach for chronic HBV infection. In preclinical studies, it was shown to significantly reduce the HBsAg level in rodent HBV models and be well tolerated in GLP (good laboratory practice) toxicology studies with rats and nonhuman primates.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> ALN-HBV is now in phase I/II clinical investigations with both healthy volunteers and HBV patients (NCT02826018).</div></div><div id="sec3_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">3.10.2 Antisense Oligonucleotide (ASO) Therapy</h4><div class="NLM_p last">Antisense oligonucleotide is either a RNA- or DNA-based short synthetic fragment which is able to bind to targeted RNA sequences with high specificity to generate RNA:RNA duplexes and DNA:RNA hybrids, respectively.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Multiple preclinical studies have reported that ASOs were able to reduce HBV viral load and HBsAg and HBeAg levels; however, challenges such as stability and intracellular delivery remain to be major hurdles for developing broadly applied ASO-based HBV treatment.<a onclick="showRef(event, 'ref156 ref157 ref158 ref159 ref160 ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref156 ref157 ref158 ref159 ref160 ref161 ref162">(156-162)</a> One advancement over the traditional ASO therapy is the antisense locked nucleic acid (LNA) technology, which could greatly improve nucleic acid in vitro and in vivo stabilities; for example, Deng et al. reported that in an HBV transgenic mouse model by using antisense LNA serum HBV DNA and HBsAg levels were reduced by 53% and 73%, respectively.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> To further improve cellular delivery, lipid-based delivery systems were developed for antisense LNA against HBV and it has demonstrated superior activities than RNAi in blocking HBV replication and HBV protein production in HepG2.2.15 cells.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> A number of ASOs for treatment of chronic HBV infection are in early clinical development including IONIS-HBVRx (GSK3228836) (NCT02981602) and IONIS-HBVLRx (GSK3389404) (NCT02647281), whose structures are not disclosed.</div></div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">3.12 Other Approaches for Treating Chronic Hepatitis B Virus Infection</h3><div id="sec3_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">3.12.1 Nucleic Acid Polymers (NAPs)</h4><div class="NLM_p last">Taking advantage of the sequence-independent amphipathic properties of the phosphorothioate oligonucleotides (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>), NAPs are suggested to interfere with the amphipathic interactions often involved in viral entry and thereby potentially be a novel class of broad-spectrum antivirals.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> In the case of HBV infection, a number of NAPs have shown entry and post entry antiviral activities both in vitro and in vivo in PDHs and DHBV infected ducks, respectively.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> For example, when used prophylactically, <b>53</b> (REP 2055, <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) was shown activities against DHBV infection at a low dose of 1 mg/kg with good tolerability.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Furthermore, there were also reports claiming that NAP analogues were able to suppress serum HBsAg in treatment-naïve Bangladeshi HBV patients.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> A leading NAP analogue, REP 2139, albeit without a disclosed structure, was claimed to be in a phase II clinical trial (NCT02565719) for the treatment of HBV and HBV/HDV coinfection both as monotherapy and combination therapy with IFNs and has demonstrated reduction in both HBsAg and HDV RNA in Caucasian patients.<a onclick="showRef(event, 'ref165 ref166 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref165 ref166 ref167 ref168">(165-168)</a> If confirmed in clinical evaluations, NAP-based therapy could be another alternative, novel treatment option for HBV and HBV/HDV coinfected patients.</div></div><div id="sec3_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.12.2 Natural Products</h4><div class="NLM_p">Natural product is a great source for drug discovery.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Helioxanthin analogues as shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, presumed HBV viral transcription inhibitors, were discovered from a natural source. Many natural products have been reported to show inhibitory activities against HBV with however often weak ones.<a onclick="showRef(event, 'ref170 ref171 ref172 ref173 ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172 ref173 ref174 ref175">(170-175)</a> As shown in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>, a number of examples including <b>54</b> (robustaflavone)<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> and <b>55</b> (caudatin)<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> demonstrated in vitro activities against HBV DNA replication in HepG2.2.15 cells with IC<sub>50</sub> values from sub-μM to double-digit μM range. Moreover, <b>56</b> (alisol A)<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> and <b>57</b> (vanitaracin A)<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> were shown to inhibit HBsAg with IC<sub>50</sub> values of 39 and 10.5 μM in HepG2.2.15 and HepG2-hNTCP-C4 cells, respectively (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). It is noted, however, that the mechanisms of actions of most anti-HBV natural products are not clearly elucidated. Furthermore, it is worthwhile to point out that although natural products often present interesting starting points for medicinal chemistry, it is also critically important to have a clear, practical optimization strategy early in the program to address key challenges specific to natural products such as chemical synthesis in order to be able to achieve viable clinical candidates in a relatively timely fashion.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Natural products for treatment of HBV with respective antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">3.12.3 Drug Repositioning</h4><div class="NLM_p">Developing new indications, sometimes seemingly distant ones, for existing drugs is probably the most efficient approach to bring a new therapy to the market; indeed, it has achieved a number of successful cases such as sildenafil for erectile dysfunction and bevacizumab for age-related macular degeneration.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> It has been found that HBV infection induces cellular DNA damage responses, during which process the signaling pathways involving ataxia telangiectasia and Rad3-related protein (ATR), ataxia telangiectasia mutate (ATM), and checkpoint kinase 1 (Chk1, ATR substrate) are activated.<a onclick="showRef(event, 'ref177 ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref177 ref178 ref179">(177-179)</a> Interestingly, known ATR/ATM inhibitors <b>58</b> (caffeine) and <b>59</b> (theophylline), as well as Chk1 inhibitor <b>60</b> (UCN-01), were demonstrated to suppress HBV DNA in HBV-infected HL7702 cells (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>).<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> In particular, <b>59</b>, a drug for treating respiratory diseases, was further shown to significantly reduce the levels of HBV DNA, HBsAg, and HBeAg at 2.5 mM in HepG2.2.15 cells as well as achieving decreased levels of serum HBV DNA and HBsAg in HBV transgenic mice.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Of course, significant amount of translational research is still required before theophylline could be considered for clinical investigation in HBV patients.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Repositioned drugs as therapeutics for HBV infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The antiviral activity of <b>61</b> (nitazoxanide, <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>), a broad-spectrum antiparasitic, was discovered serendipitously when treating AIDS patients for cryptosporidium diarrhea; incidentally, those patients were also coinfected with HBV and/or hepatitis C virus (HCV).<a onclick="showRef(event, 'ref181 ref182 ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref181 ref182 ref183 ref184">(181-184)</a> It was later confirmed that <b>61</b> and its active metabolite <b>62</b> (tizoxanide, <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>) demonstrated extracellular HBV DNA inhibition in HepG2.2.15 cells with IC<sub>50</sub> values of 0.12 and 0.15 μM, respectively.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Furthermore, they were also able to reduce the levels of extracellular HBsAg and HBeAg and intracellular HBcAg in HepG2.2.15 cells with however no effects on HBV transcription, and in an Huh7-based transient transfection assay, they further exhibited activities against several 3TC-resistant HBV strains and one ADV-resistant strain.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Mechanistic studies elucidated that <b>61</b> induces protein kinase RNA-activated (PKR) activation, which in turn causes an elevated level of intracellular phosphorylated eukaryotic initiation factor 2α (eIF2α), a known critical cellular factor against viral infection.<a onclick="showRef(event, 'ref183 ref185 ref186 ref187 ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref183 ref185 ref186 ref187 ref188 ref189">(183, 185-189)</a> Interestingly, early clinical investigations showed that <b>61</b> was effective in chronic HBV patients, demonstrating potential to promote HBsAg and HBeAg seroconversion.<a onclick="showRef(event, 'ref183 ref190'); return false;" href="javascript:void(0);" class="ref ref183 ref190">(183, 190)</a></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">4 Conclusion and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78603" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78603" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic hepatitis B virus infection remains to be a great healthcare burden worldwide, particularly in China, Southeast Asia, and sub-Sahara Africa. Together with associated liver diseases such as cirrhosis and hepatocellular carcinoma, HBV infection can result in nearly one million deaths worldwide on an annual basis. Treatment for chronic hepatitis B has evolved rather slowly, which still largely relies on nucleoside/nucleotide analogue drugs with a single mechanism of action, needing lifetime treatment only for virus DNA suppression. Since the approval of the first NA drug, lamivudine, also known as 3TC, over 20 years ago, incremental changes have been made to this class of drugs, the latest approved one being tenofovir alafenamide fumarate late last year. Step changes are absolutely and urgently needed for HBV treatment options. Currently, major efforts are being made in developing therapies that can achieve functional cure of the disease, i.e., finite treatment to accomplish HBsAg loss with or without seroconversion. None of the current drugs are able to accomplish predictable HBsAg loss in any given HBV patient, the best of which is IFN-based therapies that, despite significant side effects, have a functional cure rate of as high as 12%. The ultimate goal to cure hepatitis B is of course eradication of HBV, which, because of the nature of the Hepadnaviridae family of viruses, entails clearance and/or silence of cccDNA, a mounting task given relatively poor understanding of the cccDNA foundational biology.</div><div class="NLM_p">Hepatitis B virus life cycle is reasonably well understood, and a large number of direct antiviral agents with distinct mechanisms of actions targeting specific steps of the HBV life cycle are being actively discovered and some of which are already being tested in HBV patients. This extensive list of different DAAs covers nearly the entire HBV life cycle, including entry inhibitors, viral transcription inhibitors, viral polymerase inhibitors (both RT and RNase H domains), nucleocapsid assembly modulators, and HBsAg secretion inhibitors. The most advanced DAAs except the existing NA class of drugs are probably the compounds that interfere with HBV core protein functions for which the basic biology of nucleocapsid assembly from core protein dimers is quite well elucidated on a molecular level. In addition, the function of the elusive HBx protein is yet to be clarified, which probably involves multiple interactions with an array of host proteins. Furthermore, given the increasing realization of the indispensable roles that host factors play in the pathogenesis of HBV infection, the effort to discover host targeting agents for treating hepatitis B has been substantially increased, particularly for those involving the immune system. HBV HTAs display a wide range of mechanisms, reflecting the high complexity involved in the host–virus interactions, which includes TLR agonists, cIAP antagonists, LTβR agonists, Hsc70 inhibitors, as well as immune checkpoint inhibitors such as PD-1/PD-L1 blockers. An increasing number of HTAs with novel mechanisms of actions is constantly being identified on a regular basis; however, it remains to be seen in clinical trials whether any of the HTAs, especially as monotherapy, will be a viable treatment option for hepatitis B. Gene therapies including RNAi and ASO approaches are now in clinical evaluations for efficacy and safety against HBV, while breakthrough in delivery technologies is likely to be a key determinant in this case.</div><div class="NLM_p last">Combination therapy is a rather common approach for infectious diseases such as in the cases of HIV and HCV treatments. Multiple attempts over the years to combine existing NAs and IFNs have not yielded any meaningful benefits; that being said, the current choices for combinations are very much limited with merely two classes of drugs. It is foreseeable that given advancement in clinical development of drug candidates with different, new mechanisms of actions, the number of options for various combination strategies will be significantly increased. Soon we will be able to experiment with combination regimens involving DAAs, HTAs, and even gene therapies for functional cure of hepatitis B. Furthermore, clearance and/or silence of cccDNA is the ultimate goal for eradication of HBV and cure of the disease, while a significant volume of basic research is still required not only for better understanding of the foundational biology of cccDNA but also for development of practical, sensitive detection method. In all, deeper understanding of the biological underpinnings of hepatitis B virus life cycle, cccDNA dynamics, and host–virus interactions will lay the foundation for discovering and developing novel therapeutic agents and innovative treatment strategies that can not only accomplish functional cure of the disease but also achieve eventual eradication of the virus, cure of hepatitis B, and decreased rate of associated liver diseases including cirrhosis and hepatocellular carcinoma.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01442" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">S. Frank Yan</span> - <span class="hlFld-Affiliation affiliation">Molecular Design and Chemical Biology,
Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0f7c763d38374f61767a216a6b7a"><span class="__cf_email__" data-cfemail="37444e05000f77594e4219525342">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Tsinghua University, Beijing 100084, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5549-5686" title="Orcid link">http://orcid.org/0000-0001-5549-5686</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#284f49464f44415d1a1f685c5b41464f405d49064d4c5d064b46"><span class="__cf_email__" data-cfemail="1473757a73787d6126235460677d7a737c61753a7170613a777a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yameng Pei</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Tsinghua University, Beijing 100084, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunting Wang</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical
Sciences, Tsinghua University, Beijing 100084, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.P. and C.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Yameng Pei</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=BIO-d58e2012-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yameng Pei</b> is a Ph.D. candidate in Chemical Biology at School of Pharmaceutical Sciences, Tsinghua University, China, under the supervision of Prof. Gang Liu. Her scientific interests include developing innovative screen assays for identifying novel anti-HBV compounds as well as the molecular mechanisms of pattern recognition receptors relevant to hepatocellular carcinoma.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Chunting Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=BIO-d58e2017-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chunting Wang</b> is a Ph.D. candidate at School of Pharmaceutical Sciences, Tsinghua University, China, under the supervision of Prof. Gang Liu. He is interested in the design and synthesis of chemical compounds against hepatitis B virus and tumor metastasis.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">S. Frank Yan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=BIO-d58e2022-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>S. Frank Yan</b> received his Ph.D. in Structural Chemistry from New York University, United States, under the supervisions of Prof. Suse Broyde, Prof. Robert Shapiro, and Prof. Nicholas Geacintov in the field of chemical carcinogenesis. He then started his industry career in Novartis and later joined Roche R&D China as the Head of Molecular Design and Biostructure in 2008. He has extensive experience in various disease areas including infectious diseases, oncology, metabolic diseases, and neuroscience. His scientific contributions include over 40 journal publications and patents.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Gang Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=BIO-d58e2027-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gang Liu</b> received his Ph.D. in Chemistry from Beijing Medical University, China, and obtained his postdoctoral training in Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, China, and Scripps Research Institute, United States. He is currently Chang Jiang Scholar, Peking Union Scholar, and 100 Top Talent Program Professor at School of Pharmaceutical Sciences, Tsinghua University, China. His research interests include developing synthetic methodologies of small molecule heterocyclic compound libraries, natural products, and peptide/glycopeptide mimics and analytic assay methodologies for high throughput screening. His lab is focused on discovering, optimizing, and developing compounds for cancer and infectious diseases.</p></figure></div><div class="ack" id="ACK-d58e2035-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">G.L. gratefully acknowledges the funding support of grant from the National 863 Program of China (no. 2012AA020303).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> Abbreviations Used</h2><tr><td class="NLM_term">ADV</td><td class="NLM_def"><p class="first last">adefovir dipivoxil</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquired immune deficiency syndrome</p></td></tr><tr><td class="NLM_term">AP</td><td class="NLM_def"><p class="first last">apurinic/apyrimidinic</p></td></tr><tr><td class="NLM_term">APOBEC3</td><td class="NLM_def"><p class="first last">apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3</p></td></tr><tr><td class="NLM_term">A3B</td><td class="NLM_def"><p class="first last">apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 deaminase</p></td></tr><tr><td class="NLM_term">ASO</td><td class="NLM_def"><p class="first last">antisense oligonucleotide</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and Rad3-related protein</p></td></tr><tr><td class="NLM_term">BDCA-2</td><td class="NLM_def"><p class="first last">blood dendritic cell antigen 2</p></td></tr><tr><td class="NLM_term">CAdA</td><td class="NLM_def"><p class="first last">4′-<i>C</i>-cyano-2-amino-2′-deoxyadenosine</p></td></tr><tr><td class="NLM_term">CC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% cytotoxic concentration</p></td></tr><tr><td class="NLM_term">cccDNA</td><td class="NLM_def"><p class="first last">covalently closed circular DNA</p></td></tr><tr><td class="NLM_term">CdG</td><td class="NLM_def"><p class="first last">4′-<i>C</i>-cyano-2′-deoxyguanosine</p></td></tr><tr><td class="NLM_term">C/EBP</td><td class="NLM_def"><p class="first last">CCAAT/enhancer-binding protein</p></td></tr><tr><td class="NLM_term">Chk1</td><td class="NLM_def"><p class="first last">checkpoint kinase 1</p></td></tr><tr><td class="NLM_term">ChiCTR</td><td class="NLM_def"><p class="first last">Chinese Clinical Trial Register</p></td></tr><tr><td class="NLM_term">cIAP</td><td class="NLM_def"><p class="first last">cellular inhibitor of apoptosis protein</p></td></tr><tr><td class="NLM_term">DAA</td><td class="NLM_def"><p class="first last">direct antiviral agent</p></td></tr><tr><td class="NLM_term">DHBV</td><td class="NLM_def"><p class="first last">duck hepatitis B virus</p></td></tr><tr><td class="NLM_term">DPC</td><td class="NLM_def"><p class="first last">dynamic polyconjugate</p></td></tr><tr><td class="NLM_term">DSS</td><td class="NLM_def"><p class="first last">disubstituted sulfonamide</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% effective concentration</p></td></tr><tr><td class="NLM_term">EGCG</td><td class="NLM_def"><p class="first last">epigallocatechin-3-gallate</p></td></tr><tr><td class="NLM_term">eIF2α</td><td class="NLM_def"><p class="first last">eukaryotic initiation factor 2α</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">EMSA</td><td class="NLM_def"><p class="first last">electrophoretic mobility-shift assay</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">ETV</td><td class="NLM_def"><p class="first last">entecavir</p></td></tr><tr><td class="NLM_term">FTF</td><td class="NLM_def"><p class="first last">fetoprotein transcription factor</p></td></tr><tr><td class="NLM_term">GalNAc</td><td class="NLM_def"><p class="first last"><i>N</i>-acetylgalactosamine</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">HAP</td><td class="NLM_def"><p class="first last">heteroaryldihydropyrimidine</p></td></tr><tr><td class="NLM_term">HBcAg</td><td class="NLM_def"><p class="first last">hepatitis B virus core antigen</p></td></tr><tr><td class="NLM_term">HBeAg</td><td class="NLM_def"><p class="first last">hepatitis B virus e antigen</p></td></tr><tr><td class="NLM_term">HBsAg</td><td class="NLM_def"><p class="first last">hepatitis B virus surface antigen</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HBx</td><td class="NLM_def"><p class="first last">hepatitis B virus X protein</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HDV</td><td class="NLM_def"><p class="first last">hepatitis D virus</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HNF</td><td class="NLM_def"><p class="first last">hepatocyte nuclear factor</p></td></tr><tr><td class="NLM_term">HSPG</td><td class="NLM_def"><p class="first last">heparan sulfate proteoglycan</p></td></tr><tr><td class="NLM_term">Hsc70</td><td class="NLM_def"><p class="first last">heat stress cognate 70</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">HTA</td><td class="NLM_def"><p class="first last">host targeting agent</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% inhibitory concentration</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">kb</td><td class="NLM_def"><p class="first last">kilobase</p></td></tr><tr><td class="NLM_term">LCMV</td><td class="NLM_def"><p class="first last">lymphocytic choriomeningitis virus</p></td></tr><tr><td class="NLM_term">LNA</td><td class="NLM_def"><p class="first last">locked nucleic acid</p></td></tr><tr><td class="NLM_term">LTβR</td><td class="NLM_def"><p class="first last">lymphotoxin β receptor</p></td></tr><tr><td class="NLM_term">NAP</td><td class="NLM_def"><p class="first last">nucleic acid polymer</p></td></tr><tr><td class="NLM_term">NA</td><td class="NLM_def"><p class="first last">nucleoside/nucleotide analog</p></td></tr><tr><td class="NLM_term">NCT</td><td class="NLM_def"><p class="first last">national clinical trial</p></td></tr><tr><td class="NLM_term">NTCP</td><td class="NLM_def"><p class="first last">sodium taurocholate cotransporting polypeptide</p></td></tr><tr><td class="NLM_term">ORF</td><td class="NLM_def"><p class="first last">open reading frame</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">pDC</td><td class="NLM_def"><p class="first last">plasmacytoid dendritic cell</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1</p></td></tr><tr><td class="NLM_term">PDH</td><td class="NLM_def"><p class="first last">primary duck hepatocyte</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death ligand 1</p></td></tr><tr><td class="NLM_term">pgRNA</td><td class="NLM_def"><p class="first last">pregenomic RNA</p></td></tr><tr><td class="NLM_term">PHH</td><td class="NLM_def"><p class="first last">primary human hepatocyte</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PKR</td><td class="NLM_def"><p class="first last">protein kinase RNA-activated</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor</p></td></tr><tr><td class="NLM_term">PPIase</td><td class="NLM_def"><p class="first last">peptidyl prolyl <i>cis</i>/<i>trans</i>-isomerase</p></td></tr><tr><td class="NLM_term">PRR</td><td class="NLM_def"><p class="first last">pattern recognition receptor</p></td></tr><tr><td class="NLM_term">rcDNA</td><td class="NLM_def"><p class="first last">relaxed circular DNA</p></td></tr><tr><td class="NLM_term">RNase H</td><td class="NLM_def"><p class="first last">ribonuclease H</p></td></tr><tr><td class="NLM_term">RNAi</td><td class="NLM_def"><p class="first last">RNA interference</p></td></tr><tr><td class="NLM_term">RNP</td><td class="NLM_def"><p class="first last">ribonucleoprotein</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">reverse transcriptase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity index</p></td></tr><tr><td class="NLM_term">SMAC</td><td class="NLM_def"><p class="first last">second mitochondria-derived activator of caspases</p></td></tr><tr><td class="NLM_term">SOCS-1</td><td class="NLM_def"><p class="first last">suppressor of cytokine signaling-1</p></td></tr><tr><td class="NLM_term">SVP</td><td class="NLM_def"><p class="first last">subviral particle</p></td></tr><tr><td class="NLM_term">TAF</td><td class="NLM_def"><p class="first last">tenofovir alafenamide fumarate</p></td></tr><tr><td class="NLM_term">TDF</td><td class="NLM_def"><p class="first last">tenofovir disoproxil fumarate</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">TP</td><td class="NLM_def"><p class="first last">terminal protein</p></td></tr><tr><td class="NLM_term">uPA</td><td class="NLM_def"><p class="first last">urokinase-type plasminogen activator</p></td></tr><tr><td class="NLM_term">WHV</td><td class="NLM_def"><p class="first last">woodchuck hepatitis virus</p></td></tr><tr><td class="NLM_term">WMHBV</td><td class="NLM_def"><p class="first last">woolly monkey hepatitis B virus</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 190 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lavanchy, D.</span><span> </span><span class="NLM_article-title">Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.2003.00487.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1046%2Fj.1365-2893.2003.00487.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=14996343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gs1Whug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=97-107&author=D.+Lavanchy&title=Hepatitis+B+virus+epidemiology%2C+disease+burden%2C+treatment%2C+and+current+and+emerging+prevention+and+control+measures&doi=10.1046%2Fj.1365-2893.2003.00487.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures</span></div><div class="casAuthors">Lavanchy D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn">1352-0504</span>.
    </div><div class="casAbstract">Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection.  The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year.  In Western countries, the disease is relatively rare and acquired primarily in adulthood, whereas in Asia and most of Africa, chronic HBV infection is common and usually acquired perinatally or in childhood.  More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality.  Safe and effective vaccines against HBV infection have been available since 1982.  The implementation of mass immunization programs, which have been recommended by the World Health Organization since 1991, have dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries.  However, not all countries have adopted these recommendations and there remains a large number of persons that were infected with HBV prior to the implementation of immunization programs.  Antiviral treatment is the only way to reduce morbidity and mortality from chronic HBV infection.  Conventional interferon alfa and lamivudine have been the primary treatments to date.  Conventional interferon alfa produces a durable response in a moderate proportion of patients but has undesirable side-effects and must be administered subcutaneously three times per week.  Lamivudine also produces a response in a modest proportion of patients and causes few side-effects.  However, prolonged treatment is often necessary to prevent relapse on cessation of therapy, and continuous treatment can lead to the development of lamivudine resistance.  Promising emerging new treatments include adefovir, entecavir and peginterferon alfa-2a (40 kDa).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDqr0BBatWzy6Ufuk_1xoTfW6udTcc2eZIVZTRhJmj3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gs1Whug%253D%253D&md5=1f147336e831e56548fce6fb08b6cbae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.2003.00487.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.2003.00487.x%26sid%3Dliteratum%253Aachs%26aulast%3DLavanchy%26aufirst%3DD.%26atitle%3DHepatitis%2520B%2520virus%2520epidemiology%252C%2520disease%2520burden%252C%2520treatment%252C%2520and%2520current%2520and%2520emerging%2520prevention%2520and%2520control%2520measures%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2004%26volume%3D11%26spage%3D97%26epage%3D107%26doi%3D10.1046%2Fj.1365-2893.2003.00487.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection: epidemiology and vaccination</span> <span class="citation_source-journal">Epidemiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1093/epirev/mxj009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Fepirev%2Fmxj009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16754644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=112-125&author=C.+W.+Shepardauthor=E.+P.+Simardauthor=L.+Finelliauthor=A.+E.+Fioreauthor=B.+P.+Bell&title=Hepatitis+B+virus+infection%3A+epidemiology+and+vaccination&doi=10.1093%2Fepirev%2Fmxj009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection: epidemiology and vaccination</span></div><div class="casAuthors">Shepard Colin W; Simard Edgar P; Finelli Lyn; Fiore Anthony E; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiologic reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-25</span>
        ISSN:<span class="NLM_cas:issn">0193-936X</span>.
    </div><div class="casAbstract">Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.  This comprehensive review of hepatitis B epidemiology and vaccines focuses on definitive and influential studies and highlights current trends, policies, and directions.  HBV can be transmitted vertically, through sexual or household contact, or by unsafe injections, but chronic infections acquired during infancy or childhood account for a disproportionately large share of worldwide morbidity and mortality.  Vaccination against HBV infection can be started at birth and provides long-term protection against infection in more than 90% of healthy people.  In the 1990s, many industrialized countries and a few less-developed countries implemented universal hepatitis B immunization and experienced measurable reductions in HBV-related disease.  For example, in Taiwan, the prevalence of chronic infection in children declined by more than 90%.  Many resource-poor nations have recently initiated universal hepatitis B immunization programs with assistance from the Global Alliance for Vaccines and Immunization.  Further progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2UhAXwGC9Lv9pSBfyDvp7fW6udTcc2ebji2nA_4ta47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D&md5=59540288bd15ae148dc1b162c798c94b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fepirev%2Fmxj009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fepirev%252Fmxj009%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DSimard%26aufirst%3DE.%2BP.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DFiore%26aufirst%3DA.%2BE.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DHepatitis%2520B%2520virus%2520infection%253A%2520epidemiology%2520and%2520vaccination%26jtitle%3DEpidemiol.%2520Rev.%26date%3D2006%26volume%3D28%26spage%3D112%26epage%3D125%26doi%3D10.1093%2Fepirev%2Fmxj009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Beasley, R. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus. The major etiology of hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1942</span><span class="NLM_x">–</span> <span class="NLM_lpage">1956</span><span class="refDoi"> DOI: 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1988&pages=1942-1956&author=R.+P.+Beasley&title=Hepatitis+B+virus.+The+major+etiology+of+hepatocellular+carcinoma&doi=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252819880515%252961%253A10%253C1942%253A%253AAID-CNCR2820611003%253E3.0.CO%253B2-J%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%2BP.%26atitle%3DHepatitis%2520B%2520virus.%2520The%2520major%2520etiology%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%26date%3D1988%26volume%3D61%26spage%3D1942%26epage%3D1956%26doi%3D10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Michalak, T. I.</span><span> </span><span class="NLM_article-title">Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1034/j.1600-0528.2002.017406.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1034%2Fj.1600-0528.2002.017406.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10807510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD3cvgsVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2000&pages=98-111&author=T.+I.+Michalak&title=Occult+persistence+and+lymphotropism+of+hepadnaviral+infection%3A+insights+from+the+woodchuck+viral+hepatitis+model&doi=10.1034%2Fj.1600-0528.2002.017406.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model</span></div><div class="casAuthors">Michalak T I</div><div class="citationInfo"><span class="NLM_cas:title">Immunological reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-111</span>
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">Hepatitis B virus (HBV) is a major human pathogen that causes chronic infection and life-threatening liver diseases in millions of individuals.  While pathological and epidemiological consequences of clinically evident HBV infections are well recognized, there is no similar knowledge on an asymptomatic, silently progressing virus persistence.  Contrary to previous opinion, current evidence indicates that a serologically undetectable (occult) HBV carriage is a common outcome of recovery from symptomatic illness and that scanty amounts of the virus are carried by apparently healthy individuals for years after resolution of hepatitis B despite the presence of presumably protective antiviral antibodies.  Recent studies on this silent form of hepadnavirus carriage in an experimental woodchuck hepatitis virus (WHV) infection, which is considered to be the closest natural model of HBV disease, revealed that the life-long occult persistence of traces of pathogenic virus is an invariable consequence of recovery after hepadnaviral invasion and that this state always co-exists with a steady low-rate virus replication in both the liver and the lymphatic system.  Importantly, this serologically concealed infection can be accompanied by development of hepatocellular carcinoma in convalescent animals and is transmittable from mothers to offspring as an asymptomatic, indefinitely long infection which involves the lymphatic system but not always the liver.  This review focuses on the features of hepadnavirus occult persistence and its lymphotropism, and on what is currently understood about the contribution of the lymphatic system in maintaining hepadnavirus carriage based on insights provided by analysis of the woodchuck-WHV experimental system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpeS6vO_dxs_3jf77P2BG3fW6udTcc2ebji2nA_4ta47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvgsVanug%253D%253D&md5=341581a5b6c247cc816a1be5d9f782ee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0528.2002.017406.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0528.2002.017406.x%26sid%3Dliteratum%253Aachs%26aulast%3DMichalak%26aufirst%3DT.%2BI.%26atitle%3DOccult%2520persistence%2520and%2520lymphotropism%2520of%2520hepadnaviral%2520infection%253A%2520insights%2520from%2520the%2520woodchuck%2520viral%2520hepatitis%2520model%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D174%26spage%3D98%26epage%3D111%26doi%3D10.1034%2Fj.1600-0528.2002.017406.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bertoletti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, M. K.</span><span> </span><span class="NLM_article-title">Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span><span class="refDoi"> DOI: 10.1016/S0952-7915(00)00108-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0952-7915%2800%2900108-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10899021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=403-408&author=A.+Bertolettiauthor=M.+K.+Maini&title=Protection+or+damage%3A+a+dual+role+for+the+virus-specific+cytotoxic+T+lymphocyte+response+in+hepatitis+B+and+C+infection%3F&doi=10.1016%2FS0952-7915%2800%2900108-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?</span></div><div class="casAuthors">Bertoletti, Antonio; Maini, Mala K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-408</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 70 refs.  During infection with hepatitis B or C viruses, cytotoxic T lymphocytes (CTLs) have been implicated as both the mediators of protection and the principal effectors of liver pathol.  Recent studies have allowed an investigation of the relationship between virus-specific CTL responses, liver damage and viral replication.  In the presence of an efficient virus-specific CTL response, a scenario is emerging where inhibition of viral replication can be independent of liver pathol.  We discuss the possibility that an inadequate CTL response - unable to control viral replication - may contribute to liver pathol. not only directly but also via the recruitment of non-virus-specific T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXGd3dQL2XzrVg90H21EOLACvtfcHk0lhtKGNghD6kxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyltLo%253D&md5=a16f84e480753ae8abb58a09878c55d5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900108-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900108-4%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26atitle%3DProtection%2520or%2520damage%253A%2520a%2520dual%2520role%2520for%2520the%2520virus-specific%2520cytotoxic%2520T%2520lymphocyte%2520response%2520in%2520hepatitis%2520B%2520and%2520C%2520infection%253F%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D403%26epage%3D408%26doi%3D10.1016%2FS0952-7915%2800%2900108-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Urban, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span> </span><span class="NLM_article-title">The replication cycle of hepatitis B virus</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2009.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20056291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3c7gsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=282-284&author=S.+Urbanauthor=A.+Schulzeauthor=M.+Dandriauthor=J.+Petersen&title=The+replication+cycle+of+hepatitis+B+virus&doi=10.1016%2Fj.jhep.2009.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The replication cycle of hepatitis B virus</span></div><div class="casAuthors">Urban Stephan; Schulze Andreas; Dandri Maura; Petersen Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSRv8921fdzVQKX3ooHxWjfW6udTcc2eYI4I5HdrpR5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7gsVKjsw%253D%253D&md5=dd8f42e871a5977c29cdbda891040946</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DA.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26atitle%3DThe%2520replication%2520cycle%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2010%26volume%3D52%26spage%3D282%26epage%3D284%26doi%3D10.1016%2Fj.jhep.2009.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Chan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, I. O. L.</span><span> </span><span class="NLM_article-title">Knock-down of hepatitis B virus x protein reduces the tumorigenicity of hepatocellular carcinoma cells</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">208</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span><span class="refDoi"> DOI: 10.1002/path.1901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fpath.1901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16353167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2006&pages=372-380&author=D.+W.+Chanauthor=I.+O.+L.+Ng&title=Knock-down+of+hepatitis+B+virus+x+protein+reduces+the+tumorigenicity+of+hepatocellular+carcinoma+cells&doi=10.1002%2Fpath.1901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells</span></div><div class="casAuthors">Chan, David Wai; Ng, Irene Oi-lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC) in Southeast Asia and Hong Kong.  Among the four proteins that are encoded by the HBV genome, HBV X (HBx) is the most potentially oncogenic factor.  It is known that HBx plays an important role in hepatocarcinogenesis, but the exact functions and mol. mechanisms of HBx in HCC are not well understood.  In this study, we constructed expression vectors for small hairpin RNAs (shRNA) against HBx and investigated their regulatory effects in PLC/PRF/5 HCC cells, which constitutively produce HBx.  Our data show that this tool of RNA interference (RNAi) could successfully reduce the HBx mRNA and protein levels by 50-95%.  RNAi targeting HBx in PLC/PRF/5 cells demonstrated significant redn. in cell proliferation, cell growth, anchorage-independent growth in soft agar, and tumor development in nude mice.  In addn., depletion of HBx expression increased cell sensitivity to TNFα-mediated and serum-free-induced apoptosis, and reduced the expression levels of C-myc and Bcl-XL.  These findings suggest that HBx plays an important role in tumorigenicity and anti-apoptotic mechanisms in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlXznU7d4Z7Vg90H21EOLACvtfcHk0lhtKGNghD6kxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOntbs%253D&md5=bed2e3bb6e052b258324282f91287813</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fpath.1901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1901%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DNg%26aufirst%3DI.%2BO.%2BL.%26atitle%3DKnock-down%2520of%2520hepatitis%2520B%2520virus%2520x%2520protein%2520reduces%2520the%2520tumorigenicity%2520of%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D208%26spage%3D372%26epage%3D380%26doi%3D10.1002%2Fpath.1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Cui, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span> </span><span class="NLM_article-title">The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1002/pmic.200500218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fpmic.200500218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=498-504&author=F.+Cuiauthor=Y.+L.+Wangauthor=J.+Wangauthor=K.+K.+Weiauthor=J.+Q.+Huauthor=F.+Liuauthor=H.+L.+Wangauthor=X.+H.+Zhaoauthor=X.+M.+Zhangauthor=X.+Yang&title=The+up-regulation+of+proteasome+subunits+and+lysosomal+proteases+in+hepatocellular+carcinomas+of+the+HBx+gene+knockin+transgenic+mice&doi=10.1002%2Fpmic.200500218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fpmic.200500218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpmic.200500218%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%2BK.%26aulast%3DHu%26aufirst%3DJ.%2BQ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DZhao%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DThe%2520up-regulation%2520of%2520proteasome%2520subunits%2520and%2520lysosomal%2520proteases%2520in%2520hepatocellular%2520carcinomas%2520of%2520the%2520HBx%2520gene%2520knockin%2520transgenic%2520mice%26jtitle%3DProteomics%26date%3D2006%26volume%3D6%26spage%3D498%26epage%3D504%26doi%3D10.1002%2Fpmic.200500218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Park, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D. Y.</span><span> </span><span class="NLM_article-title">iNOS promotes HBx-induced hepatocellular carcinoma via upregulation of JNK activation</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.04.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bbrc.2013.04.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=244-249&author=Y.+H.+Parkauthor=H.+J.+Shinauthor=S.+U.+Kimauthor=J.+M.+Kimauthor=J.+H.+Kimauthor=D.+H.+Bangauthor=K.+T.+Changauthor=B.+Y.+Kimauthor=D.+Y.+Yu&title=iNOS+promotes+HBx-induced+hepatocellular+carcinoma+via+upregulation+of+JNK+activation&doi=10.1016%2Fj.bbrc.2013.04.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.04.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.04.071%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DShin%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BU.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DBang%26aufirst%3DD.%2BH.%26aulast%3DChang%26aufirst%3DK.%2BT.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DYu%26aufirst%3DD.%2BY.%26atitle%3DiNOS%2520promotes%2520HBx-induced%2520hepatocellular%2520carcinoma%2520via%2520upregulation%2520of%2520JNK%2520activation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D244%26epage%3D249%26doi%3D10.1016%2Fj.bbrc.2013.04.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. H.</span><span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e00049</span><span class="refDoi"> DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=e00049&author=H.+Yanauthor=G.+C.+Zhongauthor=G.+W.+Xuauthor=W.+H.+Heauthor=Z.+Y.+Jingauthor=Z.+C.+Gaoauthor=Y.+Huangauthor=Y.+H.+Qiauthor=B.+Pengauthor=H.+M.+Wangauthor=L.+R.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Q.+Gaoauthor=B.+J.+Renauthor=Y.+Y.+Sunauthor=T.+Caiauthor=X.+F.+Fengauthor=J.+H.+Suiauthor=W.+H.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0liuEMjZ3ASqPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DHe%26aufirst%3DW.%2BH.%26aulast%3DJing%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DFu%26aufirst%3DL.%2BR.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%2BQ.%26aulast%3DRen%26aufirst%3DB.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%2BF.%26aulast%3DSui%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DeLife%26date%3D2012%26volume%3D1%26spage%3De00049%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Guidotti, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immunobiology and pathogenesis of viral hepatitis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1146/annurev.pathol.1.110304.100230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1146%2Fannurev.pathol.1.110304.100230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18039107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=23-61&author=L.+G.+Guidottiauthor=F.+V.+Chisari&title=Immunobiology+and+pathogenesis+of+viral+hepatitis&doi=10.1146%2Fannurev.pathol.1.110304.100230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology and pathogenesis of viral hepatitis</span></div><div class="casAuthors">Guidotti, Luca G.; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV) and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause persistent infection, cirrhosis, and liver cancer.  HBV and HCV are noncytopathic viruses and, thus, immunol. mediated events play an important role in the pathogenesis and outcome of these infections.  The adaptive immune response mediates virtually all of the liver disease assocd. with viral hepatitis.  However, it is becoming increasingly clear that antigen-nonspecific inflammatory cells exacerbate cytotoxic T lymphocyte (CTL)-induced immunopathol. and that platelets enhance the accumulation of CTLs in the liver.  Chronic hepatitis is characterized by an inefficient T cell response unable to completely clear HBV or HCV from the liver, which consequently sustains continuous cycles of low-level cell destruction.  Over long periods of time, recurrent immune-mediated liver damage contributes to the development of cirrhosis and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eRjyvjhbi7Vg90H21EOLACvtfcHk0lgco4SsVfV1Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D&md5=c740de97e8b1d52a3e3f9e3e7be3bd89</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100230%26sid%3Dliteratum%253Aachs%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmunobiology%2520and%2520pathogenesis%2520of%2520viral%2520hepatitis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D23%26epage%3D61%26doi%3D10.1146%2Fannurev.pathol.1.110304.100230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollicino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">Control of cccDNA function in hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2009.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19616338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=581-592&author=M.+Levreroauthor=T.+Pollicinoauthor=J.+Petersenauthor=L.+Belloniauthor=G.+Raimondoauthor=M.+Dandri&title=Control+of+cccDNA+function+in+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2009.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cccDNA function in hepatitis B virus infection</span></div><div class="casAuthors">Levrero, Massimo; Pollicino, Teresa; Petersen, Jorg; Belloni, Laura; Raimondo, Giovanni; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA (cccDNA), plays a key role in the life cycle of the virus and permits the persistence of infection.  Novel mol. techniques have opened new possibilities to investigate the organization and the activity of the cccDNA minichromosome in vivo, and recent advances have started to shed light on the complexity of the mechanisms controlling cccDNA function.  Nuclear cccDNA accumulates in hepatocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins.  Identification of the mol. mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic levels in the course of chronic hepatitis B (CH-B) infection may reveal new potential therapeutic targets for anti-HBV drugs and hence assist in the design of strategies aimed at silencing and eventually depleting the cccDNA reservoir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04ONkDq_te7Vg90H21EOLACvtfcHk0lgco4SsVfV1Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D&md5=365616a92ba84ddc3cf7835162d3d900</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DPollicino%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DBelloni%26aufirst%3DL.%26aulast%3DRaimondo%26aufirst%3DG.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DControl%2520of%2520cccDNA%2520function%2520in%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D581%26epage%3D592%26doi%3D10.1016%2Fj.jhep.2009.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Dane, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M.</span><span> </span><span class="NLM_article-title">Virus like particles in serum of patients with Australia antigen associated hepatitis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1970</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span><span class="refDoi"> DOI: 10.1016/S0140-6736(70)90926-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0140-6736%2870%2990926-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=1970&pages=695-698&author=D.+S.+Daneauthor=C.+H.+Cameronauthor=M.+Briggs&title=Virus+like+particles+in+serum+of+patients+with+Australia+antigen+associated+hepatitis&doi=10.1016%2FS0140-6736%2870%2990926-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2870%2990926-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252870%252990926-8%26sid%3Dliteratum%253Aachs%26aulast%3DDane%26aufirst%3DD.%2BS.%26aulast%3DCameron%26aufirst%3DC.%2BH.%26aulast%3DBriggs%26aufirst%3DM.%26atitle%3DVirus%2520like%2520particles%2520in%2520serum%2520of%2520patients%2520with%2520Australia%2520antigen%2520associated%2520hepatitis%26jtitle%3DLancet%26date%3D1970%26volume%3D295%26spage%3D695%26epage%3D698%26doi%3D10.1016%2FS0140-6736%2870%2990926-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sells, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acs, G.</span><span> </span><span class="NLM_article-title">Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1009</span><span class="refDoi"> DOI: 10.1073/pnas.84.4.1005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.84.4.1005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=3029758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADyaL2sXhvV2qt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=1005-1009&author=M.+A.+Sellsauthor=M.+L.+Chenauthor=G.+Acs&title=Production+of+hepatitis+B+virus+particles+in+HepG2+cells+transfected+with+cloned+hepatitis+B+virus+DNA&doi=10.1073%2Fpnas.84.4.1005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA</span></div><div class="casAuthors">Sells, Mary Ann; Chen, Mei Ling; Acs, George</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The hepatoblastoma cell line Hep G2 was transfected with a plasmid carrying the gene that confers resistance to G418 and four 5'-3' tandem copies of the hepatitis B virus (HBV) genome positioned such that two dimers of the genomic DNA are 3'-3' with respect to one another.  Cells of one clone that grew in the presence of G418 produce high levels of hepatitis B e antigen and of hepatitis B surface antigen.  HBV DNA is carried by these cells as chromosomally integrated sequences and episomally as relaxed circular, covalently closed, and incomplete copies of the HBV genome.  Viral DNA was detected also in conditioned growth medium at the buoyant densities characteristic for infectious Dane and immature core particles.  Finally, HBV-specific components morphol. identical to the 22-nm spherical and filamentous hepatitis B surface antigen particles as well as 42-nm Dane particles were visualized by immunoelectron microscopic anal.  Therefore, the Hep G2 cell line can support the assembly and secretion not only of several of the replicative intermediates of HBV DNA but also of Dane-like particles.  This in vitro system can now be used to study the life cycle of HBV and the reaction of immunocompetent cells with cells carrying HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogbjqX6YU-W7Vg90H21EOLACvtfcHk0lgco4SsVfV1Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvV2qt7c%253D&md5=27744d6955d4701586243f651c79ab1e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.84.4.1005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.84.4.1005%26sid%3Dliteratum%253Aachs%26aulast%3DSells%26aufirst%3DM.%2BA.%26aulast%3DChen%26aufirst%3DM.%2BL.%26aulast%3DAcs%26aufirst%3DG.%26atitle%3DProduction%2520of%2520hepatitis%2520B%2520virus%2520particles%2520in%2520HepG2%2520cells%2520transfected%2520with%2520cloned%2520hepatitis%2520B%2520virus%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1987%26volume%3D84%26spage%3D1005%26epage%3D1009%26doi%3D10.1073%2Fpnas.84.4.1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Schulze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1989</span><span class="NLM_x">–</span> <span class="NLM_lpage">2000</span><span class="refDoi"> DOI: 10.1128/JVI.01902-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.01902-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20007265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FktFCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=1989-2000&author=A.+Schulzeauthor=A.+Schieckauthor=Y.+Niauthor=W.+Mierauthor=S.+Urban&title=Fine+mapping+of+pre-s+sequence+requirements+for+hepatitis+B+virus+large+envelope+protein-mediated+receptor+interaction&doi=10.1128%2FJVI.01902-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction</span></div><div class="casAuthors">Schulze Andreas; Schieck Alexa; Ni Yi; Mier Walter; Urban Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1989-2000</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Previous studies showed that the N-terminal 75 amino acids of the pre-S1 domain of the hepatitis B virus (HBV) L protein are essential for HBV and hepatitis delta virus (HDV) infectivity.  Consistently, synthetic lipopeptides encompassing this sequence or only parts of it efficiently block HBV and HDV infection, presumably through specific interference with a cellular receptor.  Crucial for both virus infectivity and the inhibitory activity of the peptides are N-terminal myristoylation and a highly conserved motif within the N-terminal 48 amino acids.  To refine the sequence requirements, we synthesized a series of HBV pre-S1 peptides containing deletions, point mutations, d-amino acid exchanges, or genotype-specific sequence permutations.  Using the HepaRG cell line and a genotype D-derived virus, we determined the specific inhibitory activities of the peptides and found that (i) lipopeptides with an artificial consensus sequence inhibit HBV genotype D infection more potently than the corresponding genotype D peptides; (ii) point mutations, d-amino acid exchanges, or deletions introduced into the highly conserved part of the pre-S1 domain result in an almost complete loss of activity; and (iii) the flanking sequences comprising amino acids 2 to 8, 16 to 20, and, to a less pronounced extent, 34 to 48 gradually increase the inhibitory activity, while amino acids 21 to 33 behave indifferently.  Taken together, our data suggest that HBV pre-S1-mediated receptor interference and, thus, HBV receptor recognition form a highly specific process.  It requires an N-terminal acyl moiety and a highly conserved sequence that is present in primate but not rodent or avian hepadnaviruses, indicating different entry pathways for the different family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJx3HykmhMWEHdcurJClFcfW6udTcc2eYJQJzjotw-y7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FktFCjsg%253D%253D&md5=aa57d5c4025f31b8cd3ecd29163b32b8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FJVI.01902-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01902-09%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DA.%26aulast%3DSchieck%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DFine%2520mapping%2520of%2520pre-s%2520sequence%2520requirements%2520for%2520hepatitis%2520B%2520virus%2520large%2520envelope%2520protein-mediated%2520receptor%2520interaction%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D1989%26epage%3D2000%26doi%3D10.1128%2FJVI.01902-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Le Duff, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span> </span><span class="NLM_article-title">The pre-s1 and antigenic loop infectivity determinants of the hepatitis B Virus envelope proteins are functionally independent</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">12443</span><span class="NLM_x">–</span> <span class="NLM_lpage">12451</span><span class="refDoi"> DOI: 10.1128/JVI.01594-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.01594-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19759159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=12443-12451&author=Y.+Le+Duffauthor=M.+Blanchetauthor=C.+Sureau&title=The+pre-s1+and+antigenic+loop+infectivity+determinants+of+the+hepatitis+B+Virus+envelope+proteins+are+functionally+independent&doi=10.1128%2FJVI.01594-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent</span></div><div class="casAuthors">Le Duff, Yann; Blanchet, Matthieu; Sureau, Camille</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12443-12451</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) envelope proteins bear two determinants of viral entry: a receptor-binding site (RBS) in the pre-S1 domain of the large envelope protein and a conformation-dependent determinant, of unknown function, in the antigenic loop (AGL) of the small, middle, and large envelope proteins.  Using an in vitro infection assay consisting of susceptible HepaRG cells and the hepatitis delta virus (HDV) as a surrogate of HBV, we first investigated whether subelements of the pre-S1 determinant (amino acids 2 to 75), i.e., the N-terminal myristoyl anchor, subdomain 2-48 (RBS), and subdomain 49-75, were functionally separable.  In transcomplementation expts., coexpression of two distinct infectivity-deficient pre-S1 mutants at the surface of HDV virions failed to restore infectivity, indicating that the myristoyl anchor, the 2-48 RBS, and the 49-75 sequence, likely cooperate in cis at viral entry.  Furthermore, we showed that as much as 52% of total pre-S1 in the HDV envelope could bear infectivity-deficient lesions without affecting entry, indicating that a small no. of pre-S1 polypeptides-estd. at three to four per virion-is sufficient for infectivity.  We next investigated the AGL activity in the small or large envelope protein background (S- and L-AGL, resp.) and found that lesions in S-AGL were more deleterious to infectivity than in L-AGL, a difference that reflects the relative stoichiometry of the small and large envelope proteins in the viral envelope.  Finally, we showed that C147S, an AGL infectivity-deficient substitution, exerted a dominant-neg. effect on infectivity, likely reflecting an involvement of C147 in intermol. disulfide bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAVXOMSWDoEbVg90H21EOLACvtfcHk0lgD2GgBh1PGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtLbM&md5=e29f64e8d0164e39b889d5f1c9856f4f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FJVI.01594-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01594-09%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDuff%26aufirst%3DY.%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26atitle%3DThe%2520pre-s1%2520and%2520antigenic%2520loop%2520infectivity%2520determinants%2520of%2520the%2520hepatitis%2520B%2520Virus%2520envelope%2520proteins%2520are%2520functionally%2520independent%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D12443%26epage%3D12451%26doi%3D10.1128%2FJVI.01594-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gripon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span><span class="refDoi"> DOI: 10.1128/JVI.79.3.1613-1622.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.79.3.1613-1622.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15650187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=1613-1622&author=P.+Griponauthor=I.+Cannieauthor=S.+Urban&title=Efficient+inhibition+of+hepatitis+B+virus+infection+by+acylated+peptides+derived+from+the+large+viral+surface+protein&doi=10.1128%2FJVI.79.3.1613-1622.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span></div><div class="casAuthors">Gripon, Philippe; Cannie, Isabelle; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1613-1622</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B virus (HBV) has prevented a mol. understanding of the early infection events of HBV.  We used the novel HBV-infectible cell line HepaRG and primary human hepatocytes to investigate the interference of infection by HBV envelope protein-derived peptides.  We found that a peptide consisting of the authentically myristoylated N-terminal 47 amino acids of the pre-S1 domain of the large viral envelope protein (L protein) specifically prevented HBV infection, with a 50% inhibitory concn. (IC50) of 8 nM.  The replacement of myristic acid with other hydrophobic moieties resulted in changes in the inhibitory activity, most notably by a decrease in the IC50 to picomolar concns. for longer unbranched fatty acids.  The obstruction of HepaRG cell susceptibility to HBV infection after short preincubation times with the peptides suggested that the peptides efficiently target and inactivate a receptor at the hepatocyte surface.  Our data both shed light on the mol. mechanism of HBV entry into hepatocytes and provide a basis for the development of potent hepadnaviral entry inhibitors as a novel therapeutic concept for the treatment of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ35R_8zOmS7Vg90H21EOLACvtfcHk0lgD2GgBh1PGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D&md5=519a08a82ce4de9e5db5692cf2a5ae80</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.3.1613-1622.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.3.1613-1622.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGripon%26aufirst%3DP.%26aulast%3DCannie%26aufirst%3DI.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DEfficient%2520inhibition%2520of%2520hepatitis%2520B%2520virus%2520infection%2520by%2520acylated%2520peptides%2520derived%2520from%2520the%2520large%2520viral%2520surface%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D1613%26epage%3D1622%26doi%3D10.1128%2FJVI.79.3.1613-1622.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutgehetmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Weizsacker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nbt1389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnbt1389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=335-341&author=J.+Petersenauthor=M.+Dandriauthor=W.+Mierauthor=M.+Lutgehetmannauthor=T.+Volzauthor=F.+Von+Weizsackerauthor=U.+Haberkornauthor=L.+Fischerauthor=J.+Pollokauthor=B.+Erbesauthor=S.+Seitzauthor=S.+Urban&title=Prevention+of+hepatitis+B+virus+infection+in+vivo+by+entry+inhibitors+derived+from+the+large+envelope+protein&doi=10.1038%2Fnbt1389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1389%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DLutgehetmann%26aufirst%3DM.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DVon%2BWeizsacker%26aufirst%3DF.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DPollok%26aufirst%3DJ.%26aulast%3DErbes%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%2520by%2520entry%2520inhibitors%2520derived%2520from%2520the%2520large%2520envelope%2520protein%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Fnbt1389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lempp, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkongolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stindt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koniger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sultmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2013.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24361467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=1070-1083&author=Y.+Niauthor=F.+A.+Lemppauthor=S.+Mehrleauthor=S.+Nkongoloauthor=C.+Kaufmanauthor=M.+Falthauthor=J.+Stindtauthor=C.+Konigerauthor=M.+Nassalauthor=R.+Kubitzauthor=H.+Sultmannauthor=S.+Urban&title=Hepatitis+B+and+D+viruses+exploit+sodium+taurocholate+co-transporting+polypeptide+for+species-specific+entry+into+hepatocytes&doi=10.1053%2Fj.gastro.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes</span></div><div class="casAuthors">Ni, Yi; Lempp, Florian A.; Mehrle, Stefan; Nkongolo, Shirin; Kaufman, Christina; Falth, Maria; Stindt, Jan; Koniger, Christian; Nassal, Michael; Kubitz, Ralf; Sultmann, Holger; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1083.e6</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells.  We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.  To identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naive cells, which do not.  Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines.  We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.  Bioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochem. approach is a bona fide receptor for HBV and HDV.  NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein.  Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV.  Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with DMSO.  We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.  Human NTCP is a specific receptor for HBV and HDV.  NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies.  Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxfIdRSMiSbVg90H21EOLACvtfcHk0lh2FEokIGIU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D&md5=9a6474af0ba645b685289066a35e972c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DFalth%26aufirst%3DM.%26aulast%3DStindt%26aufirst%3DJ.%26aulast%3DKoniger%26aufirst%3DC.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DHepatitis%2520B%2520and%2520D%2520viruses%2520exploit%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%2520for%2520species-specific%2520entry%2520into%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D1070%26epage%3D1083%26doi%3D10.1053%2Fj.gastro.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Blank, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carls, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2016.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27132172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=483-489&author=A.+Blankauthor=C.+Markertauthor=N.+Hohmannauthor=A.+Carlsauthor=G.+Mikusauthor=T.+Lehrauthor=A.+Alexandrovauthor=M.+Haagauthor=M.+Schwabauthor=S.+Urbanauthor=W.+E.+Haefeli&title=First-in-human+application+of+the+novel+hepatitis+B+and+hepatitis+D+virus+entry+inhibitor+myrcludex+B&doi=10.1016%2Fj.jhep.2016.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B</span></div><div class="casAuthors">Blank, Antje; Markert, Christoph; Hohmann, Nicolas; Carls, Alexandra; Mikus, Gerd; Lehr, Thorsten; Alexandrov, Alexander; Haag, Mathias; Schwab, Matthias; Urban, Stephan; Haefeli, Walter E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-489</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Myrcludex B is a first-in-class compd., which blocks entry of hepatitis B and D virus into hepatocytes in vitro and in animal models.  Based on the required preclin. data we aimed to translate this compd. into the first application in humans.Single ascending doses of myrcludex B, a 47 amino acid peptide, were administered up to 20 mg i.v. and 10 mg s.c. in a prospective open first-in-human, phase I clin. trial to 36 healthy volunteers.  Safety, tolerability and plasma concns. of myrcludex B were assessed and a pharmacokinetic model was derived.Myrcludex B was well tolerated and no serious or relevant AEs representing off-target effects, and no immunogenic effects were obsd. up to the highest applied dose of 20 mg (i.v.).  Myrcludex B showed dose-dependent pharmacokinetics, best described by a 2-compartment target-mediated drug disposition model.  Bioavailability of the s.c. application was large (85%).  Interindividual variability was moderate.  The pharmacokinetic model suggested that s.c. doses of 10 mg and above reach a target satn. of over 80% for at least 15 h.Myrcludex B showed excellent tolerability up to high doses.  Pharmacol. properties followed a 2-compartment target-mediated drug disposition model.  These findings are vital for planning of further multiple dose efficacy trials in patients.After showing antiviral activity in cell culture and animal models, myrcludex B, a new drug intended for the treatment of hepatitis B and D, has been administered the first time in humans.  Healthy volunteers received the drug i.v. and s.c. up to high doses (20 mg).  The drug was well tolerated and the characteristics of the drug detg. its way in the human body could be described.  These results will allow testing myrcludex B in hepatitis B and D patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoBJ0yS6pu7Vg90H21EOLACvtfcHk0lh2FEokIGIU9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2msrc%253D&md5=04a54ac56423c8692e19bd6baabff25b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DC.%26aulast%3DHohmann%26aufirst%3DN.%26aulast%3DCarls%26aufirst%3DA.%26aulast%3DMikus%26aufirst%3DG.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DHaag%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DFirst-in-human%2520application%2520of%2520the%2520novel%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520inhibitor%2520myrcludex%2520B%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D483%26epage%3D489%26doi%3D10.1016%2Fj.jhep.2016.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Nkongolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lempp, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser-Nobis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24295872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=723-731&author=S.+Nkongoloauthor=Y.+Niauthor=F.+A.+Lemppauthor=C.+Kaufmanauthor=T.+Lindnerauthor=K.+Esser-Nobisauthor=V.+Lohmannauthor=W.+Mierauthor=S.+Mehrleauthor=S.+Urban&title=Cyclosporin+A+inhibits+hepatitis+B+and+hepatitis+D+virus+entry+by+cyclophilin-independent+interference+with+the+NTCP+receptor&doi=10.1016%2Fj.jhep.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span></div><div class="casAuthors">Nkongolo, Shirin; Ni, Yi; Lempp, Florian A.; Kaufman, Christina; Lindner, Thomas; Esser-Nobis, Katharina; Lohmann, Volker; Mier, Walter; Mehrle, Stefan; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic hepatitis B and hepatitis D are global health problems caused by the human hepatitis B and hepatitis D virus.  The myristoylated preS1 domain of the large envelope protein mediates specific binding to hepatocytes by sodium taurocholate co-transporting polypeptide (NTCP).  NTCP is a bile salt transporter known to be inhibited by cyclosporin A.  This study aimed to characterize the effect of cyclosporin A on HBV/HDV infection.  HepaRG cells, primary human hepatocytes, and susceptible NTCP-expressing hepatoma cell lines were applied for infection expts.  The mode of action of cyclosporin A was studied by comparing the effect of different inhibitors, cyclophilin A/B/C-silenced cell lines as well as NTCP variants and mutants.  Bile salt transporter and HBV receptor functions were investigated by taurocholate uptake and quantification of HBVpreS binding.Cyclosporin A inhibited hepatitis B and D virus infections during and - less pronounced - prior to virus inoculation.  Binding of HBVpreS to NTCP was blocked by cyclosporin A concns. at 8 μM.  An NTCP variant deficient in HBVpreS binding but competent for bile salt transport showed resistance to cyclosporin A.  Silencing of cyclophilins A/B/C did not abrogate transporter and receptor inhibition.  In contrast, tacrolimus, a cyclophilin-independent calcineurin inhibitor, was inactive.HBV and HDV entry via sodium taurocholate co-transporting polypeptide is inhibited by cyclosporin A.  The interaction between the drug and the viral receptor is direct and overlaps with a functional binding site of the preS1 domain, which mediates viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTAVAhQe6_ErVg90H21EOLACvtfcHk0lgd1YTllQLSXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D&md5=d8c7e3698ac926cd5c06a9e7e2c4717b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DEsser-Nobis%26aufirst%3DK.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DCyclosporin%2520A%2520inhibits%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520by%2520cyclophilin-independent%2520interference%2520with%2520the%2520NTCP%2520receptor%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D723%26epage%3D731%26doi%3D10.1016%2Fj.jhep.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sluder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagamori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroto-Esoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuhara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakita, T.</span><span> </span><span class="NLM_article-title">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1726</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1002/hep.26982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.26982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24375637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1726-1737&author=K.+Watashiauthor=A.+Sluderauthor=T.+Daitoauthor=S.+Matsunagaauthor=A.+Ryoauthor=S.+Nagamoriauthor=M.+Iwamotoauthor=S.+Nakajimaauthor=S.+Tsukudaauthor=K.+Borroto-Esodaauthor=M.+Sugiyamaauthor=Y.+Tanakaauthor=Y.+Kanaiauthor=H.+Kusuharaauthor=M.+Mizokamiauthor=T.+Wakita&title=Cyclosporin+A+and+its+analogs+inhibit+hepatitis+B+virus+entry+into+cultured+hepatocytes+through+targeting+a+membrane+transporter%2C+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1002%2Fhep.26982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span></div><div class="casAuthors">Watashi, Koichi; Sluder, Ann; Daito, Takuji; Matsunaga, Satoko; Ryo, Akihide; Nagamori, Shushi; Iwamoto, Masashi; Nakajima, Syo; Tsukuda, Senko; Borroto-Esoda, Katyna; Sugiyama, Masaya; Tanaka, Yasuhito; Kanai, Yoshikatsu; Kusuhara, Hiroyuki; Mizokami, Masashi; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1726-1737</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide.  Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clin. available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets.  Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes.  The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin.  Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP).  We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not.  A series of compds. targeting NTCP could inhibit HBV infection.  CsA inhibited the binding between NTCP and large envelope protein in vitro.  Evaluation of CsA analogs identified a compd. with higher anti-HBV potency, having a median inhibitory concn. <0.2 μM.  Conclusion: This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatol. 2014;59:1726-1737).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV21kvExmObVg90H21EOLACvtfcHk0lgd1YTllQLSXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D&md5=d83ae63fbe3e8b827f9fbf5f6601b316</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fhep.26982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26982%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DBorroto-Esoda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DCyclosporin%2520A%2520and%2520its%2520analogs%2520inhibit%2520hepatitis%2520B%2520virus%2520entry%2520into%2520cultured%2520hepatocytes%2520through%2520targeting%2520a%2520membrane%2520transporter%252C%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1726%26epage%3D1737%26doi%3D10.1002%2Fhep.26982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Dong, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. E.</span><span> </span><span class="NLM_article-title">Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">–</span> <span class="NLM_lpage">1019</span><span class="refDoi"> DOI: 10.1021/mp300453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1008-1019&author=Z.+Q.+Dongauthor=S.+Ekinsauthor=J.+E.+Polli&title=Structure-activity+relationship+for+FDA+approved+drugs+as+inhibitors+of+the+human+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1021%2Fmp300453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP)</span></div><div class="casAuthors">Dong, Zhongqi; Ekins, Sean; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1019</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements.  The objectives of this study were (a) to identify FDA approved drugs that inhibit human NTCP, (b) to develop pharmacophore and Bayesian computational models for NTCP inhibition, and (c) to compare NTCP and ASBT transport inhibition requirements.  A series of NTCP inhibition studies were performed using FDA approved drugs, in concert with iterative computational model development.  Screening studies identified 27 drugs as novel NTCP inhibitors, including irbesartan (Ki = 11.9 μM) and ezetimibe (Ki = 25.0 μM).  The common feature pharmacophore indicated that two hydrophobes and one hydrogen bond acceptor were important for inhibition of NTCP.  From 72 drugs screened in vitro, a total of 31 drugs inhibited NTCP, while 51 drugs (i.e., more than half) inhibited ASBT.  Hence, while there was inhibitor overlap, ASBT unexpectedly was more permissive to drug inhibition than was NTCP, and this may be related to NTCP possessing fewer pharmacophore features.  Findings reflected that a combination of computational and in vitro approaches enriched the understanding of these poorly characterized transporters and yielded addnl. chem. probes for possible drug-transporter interaction detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGhpWyONrzbVg90H21EOLACvtfcHk0ljUXXbzNU_ZEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D&md5=0a0e0af7c8d1acb875ef8208c84f13c6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fmp300453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300453k%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%2BQ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DStructure-activity%2520relationship%2520for%2520FDA%2520approved%2520drugs%2520as%2520inhibitors%2520of%2520the%2520human%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1008%26epage%3D1019%26doi%3D10.1021%2Fmp300453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windisch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, W. S.</span><span> </span><span class="NLM_article-title">The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span><span class="refDoi"> DOI: 10.3851/IMP2965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2965" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=835-842&author=C.+Koauthor=W.+J.+Parkauthor=S.+Parkauthor=S.+Kimauthor=M.+P.+Windischauthor=W.+S.+Ryu&title=The+FDA-approved+drug+irbesartan+inhibits+HBV-infection+in+HepG2+cells+stably+expressing+sodium+taurocholate+co-transporting+polypeptide&doi=10.3851%2FIMP2965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3851%2FIMP2965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2965%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DW.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWindisch%26aufirst%3DM.%2BP.%26aulast%3DRyu%26aufirst%3DW.%2BS.%26atitle%3DThe%2520FDA-approved%2520drug%2520irbesartan%2520inhibits%2520HBV-infection%2520in%2520HepG2%2520cells%2520stably%2520expressing%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%26jtitle%3DAntiviral%2520Ther.%26date%3D2015%26volume%3D20%26spage%3D835%26epage%3D842%26doi%3D10.3851%2FIMP2965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Warner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">The new front-line in hepatitis B/D research: identification and blocking of a functional receptor</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1002/hep.26292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.26292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=9-12&author=N.+Warnerauthor=S.+Locarnini&title=The+new+front-line+in+hepatitis+B%2FD+research%3A+identification+and+blocking+of+a+functional+receptor&doi=10.1002%2Fhep.26292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fhep.26292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26292%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DN.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DThe%2520new%2520front-line%2520in%2520hepatitis%2520B%252FD%2520research%253A%2520identification%2520and%2520blocking%2520of%2520a%2520functional%2520receptor%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D9%26epage%3D12%26doi%3D10.1002%2Fhep.26292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23266293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=195-197&author=J.+Luciforaauthor=K.+Esserauthor=U.+Protzer&title=Ezetimibe+blocks+hepatitis+B+virus+infection+after+virus+uptake+into+hepatocytes&doi=10.1016%2Fj.antiviral.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span></div><div class="casAuthors">Lucifora, Julie; Esser, Knud; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current treatment of chronic hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases.  Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date.  Recently, entry of the hepatitis C virus (HCV) was shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, was shown to inhibit HCV infection.  We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG cells as a cell-culture infection model.  Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we obsd. no effect when the HBV viral genome was transduced via an adenoviral vector.  Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ1wQJ_RUkbVg90H21EOLACvtfcHk0liYvD-poXCUNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D&md5=dcfca7855b8cacdad584203e23690f85</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DEsser%26aufirst%3DK.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DEzetimibe%2520blocks%2520hepatitis%2520B%2520virus%2520infection%2520after%2520virus%2520uptake%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D97%26spage%3D195%26epage%3D197%26doi%3D10.1016%2Fj.antiviral.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Blanchet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labonte, P.</span><span> </span><span class="NLM_article-title">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24717262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=111-115&author=M.+Blanchetauthor=C.+Sureauauthor=P.+Labonte&title=Use+of+FDA+approved+therapeutics+with+hNTCP+metabolic+inhibitory+properties+to+impair+the+HDV+lifecycle&doi=10.1016%2Fj.antiviral.2014.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span></div><div class="casAuthors">Blanchet, Matthieu; Sureau, Camille; Labonte, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-115</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Worldwide there are approx. 240 million individuals chronically infected with the hepatitis B virus (HBV), including 15-20 million coinfected with the hepatitis delta virus (HDV).  Treatments available today are not fully efficient and often assocd. to important side effects and development of drug resistance.  Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008).  Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV.  This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections.  Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line.  We demonstrate the potential of three FDA approved mols., irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uuuK9vPHVbVg90H21EOLACvtfcHk0liYvD-poXCUNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D&md5=abe5262a9fa3fc4daaff030ae1a080c1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DP.%26atitle%3DUse%2520of%2520FDA%2520approved%2520therapeutics%2520with%2520hNTCP%2520metabolic%2520inhibitory%2520properties%2520to%2520impair%2520the%2520HDV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D111%26epage%3D115%26doi%3D10.1016%2Fj.antiviral.2014.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target</span> <span class="citation_source-journal">Drug Target Insights</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=9-18&author=K.+Watashiauthor=K.+Shimotohno&title=Cyclophilin+and+viruses%3A+cyclophilin+as+a+cofactor+for+viral+infection+and+possible+anti-viral+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DCyclophilin%2520and%2520viruses%253A%2520cyclophilin%2520as%2520a%2520cofactor%2520for%2520viral%2520infection%2520and%2520possible%2520anti-viral%2520target%26jtitle%3DDrug%2520Target%2520Insights%26date%3D2007%26volume%3D2%26spage%3D9%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Loor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenandy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, R.</span><span> </span><span class="NLM_article-title">Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 p-glycoprotein ABC transporter</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4598</span><span class="NLM_x">–</span> <span class="NLM_lpage">4612</span><span class="refDoi"> DOI: 10.1021/jm0109863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4598-4612&author=F.+Loorauthor=F.+O.+Tiberghienauthor=T.+Wenandyauthor=A.+Didierauthor=R.+Traber&title=Cyclosporins%3A+structure-activity+relationships+for+the+inhibition+of+the+human+MDR1+p-glycoprotein+ABC+transporter&doi=10.1021%2Fjm0109863"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm0109863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109863%26sid%3Dliteratum%253Aachs%26aulast%3DLoor%26aufirst%3DF.%26aulast%3DTiberghien%26aufirst%3DF.%2BO.%26aulast%3DWenandy%26aufirst%3DT.%26aulast%3DDidier%26aufirst%3DA.%26aulast%3DTraber%26aufirst%3DR.%26atitle%3DCyclosporins%253A%2520structure-activity%2520relationships%2520for%2520the%2520inhibition%2520of%2520the%2520human%2520MDR1%2520p-glycoprotein%2520ABC%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4598%26epage%3D4612%26doi%3D10.1021%2Fjm0109863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Xia, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S. S.</span><span> </span><span class="NLM_article-title">Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms</span> <span class="citation_source-journal">Hepatobiliary Pancreatic Dis. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15730912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=18-22&author=W.+L.+Xiaauthor=Y.+Shenauthor=S.+S.+Zheng&title=Inhibitory+effect+of+cyclosporine+A+on+hepatitis+B+virus+replication+in+vitro+and+its+possible+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms</span></div><div class="casAuthors">Xia, Wei-Liang; Shen, Yan; Zheng, Shu-Sen</div><div class="citationInfo"><span class="NLM_cas:title">Hepatobiliary & Pancreatic Diseases International</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-22</span>CODEN:
                <span class="NLM_cas:coden">HPDIAJ</span>;
        ISSN:<span class="NLM_cas:issn">1499-3872</span>.
    
            (<span class="NLM_cas:orgname">First Affiliated Hospital, Zhejiang University School of Medicine</span>)
        </div><div class="casAbstract">A review.  BACKGROUND: Hepatitis B related end-stage liver disease is recently acknowledged as one of the main indications for orthotopic liver transplantation (OLT).  However, the high recurrence rate of hepatitis B virus infection following transplantation is regarded as a major factor affecting the long-term survival of transplant recipients esp. in China.  Cyclosporine A (CsA), which is routinely used to prevent the allograft rejection, is reported to have the inhibitory activity on hepatitis B virus (HBV) replication in vitro.  In this paper, we review the inhibitory effect and its possible mechanisms of CsA on HBV replication in vitro.  DATA RESOURCES: An English-language literature search was conducted using MEDLINE (1990-2004) on cyclosporine A, hepatitis B virus, mitochondria, calcium and other related reports and review articles.  RESULTS: Hepatitis B x protein (HBx) is essential to HBV replication.  The cytosolic calcium signaling mediated by mitochondria and the Src kinase pathway were involved during HBx activation of HBV replication.  CsA inhibits the HBV replication in vitro by its binding to mitochondrial cyclophilin D, then blocking the mitochondria-mediated cytosolic calcium signaling.  The derivates of CsA also have the HBV replication inhibitory effect in vitro.  CONCLUSIONS: By interacting with mitochondria, preventing the release of intramitochondrial calcium, and then blocking the cytosolic calcium signaling, CsA inhibits the HBV replication in vitro.  The derivates of CsA also have this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsbBZ8LnoHSrVg90H21EOLACvtfcHk0lhycFg6mlAVLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWisrw%253D&md5=987868ed72067f9eefca9e891b9b6970</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%2BL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DS.%2BS.%26atitle%3DInhibitory%2520effect%2520of%2520cyclosporine%2520A%2520on%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vitro%2520and%2520its%2520possible%2520mechanisms%26jtitle%3DHepatobiliary%2520Pancreatic%2520Dis.%2520Int.%26date%3D2005%26volume%3D4%26spage%3D18%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Wang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Q.</span><span> </span><span class="NLM_article-title">Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2015&pages=140-146&author=X.+J.+Wangauthor=W.+Huauthor=T.+Y.+Zhangauthor=Y.+Y.+Maoauthor=N.+N.+Liuauthor=S.+Q.+Wang&title=Irbesartan%2C+an+FDA+approved+drug+for+hypertension+and+diabetic+nephropathy%2C+is+a+potent+inhibitor+for+hepatitis+B+virus+entry+by+disturbing+Na%2B-dependent+taurocholate+cotransporting+polypeptide+activity&doi=10.1016%2Fj.antiviral.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DT.%2BY.%26aulast%3DMao%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DN.%2BN.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3DIrbesartan%252C%2520an%2520FDA%2520approved%2520drug%2520for%2520hypertension%2520and%2520diabetic%2520nephropathy%252C%2520is%2520a%2520potent%2520inhibitor%2520for%2520hepatitis%2520B%2520virus%2520entry%2520by%2520disturbing%2520Na%252B-dependent%2520taurocholate%2520cotransporting%2520polypeptide%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D120%26spage%3D140%26epage%3D146%26doi%3D10.1016%2Fj.antiviral.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span> </span><span class="NLM_article-title">(−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=100-111&author=H.+C.+Huangauthor=M.+H.+Taoauthor=T.+M.+Hungauthor=J.+C.+Chenauthor=Z.+J.+Linauthor=C.+Huang&title=%28%E2%88%92%29-Epigallocatechin-3-gallate+inhibits+entry+of+hepatitis+B+virus+into+hepatocytes&doi=10.1016%2Fj.antiviral.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DTao%26aufirst%3DM.%2BH.%26aulast%3DHung%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DZ.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%26atitle%3D%2528%25E2%2588%2592%2529-Epigallocatechin-3-gallate%2520inhibits%2520entry%2520of%2520hepatitis%2520B%2520virus%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D111%26spage%3D100%26epage%3D111%26doi%3D10.1016%2Fj.antiviral.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Yeo, H.; Austin, D. J.; Li, L.; Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Antiviral helioxanthin analogs</span>. U.S. Patent no. 7754718, Jul 13,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Yeo&author=D.+J.+Austin&author=L.+Li&author=Y.+C.+Cheng&title=Antiviral+helioxanthin+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DH.%26atitle%3DAntiviral%2520helioxanthin%2520analogs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Cheng, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">New targets and inhibitors of HBV replication to combat drug resistance</span> <span class="citation_source-journal">J. Clin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">S147</span><span class="NLM_x">–</span> <span class="NLM_lpage">S150</span><span class="refDoi"> DOI: 10.1016/S1386-6532(05)80026-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1386-6532%2805%2980026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16461217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2005&pages=S147-S150&author=Y.+C.+Chengauthor=C.+X.+Yingauthor=C.+H.+Leungauthor=Y.+Li&title=New+targets+and+inhibitors+of+HBV+replication+to+combat+drug+resistance&doi=10.1016%2FS1386-6532%2805%2980026-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">New targets and inhibitors of HBV replication to combat drug resistance</span></div><div class="casAuthors">Cheng, Yung-Chi; Ying, Chun-Xiao; Leung, Chung-Hang; Li, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S147-S150</span>CODEN:
                <span class="NLM_cas:coden">JCVIFB</span>;
        ISSN:<span class="NLM_cas:issn">1386-6532</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  All the approved chemotherapeutic drugs for the treatment of HBV hepatitis are nucleoside analogs targeting on HBV DNA polymerase.  Drugs targeting on other viral unique targets are needed.  A new class of chems. with novel action against HBV replication was discovered.  A brief description of their mode of action is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmAx8Mv2pCzLVg90H21EOLACvtfcHk0lj3jVPov9-cWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGnu78%253D&md5=0ef8de832b8025c7fd088f2ca4cad080</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1386-6532%2805%2980026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1386-6532%252805%252980026-5%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%2BC.%26aulast%3DYing%26aufirst%3DC.%2BX.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DNew%2520targets%2520and%2520inhibitors%2520of%2520HBV%2520replication%2520to%2520combat%2520drug%2520resistance%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2005%26volume%3D34%26spage%3DS147%26epage%3DS150%26doi%3D10.1016%2FS1386-6532%2805%2980026-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ying, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robek, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">8526</span><span class="NLM_x">–</span> <span class="NLM_lpage">8531</span><span class="refDoi"> DOI: 10.1073/pnas.0609883104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0609883104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=8526-8531&author=C.+Yingauthor=Y.+Liauthor=C.+H.+Leungauthor=M.+D.+Robekauthor=Y.+C.+Cheng&title=Unique+antiviral+mechanism+discovered+in+anti-hepatitis+B+virus+research+with+a+natural+product+analogue&doi=10.1073%2Fpnas.0609883104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609883104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609883104%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DRobek%26aufirst%3DM.%2BD.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DUnique%2520antiviral%2520mechanism%2520discovered%2520in%2520anti-hepatitis%2520B%2520virus%2520research%2520with%2520a%2520natural%2520product%2520analogue%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D8526%26epage%3D8531%26doi%3D10.1073%2Fpnas.0609883104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yeo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullen, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutschman, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Synthesis and antiviral activity of helioxanthin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1021/jm034265a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034265a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCitbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=534-546&author=H.+Yeoauthor=Y.+Liauthor=L.+Fuauthor=J.+L.+Zhuauthor=E.+A.+Gullenauthor=G.+E.+Dutschmanauthor=Y.+Leeauthor=R.+Chungauthor=E.+S.+Huangauthor=D.+J.+Austinauthor=Y.+C.+Cheng&title=Synthesis+and+antiviral+activity+of+helioxanthin+analogues&doi=10.1021%2Fjm034265a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antiviral Activity of Helioxanthin Analogues</span></div><div class="casAuthors">Yeo, Hosup; Li, Ying; Fu, Lei; Zhu, Ju-Liang; Gullen, Elizabeth A.; Dutschman, Ginger E.; Lee, Yashang; Chung, Raymond; Huang, Eng-Shang; Austin, David J.; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of natural product analogs based on helioxanthin, with particular attention to modification of the lactone ring and methylenedioxy group, were synthesized and evaluated for their antiviral activities.  Among them, lactam deriv. I and helioxanthin cyclic hydrazide II exhibited significant in vitro antiviral activity against hepatitis B virus (EC50 = 0.08 and 0.03 μM, resp.).  Compd. I showed the most potent antiviral activity against hepatitis C virus (55% inhibition at 1.0 μM).  An acid-hydrolyzed product of helioxanthin cyclic imide deriv. was found to exhibit broad-spectrum antiviral activity against hepatitis B virus (EC50 = 0.8 μM), herpes simplex virus type 1 (EC50 = 0.15 μM) and type 2 (EC50 < 0.1 μM), Epstein-Barr virus (EC50 = 9.0 μM), and cytomegalovirus (EC50 = 0.45 μM).  Helioxanthin lactam deriv. I also showed marked inhibition of herpes simplex virus type 1 (EC50 = 0.29 μM) and type 2 (EC50 = 0.16 μM).  The cyclic hydrazide deriv. of helioxanthin II and its brominated product exhibited moderately potent activities against human immunodeficiency virus (EC50 = 2.7 and 2.5 μM, resp.).  Collectively, these mols. represent a novel set of antiviral compds. with unique structural features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA1Xk5HKEMKLVg90H21EOLACvtfcHk0lj3jVPov9-cWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCitbfK&md5=cd20af18bd272f6b1e8ea194ce66f596</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm034265a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034265a%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DGullen%26aufirst%3DE.%2BA.%26aulast%3DDutschman%26aufirst%3DG.%2BE.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DE.%2BS.%26aulast%3DAustin%26aufirst%3DD.%2BJ.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DSynthesis%2520and%2520antiviral%2520activity%2520of%2520helioxanthin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D534%26epage%3D546%26doi%3D10.1021%2Fjm034265a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1177/095632020501600305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1177%2F095632020501600305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16004082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=193-201&author=Y.+Liauthor=L.+Fuauthor=H.+Yeoauthor=J.+L.+Zhuauthor=C.+K.+Chouauthor=Y.+H.+Kouauthor=S.+F.+Yehauthor=E.+Gullenauthor=D.+Austinauthor=Y.+C.+Cheng&title=Inhibition+of+hepatitis+B+virus+gene+expression+and+replication+by+helioxanthin+and+its+derivative&doi=10.1177%2F095632020501600305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative</span></div><div class="casAuthors">Li, Ying; Fu, Lei; Yeo, Hosup; Zhu, Ju-Liang; Chou, Chen-Kung; Kou, Yueh-Hsiung; Yeh, Sheau-Farn; Gullen, Elizabeth; Austin, David; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-201</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection continues to be an important worldwide cause of morbidity and mortality.  All the currently approved therapeutic drugs have their limitations: interferon-α (IFN-α) has limited efficacy and a high incidence of adverse effects; nucleoside analogs are very efficient HBV DNA inhibitors, but resistance occurs eventually.  Therefore, it is important to develop new nonnucleoside/nucleotide agents with different modes of action that can be used for antiviral combination therapy.  Here, the authors report on a novel class of compds., helioxanthin and its deriv. 5-4-2, which had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 μM, resp.  The lamivudine-resistant HBV, L526M/M550V double mutant strain, was also sensitive to helioxanthin and 5-4-2.  This class of compds. not only inhibited HBV DNA, but also decreased HBV mRNA and HBV protein expression.  The EC50 of HBV DNA inhibition was consistent with the EC50 of HBV 3.5 Kb transcript inhibition, which was 1 and 0.09 μM for helioxanthin and 5-4-2 resp.  Western blot anal. of cell lysate from HepG2.2.15 cells showed that the core protein expression decreased in a dose-dependent manner after drug treatment.  In conclusion, helioxanthin and 5-4-2 are potentially unique new anti-HBV agents, which possess a different mechanism of action from existing therapeutic drugs.  Both compds. inhibited HBV RNA and protein expression in addn. to inhibiting HBV DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCAqB4xiNNrVg90H21EOLACvtfcHk0lhCfChhX7pDEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsrk%253D&md5=00e3b23f39429cb610227ffaefc812d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F095632020501600305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600305%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYeo%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DKou%26aufirst%3DY.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26aulast%3DGullen%26aufirst%3DE.%26aulast%3DAustin%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520gene%2520expression%2520and%2520replication%2520by%2520helioxanthin%2520and%2520its%2520derivative%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D193%26epage%3D201%26doi%3D10.1177%2F095632020501600305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Janmanchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhuang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of helioxanthin analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2163</span><span class="NLM_x">–</span> <span class="NLM_lpage">2176</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2012.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2163-2176&author=D.+Janmanchiauthor=C.+H.+Linauthor=J.+Y.+Hsiehauthor=Y.+P.+Tsengauthor=T.+A.+Chenauthor=H.+J.+Jhuangauthor=S.+F.+Yeh&title=Synthesis+and+biological+evaluation+of+helioxanthin+analogues&doi=10.1016%2Fj.bmc.2012.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DJanmanchi%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DHsieh%26aufirst%3DJ.%2BY.%26aulast%3DTseng%26aufirst%3DY.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BA.%26aulast%3DJhuang%26aufirst%3DH.%2BJ.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520helioxanthin%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2163%26epage%3D2176%26doi%3D10.1016%2Fj.bmc.2012.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Tseng, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janmanchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span> </span><span class="NLM_article-title">The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=206-214&author=Y.+P.+Tsengauthor=Y.+H.+Kuoauthor=C.+P.+Huauthor=K.+S.+Jengauthor=D.+Janmanchiauthor=C.+H.+Linauthor=C.+K.+Chouauthor=S.+F.+Yeh&title=The+role+of+helioxanthin+in+inhibiting+human+hepatitis+B+viral+replication+and+gene+expression+by+interfering+with+the+host+transcriptional+machinery+of+viral+promoters&doi=10.1016%2Fj.antiviral.2007.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DY.%2BP.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DHu%26aufirst%3DC.%2BP.%26aulast%3DJeng%26aufirst%3DK.%2BS.%26aulast%3DJanmanchi%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26atitle%3DThe%2520role%2520of%2520helioxanthin%2520in%2520inhibiting%2520human%2520hepatitis%2520B%2520viral%2520replication%2520and%2520gene%2520expression%2520by%2520interfering%2520with%2520the%2520host%2520transcriptional%2520machinery%2520of%2520viral%2520promoters%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D206%26epage%3D214%26doi%3D10.1016%2Fj.antiviral.2007.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, R. W.</span><span> </span><span class="NLM_article-title">Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1720</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1715-1720&author=S.+K.+Ladnerauthor=M.+J.+Ottoauthor=C.+S.+Barkerauthor=K.+Zaifertauthor=G.+H.+Wangauthor=J.+T.+Guoauthor=C.+Seegerauthor=R.+W.+King&title=Inducible+expression+of+human+hepatitis+B+virus+%28HBV%29+in+stably+transfected+hepatoblastoma+cells%3A+a+novel+system+for+screening+potential+inhibitors+of+HBV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DBarker%26aufirst%3DC.%2BS.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DSeeger%26aufirst%3DC.%26aulast%3DKing%26aufirst%3DR.%2BW.%26atitle%3DInducible%2520expression%2520of%2520human%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520in%2520stably%2520transfected%2520hepatoblastoma%2520cells%253A%2520a%2520novel%2520system%2520for%2520screening%2520potential%2520inhibitors%2520of%2520HBV%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D1715%26epage%3D1720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span> </span><span class="NLM_article-title">Antiviral therapies and prospects for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">a021501</span><span class="refDoi"> DOI: 10.1101/cshperspect.a021501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1101%2Fcshperspect.a021501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25833942" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021501&author=F.+Zoulimauthor=D.+Durantel&title=Antiviral+therapies+and+prospects+for+a+cure+of+chronic+hepatitis+B&doi=10.1101%2Fcshperspect.a021501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021501%26sid%3Dliteratum%253Aachs%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520therapies%2520and%2520prospects%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021501%26doi%3D10.1101%2Fcshperspect.a021501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">You, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. K.</span><span> </span><span class="NLM_article-title">Update on hepatitis B virus infection</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">13293</span><span class="NLM_x">–</span> <span class="NLM_lpage">13305</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i37.13293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.v20.i37.13293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25309066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKntrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=13293-13305&author=C.+R.+Youauthor=S.+W.+Leeauthor=J.+W.+Jangauthor=S.+K.+Yoon&title=Update+on+hepatitis+B+virus+infection&doi=10.3748%2Fwjg.v20.i37.13293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Update on hepatitis B virus infection</span></div><div class="casAuthors">You, Chan Ran; Lee, Sung Won; Jang, Jeong Won; Yoon, Seung Kew</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13293-13305</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic infection with hepatitis B virus (HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure.  Despite extensive research, the immunopathogenesis is not completely understood.  Viral persistence and clin. outcomes following HBV infection depend on viral factors and host factors; including genetic factors that det. a host's immune mechanisms.  The primary goal of chronic hepatitis B (CHB) treatment is to eradicate HBV or to at least maintain suppression of HBV replication.  Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve.  Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogs (NAs).  Although NAs are safe, effective and easily administered orally, their long-term use poses the risk of drug resistance.  Currently, international evidence-based guidelines have been developed to support physicians in managing CHB patients.  However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur.  In addn., as the currently available genotypic test for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virol. test to overcome this limitation is necessary.  Among the predictive factors assocd. with response to pegylated interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN.  Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients.  To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virol. response.  This review highlights recent advances in the understanding of the immunopathogenesis of HBV and currently available and developing treatment strategies against HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4R2NC4R1obVg90H21EOLACvtfcHk0lhn91vUTa9FOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKntrbE&md5=bae4ee7caaed772318f0389455a409b2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i37.13293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i37.13293%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DJ.%2BW.%26aulast%3DYoon%26aufirst%3DS.%2BK.%26atitle%3DUpdate%2520on%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D13293%26epage%3D13305%26doi%3D10.3748%2Fwjg.v20.i37.13293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span> </span><span class="NLM_article-title">Combination therapy for chronic hepatitis B: simultaneous or sequential?</span> <span class="citation_source-journal">Am. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1111/j.1572-0241.2006.00997.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1572-0241.2006.00997.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17266690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVOms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=105-106&author=M.+F.+Yuenauthor=C.+L.+Lai&title=Combination+therapy+for+chronic+hepatitis+B%3A+simultaneous+or+sequential%3F&doi=10.1111%2Fj.1572-0241.2006.00997.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for chronic hepatitis B: simultaneous or sequential?</span></div><div class="casAuthors">Yuen, Man-Fung; Lai, Ching-Lung</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-106</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Various regimens of combination or sequential therapy using nucleoside/nucleotide analogs (NAs) and interferon-alfa (IFN-α) have been tried for the treatment of chronic hepatitis B.  To date, combination therapy of two NAs and of IFN-α and NAs fails to achieve extra viral suppression.  Sequential therapy with lamivudine followed by IFN-α seems to have better sustained virol. response.  However, the long-term beneficial effect of using this approach remains to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk8v-2Z8oF47Vg90H21EOLACvtfcHk0lhn91vUTa9FOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVOms7c%253D&md5=4605865f7b978e249cb8dc797df21bcf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2006.00997.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2006.00997.x%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DLai%26aufirst%3DC.%2BL.%26atitle%3DCombination%2520therapy%2520for%2520chronic%2520hepatitis%2520B%253A%2520simultaneous%2520or%2520sequential%253F%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2007%26volume%3D102%26spage%3D105%26epage%3D106%26doi%3D10.1111%2Fj.1572-0241.2006.00997.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Takamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohgo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venzon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashi-Kuwata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delino, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukenaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haraguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarafianos, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">4-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1024</span><span class="NLM_x">–</span> <span class="NLM_lpage">1036</span><span class="refDoi"> DOI: 10.1002/hep.27962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.27962" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1024-1036&author=Y.+Takamatsuauthor=Y.+Tanakaauthor=S.+Kohgoauthor=S.+Murakamiauthor=K.+Singhauthor=D.+Dasauthor=D.+J.+Venzonauthor=M.+Amanoauthor=N.+Higashi-Kuwataauthor=M.+Aokiauthor=N.+S.+Delinoauthor=S.+Hayashiauthor=S.+Takahashiauthor=Y.+Sukenagaauthor=K.+Haraguchiauthor=S.+G.+Sarafianosauthor=K.+Maedaauthor=H.+Mitsuya&title=4-modified+nucleoside+analogs%3A+potent+inhibitors+active+against+entecavir-resistant+hepatitis+B+virus&doi=10.1002%2Fhep.27962"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fhep.27962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27962%26sid%3Dliteratum%253Aachs%26aulast%3DTakamatsu%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKohgo%26aufirst%3DS.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DVenzon%26aufirst%3DD.%2BJ.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DHigashi-Kuwata%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DDelino%26aufirst%3DN.%2BS.%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DSukenaga%26aufirst%3DY.%26aulast%3DHaraguchi%26aufirst%3DK.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3D4-modified%2520nucleoside%2520analogs%253A%2520potent%2520inhibitors%2520active%2520against%2520entecavir-resistant%2520hepatitis%2520B%2520virus%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1024%26epage%3D1036%26doi%3D10.1002%2Fhep.27962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Li, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfredson, T.</span><span> </span><span class="NLM_article-title">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1002/jps.21047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fjps.21047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17696166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=1109-1134&author=F.+J.+Liauthor=H.+Maagauthor=T.+Alfredson&title=Prodrugs+of+nucleoside+analogues+for+improved+oral+absorption+and+tissue+targeting&doi=10.1002%2Fjps.21047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span></div><div class="casAuthors">Li Fujun; Maag Hans; Alfredson Tom</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1109-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">Nucleoside analogues are widely used for the treatment of antiviral infections and anticancer chemotherapy.  However, many nucleoside analogues suffer from poor oral bioavailability due to their high polarity and low intestinal permeability.  In order to improve oral absorption of these polar drugs, prodrugs have been employed to increase lipophilicity by chemical modification of the parent.  Alternatively, prodrugs targeting transporters present in the intestine have been exploited to facilitate the transport of the nucleoside analogues.  Valacyclovir and valganciclovir are two successful valine ester prodrugs transported by the PepT1 transporter.  Recently, research efforts have focused on design of prodrugs for tissue specific delivery to improve efficacy and safety.  This review presents advances of prodrug approaches for improved oral absorption of nucleoside analogues and recent developments in tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-KOBK65zide2qxNLjzXe8fW6udTcc2eZppPp8q4_FXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D&md5=ed6aeaf75134be8bc9ef23a89b673b80</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjps.21047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21047%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BJ.%26aulast%3DMaag%26aufirst%3DH.%26aulast%3DAlfredson%26aufirst%3DT.%26atitle%3DProdrugs%2520of%2520nucleoside%2520analogues%2520for%2520improved%2520oral%2520absorption%2520and%2520tissue%2520targeting%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D1109%26epage%3D1134%26doi%3D10.1002%2Fjps.21047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Painter, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trost, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampert, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De-Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beadle, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostetler, K. Y.</span><span> </span><span class="NLM_article-title">Evaluation of hexadecyloxypropyl-9-R-2-(phosphonomethoxy)propyl adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3505</span><span class="NLM_x">–</span> <span class="NLM_lpage">3509</span><span class="refDoi"> DOI: 10.1128/AAC.00460-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00460-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3505-3509&author=G.+R.+Painterauthor=M.+R.+Almondauthor=L.+C.+Trostauthor=B.+M.+Lampertauthor=J.+Neytsauthor=E.+De-Clercqauthor=B.+E.+Korbaauthor=K.+A.+Aldernauthor=J.+R.+Beadleauthor=K.+Y.+Hostetler&title=Evaluation+of+hexadecyloxypropyl-9-R-2-%28phosphonomethoxy%29propyl+adenine%2C+CMX157%2C+as+a+potential+treatment+for+human+immunodeficiency+virus+type+1+and+hepatitis+B+virus+infections&doi=10.1128%2FAAC.00460-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.00460-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00460-07%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DAlmond%26aufirst%3DM.%2BR.%26aulast%3DTrost%26aufirst%3DL.%2BC.%26aulast%3DLampert%26aufirst%3DB.%2BM.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe-Clercq%26aufirst%3DE.%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DAldern%26aufirst%3DK.%2BA.%26aulast%3DBeadle%26aufirst%3DJ.%2BR.%26aulast%3DHostetler%26aufirst%3DK.%2BY.%26atitle%3DEvaluation%2520of%2520hexadecyloxypropyl-9-R-2-%2528phosphonomethoxy%2529propyl%2520adenine%252C%2520CMX157%252C%2520as%2520a%2520potential%2520treatment%2520for%2520human%2520immunodeficiency%2520virus%2520type%25201%2520and%2520hepatitis%2520B%2520virus%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3505%26epage%3D3509%26doi%3D10.1128%2FAAC.00460-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Murakami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babusis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span> </span><span class="NLM_article-title">Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3569</span><span class="refDoi"> DOI: 10.1128/AAC.00128-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00128-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25870059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFCqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3563-3569&author=E.+Murakamiauthor=T.+Wangauthor=Y.+Parkauthor=J.+Haoauthor=E.+I.+Lepistauthor=D.+Babusisauthor=A.+S.+Ray&title=Implications+of+efficient+hepatic+delivery+by+tenofovir+alafenamide+%28GS-7340%29+for+hepatitis+B+virus+therapy&doi=10.1128%2FAAC.00128-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B Virus therapy</span></div><div class="casAuthors">Murakami, Eisuke; Wang, Ting; Park, Yeojin; Hao, Jia; Lepist, Eve-Irene; Babusis, Darius; Ray, Adrian S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3563-3569</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tenofovir alafenamide (TAF) is a prodrug of tenofovir (TFV) currently in clin. evaluation for treatment for HIV and hepatitis B virus (HBV) infections.  Since the target tissue for HBV is the liver, the hepatic delivery and metab. of TAF in primary human hepatocytes in vitro and in dogs in vivo were evaluated here.  Incubation of primary human hepatocytes with TAF resulted in high levels of the pharmacol. active metabolite tenofovir diphosphate (TFV-DP), which persisted in the cell with a half life of > 24 h.  In addn. to passive permeability, studies of transfected cell lines suggest that the hepatic uptake of TAF is also facilitated by the org. anion-transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3, resp.).  In order to inhibit HBV reverse transcriptase, TAF must be converted to the pharmacol. active form, TFV-DP.  While cathepsin A is known to be the major enzyme hydrolyzing TAF in cells targeted by HIV, including lymphocytes and macrophages, TAF was primarily hydrolyzed by carboxylesterase 1 (CES1) in primary human hepatocytes, with cathepsin A making a small contribution.  Following oral administration of TAF to dogs for 7 days, TAF was rapidly absorbed.  The appearance of the major metabolite TFV in plasma was accompanied by a rapid decline in circulating TAF.  Consistent with the in vitro data, high and persistent levels of TFV-DP were obsd. in dog livers.  Notably, higher liver TFV-DP levels were obsd. after administration of TAF than those given TDF.  These results support the clin. testing of once-daily low-dose TAF for the treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeY0bOfccxebVg90H21EOLACvtfcHk0lhmHgaWHioUhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFCqur4%253D&md5=f09a7f5420215dd0a626aedf57933be6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FAAC.00128-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00128-15%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DLepist%26aufirst%3DE.%2BI.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DRay%26aufirst%3DA.%2BS.%26atitle%3DImplications%2520of%2520efficient%2520hepatic%2520delivery%2520by%2520tenofovir%2520alafenamide%2520%2528GS-7340%2529%2520for%2520hepatitis%2520B%2520virus%2520therapy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3563%26epage%3D3569%26doi%3D10.1128%2FAAC.00128-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span> </span><span class="NLM_article-title">Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2014.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25450717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFCjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=533-540&author=K.+Agarwalauthor=S.+K.+Fungauthor=T.+T.+Nguyenauthor=W.+Chengauthor=E.+Sicardauthor=S.+D.+Ryderauthor=J.+F.+Flahertyauthor=E.+Lawsonauthor=S.+Zhaoauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=E.+J.+Ganeauthor=G.+R.+Foster&title=Twenty-eight+day+safety%2C+antiviral+activity%2C+and+pharmacokinetics+of+tenofovir+alafenamide+for+treatment+of+chronic+hepatitis+B+infection&doi=10.1016%2Fj.jhep.2014.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection</span></div><div class="casAuthors">Agarwal, Kosh; Fung, Scott K.; Nguyen, Tuan T.; Cheng, Wendy; Sicard, Eric; Ryder, Stephen D.; Flaherty, John F.; Lawson, Eileen; Zhao, Sally; Subramanian, G. Mani; McHutchison, John G.; Gane, Edward J.; Foster, Graham R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug to hepatocytes at reduced systemic tenofovir exposures.  Non-cirrhotic, treatment-na.ovrddot.ive subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 wk.51 subjects were randomized and all completed study treatment.  Groups were generally well matched (67% male, 57% Asian, 53% HBeAg-neg., mean HBV DNA approx. 6.0 log10 IU/mL) with HBV genotypes reflective of the population.  No subject experienced an adverse event that was serious or severe (grade 3/4).  Across the tenofovir alafenamide groups, similar mean changes in serum HBV DNA were found at Week 4 (-2.81, -2.55, -2.19, and -2.76 log10 IU/mL for the 8, 25, 40, and 120 mg groups, resp.) which were also comparable to the control (-2.68 log10 IU/mL for tenofovir disoproxil fumarate 300 mg).  Kinetics of viral decline were also similar among groups.  Tenofovir alafenamide pharmacokinetics were linear and proportional to the dose; doses ≤25 mg were assocd. with ≥92% redns. in mean tenofovir area under the curve relative to tenofovir disoproxil fumarate 300 mg.  Tenofovir alafenamide was safe and well tolerated; declines in HBV DNA were similar to tenofovir disoproxil fumarate at all doses evaluated.  Tenofovir alafenamide 25 mg has been selected for further hepatitis B clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKrJztqILtfbVg90H21EOLACvtfcHk0lgzmDRvXT7YmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFCjsr0%253D&md5=da729a4b4fe0b19430e2dbe14282bc9a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DFung%26aufirst%3DS.%2BK.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DSicard%26aufirst%3DE.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DFlaherty%26aufirst%3DJ.%2BF.%26aulast%3DLawson%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26atitle%3DTwenty-eight%2520day%2520safety%252C%2520antiviral%2520activity%252C%2520and%2520pharmacokinetics%2520of%2520tenofovir%2520alafenamide%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D533%26epage%3D540%26doi%3D10.1016%2Fj.jhep.2014.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Tavis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michailidis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurora, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parniak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarafianos, S. G.</span><span> </span><span class="NLM_article-title">The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003125</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1003125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.ppat.1003125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23349632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVOrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003125&author=J.+E.+Tavisauthor=X.+H.+Chengauthor=Y.+Huauthor=M.+Tottenauthor=F.+Caoauthor=E.+Michailidisauthor=R.+Auroraauthor=M.+J.+Meyersauthor=E.+J.+Jacobsenauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=The+hepatitis+B+virus+ribonuclease+H+is+sensitive+to+inhibitors+of+the+human+immunodeficiency+virus+ribonuclease+H+and+integrase+enzymes&doi=10.1371%2Fjournal.ppat.1003125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes</span></div><div class="casAuthors">Tavis, John E.; Cheng, Xiaohong; Hu, Yuan; Totten, Michael; Cao, Feng; Michailidis, Eleftherios; Aurora, Rajeev; Meyers, Marvin J.; Jacobsen, E. Jon; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1003125</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects.  The profound suppression of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of extinction.  Consequently, more patients could be cured by suppressing HBV replication further using a new drug in combination with the nucleos(t)ide analogs.  The HBV RNase H (RNAseH) is a logical drug target because it is the second of only two viral enzymes that are essential for viral replication, but it has not been exploited, primarily because it is very difficult to produce active enzyme.  To address this difficulty, we expressed HBV genotype D and H RNAseHs in E. coli and enriched the enzymes by nickel-affinity chromatog.  HBV RNAseH activity in the enriched lysates was characterized in prepn. for drug screening.  Twenty-one candidate HBV RNAseH inhibitors were identified using chem. structureactivity analyses based on inhibitors of the HIV RNAseH and integrase.  Twelve anti-RNAseH and anti-integrase compds. inhibited the HBV RNAseH at 10 μM, the best compds. had low micromolar IC50 values against the RNAseH and one compd. inhibited HBV replication in tissue culture at 10 μM.  Recombinant HBV genotype D RNAseH was more sensitive to inhibition than genotype H.  This study demonstrates that recombinant HBV RNAseH suitable for low-throughput antiviral drug screening has been produced.  The high percentage of compds. developed against the HIV RNAseH and integrase that were active against the HBV RNAseH indicates that the extensive drug design efforts against these HIV enzymes can guide anti-HBV RNAseH drug discovery.  Finally, differential inhibition of HBV genotype D and H RNAseHs indicates that viral genetic variability will be a factor during drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoFFUjTDO7rVg90H21EOLACvtfcHk0lgzmDRvXT7YmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVOrsbg%253D&md5=f7841946904e4fe9ae6cc7a7b4502de5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003125%26sid%3Dliteratum%253Aachs%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTotten%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DF.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DAurora%26aufirst%3DR.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DThe%2520hepatitis%2520B%2520virus%2520ribonuclease%2520H%2520is%2520sensitive%2520to%2520inhibitors%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520ribonuclease%2520H%2520and%2520integrase%2520enzymes%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26spage%3De1003125%26doi%3D10.1371%2Fjournal.ppat.1003125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Lu, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomonosova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Grice, S. F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Erasmo, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suyabatmaz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murelli, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1079</span><span class="refDoi"> DOI: 10.1128/AAC.04617-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.04617-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25451058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Kqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1070-1079&author=G.+F.+Luauthor=E.+Lomonosovaauthor=X.+H.+Chengauthor=E.+A.+Moranauthor=M.+J.+Meyersauthor=S.+F.+J.+Le+Griceauthor=C.+J.+Thomasauthor=J.+K.+Jiangauthor=C.+Meckauthor=D.+R.+Hirschauthor=M.+P.+D%E2%80%99Erasmoauthor=D.+M.+Suyabatmazauthor=R.+P.+Murelliauthor=J.+E.+Tavis&title=Hydroxylated+tropolones+inhibit+hepatitis+B+virus+replication+by+blocking+viral+ribonuclease+H+activity&doi=10.1128%2FAAC.04617-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity</span></div><div class="casAuthors">Lu, Gaofeng; Lomonosova, Elena; Cheng, Xiaohong; Moran, Eileen A.; Meyers, Marvin J.; Le Grice, Stuart F. J.; Thomas, Craig J.; Jiang, Jian-kang; Meck, Christine; Hirsch, Danielle R.; D'Erasmo, Michael P.; Suyabatmaz, Duygu M.; Murelli, Ryan P.; Tavis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1070-1079, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) remains a major human pathogen despite the development of both antiviral drugs and a vaccine, in part because the current therapies do not suppress HBV replication far enough to eradicate the virus.  Here, we screened 51 troponoid compds. for their ability to suppress HBV RNaseH activity and HBV replication based on the activities of α-hydroxytropolones against HIV RNaseH, with the goal of detg. whether the tropolone pharmacophore may be a promising scaffold for anti-HBV drug development.  Thirteen compds. inhibited HBV RNaseH, with the best 50% inhibitory concn. (IC50) being 2.3 μM.  Similar inhibition patterns were obsd. against HBV genotype D and C RNaseHs, implying limited genotype specificity.  Six of 10 compds. tested against HBV replication in culture suppressed replication via blocking of viral RNaseH activity, with the best 50% effective concn. (EC50) being 0.34 μM.  Eighteen compds. inhibited recombinant human RNaseH1, and moderate cytotoxicity was obsd. for all compds. (50% cytotoxic concn. [CC50] = 25 to 79 μM).  Therapeutic indexes ranged from 3.8 to 94.  Efficient inhibition required an intact α-hydroxytropolone moiety plus one or more short appendages on the tropolone ring, but a wide variety of constituents were permissible.  These data indicate that troponoids and specifically α-hydroxytropolones are promising lead candidates for development as anti-HBV drugs, providing that toxicity can be minimized.  Potential anti-RNaseH drugs are envisioned to be employed in combination with the existing nucleos(t)ide analogs to suppress HBV replication far enough to block genomic maintenance, with the goal of eradicating infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpknK2lLWuF87Vg90H21EOLACvtfcHk0lgz8I7ZNqNVFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Kqsrg%253D&md5=ad57f43a17b6aaf4a68a5912a7e72c1e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1128%2FAAC.04617-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04617-14%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%2BF.%26aulast%3DLomonosova%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DMoran%26aufirst%3DE.%2BA.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DLe%2BGrice%26aufirst%3DS.%2BF.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DMeck%26aufirst%3DC.%26aulast%3DHirsch%26aufirst%3DD.%2BR.%26aulast%3DD%25E2%2580%2599Erasmo%26aufirst%3DM.%2BP.%26aulast%3DSuyabatmaz%26aufirst%3DD.%2BM.%26aulast%3DMurelli%26aufirst%3DR.%2BP.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DHydroxylated%2520tropolones%2520inhibit%2520hepatitis%2520B%2520virus%2520replication%2520by%2520blocking%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1070%26epage%3D1079%26doi%3D10.1128%2FAAC.04617-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Beta-thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2013.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2013.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2013&pages=221-229&author=Y.+Huauthor=X.+H.+Chengauthor=F.+Caoauthor=A.+L.+Huangauthor=J.+E.+Tavis&title=Beta-thujaplicinol+inhibits+hepatitis+B+virus+replication+by+blocking+the+viral+ribonuclease+H+activity&doi=10.1016%2Fj.antiviral.2013.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DCao%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DA.%2BL.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DBeta-thujaplicinol%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520blocking%2520the%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D99%26spage%3D221%26epage%3D229%26doi%3D10.1016%2Fj.antiviral.2013.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Cai, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomonosova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24858512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=48-55&author=C.+W.+Caiauthor=E.+Lomonosovaauthor=E.+A.+Moranauthor=X.+H.+Chengauthor=K.+B.+Patelauthor=F.+Baillyauthor=P.+Cotelleauthor=M.+J.+Meyersauthor=J.+E.+Tavis&title=Hepatitis+B+virus+replication+is+blocked+by+a+2-hydroxyisoquinoline-1%2C3%282H%2C4H%29-dione+%28HID%29+inhibitor+of+the+viral+ribonuclease+H+activity&doi=10.1016%2Fj.antiviral.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity</span></div><div class="casAuthors">Cai, Catherine W.; Lomonosova, Elena; Moran, Eileen A.; Cheng, Xiaohong; Patel, Kunjan B.; Bailly, Fabrice; Cotelle, Philippe; Meyers, Marvin J.; Tavis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-55</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog drugs profoundly suppress Hepatitis B virus (HBV) replication but rarely cure the infection, so therapy is usually life-long.  The nucleos(t)ide analogs inhibit the viral DNA polymerase and often push HBV to the brink of extinction, so it may be possible to eradicate HBV by suppressing HBV replication further.  The HBV RNase H (RNaseH) is a logical new drug target because it is the second of only two viral enzymes essential for viral replication.  We recently developed a low throughput screening pipeline for inhibitors of the HBV RNaseH and viral replication.  Here, we screened a series of twenty-three nitrogen-based polyoxygenated heterocycles including sixteen 2-hydroxyisoquinoline-1,3(2H,4H)-dione derivs. for anti-HBV RNaseH activity.  Nine compds. inhibited the HBV RNaseH, but activity was marginal for eight of them.  Compd. #1 [2-hydroxyisoquinoline-1,3(2H,4H)-dione, HID] was the best hit with an IC50 of 28.1 μM and an EC50 of 4.2 μM.  It preferentially suppressed accumulation of the viral plus-polarity DNA strand in replication inhibition assays, indicating that replication was blocked due to suppression of HBV RNaseH activity.  It had a CC50 of 75 μM, yielding a therapeutic index of ∼18.  The EC50 value was 7-fold lower than the IC50, possibly due to cellular retention or metab. of the compd., or higher affinity for the full-length enzyme than the recombinant form used for screening.  These data indicate that the 2-hydroxyisoquinoline-1,3(2H,4H)-diones will have different structure-activity relationships for the HBV and HIV RNaseHs.  Therefore, HID compds. may provide a foundation for development of more effective RNaseH inhibitors of HBV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJVUWhOxXkALVg90H21EOLACvtfcHk0lgz8I7ZNqNVFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGqsrnE&md5=790a7c0b6496897f62a68cbcfc747135</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DC.%2BW.%26aulast%3DLomonosova%26aufirst%3DE.%26aulast%3DMoran%26aufirst%3DE.%2BA.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DPatel%26aufirst%3DK.%2BB.%26aulast%3DBailly%26aufirst%3DF.%26aulast%3DCotelle%26aufirst%3DP.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DHepatitis%2520B%2520virus%2520replication%2520is%2520blocked%2520by%2520a%25202-hydroxyisoquinoline-1%252C3%25282H%252C4H%2529-dione%2520%2528HID%2529%2520inhibitor%2520of%2520the%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D108%26spage%3D48%26epage%3D55%26doi%3D10.1016%2Fj.antiviral.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Bruss, V.</span><span> </span><span class="NLM_article-title">Envelopment of the hepatitis B virus nucleocapsid</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1016/j.virusres.2004.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.virusres.2004.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15567498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVantLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2004&pages=199-209&author=V.+Bruss&title=Envelopment+of+the+hepatitis+B+virus+nucleocapsid&doi=10.1016%2Fj.virusres.2004.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Envelopment of the hepatitis B virus nucleocapsid</span></div><div class="casAuthors">Bruss, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis B virus (HBV) is an enveloped DNA virus with an icosahedral capsid replicating via reverse transcription.  The crystal structure of the capsid is known.  It has a diam. of 36 nm and is formed by one protein species (C protein).  The viral envelope contains three different coterminal proteins (S, M, and L proteins) spanning the membrane several times.  These proteins are not only released from infected cells as components of the viral envelope but in 10,000-fold excess as subviral lipoprotein particles with a diam. of 22 nm contg. no capsid.  Assembly of the capsid occurs in the cytosol and results in packaging of a 3.5 kb RNA mol. together with viral and cellular factors.  This newly formed capsid cannot be enveloped.  Rather, synthesis of the viral DNA genome in the lumen of the capsid by reverse transcription is required to induce a budding competent state.  Envelopment then takes place at an intracellular membrane of the pre-Golgi compartment.  The S and the L protein, but not the M protein, is required for this process.  The L protein forms two different transmembrane topologies.  The isoform exposing the N-terminal part at the cytosolic side of the membrane is essential for budding.  In this domain, a 22 amino acid (aa) long linear stretch has been mapped genetically to play a vital role in the morphogenetic process.  This domain probably mediates the contact to the capsid.  A second matrix domain was mapped to the cytosolic loop of the S protein.  A similar genetic approach identified two small areas on the capsid surface, which might interact with the envelope proteins during envelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxadiOhpcOhLVg90H21EOLACvtfcHk0lggWRW2qx2fgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVantLnO&md5=b5355066968d9553b30d27d3dd48e307</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2004.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2004.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DV.%26atitle%3DEnvelopment%2520of%2520the%2520hepatitis%2520B%2520virus%2520nucleocapsid%26jtitle%3DVirus%2520Res.%26date%3D2004%26volume%3D106%26spage%3D199%26epage%3D209%26doi%3D10.1016%2Fj.virusres.2004.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Chain, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span> </span><span class="NLM_article-title">Variability and conservation in hepatitis B virus core protein</span> <span class="citation_source-journal">BMC Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1186/1471-2180-5-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1186%2F1471-2180-5-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15649330" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1-14&author=B.+M.+Chainauthor=R.+Myers&title=Variability+and+conservation+in+hepatitis+B+virus+core+protein&doi=10.1186%2F1471-2180-5-33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1471-2180-5-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2180-5-33%26sid%3Dliteratum%253Aachs%26aulast%3DChain%26aufirst%3DB.%2BM.%26aulast%3DMyers%26aufirst%3DR.%26atitle%3DVariability%2520and%2520conservation%2520in%2520hepatitis%2520B%2520virus%2520core%2520protein%26jtitle%3DBMC%2520Microbiol.%26date%3D2005%26volume%3D5%26spage%3D1%26epage%3D14%26doi%3D10.1186%2F1471-2180-5-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Zlotnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewellyn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S.</span><span> </span><span class="NLM_article-title">Core protein: a pleiotropic keystone in the HBV lifecycle</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26129969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=82-93&author=A.+Zlotnickauthor=B.+Venkatakrishnanauthor=Z.+N.+Tanauthor=E.+Lewellynauthor=W.+Turnerauthor=S.+Francis&title=Core+protein%3A+a+pleiotropic+keystone+in+the+HBV+lifecycle&doi=10.1016%2Fj.antiviral.2015.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Core protein: A pleiotropic keystone in the HBV lifecycle</span></div><div class="casAuthors">Zlotnick, Adam; Venkatakrishnan, Balasubramanian; Tan, Zhenning; Lewellyn, Eric; Turner, William; Francis, Samson</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-93</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B Virus (HBV) is a small virus whose genome has only four open reading frames.  We argue that the simplicity of the virion correlates with a complexity of functions for viral proteins.  We focus on the HBV core protein (Cp), a small (183 residue) protein that self-assembles to form the viral capsid.  However, its functions are a little more complicated than that.  In an infected cell Cp modulates almost every step of the viral lifecycle.  Cp is bound to nuclear viral DNA and affects its epigenetics.  Cp correlates with RNA specificity.  Cp assembles specifically on a reverse transcriptase-viral RNA complex or, apparently, nothing at all.  Indeed Cp has been one of the model systems for investigation of virus self-assembly.  Cp participates in regulation of reverse transcription.  Cp signals completion of reverse transcription to support virus secretion.  Cp carries both nuclear localization signals and HBV surface antigen (HBsAg) binding sites; both of these functions appear to be regulated by contents of the capsid.  Cp can be targeted by antivirals - while self-assembly is the most accessible of Cp activities, we argue that it makes sense to engage the broader spectrum of Cp function.  This article forms part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyafN5HJZSQLVg90H21EOLACvtfcHk0lggWRW2qx2fgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM&md5=e1bd58b97219cb54136dbb2db2fadb70</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DZ.%2BN.%26aulast%3DLewellyn%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DS.%26atitle%3DCore%2520protein%253A%2520a%2520pleiotropic%2520keystone%2520in%2520the%2520HBV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D82%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2015.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagelschur, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruebsamen-Waigmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlfeil, S.</span><span> </span><span class="NLM_article-title">Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/S0166-3542(01)00216-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0166-3542%2801%2900216-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12062392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=69-78&author=O.+Weberauthor=K.+H.+Schlemmerauthor=E.+Hartmannauthor=I.+Hagelschurauthor=A.+Paessensauthor=E.+Graefauthor=K.+Deresauthor=S.+Goldmannauthor=U.+Niewoehnerauthor=J.+Stoltefussauthor=D.+Haebichauthor=H.+Ruebsamen-Waigmannauthor=S.+Wohlfeil&title=Inhibition+of+human+hepatitis+B+virus+%28HBV%29+by+a+novel+non-nucleosidic+compound+in+a+transgenic+mouse+model&doi=10.1016%2FS0166-3542%2801%2900216-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model</span></div><div class="casAuthors">Weber, O.; Schlemmer, K.-H.; Hartmann, E.; Hagelschuer, Ina; Paessens, A.; Graef, E.; Deres, K.; Goldmann, S.; Niewoehner, U.; Stoltefuss, J.; Haebich, D.; Ruebsamen-Waigmann, H.; Wohlfeil, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-78</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">BAY 41-4109 is a member of a class of heteroaryl-pyrimidines that was recently identified as potent inhibitors of human hepatitis B virus (HBV) replication.  We have investigated the antiviral activity of BAY 41-4109 (Me (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylate) in HBV-transgenic mice (Tg [HBV1.3 fsX-3'5']).  Bay 41-4109 was administered per os using different schedules (b.i.d. or t.i.d. for up to 28 days) and dosages ranging from 3 to 30 mg/kg.  The compd. reduced viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC.  In contrast to 3TC-treated mice, we found a redn. of cytoplasmic hepatitis B virus core antigen (HBcAg) in liver sections of BAY 41-4109-treated mice, which indicated a different mode of action.  Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concns.  We conclude that BAY 41-4109 is a new anti-HBV drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj4XpaXvzGrVg90H21EOLACvtfcHk0lggWRW2qx2fgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVShsLg%253D&md5=bae520cd731096858f86f4ce28674231</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2801%2900216-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252801%252900216-9%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHartmann%26aufirst%3DE.%26aulast%3DHagelschur%26aufirst%3DI.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DNiewoehner%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRuebsamen-Waigmann%26aufirst%3DH.%26aulast%3DWohlfeil%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520human%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520by%2520a%2520novel%2520non-nucleosidic%2520compound%2520in%2520a%2520transgenic%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2002%26volume%3D54%26spage%3D69%26epage%3D78%26doi%3D10.1016%2FS0166-3542%2801%2900216-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacker, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewohner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koletzki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masantschek, R. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubsamen-Waigmann, H.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.1126/science.1077215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1077215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12574631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=893-896&author=K.+Deresauthor=C.+H.+Schroderauthor=A.+Paessensauthor=S.+Goldmannauthor=H.+J.+Hackerauthor=O.+Weberauthor=T.+Kramerauthor=U.+Niewohnerauthor=U.+Pleissauthor=J.+Stoltefussauthor=E.+Graefauthor=D.+Koletzkiauthor=R.+N.+A.+Masantschekauthor=A.+Reimannauthor=R.+Jaegerauthor=R.+Grossauthor=B.+Beckermannauthor=K.+H.+Schlemmerauthor=D.+Haebichauthor=H.+Rubsamen-Waigmann&title=Inhibition+of+hepatitis+B+virus+replication+by+drug-induced+depletion+of+nucleocapsids&doi=10.1126%2Fscience.1077215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids</span></div><div class="casAuthors">Deres, Karl; Schroeder, Claus H.; Paessens, Arnold; Goldmann, Siegfried; Hacker, Hans Joerg; Weber, Olaf; Kraemer, Thomas; Niewoehner, Ulrich; Pleiss, Ulrich; Stoltefuss, Juergen; Graef, Erwin; Koletzki, Diana; Masantschek, Ralf N. A.; Reimann, Anja; Jaeger, Rainer; Gro, Rainer; Beckermann, Bernhard; Schlemmer, Karl-Heinz; Haebich, Dieter; Ruebsamen-Waigmann, Helga</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5608</span>),
    <span class="NLM_cas:pages">893-896</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major cause of liver disease.  Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy.  However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors.  Potent new antiviral compds. suitable for monotherapy or combination therapy are highly desired.  We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity.  These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlJUFASSEhLVg90H21EOLACvtfcHk0liFOMQPPGohFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D&md5=a5e74b45d335f74ba17ec9fe4d31e24b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1126%2Fscience.1077215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1077215%26sid%3Dliteratum%253Aachs%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DSchroder%26aufirst%3DC.%2BH.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DHacker%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DKoletzki%26aufirst%3DD.%26aulast%3DMasantschek%26aufirst%3DR.%2BN.%2BA.%26aulast%3DReimann%26aufirst%3DA.%26aulast%3DJaeger%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DBeckermann%26aufirst%3DB.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRubsamen-Waigmann%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520drug-induced%2520depletion%2520of%2520nucleocapsids%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D893%26epage%3D896%26doi%3D10.1126%2Fscience.1077215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Stray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">BAY 41–4109 has multiple effects on Hepatitis B virus capsid assembly</span> <span class="citation_source-journal">J. Mol. Recognit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1002/jmr.801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fjmr.801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17006877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=542-548&author=S.+J.+Strayauthor=A.+Zlotnick&title=BAY+41%E2%80%934109+has+multiple+effects+on+Hepatitis+B+virus+capsid+assembly&doi=10.1002%2Fjmr.801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Recognition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JMORE4</span>;
        ISSN:<span class="NLM_cas:issn">0952-3499</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Here we report the effect of a heteroaryldihydropyrimidine (HAP) antiviral compd., BAY 41-4109, on Hepatitis B virus (HBV) capsid assembly and on preformed HBV capsids.  The HBV capsid is an icosahedral complex of 120 capsid protein dimers.  BAY41-4109 inhibits virus prodn. in vivo by a mechanism that targets the viral capsid.  We found that BAY 41-4109 was able to both accelerate and misdirect capsid assembly in vitro.  As little as one HAP mol. for every five HBV dimers was sufficient to induce formation of non-capsid polymers.  Unlike the related mol. HAP-1, no stable assembly intermediates were obsd. in assembly reactions with BAY 41-4109, indicating that accelerated assembly by BAY 41-4109 was still kinetically regulated by the nucleation rate.  Preformed capsids were stabilized by BAY 41-4109, up to a ratio of one inhibitor mol. per two dimers.  However, at BAY 41-4109:dimer ratios of 1:1 and greater, capsids were destabilized to yield very large noncapsid polymers.  These data suggest the existence of two functionally distinguishable classes of drug-binding sites on HBV capsids.  Occupation of the first class of site stabilizes capsid, while binding at the second class requires or induces structural changes that cannot be tolerated without destabilizing the capsid.  Our data suggest that HAP compds. may inhibit virus replication by inducing assembly inappropriately and, when in excess, by misdirecting assembly decreasing the stability of normal capsids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorOaQz7SajJrVg90H21EOLACvtfcHk0liFOMQPPGohFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D&md5=15c132fcc380b09f691561adf737fbd3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjmr.801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.801%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DBAY%252041%25E2%2580%25934109%2520has%2520multiple%2520effects%2520on%2520Hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2006%26volume%3D19%26spage%3D542%26epage%3D548%26doi%3D10.1002%2Fjmr.801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Stray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">8138</span><span class="NLM_x">–</span> <span class="NLM_lpage">8143</span><span class="refDoi"> DOI: 10.1073/pnas.0409732102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0409732102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15928089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsV2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=8138-8143&author=S.+J.+Strayauthor=C.+R.+Bourneauthor=S.+Punnaauthor=W.+G.+Lewisauthor=M.+G.+Finnauthor=A.+Zlotnick&title=A+heteroaryldihydropyrimidine+activates+and+can+misdirect+hepatitis+B+virus+capsid+assembly&doi=10.1073%2Fpnas.0409732102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Bourne, Christina R.; Punna, Sreenivas; Lewis, Warren G.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8138-8143</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heteroaryldihydropyrimidines (HAPs) are a new class of antivirals inhibiting prodn. of hepatitis B virus (HBV) virions in tissue culture.  Here, we examine the effect of a representative HAP mol., Me 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP-1), on the in vitro assembly of HBV capsid protein (Cp).  HAP-1 enhances the rate and extent of Cp assembly over a broad concn. range.  Aberrant particles, dominated by hexagonal arrays of Cp, were obsd. from assembly reactions with high HAP-1 concns.  HAP-1 also led to dissocn. of metastable HBV capsids, overcoming a kinetic barrier to dissocn. by scavenging Cp and redirecting its assembly into hexamer-rich structures.  Thus, HAP drugs act as allosteric effectors that induce an assembly-active state and, at high concn., preferentially stabilize noncapsid polymers of Cp.  HAP compds. may have multiple effects in vivo stemming from inappropriate assembly of Cp.  These results show that activating and deregulating virus assembly may be a powerful general approach for antiviral therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IO3o_Hqhk7Vg90H21EOLACvtfcHk0liRW1_Q2zgmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsV2msbc%253D&md5=30abe296011a5e771047ce4fdc0343a8</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0409732102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0409732102%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DPunna%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DW.%2BG.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DA%2520heteroaryldihydropyrimidine%2520activates%2520and%2520can%2520misdirect%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D8138%26epage%3D8143%26doi%3D10.1073%2Fpnas.0409732102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span> </span><span class="NLM_article-title">The novel compound Z060228 inhibits assembly of the HBV capsid</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1016/j.lfs.2015.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.lfs.2015.04.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2015&pages=1-7&author=H.+Guanauthor=G.+Zhaoauthor=W.+Chenauthor=G.+Wuauthor=H.+Liuauthor=X.+Jiangauthor=S.+Liauthor=L.+L.+Wang&title=The+novel+compound+Z060228+inhibits+assembly+of+the+HBV+capsid&doi=10.1016%2Fj.lfs.2015.04.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2015.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2015.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BL.%26atitle%3DThe%2520novel%2520compound%2520Z060228%2520inhibits%2520assembly%2520of%2520the%2520HBV%2520capsid%26jtitle%3DLife%2520Sci.%26date%3D2015%26volume%3D133%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.lfs.2015.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. S.</span><span> </span><span class="NLM_article-title">In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.3851/IMP2152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=793-803&author=X.+Y.+Wangauthor=Z.+M.+Weiauthor=G.+Y.+Wuauthor=J.+H.+Wangauthor=Y.+J.+Zhangauthor=J.+Liauthor=H.+H.+Zhangauthor=X.+W.+Xieauthor=X.+Wangauthor=Z.+H.+Wangauthor=L.+Weiauthor=Y.+Wangauthor=H.+S.+Chen&title=In+vitro+inhibition+of+HBV+replication+by+a+novel+compound%2C+GLS4%2C+and+its+efficacy+against+adefovir-dipivoxil-resistant+HBV+mutations&doi=10.3851%2FIMP2152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3851%2FIMP2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2152%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DZ.%2BM.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DXie%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%2BS.%26atitle%3DIn%2520vitro%2520inhibition%2520of%2520HBV%2520replication%2520by%2520a%2520novel%2520compound%252C%2520GLS4%252C%2520and%2520its%2520efficacy%2520against%2520adefovir-dipivoxil-resistant%2520HBV%2520mutations%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D793%26epage%3D803%26doi%3D10.3851%2FIMP2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baydo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abendroth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O. A.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">15196</span><span class="NLM_x">–</span> <span class="NLM_lpage">15201</span><span class="refDoi"> DOI: 10.1073/pnas.1513803112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1513803112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26598693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15196-15201&author=K.+Klumppauthor=A.+M.+Lamauthor=C.+Lukacsauthor=R.+Vogelauthor=S.+P.+Renauthor=C.+Espirituauthor=R.+Baydoauthor=K.+Atkinsauthor=J.+Abendrothauthor=G.+C.+Liaoauthor=A.+Efimovauthor=G.+Hartmanauthor=O.+A.+Flores&title=High-resolution+crystal+structure+of+a+hepatitis+B+virus+replication+inhibitor+bound+to+the+viral+core+protein&doi=10.1073%2Fpnas.1513803112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span></div><div class="casAuthors">Klumpp, Klaus; Lam, Angela M.; Lukacs, Christine; Vogel, Robert; Ren, Suping; Espiritu, Christine; Baydo, Ruth; Atkins, Kateri; Abendroth, Jan; Liao, Guochun; Efimov, Andrey; Hartman, George; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15196-15201</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery.  We report the first, to our knowledge, high-resoln. crystal structure of an antiviral compd. bound to the HBV core protein.  The compd. NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C.  NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability.  The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions detd. by crystallog.  The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxV-odPonGbVg90H21EOLACvtfcHk0liRW1_Q2zgmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK&md5=bf487dda7165d1637fad0ebab8f46142</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1513803112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1513803112%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%2BP.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DBaydo%26aufirst%3DR.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DG.%2BC.%26aulast%3DEfimov%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520a%2520hepatitis%2520B%2520virus%2520replication%2520inhibitor%2520bound%2520to%2520the%2520viral%2520core%2520protein%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D15196%26epage%3D15201%26doi%3D10.1073%2Fpnas.1513803112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Yang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">A new series of HAPs as anti-HBV agents targeting at capsid assembly</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4247</span><span class="NLM_x">–</span> <span class="NLM_lpage">4249</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2014.07.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4247-4249&author=X.+Y.+Yangauthor=X.+Q.+Xuauthor=H.+Guanauthor=L.+L.+Wangauthor=Q.+Wuauthor=G.+M.+Zhaoauthor=S.+Li&title=A+new+series+of+HAPs+as+anti-HBV+agents+targeting+at+capsid+assembly&doi=10.1016%2Fj.bmcl.2014.07.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.032%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DX.%2BQ.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DG.%2BM.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DA%2520new%2520series%2520of%2520HAPs%2520as%2520anti-HBV%2520agents%2520targeting%2520at%2520capsid%2520assembly%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4247%26epage%3D4249%26doi%3D10.1016%2Fj.bmcl.2014.07.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.10.119" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=299-301&author=X.+Zhuauthor=G.+Zhaoauthor=X.+Zhouauthor=X.+Xuauthor=G.+Xiaauthor=Z.+Zhengauthor=L.+Wangauthor=X.+Yangauthor=S.+Li&title=2%2C4-Diaryl-4%2C6%2C7%2C8-tetrahydroquinazolin-5%281H%29-one+derivatives+as+anti-HBV+agents+targeting+at+capsid+assembly&doi=10.1016%2Fj.bmcl.2009.10.119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.119%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26atitle%3D2%252C4-Diaryl-4%252C6%252C7%252C8-tetrahydroquinazolin-5%25281H%2529-one%2520derivatives%2520as%2520anti-HBV%2520agents%2520targeting%2520at%2520capsid%2520assembly%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D299%26epage%3D301%26doi%3D10.1016%2Fj.bmcl.2009.10.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Qiu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7651</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&author=Z.+Qiuauthor=X.+Linauthor=M.+Zhouauthor=Y.+Liuauthor=W.+Zhuauthor=W.+Chenauthor=W.+Zhangauthor=L.+Guoauthor=H.+Liuauthor=G.+Wuauthor=M.+Huangauthor=M.+Jiangauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+Qiuauthor=S.+Zhongauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Wang, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naduthambi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4642</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2011.05.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4642-4647&author=P.+Y.+Wangauthor=D.+Naduthambiauthor=R.+T.+Mosleyauthor=C.+R.+Niuauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Phenylpropenamide+derivatives%3A+anti-hepatitis+B+virus+activity+of+the+Z+isomer%2C+SAR+and+the+search+for+novel+analogs&doi=10.1016%2Fj.bmcl.2011.05.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.077%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%2BY.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DNiu%26aufirst%3DC.%2BR.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPhenylpropenamide%2520derivatives%253A%2520anti-hepatitis%2520B%2520virus%2520activity%2520of%2520the%2520Z%2520isomer%252C%2520SAR%2520and%2520the%2520search%2520for%2520novel%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4642%26epage%3D4647%26doi%3D10.1016%2Fj.bmcl.2011.05.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">King, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span> </span><span class="NLM_article-title">Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (−)beta-L-2′,3′-dideoxy-3′-thiacytidine</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3179</span><span class="NLM_x">–</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3179-3186&author=R.+W.+Kingauthor=S.+K.+Ladnerauthor=T.+J.+Millerauthor=K.+Zaifertauthor=R.+B.+Perniauthor=S.+C.+Conwayauthor=M.+J.+Otto&title=Inhibition+of+human+hepatitis+B+virus+replication+by+AT-61%2C+a+phenylpropenamide+derivative%2C+alone+and+in+combination+with+%28%E2%88%92%29beta-L-2%E2%80%B2%2C3%E2%80%B2-dideoxy-3%E2%80%B2-thiacytidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DR.%2BW.%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DMiller%26aufirst%3DT.%2BJ.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DConway%26aufirst%3DS.%2BC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26atitle%3DInhibition%2520of%2520human%2520hepatitis%2520B%2520virus%2520replication%2520by%2520AT-61%252C%2520a%2520phenylpropenamide%2520derivative%252C%2520alone%2520and%2520in%2520combination%2520with%2520%2528%25E2%2588%2592%2529beta-L-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxy-3%25E2%2580%25B2-thiacytidine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3179%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, R. W.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2687</span><span class="NLM_x">–</span> <span class="NLM_lpage">2690</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00544-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0960-894X%2800%2900544-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11128652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotlantbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2687-2690&author=R.+B.+Perniauthor=S.+C.+Conwayauthor=S.+K.+Ladnerauthor=K.+Zaifertauthor=M.+J.+Ottoauthor=R.+W.+King&title=Phenylpropenamide+derivatives+as+inhibitors+of+hepatitis+B+virus+replication&doi=10.1016%2FS0960-894X%2800%2900544-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives as inhibitors of Hepatitis B virus replication</span></div><div class="casAuthors">Perni, R. B.; Conway, S. C.; Ladner, S. K.; Zaifert, K.; Otto, M. J.; King, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2687-2690</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A non-nucleoside class of compds. that inhibits the replication of hepatitis B virus (HBV) in cell culture has been discovered.  A series of substituted analogs of phenylpropenamide has been prepd. and evaluated in the HepAD38 cellular assay.  Structure-activity relationships of this series are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZcKEPcrqkbVg90H21EOLACvtfcHk0liKYeODhQkWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotlantbw%253D&md5=4c3ee48f05dc8bee0724ba928d89f8a1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900544-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900544-8%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DConway%26aufirst%3DS.%2BC.%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DKing%26aufirst%3DR.%2BW.%26atitle%3DPhenylpropenamide%2520derivatives%2520as%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520replication%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2687%26epage%3D2690%26doi%3D10.1016%2FS0960-894X%2800%2900544-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Delaney, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Painter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3057</span><span class="NLM_x">–</span> <span class="NLM_lpage">3060</span><span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12183271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&author=W.+E.+Delaneyauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span></div><div class="casAuthors">Delaney, William E., IV; Edwards, Ros; Colledge, Danni; Shaw, Tim; Furman, Phil; Painter, George; Locarnini, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3057-3060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The phenylpropenamide derivs. AT-61 and AT-130 are nonnucleoside analog inhibitors of hepatitis B virus (HBV) replication.  They inhibited the replication of wild-type HBV with 50% inhibitory concns. of 21.2±9.5 and 2.40±0.92 μM, resp., compared to 0.064±0.020 μM lamivudine.  There were no significant differences in sensitivity between wild-type and nucleoside analog-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UNW_6bFxUrVg90H21EOLACvtfcHk0liKYeODhQkWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D&md5=ffb8ff070fda879480d93597468cbd9b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlejohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S. A.</span><span> </span><span class="NLM_article-title">The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17709147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOgtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=168-177&author=J.+J.+Feldauthor=D.+Colledgeauthor=V.+Sozziauthor=R.+Edwardsauthor=M.+Littlejohnauthor=S.+A.+Locarnini&title=The+phenylpropenamide+derivative+AT-130+blocks+HBV+replication+at+the+level+of+viral+RNA+packaging&doi=10.1016%2Fj.antiviral.2007.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging</span></div><div class="casAuthors">Feld, J. J.; Colledge, D.; Sozzi, V.; Edwards, R.; Littlejohn, M.; Locarnini, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-177</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog antiviral therapy for chronic hepatitis B has proven to be effective in the short term but the frequent development of resistance limits its clin. utility.  Agents targeting other stages of viral replication are needed in order to develop improved combination therapies.  The phenylpropenamide derivs. AT-61 and AT-130 have been shown to inhibit HBV replication in vitro, but the mechanism of action of these compds. remains undefined.  The aim of this study was to det. the mechanism of action of AT-130, a nonnucleoside inhibitor of HBV in several in vitro models of replication.  These studies found that AT-130 inhibited HBV DNA replication in hepatoma cells but had no effect on viral DNA polymerase activity or core protein translation.  Total HBV RNA prodn. was also unaffected in the presence of the drug while the amt. of encapsidated RNA was significantly reduced, thereby inhibiting subsequent viral reverse transcription.  These studies have established that the inhibition of HBV genome replication by a nonnucleoside analog acting at the level of viral encapsidation and packaging is a potentially useful strategy for future therapeutic drug development in the management of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGXzYFUdjuOrVg90H21EOLACvtfcHk0li6MNE05IR0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOgtb3K&md5=d8989ca5da33e96859f3de9f87f38872</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DSozzi%26aufirst%3DV.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DLittlejohn%26aufirst%3DM.%26aulast%3DLocarnini%26aufirst%3DS.%2BA.%26atitle%3DThe%2520phenylpropenamide%2520derivative%2520AT-130%2520blocks%2520HBV%2520replication%2520at%2520the%2520level%2520of%2520viral%2520RNA%2520packaging%26jtitle%3DAntiviral%2520Res.%26date%3D2007%26volume%3D76%26spage%3D168%26epage%3D177%26doi%3D10.1016%2Fj.antiviral.2007.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Katen, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirapu, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1125</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1021/cb100275b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100275b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1125-1136&author=S.+P.+Katenauthor=S.+R.+Chirapuauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Trapping+of+hepatitis+B+virus+capsid+assembly+intermediates+by+phenylpropenamide+assembly+accelerators&doi=10.1021%2Fcb100275b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of Hepatitis B Virus Capsid Assembly Intermediates by Phenylpropenamide Assembly Accelerators</span></div><div class="casAuthors">Katen, Sarah P.; Chirapu, Srinivas Reddy; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1125-1136</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the biol. self-assembly process of virus capsids is key to understanding the viral life cycle, as well as serving as a platform for the design of assembly-based antiviral drugs.  Here we identify and characterize the phenylpropenamide family of small mols., known to have antiviral activity in vivo, as assembly effectors of the hepatitis B virus (HBV) capsid.  We have found two representative phenylpropenamides to be assembly accelerators, increasing the rate of assembly with only modest increases in the stability of the HBV capsids; these data provide a phys.-chem. basis for their antiviral activity.  Unlike previously described HBV assembly effectors, the phenylpropenamides do not misdirect assembly; rather, the accelerated reactions proceed on-path to produce morphol. normal capsids.  However, capsid assembly in the presence of phenylpropenamides is characterized by kinetic trapping of assembly intermediates.  These traps resolve under conditions close to physiol., but we found that trapped intermediates persist under conditions that favor phenylpropenamide binding and strong core protein-protein interactions.  The phenylpropenamides serve as chem. probes of the HBV capsid assembly pathway by trapping on-path assembly intermediates, illustrating the governing influence of reaction kinetics on capsid assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0sU96uRbhi7Vg90H21EOLACvtfcHk0li6MNE05IR0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku7jL&md5=90a8728ca9cc6bb2ff3acf47694e0d50</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fcb100275b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100275b%26sid%3Dliteratum%253Aachs%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DChirapu%26aufirst%3DS.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DTrapping%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%2520intermediates%2520by%2520phenylpropenamide%2520assembly%2520accelerators%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2010%26volume%3D5%26spage%3D1125%26epage%3D1136%26doi%3D10.1021%2Fcb100275b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Cole, A. G.</span><span> </span><span class="NLM_article-title">Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1016/j.coph.2016.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.coph.2016.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27636324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWksLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=131-137&author=A.+G.+Cole&title=Modulators+of+HBV+capsid+assembly+as+an+approach+to+treating+hepatitis+B+virus+infection&doi=10.1016%2Fj.coph.2016.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection</span></div><div class="casAuthors">Cole, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-137</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for a cure for hepatitis B virus infection extends beyond interferon and the existing polymerase inhibitors, and targets different aspects of the virus life cycle to develop agents that operate by alternative mechanisms.  Examples of small mols. that disrupt the encapsidation of pgRNA have been known for some time, but recent advances in the understanding of nucleocapsid formation, how compds. interact with core protein, and the development of drug-like mols. have recently progressed the study of capsid assembly modulators to proof of concept in the clinic with respect to redn. of viral load in chronic HBV patients.  Interference with HBV capsid assembly is thus a legitimate approach to treating HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsPSq66Ons2rVg90H21EOLACvtfcHk0li6MNE05IR0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWksLbF&md5=9ed4b04d1c497ecf976b40a1b62a52f7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%2BG.%26atitle%3DModulators%2520of%2520HBV%2520capsid%2520assembly%2520as%2520an%2520approach%2520to%2520treating%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D131%26epage%3D137%26doi%3D10.1016%2Fj.coph.2016.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0lg96_JA9qwQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Katen, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirapu, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1406</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span><span class="refDoi"> DOI: 10.1016/j.str.2013.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.str.2013.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23871485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCgs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1406-1416&author=S.+P.+Katenauthor=Z.+N.+Tanauthor=S.+R.+Chirapuauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Assembly-directed+antivirals+differentially+bind+quasiequivalent+pockets+to+modify+hepatitis+B+virus+capsid+tertiary+and+quaternary+structure&doi=10.1016%2Fj.str.2013.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly-Directed Antivirals Differentially Bind Quasiequivalent Pockets to Modify Hepatitis B Virus Capsid Tertiary and Quaternary Structure</span></div><div class="casAuthors">Katen, Sarah P.; Tan, Zhenning; Chirapu, Srinivas Reddy; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1406-1416</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a major cause of liver disease.  Assembly of the HBV capsid is a crit. step in virus prodn. and an attractive target for new antiviral therapies.  We detd. the structure of HBV capsid in complex with AT-130, a member of the phenylpropenamide family of assembly effectors.  AT-130 causes tertiary and quaternary structural changes but does not disrupt capsid structure.  AT-130 binds a hydrophobic pocket that also accommodates the previously characterized heteroaryldihydropyrimidine compds. but favors a unique quasiequivalent location on the capsid surface.  Thus, this pocket is a promiscuous drug-binding site and a likely target for different assembly effectors with a broad range of mechanisms of activity.  That AT-130 successfully decreases virus prodn. by increasing capsid assembly rate without disrupting capsid structure delineates a paradigm in antiviral design, that disrupting reaction timing is a viable strategy for assembly effectors of HBV and other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZur3DCpnS3LVg90H21EOLACvtfcHk0lg96_JA9qwQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCgs7fF&md5=bb515fd504fb69f82755409c4c8f2079</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DTan%26aufirst%3DZ.%2BN.%26aulast%3DChirapu%26aufirst%3DS.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DAssembly-directed%2520antivirals%2520differentially%2520bind%2520quasiequivalent%2520pockets%2520to%2520modify%2520hepatitis%2520B%2520virus%2520capsid%2520tertiary%2520and%2520quaternary%2520structure%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D1406%26epage%3D1416%26doi%3D10.1016%2Fj.str.2013.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Campagna, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6931</span><span class="NLM_x">–</span> <span class="NLM_lpage">6942</span><span class="refDoi"> DOI: 10.1128/JVI.00582-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00582-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23576513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=6931-6942&author=M.+R.+Campagnaauthor=F.+Liuauthor=R.+C.+Maoauthor=C.+Millsauthor=D.+W.+Caiauthor=F.+Guoauthor=X.+S.+Zhaoauthor=H.+Yeauthor=A.+Cuconatiauthor=H.+T.+Guoauthor=J.+H.+Changauthor=X.+D.+Xuauthor=T.+M.+Blockauthor=J.+T.+Guo&title=Sulfamoylbenzamide+derivatives+inhibit+the+assembly+of+hepatitis+B+virus+nucleocapsids&doi=10.1128%2FJVI.00582-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span></div><div class="casAuthors">Campagna, Matthew R.; Liu, Fei; Mao, Richeng; Mills, Courtney; Cai, Dawei; Guo, Fang; Zhao, Xuesen; Ye, Hong; Cuconati, Andrea; Guo, Haitao; Chang, Jinhong; Xu, Xiaodong; Block, Timothy M.; Guo, Ju-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6931-6942</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos(t)ide analog viral DNA polymerase inhibitors.  However, neither pegIFN-α nor nucleos(t)ide analogs are capable of reliably curing the viral infection.  In order to develop novel antiviral drugs against HBV, we established a cell-based screening assay by using an immortalized mouse hepatocyte-derived stable cell line supporting a high level of HBV replication in a tetracycline-inducible manner.  Screening of a library consisting of 26,900 small mols. led to the discovery of a series of sulfamoylbenzamide (SBA) derivs. that significantly reduced the amt. of cytoplasmic HBV DNA.  Structure-activity relationship studies have thus far identified a group of fluorine-substituted SBAs with submicromolar antiviral activity against HBV in human hepatoma cells.  Mechanistic analyses reveal that the compds. dose dependently inhibit the formation of pregenomic RNA (pgRNA)-contg. nucleocapsids of HBV but not other animal hepadnaviruses, such as woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV).  Moreover, heterologous genetic complementation studies of capsid protein, DNA polymerase, and pgRNA between HBV and WHV suggest that HBV capsid protein confers sensitivity to the SBAs.  In summary, SBAs represent a novel chem. entity with superior activity and a unique antiviral mechanism and are thus warranted for further development as novel antiviral therapeutics for the treatment of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNUsTkQKVBQbVg90H21EOLACvtfcHk0lg96_JA9qwQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D&md5=80cd9d05d889ecf1bd2f6c28f7946bcf</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FJVI.00582-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00582-13%26sid%3Dliteratum%253Aachs%26aulast%3DCampagna%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DR.%2BC.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DD.%2BW.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%2BS.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%2BT.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BD.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DSulfamoylbenzamide%2520derivatives%2520inhibit%2520the%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520nucleocapsids%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D6931%26epage%3D6942%26doi%3D10.1128%2FJVI.00582-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Hartman, G. D.; Flores, O. A.</span><span> </span><span class="NLM_article-title">Hepatitis B antivial agents</span>. PCT Int. Appl. WO 2013096744 A1, Jun 27,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+D.+Hartman&author=O.+A.+Flores&title=Hepatitis+B+antivial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DHepatitis%2520B%2520antivial%2520agents%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span> </span><span class="NLM_article-title">P0640: effect of the combination of the HBV core inhibitor NVR 3–778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG2.2.15 cells</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S559</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30845-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930845-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S559&author=A.+Lamauthor=C.+Espirituauthor=O.+Floresauthor=G.+Hartmanauthor=K.+Klumpp&title=P0640%3A+effect+of+the+combination+of+the+HBV+core+inhibitor+NVR+3%E2%80%93778+with+nucleoside+analogs+or+other+HBV+core+inhibitors+on+the+inhibition+of+HBV+DNA+replication+in+HepG2.2.15+cells&doi=10.1016%2FS0168-8278%2815%2930845-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930845-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930845-X%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DP0640%253A%2520effect%2520of%2520the%2520combination%2520of%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203%25E2%2580%2593778%2520with%2520nucleoside%2520analogs%2520or%2520other%2520HBV%2520core%2520inhibitors%2520on%2520the%2520inhibition%2520of%2520HBV%2520DNA%2520replication%2520in%2520HepG2.2.15%2520cells%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS559%26doi%3D10.1016%2FS0168-8278%2815%2930845-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allweiss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetgehetman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">High antiviral activity of the HBV core inhibitor NVR 3–778 in the humanized UPA/SCID mouse model</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S250</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30134-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930134-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25281864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S250&author=K.+Klumppauthor=T.+Shimadaauthor=L.+Allweissauthor=T.+Volzauthor=M.+Luetgehetmanauthor=O.+Floresauthor=G.+Hartmanauthor=A.+Lamauthor=M.+Dandri&title=High+antiviral+activity+of+the+HBV+core+inhibitor+NVR+3%E2%80%93778+in+the+humanized+UPA%2FSCID+mouse+model&doi=10.1016%2FS0168-8278%2815%2930134-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930134-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930134-3%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DAllweiss%26aufirst%3DL.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DLuetgehetman%26aufirst%3DM.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DA.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DHigh%2520antiviral%2520activity%2520of%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203%25E2%2580%2593778%2520in%2520the%2520humanized%2520UPA%252FSCID%2520mouse%2520model%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS250%26doi%3D10.1016%2FS0168-8278%2815%2930134-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by the HBV core inhibitor NVR 3-778</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">223A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=223A&author=A.+Lamauthor=S.+P.+Renauthor=R.+Vogelauthor=C.+Espirituauthor=M.+Kellyauthor=V.+Lauauthor=G.+D.+Hartmanauthor=L.+Floresauthor=K.+Klumpp&title=Inhibition+of+hepatitis+B+virus+replication+by+the+HBV+core+inhibitor+NVR+3-778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DS.%2BP.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DV.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203-778%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D223A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. A.</span><span> </span><span class="NLM_article-title">Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV coreInhibitor</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1279A&author=E.+J.+Ganeauthor=C.+Schwabeauthor=K.+Walkerauthor=L.+Floresauthor=G.+D.+Hartmanauthor=K.+Klumppauthor=S.+Liawauthor=N.+A.+Brown&title=Phase+1a+safety+and+pharmacokinetics+of+NVR+3-778%2C+a+potential+first-in-class+HBV+coreInhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%2BA.%26atitle%3DPhase%25201a%2520safety%2520and%2520pharmacokinetics%2520of%2520NVR%25203-778%252C%2520a%2520potential%2520first-in-class%2520HBV%2520coreInhibitor%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1279A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weilert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span> </span><span class="NLM_article-title">Phase 1b efficacy and safety of NVR 3-778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385A</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1385A-1386A&author=M.+F.+Yuenauthor=D.+J.+Kimauthor=F.+Weilertauthor=H.+L.+Y.+Chanauthor=J.+P.+Lalezariauthor=S.+G.+Hwangauthor=T.+T.+Nguyenauthor=S.+Liawauthor=N.+Brownauthor=K.+Klumppauthor=L.+Floresauthor=G.+D.+Hartmanauthor=E.+J.+Gane&title=Phase+1b+efficacy+and+safety+of+NVR+3-778%2C+a+first-in-class+HBV+core+inhibitor%2C+in+HBeAg-positive+patients+with+chronic+HBV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DWeilert%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26atitle%3DPhase%25201b%2520efficacy%2520and%2520safety%2520of%2520NVR%25203-778%252C%2520a%2520first-in-class%2520HBV%2520core%2520inhibitor%252C%2520in%2520HBeAg-positive%2520patients%2520with%2520chronic%2520HBV%2520infection%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1385A%26epage%3D1386A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1002/cmdc.200800136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fcmdc.200800136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1316-1321&author=H.+J.+Chenauthor=W.+L.+Wangauthor=G.+F.+Wangauthor=L.+P.+Shiauthor=M.+Guauthor=Y.+D.+Renauthor=L.+F.+Houauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=X.+G.+Zhongauthor=W.+Tangauthor=J.+P.+Zuoauthor=F.+J.+Nan&title=Rational+design+and+synthesis+of+2%2C2-bisheterocycle+tandem+derivatives+as+non-nucleoside+hepatitis+B+virus+inhibitors&doi=10.1002%2Fcmdc.200800136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800136%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DRen%26aufirst%3DY.%2BD.%26aulast%3DHou%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DZhong%26aufirst%3DX.%2BG.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%25202%252C2-bisheterocycle%2520tandem%2520derivatives%2520as%2520non-nucleoside%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D1316%26epage%3D1321%26doi%3D10.1002%2Fcmdc.200800136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+P.+Shiauthor=H.+J.+Chenauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=Y.+M.+Zhangauthor=W.+L.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=Y.+H.+Haoauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=W.+Tangauthor=F.+J.+Nanauthor=J.+P.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0lgU05tu67Y5Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Cho, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, G.</span><span> </span><span class="NLM_article-title">2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1111/jvh.12214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fjvh.12214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24372792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=843-852&author=M.+H.+Choauthor=H.+Jeongauthor=Y.+S.+Kimauthor=J.+W.+Kimauthor=G.+Jung&title=2-Amino-N-%282%2C6-dichloropyridin-3-yl%29acetamide+derivatives+as+a+novel+class+of+HBV+capsid+assembly+inhibitor&doi=10.1111%2Fjvh.12214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor</span></div><div class="casAuthors">Cho, M. H.; Jeong, H.; Kim, Y. S.; Kim, J.-W.; Jung, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : Capsid structure is crucial for the maturation and maintenance of the stable hepatitis B virion.  Therefore, chems. that inhibit capsid assembly might potentially act as potent antiviral compds.  However, only a few chems. are known to block the capsid assembly process and further viral proliferation.  In this study, we present a novel family of capsid assembly inhibitors that act against hepatitis B virus (HBV).  Based on X-ray crystallog. data of the HBV core protein (Cp), we built dimer and hexamer structural models to be used in library searches.  Several chems. in the 2-amino-N-(2,6-dichloropyridin-3-yl)acetamide family were predicted to have high affinity for the groove structure in Cp.  Using in vitro assembly and the HepG2.2.15 cell culture test, we verified that these chems. demonstrated inhibitory effects on capsid assembly.  Furthermore, we investigated the combinatorial effects of these assembly inhibitor chems. with lamivudine and revealed that, in combination, they have synergistic inhibitory effects on decreasing viral concn.  We propose that these inhibitors could be utilized as an effective combination treatment against HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUuUFPBCmP7Vg90H21EOLACvtfcHk0liknJ4QwxxIPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegsrjP&md5=8ea975bf569a0ba1a79e2b88017e6950</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12214%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DM.%2BH.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DG.%26atitle%3D2-Amino-N-%25282%252C6-dichloropyridin-3-yl%2529acetamide%2520derivatives%2520as%2520a%2520novel%2520class%2520of%2520HBV%2520capsid%2520assembly%2520inhibitor%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26spage%3D843%26epage%3D852%26doi%3D10.1111%2Fjvh.12214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7061</span><span class="NLM_x">–</span> <span class="NLM_lpage">7072</span><span class="refDoi"> DOI: 10.1128/AAC.01558-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01558-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=7061-7072&author=Y.+J.+Wangauthor=D.+Luauthor=Y.+B.+Xuauthor=W.+Q.+Xingauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=L.+Yangauthor=W.+Tangauthor=Y.+H.+Huauthor=J.+P.+Zuo&title=A+novel+pyridazinone+derivative+inhibits+hepatitis+B+virus+replication+by+inducing+genome-free+capsid+formation&doi=10.1128%2FAAC.01558-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1128%2FAAC.01558-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01558-15%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%2BB.%26aulast%3DXing%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%2BH.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DA%2520novel%2520pyridazinone%2520derivative%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D7061%26epage%3D7072%26doi%3D10.1128%2FAAC.01558-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Hartman, G. D.; Kuduk, S.</span><span> </span><span class="NLM_article-title">Azepane derivatives and methods of treating hepatitis B infections</span>. U.S. Pat. Appl. 20150132258 A1, May 14,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+D.+Hartman&author=S.+Kuduk&title=Azepane+derivatives+and+methods+of+treating+hepatitis+B+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DAzepane%2520derivatives%2520and%2520methods%2520of%2520treating%2520hepatitis%2520B%2520infections%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Zlotnick, A.; Li, L. C.; Turner, W. J.; Francis, S.</span><span> </span><span class="NLM_article-title">Hepatitis B viral assembly effector</span>. PCT Int. Appl. WO 2015057945 A1, Apr 23,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Zlotnick&author=L.+C.+Li&author=W.+J.+Turner&author=S.+Francis&title=Hepatitis+B+viral+assembly+effector"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DHepatitis%2520B%2520viral%2520assembly%2520effector%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Vandyck, K. V.; Wim, G.; Raboisson; Pierre, J. M. B.</span><span> </span><span class="NLM_article-title">Fused bicyclic sulfamoyl derivatives for the treatment of hepatitis B</span>. PCT Int. Appl. WO 2014033167, Mar 6,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+V.+Vandyck&author=G.+Wim&author=+Raboisson&author=J.+M.+B.+Pierre&title=Fused+bicyclic+sulfamoyl+derivatives+for+the+treatment+of+hepatitis+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVandyck%26aufirst%3DK.%2BV.%26atitle%3DFused%2520bicyclic%2520sulfamoyl%2520derivatives%2520for%2520the%2520treatment%2520of%2520hepatitis%2520B%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Turner, W. W. A.; Lee, D.; Maag, H.; Zlotnick, A.</span><span> </span><span class="NLM_article-title">Hepatitis B core protein allosteric modulators</span>. PCT Int. Appl. WO 2015138895, Sep 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+W.+A.+Turner&author=D.+Lee&author=H.+Maag&author=A.+Zlotnick&title=Hepatitis+B+core+protein+allosteric+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DW.%2BW.%2BA.%26atitle%3DHepatitis%2520B%2520core%2520protein%2520allosteric%2520modulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Asif-Ullah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. G.</span><span> </span><span class="NLM_article-title">Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2006.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2006.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=85-90&author=M.+Asif-Ullahauthor=K.+J.+Choiauthor=K.+I.+Choiauthor=Y.+J.+Jeongauthor=Y.+G.+Yu&title=Identification+of+compounds+that+inhibit+the+interaction+between+core+and+surface+protein+of+hepatitis+B+virus&doi=10.1016%2Fj.antiviral.2006.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2006.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2006.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAsif-Ullah%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DK.%2BJ.%26aulast%3DChoi%26aufirst%3DK.%2BI.%26aulast%3DJeong%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520compounds%2520that%2520inhibit%2520the%2520interaction%2520between%2520core%2520and%2520surface%2520protein%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DAntiviral%2520Res.%26date%3D2006%26volume%3D70%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.antiviral.2006.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Hadziyannis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadziyannis, S. J.</span><span> </span><span class="NLM_article-title">Quantitative HBsAg titer as predictor of response to therapy</span> <span class="citation_source-journal">Curr. Hepat. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1007/s11901-009-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1007%2Fs11901-009-0024-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=169-172&author=E.+Hadziyannisauthor=D.+Vassilopoulosauthor=S.+J.+Hadziyannis&title=Quantitative+HBsAg+titer+as+predictor+of+response+to+therapy&doi=10.1007%2Fs11901-009-0024-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs11901-009-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11901-009-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DHadziyannis%26aufirst%3DE.%26aulast%3DVassilopoulos%26aufirst%3DD.%26aulast%3DHadziyannis%26aufirst%3DS.%2BJ.%26atitle%3DQuantitative%2520HBsAg%2520titer%2520as%2520predictor%2520of%2520response%2520to%2520therapy%26jtitle%3DCurr.%2520Hepat.%2520Rep.%26date%3D2009%26volume%3D8%26spage%3D169%26epage%3D172%26doi%3D10.1007%2Fs11901-009-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinot-Peignoux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piratvisuth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillmann, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Hepatitis B surface antigen quantification: why and how to use it in 2011-A core group report</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1016/j.jhep.2011.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2011.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21718667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3MbitFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1121-1131&author=H.+L.+Y.+Chanauthor=A.+Thompsonauthor=M.+Martinot-Peignouxauthor=T.+Piratvisuthauthor=M.+Cornbergauthor=M.+R.+Brunettoauthor=H.+L.+Tillmannauthor=J.+H.+Kaoauthor=J.+D.+Jiaauthor=H.+Wedemeyerauthor=S.+Locarniniauthor=H.+L.+A.+Janssenauthor=P.+Marcellin&title=Hepatitis+B+surface+antigen+quantification%3A+why+and+how+to+use+it+in+2011-A+core+group+report&doi=10.1016%2Fj.jhep.2011.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report</span></div><div class="casAuthors">Chan Henry Lik-Yuen; Thompson Alex; Martinot-Peignoux Michelle; Piratvisuth Teerha; Cornberg Markus; Brunetto Maurizia Rossana; Tillmann Hans L; Kao Jia-Horng; Jia Ji-Dong; Wedemeyer Heiner; Locarnini Stephen; Janssen Harry L A; Marcellin Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1121-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome.  The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B.  HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies.  Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients.  Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients.  The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment.  On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders.  The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection.  A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term.  There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment.  In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4Ym-TR-Q2esRAV4D_Ins_fW6udTcc2ebKvI-Jp3ihrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbitFShsg%253D%253D&md5=025b70ddfc809716d6d24c534ae3b334</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DMartinot-Peignoux%26aufirst%3DM.%26aulast%3DPiratvisuth%26aufirst%3DT.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DTillmann%26aufirst%3DH.%2BL.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DJia%26aufirst%3DJ.%2BD.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DLocarnini%26aufirst%3DS.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DHepatitis%2520B%2520surface%2520antigen%2520quantification%253A%2520why%2520and%2520how%2520to%2520use%2520it%2520in%25202011-A%2520core%2520group%2520report%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D55%26spage%3D1121%26epage%3D1131%26doi%3D10.1016%2Fj.jhep.2011.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span> </span><span class="NLM_article-title">HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2646</span><span class="refDoi"> DOI: 10.1016/j.molimm.2009.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.molimm.2009.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19501403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Omu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=2640-2646&author=Y.+Xuauthor=Y.+Huauthor=B.+Shiauthor=X.+Zhangauthor=J.+Wangauthor=Z.+Zhangauthor=F.+Shenauthor=Q.+Zhangauthor=S.+Sunauthor=Z.+Yuan&title=HBsAg+inhibits+TLR9-mediated+activation+and+IFN-alpha+production+in+plasmacytoid+dendritic+cells&doi=10.1016%2Fj.molimm.2009.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">HBsAg inhibits TLR9-mediated activation and IFN-α production in plasmacytoid dendritic cells</span></div><div class="casAuthors">Xu, Yongfen; Hu, Yunwen; Shi, Bisheng; Zhang, Xiaonan; Wang, Jiefei; Zhang, Zhanqing; Shen, Fang; Zhang, Qin; Sun, Shuhui; Yuan, Zhenghong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2640-2646</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Plasmacytoid dendritic cells (pDCs), the professional producers of type I interferons (IFN-α/β), play a pivotal role in innate and adaptive immune responses against viral infections.  Although functional impairment of circulating pDCs in chronic hepatitis B (CHB) patients has been reported previously, the mechanism responsible for these defects remains unclear.  The authors hypothesize that HBsAg circulating in high amts. during HBV infection may interact with pDC and contribute to pDC dysfunction.  In support of this hypothesis the authors show that pDCs treated with HBsAg secreted much less IFN-α than control pDCs.  Furthermore, suppression is specific for TLR9, with no effects upon TLR7-mediated IFN-α secretion.  HBsAg inhibited TLR9-mediated IRF-7 expression and nuclear translocation, which are important for induction of IFN-α gene transcription.  HBsAg up-regulated the SOCS-1 expression and bound to BDCA-2 receptors on the plasma membrane of pDCs, resulting in the inhibition of the IFN-α prodn.  In conclusion, the above data suggested that HBsAg may directly interfere with the function of pDC through HBsAg-mediated upregulation of SOCS-1 expression and BDCA-2 ligation, which could partially explain how HBV evades the immune system to establish a persistent infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfplXW2jsQA7Vg90H21EOLACvtfcHk0ljMOAHQ0WZgdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Omu7s%253D&md5=67a6c0d6ccc02ce8f56e29edbf962bb5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2009.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2009.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DZ.%26atitle%3DHBsAg%2520inhibits%2520TLR9-mediated%2520activation%2520and%2520IFN-alpha%2520production%2520in%2520plasmacytoid%2520dendritic%2520cells%26jtitle%3DMol.%2520Immunol.%26date%3D2009%26volume%3D46%26spage%3D2640%26epage%3D2646%26doi%3D10.1016%2Fj.molimm.2009.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Dougherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simsek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span> </span><span class="NLM_article-title">A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4427</span><span class="NLM_x">–</span> <span class="NLM_lpage">4437</span><span class="refDoi"> DOI: 10.1128/AAC.00541-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00541-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=4427-4437&author=A.+M.+Doughertyauthor=H.+Guoauthor=G.+Westbyauthor=Y.+Liuauthor=E.+Simsekauthor=J.+T.+Guoauthor=A.+Mehtaauthor=P.+Nortonauthor=B.+Guauthor=T.+Blockauthor=A.+Cuconati&title=A+substituted+tetrahydro-tetrazolo-pyrimidine+is+a+specific+and+novel+inhibitor+of+hepatitis+B+virus+surface+antigen+secretion&doi=10.1128%2FAAC.00541-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FAAC.00541-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00541-07%26sid%3Dliteratum%253Aachs%26aulast%3DDougherty%26aufirst%3DA.%2BM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWestby%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSimsek%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DNorton%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DB.%26aulast%3DBlock%26aufirst%3DT.%26aulast%3DCuconati%26aufirst%3DA.%26atitle%3DA%2520substituted%2520tetrahydro-tetrazolo-pyrimidine%2520is%2520a%2520specific%2520and%2520novel%2520inhibitor%2520of%2520hepatitis%2520B%2520virus%2520surface%2520antigen%2520secretion%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D4427%26epage%3D4437%26doi%3D10.1128%2FAAC.00541-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clearfield, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrey, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motter, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5660</span><span class="NLM_x">–</span> <span class="NLM_lpage">5670</span><span class="refDoi"> DOI: 10.1021/jm200696v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200696v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5660-5670&author=W.+Yuauthor=G.+Goddardauthor=E.+Clearfieldauthor=C.+Millsauthor=T.+Xiaoauthor=H.+Guoauthor=J.+D.+Morreyauthor=N.+E.+Motterauthor=K.+Zhaoauthor=T.+M.+Blockauthor=A.+Cuconatiauthor=X.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+triazolo-pyrimidine+derivatives+as+novel+inhibitors+of+hepatitis+B+virus+surface+antigen+%28HBsAg%29+secretion&doi=10.1021%2Fjm200696v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm200696v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200696v%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGoddard%26aufirst%3DG.%26aulast%3DClearfield%26aufirst%3DE.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMorrey%26aufirst%3DJ.%2BD.%26aulast%3DMotter%26aufirst%3DN.%2BE.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520triazolo-pyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520surface%2520antigen%2520%2528HBsAg%2529%2520secretion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5660%26epage%3D5670%26doi%3D10.1021%2Fjm200696v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robek, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Toll-like receptor signaling inhibits hepatitis B virus replication in vivo</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">7269</span><span class="NLM_x">–</span> <span class="NLM_lpage">7272</span><span class="refDoi"> DOI: 10.1128/JVI.79.11.7269-7272.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.79.11.7269-7272.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15890966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=7269-7272&author=M.+Isogawaauthor=M.+D.+Robekauthor=Y.+Furuichiauthor=F.+V.+Chisari&title=Toll-like+receptor+signaling+inhibits+hepatitis+B+virus+replication+in+vivo&doi=10.1128%2FJVI.79.11.7269-7272.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor signaling inhibits hepatitis B virus replication in vivo</span></div><div class="casAuthors">Isogawa, Masanori; Robek, Michael D.; Furuichi, Yoshihiro; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7269-7272</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Toll-like receptors (TLR) play a key role in innate immunity.  To examine the ability of diverse TLRs to modulate hepatitis B virus (HBV) replication, HBV transgenic mice received a single i.v. injection of ligands specific for TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9.  All of the ligands except for TLR2 inhibited HBV replication in the liver noncytopathically within 24 h in a α/β interferon-dependent manner.  The ability of these TLR ligands to induce antiviral cytokines at the site of HBV replication suggests that TLR activation could represent a powerful and novel therapeutic strategy for the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogjxi1EvUpKrVg90H21EOLACvtfcHk0ljMOAHQ0WZgdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKgtr0%253D&md5=6761f9d0a746a06c3c4b67044e1721f6</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.11.7269-7272.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.11.7269-7272.2005%26sid%3Dliteratum%253Aachs%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DRobek%26aufirst%3DM.%2BD.%26aulast%3DFuruichi%26aufirst%3DY.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DToll-like%2520receptor%2520signaling%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D7269%26epage%3D7272%26doi%3D10.1128%2FJVI.79.11.7269-7272.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Vincent, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainaut, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemin, I.</span><span> </span><span class="NLM_article-title">Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26315</span><span class="refDoi"> DOI: 10.1371/journal.pone.0026315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.pone.0026315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26315&author=I.+E.+Vincentauthor=C.+Zannettiauthor=J.+Luciforaauthor=H.+Norderauthor=U.+Protzerauthor=P.+Hainautauthor=F.+Zoulimauthor=M.+Tommasinoauthor=C.+Trepoauthor=U.+Hasanauthor=I.+Chemin&title=Hepatitis+B+virus+impairs+TLR9+expression+and+function+in+plasmacytoid+dendritic+cells&doi=10.1371%2Fjournal.pone.0026315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0026315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0026315%26sid%3Dliteratum%253Aachs%26aulast%3DVincent%26aufirst%3DI.%2BE.%26aulast%3DZannetti%26aufirst%3DC.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DNorder%26aufirst%3DH.%26aulast%3DProtzer%26aufirst%3DU.%26aulast%3DHainaut%26aufirst%3DP.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DTommasino%26aufirst%3DM.%26aulast%3DTrepo%26aufirst%3DC.%26aulast%3DHasan%26aufirst%3DU.%26aulast%3DChemin%26aufirst%3DI.%26atitle%3DHepatitis%2520B%2520virus%2520impairs%2520TLR9%2520expression%2520and%2520function%2520in%2520plasmacytoid%2520dendritic%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26315%26doi%3D10.1371%2Fjournal.pone.0026315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Koumbi, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastassiadou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machaira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafetzis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papaevangelou, V.</span><span> </span><span class="NLM_article-title">Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers</span> <span class="citation_source-journal">Clin. Vaccine Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1085</span><span class="refDoi"> DOI: 10.1128/CVI.00074-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FCVI.00074-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20463102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1079-1085&author=L.+J.+Koumbiauthor=N.+G.+Papadopoulosauthor=V.+Anastassiadouauthor=M.+Machairaauthor=D.+A.+Kafetzisauthor=V.+Papaevangelou&title=Dendritic+cells+in+uninfected+infants+born+to+hepatitis+B+virus-positive+mothers&doi=10.1128%2FCVI.00074-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers</span></div><div class="casAuthors">Koumbi, Lemonica J.; Papadopoulos, Nikolaos, G.; Anastassiadou, Vassiliki; Machaira, Maria; Kafetzis, Dimitris A.; Papaevangelou, Vassiliki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Vaccine Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1079-1085</span>CODEN:
                <span class="NLM_cas:coden">CVILA6</span>;
        ISSN:<span class="NLM_cas:issn">1556-679X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Plasmacytoid dendritic cells (pDCs) play a central role in antiviral immunity, detecting viruses via Toll-like receptors (TLR) and producing in response vast amts. of type I interferons (IFNs).  Hepatitis B virus (HBV) causes chronic infection after vertical transmission.  This study investigated whether an HBV-infected maternal environment might influence DC nos. and pDC function in uninfected infants.  Blood was collected from inactive HBsAg carrier and control mothers and their infants at birth and 1 and 6 mo of age.  HBV DNA was measured in maternal and neonatal perinatal sera using real-time PCR.  The circulating frequencies of myeloid DCs (mDCs) and pDCs were detd. in the babies by flow cytometry.  Peripheral blood mononuclear cells (PBMCs) and cord blood pDCs were stimulated with resiquimod, and alpha interferon (IFN-α) prodn. and the pDC phenotype were assessed.  The effect of the common-cold virus, rhinovirus (RV), on resiquimod stimulation was also detd. HBV DNA was detected in 62.3% of the mothers and 41% of their infants.  DC nos. and pDC functions were similar between subjects and controls and were not correlated with maternal or neonatal viremia.  RV infection did not induce pDC maturation until the age of 6 mo, and it reduced TLR7-dependent resiquimod-induced IFN- prodn. similarly in both groups. Although the DC system is immature at birth, DCs of uninfected neonates of HBV-pos. mothers are competent to initiate and maintain T-cell responses.  RV is a weak inducer of IFN-α prodn. until the age of 6 mo and inhibits IFN-α responses triggered by the TLR7 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1armtC5dqVLVg90H21EOLACvtfcHk0lif6gB4Cbw-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGit74%253D&md5=9212ef305a5454b54ad9466e36c8277c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1128%2FCVI.00074-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCVI.00074-10%26sid%3Dliteratum%253Aachs%26aulast%3DKoumbi%26aufirst%3DL.%2BJ.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BG.%26aulast%3DAnastassiadou%26aufirst%3DV.%26aulast%3DMachaira%26aufirst%3DM.%26aulast%3DKafetzis%26aufirst%3DD.%2BA.%26aulast%3DPapaevangelou%26aufirst%3DV.%26atitle%3DDendritic%2520cells%2520in%2520uninfected%2520infants%2520born%2520to%2520hepatitis%2520B%2520virus-positive%2520mothers%26jtitle%3DClin.%2520Vaccine%2520Immunol.%26date%3D2010%26volume%3D17%26spage%3D1079%26epage%3D1085%26doi%3D10.1128%2FCVI.00074-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Shim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 facilitates formation of the HBV capsid via interacting with the HBV core protein dimers</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">410</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1016/j.virol.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.virol.2010.11.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2011&pages=161-169&author=H.+Y.+Shimauthor=X.+Quanauthor=Y.+S.+Yiauthor=G.+Jung&title=Heat+shock+protein+90+facilitates+formation+of+the+HBV+capsid+via+interacting+with+the+HBV+core+protein+dimers&doi=10.1016%2Fj.virol.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DShim%26aufirst%3DH.%2BY.%26aulast%3DQuan%26aufirst%3DX.%26aulast%3DYi%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520facilitates%2520formation%2520of%2520the%2520HBV%2520capsid%2520via%2520interacting%2520with%2520the%2520HBV%2520core%2520protein%2520dimers%26jtitle%3DVirology%26date%3D2011%26volume%3D410%26spage%3D161%26epage%3D169%26doi%3D10.1016%2Fj.virol.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span> </span><span class="NLM_article-title">STING agonists induce an innate antiviral immune response against hepatitis B virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span><span class="refDoi"> DOI: 10.1128/AAC.04321-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.04321-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1273-1281&author=F.+Guoauthor=Y.+Hanauthor=X.+Zhaoauthor=J.+Wangauthor=F.+Liuauthor=C.+Xuauthor=L.+Weiauthor=J.+D.+Jiangauthor=T.+M.+Blockauthor=J.+T.+Guoauthor=J.+Chang&title=STING+agonists+induce+an+innate+antiviral+immune+response+against+hepatitis+B+virus&doi=10.1128%2FAAC.04321-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1128%2FAAC.04321-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04321-14%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DChang%26aufirst%3DJ.%26atitle%3DSTING%2520agonists%2520induce%2520an%2520innate%2520antiviral%2520immune%2520response%2520against%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1273%26epage%3D1281%26doi%3D10.1128%2FAAC.04321-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Baumert, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrier, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span> </span><span class="NLM_article-title">Host-targeting agents for treatment of hepatitis B virus infection</span> <span class="citation_source-journal">Curr. Opin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.coviro.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.coviro.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26262886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=41-46&author=T.+F.+Baumertauthor=E.+R.+Verrierauthor=M.+Nassalauthor=R.+T.+Chungauthor=M.+B.+Zeisel&title=Host-targeting+agents+for+treatment+of+hepatitis+B+virus+infection&doi=10.1016%2Fj.coviro.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Host-targeting agents for treatment of hepatitis B virus infection</span></div><div class="casAuthors">Baumert, Thomas F.; Verrier, Eloi R.; Nassal, Michael; Chung, Raymond T.; Zeisel, Mirjam B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infection is a major cause of chronic liver disease, including liver cirrhosis, liver failure and hepatocellular carcinoma (HCC) - the second leading and fastest rising cause of cancer death world-wide.  While de novo infection can be efficiently prevented by vaccination and chronic infection can be controlled using antivirals targeting the viral polymerase, the development of efficient antiviral strategies to eliminate the virus and thus to cure infection remains a key unmet medical need.  The recent progress in the development of robust infectious HBV cell culture models now enables the investigation of the full viral life cycle, including a more detailed study of the mol. mechanisms of virus-host interactions responsible for viral persistence.  The understanding of these virus-host interactions will be instrumental for the development of curative treatments.  Host-dependency factors have recently emerged as promising candidates to treat and prevent infection by various pathogens.  This review focuses on the potential of host-targeting agents (HTAs) as novel antivirals to treat and cure HBV infection.  These include HTAs that inhibit de novo and re-infection, synthesis and spread of cc-cDNA as well as development of immune-based approaches eliminating or curing infected hepatocytes, including the eradication of viral cc-cDNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYl0SYCgrHVrVg90H21EOLACvtfcHk0li3JpOBdvelIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7fP&md5=ede8bc8ef59438814df31e158abad292</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DVerrier%26aufirst%3DE.%2BR.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26atitle%3DHost-targeting%2520agents%2520for%2520treatment%2520of%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2015%26volume%3D14%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fj.coviro.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.07.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=152-159&author=J.+Changauthor=J.+T.+Guo&title=Treatment+of+chronic+hepatitis+B+with+pattern+recognition+receptor+agonists%3A+current+status+and+potential+for+a+cure&doi=10.1016%2Fj.antiviral.2015.07.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520B%2520with%2520pattern%2520recognition%2520receptor%2520agonists%253A%2520current%2520status%2520and%2520potential%2520for%2520a%2520cure%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D152%26epage%3D159%26doi%3D10.1016%2Fj.antiviral.2015.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span> </span><span class="NLM_article-title">Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways</span> <span class="citation_source-journal">Cell. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">–</span> <span class="NLM_lpage">1637</span><span class="refDoi"> DOI: 10.1111/j.1462-5822.2009.01353.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1462-5822.2009.01353.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19573162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOisLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1624-1637&author=X.+Zhangauthor=Z.+Mengauthor=S.+Qiuauthor=Y.+Xuauthor=D.+Yangauthor=J.+F.+Schlaakauthor=M.+Roggendorfauthor=M.+Lu&title=Lipopolysaccharide-induced+innate+immune+responses+in+primary+hepatocytes+downregulates+woodchuck+hepatitis+virus+replication+via+interferon-independent+pathways&doi=10.1111%2Fj.1462-5822.2009.01353.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways</span></div><div class="casAuthors">Zhang, Xiaoyong; Meng, Zhongji; Qiu, Song; Xu, Yang; Yang, Dongliang; Schlaak, Joerg F.; Roggendorf, Michael; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1624-1637</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Our previous studies have shown that Toll-like receptor (TLR) ligands, Poly I:C and lipopolysaccharide (LPS), are able to activate non-parenchymal liver cells and trigger the prodn. of interferon (IFN) to inhibit hepatitis B virus replication in vivo and in vitro.  However, little is known about TLR-mediated cellular responses in primary hepatocytes.  By the model of woodchuck hepatitis virus (WHV) infected primary woodchuck hepatocytes (PWHs), Poly I:C and LPS stimulation resulted in upregulation of cellular antiviral genes and relevant TLRs mRNA expression resp.  LPS stimulation led to a pronounced redn. of WHV replicative intermediates without a significant IFN induction.  Poly I:C transfection resulted in the prodn. of IFN and a highly increased expression of antiviral genes in PWHs and slight inhibitory effect on WHV replication.  LPS could activate nuclear factor kappa B, MAPK and PI-3k/Akt pathways in PWHs.  Further, inhibitors of MAPK-ERK and PI-3k/Akt pathways, but not that of IFN signalling pathway, were able to block the antiviral effect of LPS.  These results indicate that IFN-independent pathways which activated by LPS are able to downregulate hepadnaviral replication in hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokYTWEzEEIvLVg90H21EOLACvtfcHk0li3JpOBdvelIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOisLzJ&md5=01f5d14af0dbabbc998a7b8bfbf6eee9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2009.01353.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2009.01353.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DLipopolysaccharide-induced%2520innate%2520immune%2520responses%2520in%2520primary%2520hepatocytes%2520downregulates%2520woodchuck%2520hepatitis%2520virus%2520replication%2520via%2520interferon-independent%2520pathways%26jtitle%3DCell.%2520Microbiol.%26date%3D2009%26volume%3D11%26spage%3D1624%26epage%3D1637%26doi%3D10.1111%2Fj.1462-5822.2009.01353.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span> </span><span class="NLM_article-title">Role of toll-like receptor 2 in the immune response against hepadnaviral infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">522</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2012.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=22617154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=522-528&author=X.+Zhangauthor=Z.+Maauthor=H.+Liuauthor=J.+Liuauthor=Z.+Mengauthor=R.+Broeringauthor=D.+Yangauthor=J.+F.+Schlaakauthor=M.+Roggendorfauthor=M.+Lu&title=Role+of+toll-like+receptor+2+in+the+immune+response+against+hepadnaviral+infection&doi=10.1016%2Fj.jhep.2012.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Toll-like receptor 2 in the immune response against hepadnaviral infection</span></div><div class="casAuthors">Zhang, Xiaoyong; Ma, Zhiyong; Liu, Hongyan; Liu, Jia; Meng, Zhongji; Broering, Ruth; Yang, Dongliang; Schlaak, Joerg F.; Roggendorf, Michael; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">522-528</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: The Toll-like receptor 2 (TLR2) has recently been recognized to play an important role in the pathogenesis of chronic hepatitis B virus (HBV) infection.  In the present study, we examd. the role of TLR2 in hepadnaviral infection in hepatoma cell lines and the woodchuck model.  Methods: The expression of TLR2 and pro-inflammatory cytokines was quantified by real time RT-PCR.  TLR2-assocd. signaling pathways in hepatocytes were examd. by Western blot.  HBV replication and gene expression were assessed by Southern blot, Northern blot and specific ELISA, resp.  Results: TLR2 ligands activated NF-κB, PI3K/Akt, and different arms of MAPK signaling pathways and induced the prodn. of pro-inflammatory cytokines in hepatocytes.  TLR2-mediated innate immune responses led to redn. of HBV/woodchuck hepatitis virus (WHV) replication and gene expression in HepG2.2.15 cells and primary woodchuck hepatocytes.  Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, resp.  In the woodchuck model, relatively low levels of TLR2 expression were found in peripheral blood mononuclear cells (PBMCs) and in liver tissues from chronic WHV carriers.  TLR2 expression in PBMCs was inversely correlated with WHV DNA titers in acute WHV infection and in entecavir-treated chronic WHV carriers.  Conclusions: These data suggest that hepatocytes play an active role in TLR2-mediated antiviral responses during hepadnaviral infection.  The mutual inhibition of HBV replication and TLR2 signaling represents an important aspect of HBV infection and should be considered in the new therapeutic concept against chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4u9PCys4aa7Vg90H21EOLACvtfcHk0ljSgAqBdZYM-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrzK&md5=49f9185fce2a355f8dfa2bcaa0a52542</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DBroering%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DRole%2520of%2520toll-like%2520receptor%25202%2520in%2520the%2520immune%2520response%2520against%2520hepadnaviral%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D522%26epage%3D528%26doi%3D10.1016%2Fj.jhep.2012.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span> </span><span class="NLM_article-title">Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">10421</span><span class="NLM_x">–</span> <span class="NLM_lpage">10431</span><span class="refDoi"> DOI: 10.1128/JVI.00996-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00996-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24920792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yktrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=10421-10431&author=J.+Wuauthor=S.+Huangauthor=X.+Zhaoauthor=M.+Chenauthor=Y.+Linauthor=Y.+Xiaauthor=C.+Sunauthor=X.+Yangauthor=J.+Wangauthor=Y.+Guoauthor=J.+Songauthor=E.+Zhangauthor=B.+Wangauthor=X.+Zhengauthor=J.+F.+Schlaakauthor=M.+Luauthor=D.+Yang&title=Poly%28I%3AC%29+treatment+leads+to+interferon-dependent+clearance+of+hepatitis+B+virus+in+a+hydrodynamic+injection+mouse+model&doi=10.1128%2FJVI.00996-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model</span></div><div class="casAuthors">Wu, Jun; Huang, Shunmei; Zhao, Xiaoli; Chen, Mingfa; Lin, Yong; Xia, Youchen; Sun, Chan; Yang, Xuecheng; Wang, Junzhong; Guo, Yan; Song, Jingjiao; Zhang, Ejuan; Wang, Baoju; Zheng, Xin; Schlaak, Joerg F.; Lu, Mengji; Yang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10421-10431, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We have previously shown that poly(I:C) activates murine hepatic cells to produce interferon (IFN) and suppresses hepatitis B virus (HBV) replication in vitro.  Therefore, we addressed whether poly(I:C) is able to induce the clearance of HBV in vivo.  The chronic HBV replication mouse model was established by the hydrodynamic injection (HI) of pAAV-HBV1.2 into the tail veins of wild-type and IFN-α/βR-, IFN-γ-, and CXCR3-deficient C57BL/6 mice.  Fourteen days post-HI of pAAV-HBV1.2, mice were administered poly(I:C) by i.p. injection, i.m. injection, or HI.  Only treatment of poly(I:C) by HI led to HBV clearance in wild-type C57BL/6 mice.  Serum HBsAg disappeared within 40 days postinfection (dpi) in mice that received poly(I:C) by HI, and this was accompanied by the appearance of anti-HBs antibodies.  HBV-specific T-cell and antibody responses were significantly enhanced by HI of poly(I:C).  HBV replication intermediates and HBcAg-pos. hepatocytes were eliminated in the liver.  HI of poly(I:C) induced the prodn. of IFNs in mice and enhanced the levels of cytokines, IFN-stimulated genes, and T-cell markers in the liver.  Importantly, poly(I:C)-induced HBV clearance was impaired in IFN-α/βR-, IFN-γ-, and CXCR3-deficient mice, indicating that the induction of type I IFN and the stimulation and recruitment of T cells into the liver are essential for HBV clearance in this model.  Taken together, the application of poly(I:C) by HI into the liver enhances innate and adaptive immune responses and leads to HBV clearance in an HBV mouse model, implicating the potential of intrahepatic Toll-like receptor 3 (TLR3) activation for the treatment of chronic hepatitis B patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3OMxRsoQOLVg90H21EOLACvtfcHk0ljSgAqBdZYM-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yktrjF&md5=7d063d4c2b61ff3d8da276df3edf431a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1128%2FJVI.00996-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00996-14%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DD.%26atitle%3DPoly%2528I%253AC%2529%2520treatment%2520leads%2520to%2520interferon-dependent%2520clearance%2520of%2520hepatitis%2520B%2520virus%2520in%2520a%2520hydrodynamic%2520injection%2520mouse%2520model%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D10421%26epage%3D10431%26doi%3D10.1128%2FJVI.00996-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span> </span><span class="NLM_article-title">Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication</span> <span class="citation_source-journal">Zhonghua Ganzangbing Zazhi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">838</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12isbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=838-842&author=J.+Wuauthor=M.+F.+Chenauthor=Y.+C.+Xiaauthor=Y.+Guoauthor=Y.+Linauthor=C.+Sunauthor=C.+Y.+Zhangauthor=Y.+Chenauthor=S.+P.+Liuauthor=Y.+H.+Haoauthor=M.+J.+Luauthor=J.+F.+Schlaakauthor=D.+L.+Yang&title=Toll-like+receptor+dependent+innate+immune+responses+by+primary+mouse+hepatocytes+and+its+control+of+HBV+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication</span></div><div class="casAuthors">Wu, Jun; Chen, Mingfa; Xia, Youchen; Guo, Yan; Lin, Yong; Sun, Chan; Zhang, Chunyan; Chen, Yan; Liu, Shenpei; Hao, Youhua; Lu, Mengji; Schlaak, Jorg F.; Yang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua Ganzangbing Zazhi</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">838-842</span>CODEN:
                <span class="NLM_cas:coden">ZGZZFE</span>;
        ISSN:<span class="NLM_cas:issn">1007-3418</span>.
    
            (<span class="NLM_cas:orgname">Chongqing Yike Daxue, Dier Linchuang Xueyuan</span>)
        </div><div class="casAbstract">This report aimed to investigate the Toll-like receptor (TLR) signaling pathways and induced antiviral activity in hepatocytes.  We isolated primary hepatocytes from wild-type C57BL/6 mice and examd. the expression of TLR by real-time RT-PCR.  Hepatocytes were stimulated with TLR 1-9 agonists and the supernatants were harvested.  The secretion of cytokines was tested by ELISA.  The antiviral effectors in supernatants were assayed via virus protection assay (in EMCV system) and the control of HBV replication was assessed via Southern blotting (in HBV system).  We demonstrated that hepatocytes expressed TLR1-9.  In accordance with these TLR expression profiles, hepatocytes responded to all TLR ligands by producing inflammatory cytokines (TNF-α or IL-6), to TLR-1, -3, -7 and -9 ligands by producing type I IFN (IFN-α or IFN-β).  Only TLR 3 and TLR 7 agonists could stimulate the prodn. of high amts. of antiviral mediators by hepatocytes in virus protection assay.  By contrast, supernatants from TLR1, -3 and -4 directly stimulated hepatocytes and TLR 3, -7 and -9 transfected hepatocytes were able to potently suppress HBV replication.  Primary hepatocytes display a unique TLR signaling pathway and can control HBV replication after stimulation by TLR agonists in mice.  It may be helpful for the development of TLR-based therapeutic approaches against hepatotropism virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHkJmZGBAInrVg90H21EOLACvtfcHk0ljSgAqBdZYM-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12isbfM&md5=97a4d000c28f301fd33cc12b9ebb1a87</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DM.%2BF.%26aulast%3DXia%26aufirst%3DY.%2BC.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%2BP.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DToll-like%2520receptor%2520dependent%2520innate%2520immune%2520responses%2520by%2520primary%2520mouse%2520hepatocytes%2520and%2520its%2520control%2520of%2520HBV%2520replication%26jtitle%3DZhonghua%2520Ganzangbing%2520Zazhi%26date%3D2011%26volume%3D19%26spage%3D838%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groothuismink, Z. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruijne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotho, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Vliet, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Wetering de Rooij, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de-Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span> </span><span class="NLM_article-title">Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via toll-like receptor 7</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.3851/IMP2023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=657-667&author=A.+Boonstraauthor=B.+S.+Liuauthor=Z.+M.+A.+Groothuisminkauthor=J.+F.+Bergmannauthor=J.+de+Bruijneauthor=D.+M.+Hothoauthor=B.+E.+Hansenauthor=A.+A.+van+Vlietauthor=J.+V.+van+de+Wetering+de+Rooijauthor=S.+P.+Fletcherauthor=L.+A.+Baumanauthor=M.+Rahimyauthor=J.+R.+Applemanauthor=J.+L.+Freddoauthor=H.+W.+Reesinkauthor=R.+J.+de-Knegtauthor=H.+L.+A.+Janssen&title=Potent+immune+activation+in+chronic+hepatitis+C+patients+upon+administration+of+an+oral+inducer+of+endogenous+interferons+that+acts+via+toll-like+receptor+7&doi=10.3851%2FIMP2023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3851%2FIMP2023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2023%26sid%3Dliteratum%253Aachs%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DB.%2BS.%26aulast%3DGroothuismink%26aufirst%3DZ.%2BM.%2BA.%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DHotho%26aufirst%3DD.%2BM.%26aulast%3DHansen%26aufirst%3DB.%2BE.%26aulast%3Dvan%2BVliet%26aufirst%3DA.%2BA.%26aulast%3Dvan%2Bde%2BWetering%2Bde%2BRooij%26aufirst%3DJ.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DBauman%26aufirst%3DL.%2BA.%26aulast%3DRahimy%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3Dde-Knegt%26aufirst%3DR.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26atitle%3DPotent%2520immune%2520activation%2520in%2520chronic%2520hepatitis%2520C%2520patients%2520upon%2520administration%2520of%2520an%2520oral%2520inducer%2520of%2520endogenous%2520interferons%2520that%2520acts%2520via%2520toll-like%2520receptor%25207%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D657%26epage%3D667%26doi%3D10.3851%2FIMP2023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Bergmann, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruijne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotho, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van-Vliet, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van-de-Wetering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span> </span><span class="NLM_article-title">Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2011.04745.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1365-2036.2011.04745.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21707679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=443-453&author=J.+F.+Bergmannauthor=J.+de+Bruijneauthor=D.+M.+Hothoauthor=R.+J.+de+Knegtauthor=A.+Boonstraauthor=C.+J.+Weeginkauthor=A.+A.+van-Vlietauthor=J.+van-de-Weteringauthor=S.+P.+Fletcherauthor=L.+A.+Baumanauthor=M.+Rahimyauthor=J.+R.+Applemanauthor=J.+L.+Freddoauthor=H.+L.+A.+Janssenauthor=H.+W.+Reesink&title=Randomised+clinical+trial%3A+anti-viral+activity+of+ANA773%2C+an+oral+inducer+of+endogenous+interferons+acting+via+TLR7%2C+in+chronic+HCV&doi=10.1111%2Fj.1365-2036.2011.04745.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV</span></div><div class="casAuthors">Bergmann, J. F.; de Bruijne, J.; Hotho, D. M.; de Knegt, R. J.; Boonstra, A.; Weegink, C. J.; van Vliet, A. A.; van de Wetering, J.; Fletcher, S. P.; Bauman, L. A.; Rahimy, M.; Appleman, J. R.; Freddo, J. L.; Janssen, H. L. A.; Reesink, H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-453</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The ANA773 is an oral prodrug of a small-mol. toll-like receptor (TLR)7 agonist.  Preclin. and healthy volunteer clin. studies with ANA773 have demonstrated induction of endogenous interferon-α (IFN-α) of multiple subtypes, which supports the potential utility in the treatment of chronic hepatitis C virus (HCV) infection.  Aim: To examine safety, tolerability, pharmacodynamics, pharmacokinetics and anti-viral activity of ANA773.  Methods: The ANA773 was investigated in a double-blind, placebo-controlled study in 34 patients chronically infected with HCV of any genotype.  Patients were treatment-naive or had relapsed following previous interferon-based treatment.  This dose escalation study was composed of four dose groups (800, 1200, 1600 and 2000 mg).  In each group, six to eight patients received ANA773 and two received placebo.  Patients were dosed with ANA773 every-other-day for either 28 days (800, 1200 or 1600 mg) or 10 days (2000 mg).  Results: Mild to moderate adverse events were reported, with an increase in frequency and intensity with increasing dose.  No serious AEs were reported and there were no early discontinuations.  There were dose-related increases in various markers of IFN-α response.  The mean max. change in serum HCV RNA level from baseline was -0.34, -0.29, -0.40, -0.97 and -1.26 log10 in the placebo, 800, 1200, 1600 and 2000 mg cohorts, resp.  At the 2000 mg dose, ANA773 significantly (P = 0.037) reduced serum HCV RNA levels (range: 0.14 to -3.10 log10).  Conclusion: The ANA773 was generally well tolerated and resulted in a dose-related IFN-dependent response leading to a significant decrease in serum HCV RNA levels in the 2000 mg dose group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsKL6ETdoGvbVg90H21EOLACvtfcHk0lg18OcW91ffRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjtLfI&md5=62c9aba2d263f87170d4b45673fad597</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2011.04745.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2011.04745.x%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DHotho%26aufirst%3DD.%2BM.%26aulast%3Dde%2BKnegt%26aufirst%3DR.%2BJ.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DWeegink%26aufirst%3DC.%2BJ.%26aulast%3Dvan-Vliet%26aufirst%3DA.%2BA.%26aulast%3Dvan-de-Wetering%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DBauman%26aufirst%3DL.%2BA.%26aulast%3DRahimy%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26atitle%3DRandomised%2520clinical%2520trial%253A%2520anti-viral%2520activity%2520of%2520ANA773%252C%2520an%2520oral%2520inducer%2520of%2520endogenous%2520interferons%2520acting%2520via%2520TLR7%252C%2520in%2520chronic%2520HCV%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D34%26spage%3D443%26epage%3D453%26doi%3D10.1111%2Fj.1365-2036.2011.04745.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Kurimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sajiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5501</span><span class="NLM_x">–</span> <span class="NLM_lpage">5508</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.09.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2003.09.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5501-5508&author=A.+Kurimotoauthor=T.+Oginoauthor=S.+Ichiiauthor=Y.+Isobeauthor=M.+Tobeauthor=H.+Ogitaauthor=H.+Takakuauthor=H.+Sajikiauthor=K.+Hirotaauthor=H.+Kawakami&title=Synthesis+and+structure-activity+relationships+of+2-amino-8-hydroxyadenines+as+orally+active+interferon+inducing+agents&doi=10.1016%2Fj.bmc.2003.09.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.09.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.09.032%26sid%3Dliteratum%253Aachs%26aulast%3DKurimoto%26aufirst%3DA.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DIchii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DOgita%26aufirst%3DH.%26aulast%3DTakaku%26aufirst%3DH.%26aulast%3DSajiki%26aufirst%3DH.%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25202-amino-8-hydroxyadenines%2520as%2520orally%2520active%2520interferon%2520inducing%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5501%26epage%3D5508%26doi%3D10.1016%2Fj.bmc.2003.09.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Kurimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sajiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, H.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2003.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=14980621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFWht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1091-1099&author=A.+Kurimotoauthor=T.+Oginoauthor=S.+Ichiiauthor=Y.+Isobeauthor=M.+Tobeauthor=H.+Ogitaauthor=H.+Takakuauthor=H.+Sajikiauthor=K.+Hirotaauthor=H.+Kawakami&title=Synthesis+and+evaluation+of+2-substituted+8-hydroxyadenines+as+potent+interferon+inducers+with+improved+oral+bioavailabilities&doi=10.1016%2Fj.bmc.2003.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities</span></div><div class="casAuthors">Kurimoto, Ayumu; Ogino, Tetsuhiro; Ichii, Shinji; Isobe, Yoshiaki; Tobe, Masanori; Ogita, Haruhisa; Takaku, Haruo; Sajiki, Hironao; Hirota, Kosaku; Kawakami, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1091-1099</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In order to create novel compds. which possess potent interferon (IFN) inducing activities with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various alkoxy or alkylthio moieties at the adenine C(2)-position, were synthesized and evaluated.  The introduction of hydrophobic groups was not considered to be effective for potentiating the IFN-inducing activity, but several compds. having hydrophilic groups were effective.  Among the compds. tested, compd. I induced IFN from the dosage of 0.03 mg/kg, which was approx. 100-fold more potent than that of Imiquimod, and showed an excellent oral bioavailability (F=40%) which was 10-fold improved over the lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqY8-Ou6UMlbVg90H21EOLACvtfcHk0li8AyPdJ3cStg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFWht7g%253D&md5=7786077b1ccac729aaaa96ec4254c1cf</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DKurimoto%26aufirst%3DA.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DIchii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DOgita%26aufirst%3DH.%26aulast%3DTakaku%26aufirst%3DH.%26aulast%3DSajiki%26aufirst%3DH.%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202-substituted%25208-hydroxyadenines%2520as%2520potent%2520interferon%2520inducers%2520with%2520improved%2520oral%2520bioavailabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D1091%26epage%3D1099%26doi%3D10.1016%2Fj.bmc.2003.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Roethle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadden, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrvatin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graupe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duatschek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span> </span><span class="NLM_article-title">Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7324</span><span class="NLM_x">–</span> <span class="NLM_lpage">7333</span><span class="refDoi"> DOI: 10.1021/jm400815m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400815m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7324-7333&author=P.+A.+Roethleauthor=R.+M.+McFaddenauthor=H.+Yangauthor=P.+Hrvatinauthor=H.+Huiauthor=M.+Graupeauthor=B.+Gallagherauthor=J.+Chaoauthor=J.+Hesselgesserauthor=P.+Duatschekauthor=J.+Zhengauthor=B.+Luauthor=D.+B.+Tumasauthor=J.+Perryauthor=R.+L.+Halcomb&title=Identification+and+optimization+of+pteridinone+toll-like+receptor+7+%28TLR7%29+agonists+for+the+oral+treatment+of+viral+hepatitis&doi=10.1021%2Fjm400815m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span></div><div class="casAuthors">Roethle, Paul A.; McFadden, Ryan M.; Yang, Hong; Hrvatin, Paul; Hui, Hon; Graupe, Michael; Gallagher, Brian; Chao, Jessica; Hesselgesser, Joseph; Duatschek, Paul; Zheng, Jim; Lu, Bing; Tumas, Daniel B.; Perry, Jason; Halcomb, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7324-7333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620 (I).  Analogs were optimized for the immunomodulatory activity and selectivity vs. other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α).  In addn., physicochem. properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties.  GS-9620 is currently in clin. evaluation for the treatment of chronic hepatitis B (HBV) infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2wrWq68pK7Vg90H21EOLACvtfcHk0li8AyPdJ3cStg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL&md5=753aa20b0d0f9b16eb3a1d205fbe0a30</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm400815m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400815m%26sid%3Dliteratum%253Aachs%26aulast%3DRoethle%26aufirst%3DP.%2BA.%26aulast%3DMcFadden%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHrvatin%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DGraupe%26aufirst%3DM.%26aulast%3DGallagher%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DDuatschek%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520pteridinone%2520toll-like%2520receptor%25207%2520%2528TLR7%2529%2520agonists%2520for%2520the%2520oral%2520treatment%2520of%2520viral%2520hepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7324%26epage%3D7333%26doi%3D10.1021%2Fjm400815m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Jurk, M. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="refDoi"> DOI: 10.1038/ni0602-499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fni0602-499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12032557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=499&author=M.+H.+F.+Jurkauthor=F.+Heilauthor=J.+Vollmerauthor=C.+Schetterauthor=A.+M.+Kriegauthor=H.+Wagnerauthor=G.+Lipfordauthor=S.+Bauer&title=Human+TLR7+or+TLR8+independently+confer+responsiveness+to+the+antiviral+compound+R-848&doi=10.1038%2Fni0602-499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848</span></div><div class="casAuthors">Jurk, Marion; Heil, Florian; Vollmer, Joerg; Schetter, Christian; Krieg, Arthur M.; Wagner, Hermann; Lipford, Grayson; Bauer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">In their quest to identify ligands for TLRs, the authors found that the antiviral immunostimulant drug imidazoquinoline resiquimod R-848 induced NF-κB activation in HEK293 cells transfected with human TLR8 in a dose-dependent manner.  The results of the study showed that both human TLR7 and TLR* can independently mediate recognition of the same antiviral compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonRoNyuBI4w7Vg90H21EOLACvtfcHk0ljldfENJJnSvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFOmsLo%253D&md5=f8d7a53ffd849013dba07c33807ccc8f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fni0602-499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni0602-499%26sid%3Dliteratum%253Aachs%26aulast%3DJurk%26aufirst%3DM.%2BH.%2BF.%26aulast%3DHeil%26aufirst%3DF.%26aulast%3DVollmer%26aufirst%3DJ.%26aulast%3DSchetter%26aufirst%3DC.%26aulast%3DKrieg%26aufirst%3DA.%2BM.%26aulast%3DWagner%26aufirst%3DH.%26aulast%3DLipford%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DHuman%2520TLR7%2520or%2520TLR8%2520independently%2520confer%2520responsiveness%2520to%2520the%2520antiviral%2520compound%2520R-848%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D499%26doi%3D10.1038%2Fni0602-499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Lanford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavedoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodara, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasky, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosdick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfgang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span> </span><span class="NLM_article-title">GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">1508</span><span class="NLM_x">–</span> <span class="NLM_lpage">1517</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2013.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2013&pages=1508-1517&author=R.+E.+Lanfordauthor=B.+Guerraauthor=D.+Chavezauthor=L.+Giavedoniauthor=V.+L.+Hodaraauthor=K.+M.+Braskyauthor=A.+Fosdickauthor=C.+R.+Freyauthor=J.+Zhengauthor=G.+Wolfgangauthor=R.+L.+Halcombauthor=D.+B.+Tumas&title=GS-9620%2C+an+oral+agonist+of+Toll-like+receptor-7%2C+induces+prolonged+suppression+of+hepatitis+B+virus+in+chronically+infected+chimpanzees&doi=10.1053%2Fj.gastro.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLanford%26aufirst%3DR.%2BE.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DGiavedoni%26aufirst%3DL.%26aulast%3DHodara%26aufirst%3DV.%2BL.%26aulast%3DBrasky%26aufirst%3DK.%2BM.%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWolfgang%26aufirst%3DG.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DGS-9620%252C%2520an%2520oral%2520agonist%2520of%2520Toll-like%2520receptor-7%252C%2520induces%2520prolonged%2520suppression%2520of%2520hepatitis%2520B%2520virus%2520in%2520chronically%2520infected%2520chimpanzees%26jtitle%3DGastroenterology%26date%3D2013%26volume%3D144%26spage%3D1508%26epage%3D1517%26doi%3D10.1053%2Fj.gastro.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Fosdick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfgang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1124/jpet.113.207878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1124%2Fjpet.113.207878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24133297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=96-105&author=A.+Fosdickauthor=J.+Zhengauthor=S.+Pflanzauthor=C.+R.+Freyauthor=J.+Hesselgesserauthor=R.+L.+Halcombauthor=G.+Wolfgangauthor=D.+B.+Tumas&title=Pharmacokinetic+and+pharmacodynamic+properties+of+GS-9620%2C+a+novel+toll-like+receptor+7+agonist%2C+demonstrate+interferon-stimulated+gene+induction+without+detectable+serum+interferon+at+low+oral+doses&doi=10.1124%2Fjpet.113.207878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses</span></div><div class="casAuthors">Fosdick, Abigail; Zheng, Jim; Pflanz, Stefan; Frey, Christian R.; Hesselgesser, Joseph; Halcomb, Randall L.; Wolfgang, Grushenka; Tumas, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-mol. agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects assocd. with current systemic interferon-a (IFN-α) therapies.  We characterized the pharmacodynamic response of GS-9620 in CD-1 mice and cynomolgus monkeys following i.v. or oral administration and showed that GS-9620 induces the prodn. of select chemokines and cytokines, including IFN-α and interferon-stimulated genes (ISGs).  It is noteworthy that we also demonstrated that, in animals and healthy human volunteers, oral administration of GS-9620 can induce a type I interferon-dependent antiviral innate immune response, as measured by whole-blood mRNA of the ISGs 2'5'-oligoadenylate synthetase 1 (OAS1) and myxovirus resistance 1 (MX1), without the induction of detectable systemic IFN-α, i.e., a presystemic response.  Addnl., presystemic induction of hepatic OAS1 and MX1 mRNA was obsd. in CD-1 mice in the absence of detectable systemic IFN-α.  We propose that the mechanism of this presystemic response is likely its high intestinal absorption, which facilitates localized activation of TLR7, probably in plasmacytoid dendritic cells at the level of gut-assocd. lymphoid tissue and/or the liver.  This localized response is further supported by data that indicate only minimal contributions of systemic immune stimulation to the overall pharmacodynamic response to orally administered GS-9620.  These data demonstrate that GS-9620 can induce an antiviral innate immune response without inducing a systemic IFN-α response and thus suggest the therapeutic potential of this approach in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGLt0m-dYGx7Vg90H21EOLACvtfcHk0ljldfENJJnSvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjurw%253D&md5=002591f8338f6bfacaaa13be4297cf87</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207878%26sid%3Dliteratum%253Aachs%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26aulast%3DWolfgang%26aufirst%3DG.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520properties%2520of%2520GS-9620%252C%2520a%2520novel%2520toll-like%2520receptor%25207%2520agonist%252C%2520demonstrate%2520interferon-stimulated%2520gene%2520induction%2520without%2520detectable%2520serum%2520interferon%2520at%2520low%2520oral%2520doses%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fjpet.113.207878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visvanathan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorak, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. J.</span><span> </span><span class="NLM_article-title">The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2015.02.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25733157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=320-328&author=E.+J.+Ganeauthor=Y.-S.+Limauthor=S.+C.+Gordonauthor=K.+Visvanathanauthor=E.+Sicardauthor=R.+N.+Fedorakauthor=S.+Robertsauthor=B.+Massettoauthor=Z.+Yeauthor=S.+Pflanzauthor=K.+L.+Garrisonauthor=A.+Gaggarauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=S.+Kottililauthor=B.+Freilichauthor=C.+S.+Coffinauthor=W.+Chengauthor=Y.+J.+Kim&title=The+oral+toll-like+receptor-7+agonist+GS-9620+in+patients+with+chronic+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2015.02.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection</span></div><div class="casAuthors">Gane, Edward J.; Lim, Young-Suk; Gordon, Stuart C.; Visvanathan, Kumar; Sicard, Eric; Fedorak, Richard N.; Roberts, Stuart; Massetto, Benedetta; Ye, Zhishen; Pflanz, Stefan; Garrison, Kimberly L.; Gaggar, Anuj; Mani Subramanian, G.; McHutchison, John G.; Kottilil, Shyamasundaran; Freilich, Bradley; Coffin, Carla S.; Cheng, Wendy; Kim, Yoon Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-328</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GS-9620 is an oral agonist of toll-like receptor 7, a pattern-recognition receptor whose activation results in innate and adaptive immune stimulation.  We evaluated the safety, pharmacokinetics, and pharmacodynamics of GS-9620 in patients with chronic hepatitis B.  In two double-blind, phase 1b trials of identical design, 49 treatment-naive and 51 virol. suppressed patients were randomized 5:1 to receive GS-9620 (at doses of 0.3 mg, 1 mg, 2 mg, 4 mg) or placebo as a single dose or as two doses seven days apart.  Pharmacodynamic assessment included evaluation of peripheral mRNA expression of interferon-stimulated gene 15 (ISG15), serum interferon gamma-induced protein 10 and serum interferon (IFN)-alpha.  Overall, 74% of patients were male and 75% were HBeAg neg. at baseline.  No subject discontinued treatment due to adverse events.  Fifty-eight percent experienced ≥1 adverse event, all of which were mild to moderate in severity.  The most common adverse event was headache.  No clin. significant changes in HBsAg or HBV DNA levels were obsd.  Overall, a transient dose-dependent induction of peripheral ISG15 gene expression was obsd. peaking within 48 h of dosing followed by return to baseline levels within seven days.  Higher GS-9620 dose, HBeAg pos. status, and low HBsAg level at baseline were independently assocd. with greater probability of ISG15 response.  Most patients (88%) did not show detectable levels of serum IFN-alpha at any time point.  Oral GS-9620 was safe, well tolerated, and assocd. with induction of peripheral ISG15 prodn. in the absence of significant systemic IFN-alpha levels or related symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdIo77Po2by7Vg90H21EOLACvtfcHk0lj5uSSeFzP67g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCnurc%253D&md5=51aa5f91d1002dc228abf96a93602791</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DLim%26aufirst%3DY.-S.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DVisvanathan%26aufirst%3DK.%26aulast%3DSicard%26aufirst%3DE.%26aulast%3DFedorak%26aufirst%3DR.%2BN.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DGarrison%26aufirst%3DK.%2BL.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DCoffin%26aufirst%3DC.%2BS.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26atitle%3DThe%2520oral%2520toll-like%2520receptor-7%2520agonist%2520GS-9620%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D320%26epage%3D328%26doi%3D10.1016%2Fj.jhep.2015.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">708</span><span class="refDoi"> DOI: 10.3851/IMP2845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2845" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=699-708&author=E.+Lawitzauthor=D.+Gruenerauthor=T.+Marburyauthor=J.+Hillauthor=L.+Websterauthor=D.+Hassmanauthor=A.+H.+Nguyenauthor=S.+Pflanzauthor=E.+Mogalianauthor=A.+Gaggarauthor=B.+Massettoauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=I.+M.+Jacobsonauthor=B.+Freilichauthor=M.+Rodriguez-Torres&title=Safety%2C+pharmacokinetics+and+pharmacodynamics+of+the+oral+toll-like+receptor+7+agonist+GS-9620+in+treatment-naive+patients+with+chronic+hepatitis+C&doi=10.3851%2FIMP2845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3851%2FIMP2845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2845%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGruener%26aufirst%3DD.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DA.%2BH.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520the%2520oral%2520toll-like%2520receptor%25207%2520agonist%2520GS-9620%2520in%2520treatment-naive%2520patients%2520with%2520chronic%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Ther.%26date%3D2015%26volume%3D20%26spage%3D699%26epage%3D708%26doi%3D10.3851%2FIMP2845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akira, S.</span><span> </span><span class="NLM_article-title">Antiviral signaling through pattern recognition receptors</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span><span class="refDoi"> DOI: 10.1093/jb/mvm032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Fjb%2Fmvm032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17190786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltF2it7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2007&pages=137-145&author=T.+Kawaiauthor=S.+Akira&title=Antiviral+signaling+through+pattern+recognition+receptors&doi=10.1093%2Fjb%2Fmvm032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral signaling through pattern recognition receptors</span></div><div class="casAuthors">Kawai, Taro; Akira, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-145</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">A review.  Viral infection is detected by the host innate immune system.  Innate immune cells such as dendritic cells and macrophages detect nucleic acids derived from viruses through pattern recognition receptors (PRRs).  Viral recognition by PRRs initiates the activation of signaling pathways that lead to prodn. of type I interferon and inflammatory cytokines, which are important for the elimination of viruses.  Two types of PRRs that recognize viral nucleic acids, Toll-like receptors (TLR) and RIG-I-like RNA helicases (RLH), have been identified.  Of the TLRs, TLR3 recognizes viral double-stranded (ds) RNA, TLR7 and human TLR8 identify viral single-stranded (ss) RNA and TLR9 detects viral DNA.  TLRs are located in endosomal compartments, whereas RLH are present in the cytoplasm where they detect viral dsRNA or ssRNA.  Here the authors review the role of TLRs and RLHs in the antiviral innate immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjoRNXj3KSbLVg90H21EOLACvtfcHk0lj5uSSeFzP67g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltF2it7w%253D&md5=823993e4611230830fe639ed23ef6534</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1093%2Fjb%2Fmvm032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjb%252Fmvm032%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DAkira%26aufirst%3DS.%26atitle%3DAntiviral%2520signaling%2520through%2520pattern%2520recognition%2520receptors%26jtitle%3DJ.%2520Biochem.%26date%3D2007%26volume%3D141%26spage%3D137%26epage%3D145%26doi%3D10.1093%2Fjb%2Fmvm032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trippler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczeponek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span> </span><span class="NLM_article-title">Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1769</span><span class="NLM_x">–</span> <span class="NLM_lpage">1778</span><span class="refDoi"> DOI: 10.1002/hep.21897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.21897" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=1769-1778&author=J.+Wuauthor=M.+Luauthor=Z.+Mengauthor=M.+Tripplerauthor=R.+Broeringauthor=A.+Szczeponekauthor=F.+Kruxauthor=U.+Dittmerauthor=M.+Roggendorfauthor=G.+Gerkenauthor=J.+F.+Schlaak&title=Toll-like+receptor-mediated+control+of+HBV+replication+by+nonparenchymal+liver+cells+in+mice&doi=10.1002%2Fhep.21897"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fhep.21897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21897%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DTrippler%26aufirst%3DM.%26aulast%3DBroering%26aufirst%3DR.%26aulast%3DSzczeponek%26aufirst%3DA.%26aulast%3DKrux%26aufirst%3DF.%26aulast%3DDittmer%26aufirst%3DU.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26atitle%3DToll-like%2520receptor-mediated%2520control%2520of%2520HBV%2520replication%2520by%2520nonparenchymal%2520liver%2520cells%2520in%2520mice%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D1769%26epage%3D1778%26doi%3D10.1002%2Fhep.21897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althage, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immune effectors required for hepatitis B virus clearance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">798</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1073/pnas.0913498107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0913498107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=798-802&author=P.+L.+Yangauthor=A.+Althageauthor=J.+Chungauthor=H.+Maierauthor=S.+Wielandauthor=M.+Isogawaauthor=F.+V.+Chisari&title=Immune+effectors+required+for+hepatitis+B+virus+clearance&doi=10.1073%2Fpnas.0913498107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0913498107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0913498107%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DAlthage%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmune%2520effectors%2520required%2520for%2520hepatitis%2520B%2520virus%2520clearance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D798%26epage%3D802%26doi%3D10.1073%2Fpnas.0913498107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Ebert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stutz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojaimi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baschuk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachbur, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torresi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, M.</span><span> </span><span class="NLM_article-title">Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5797</span><span class="NLM_x">–</span> <span class="NLM_lpage">5802</span><span class="refDoi"> DOI: 10.1073/pnas.1502390112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1502390112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25902529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5797-5802&author=G.+Ebertauthor=S.+Prestonauthor=C.+Allisonauthor=J.+Cooneyauthor=J.+G.+Toeauthor=M.+D.+Stutzauthor=S.+Ojaimiauthor=H.+W.+Scottauthor=N.+Baschukauthor=U.+Nachburauthor=J.+Torresiauthor=R.+Chinauthor=D.+Colledgeauthor=X.+Liauthor=N.+Warnerauthor=P.+Revillauthor=S.+Bowdenauthor=J.+Silkeauthor=C.+G.+Begleyauthor=M.+Pellegrini&title=Cellular+inhibitor+of+apoptosis+proteins+prevent+clearance+of+hepatitis+B+virus&doi=10.1073%2Fpnas.1502390112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus</span></div><div class="casAuthors">Ebert, Gregor; Preston, Simon; Allison, Cody; Cooney, James; Toe, Jesse G.; Stutz, Michael D.; Ojaimi, Samar; Scott, Hamish W.; Baschuk, Nikola; Nachbur, Ueli; Torresi, Joseph; Chin, Ruth; Colledge, Danielle; Li, Xin; Warner, Nadia; Revill, Peter; Bowden, Scott; Silke, John; Begley, C. Glenn; Pellegrini, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5797-5802</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) infection can result in a spectrum of outcomes from immune-mediated control to disease progression, cirrhosis, and liver cancer.  The host mol. pathways that influence and contribute to these outcomes need to be defined.  Using an immunocompetent mouse model of chronic HBV infection, we identified some of the host cellular and mol. factors that impact on infection outcomes.  Here, we show that cellular inhibitor of apoptosis proteins (cIAPs) attenuate TNF signaling during hepatitis B infection, and they restrict the death of infected hepatocytes, thus allowing viral persistence.  Animals with a liver-specific cIAP1 and total cIAP2 deficiency efficiently control HBV infection compared with WT mice.  This phenotype was partly recapitulated in mice that were deficient in cIAP2 alone.  These results indicate that antagonizing the function of cIAPs may promote the clearance of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5MHwS37sJbVg90H21EOLACvtfcHk0lhkTpMM6l26Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLg%253D&md5=098384720ec928dc72c3b0c41bb88d02</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502390112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502390112%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DG.%26aulast%3DPreston%26aufirst%3DS.%26aulast%3DAllison%26aufirst%3DC.%26aulast%3DCooney%26aufirst%3DJ.%26aulast%3DToe%26aufirst%3DJ.%2BG.%26aulast%3DStutz%26aufirst%3DM.%2BD.%26aulast%3DOjaimi%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DH.%2BW.%26aulast%3DBaschuk%26aufirst%3DN.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DTorresi%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DN.%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DBowden%26aufirst%3DS.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DBegley%26aufirst%3DC.%2BG.%26aulast%3DPellegrini%26aufirst%3DM.%26atitle%3DCellular%2520inhibitor%2520of%2520apoptosis%2520proteins%2520prevent%2520clearance%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5797%26epage%3D5802%26doi%3D10.1073%2Fpnas.1502390112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Ebert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stutz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojaimi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baschuk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachbur, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torresi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, M.</span><span> </span><span class="NLM_article-title">Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5803</span><span class="NLM_x">–</span> <span class="NLM_lpage">5808</span><span class="refDoi"> DOI: 10.1073/pnas.1502400112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1502400112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25902530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5803-5808&author=G.+Ebertauthor=C.+Allisonauthor=S.+Prestonauthor=J.+Cooneyauthor=J.+G.+Toeauthor=M.+D.+Stutzauthor=S.+Ojaimiauthor=N.+Baschukauthor=U.+Nachburauthor=J.+Torresiauthor=J.+Silkeauthor=C.+G.+Begleyauthor=M.+Pellegrini&title=Eliminating+hepatitis+B+by+antagonizing+cellular+inhibitors+of+apoptosis&doi=10.1073%2Fpnas.1502400112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis</span></div><div class="casAuthors">Ebert, Gregor; Allison, Cody; Preston, Simon; Cooney, James; Toe, Jesse G.; Stutz, Michael D.; Ojaimi, Samar; Baschuk, Nikola; Nachbur, Ueli; Torresi, Joseph; Silke, John; Begley, C. Glenn; Pellegrini, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5803-5808</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We have shown that cellular inhibitor of apoptosis proteins (cIAPs) impair clearance of hepatitis B virus (HBV) infection by preventing TNF-mediated killing/death of infected cells.  A key question, with profound therapeutic implications, is whether this finding can be translated to the development of drugs that promote elimination of infected cells.  Drug inhibitors of cIAPs were developed as cancer therapeutics to promote TNF-mediated tumor killing.  These drugs are also known as Smac mimetics, because they mimic the action of the endogenous protein Smac/Diablo that antagonizes cIAP function.  Here, we show using an immunocompetent mouse model of chronic HBV infection that birinapant and other Smac mimetics are able to rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hepatocytes contg. HBV core antigen.  The efficacy of Smac mimetics in treating HBV infection is dependent on their chem., host CD4+ T cells, and TNF.  Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA prodn. in HBV-infected animals.  These results indicate that birinapant and other Smac mimetics may have efficacy in treating HBV infection and perhaps, other intracellular infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6fFsKqFdCAbVg90H21EOLACvtfcHk0lhkTpMM6l26Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLk%253D&md5=dd522bba71dfdeba3f9804c680745f78</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502400112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502400112%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DG.%26aulast%3DAllison%26aufirst%3DC.%26aulast%3DPreston%26aufirst%3DS.%26aulast%3DCooney%26aufirst%3DJ.%26aulast%3DToe%26aufirst%3DJ.%2BG.%26aulast%3DStutz%26aufirst%3DM.%2BD.%26aulast%3DOjaimi%26aufirst%3DS.%26aulast%3DBaschuk%26aufirst%3DN.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DTorresi%26aufirst%3DJ.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DBegley%26aufirst%3DC.%2BG.%26aulast%3DPellegrini%26aufirst%3DM.%26atitle%3DEliminating%2520hepatitis%2520B%2520by%2520antagonizing%2520cellular%2520inhibitors%2520of%2520apoptosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5803%26epage%3D5808%26doi%3D10.1073%2Fpnas.1502400112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">McClary, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guidotti, L. G.</span><span> </span><span class="NLM_article-title">Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2255</span><span class="NLM_x">–</span> <span class="NLM_lpage">2264</span><span class="refDoi"> DOI: 10.1128/JVI.74.5.2255-2264.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.74.5.2255-2264.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10666256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtF2kt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2255-2264&author=H.+McClaryauthor=R.+Kochauthor=F.+V.+Chisariauthor=L.+G.+Guidotti&title=Relative+sensitivity+of+hepatitis+B+virus+and+other+hepatotropic+viruses+to+the+antiviral+effects+of+cytokines&doi=10.1128%2FJVI.74.5.2255-2264.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines</span></div><div class="casAuthors">McClary, Heike; Koch, Rick; Chisari, Francis V.; Guidotti, Luca G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2255-2264</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The authors have previously shown that hepatitis B virus (HBV) replication is inhibited noncytopathically in the livers of transgenic mice following injection of HBV-specific cytotoxic T lymphocytes (CTLs) or infection with unrelated hepatotropic viruses, including lymphocytic choriomeningitis virus (LCMV) and adenovirus.  These effects are mediated by gamma interferon (IFNγ), tumor necrosis factor alpha (TNFα), and IFNα/β.  In the present study, the authors crossed HBV transgenic mice with mice genetically deficient for IFNγ (IFNγKO), the TNFα receptor (TNFαRKO), or the IFNα/β receptor (IFNα/βRKO) to det. the relative contribution of each cytokine to the antiviral effects obsd. in each of these systems.  Interestingly, the authors showed that HBV replicates in unmanipulated IFNγKO and IFNα/βRKO mice at levels higher than those obsd. in control mice, implying that baseline levels of these cytokines control HBV replication in the absence of inflammation.  The authors also showed that IFNγ mediates most of the antiviral effect of the CTLs while IFNα/β is primarily responsible for the early inhibitory effect of LCMV and adenovirus on HBV replication.  In addn., the authors showed that the hepatic induction of IFNα/β obsd. after injection of poly(I·C) is sufficient to inhibit HBV replication and that a similar antiviral effect is achieved by systemic administration of very high doses of IFNα.  The authors also compared the relative sensitivity of LCMV and adenovirus to control by IFNγ, TNFα, or IFNα/β in these animals.  Importantly, IFNα/βRKO mice, and to a lesser extent IFNγKO mice, showed higher hepatic levels of LCMV RNA and adenovirus DNA and RNA than control mice, underscoring the importance of both interferons in controlling these other viral infections as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTeQxPXCUCIrVg90H21EOLACvtfcHk0li3DJZ1yBS-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtF2kt7g%253D&md5=a7a856dc10b170399536a70e3b916af7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.5.2255-2264.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.5.2255-2264.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMcClary%26aufirst%3DH.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26atitle%3DRelative%2520sensitivity%2520of%2520hepatitis%2520B%2520virus%2520and%2520other%2520hepatotropic%2520viruses%2520to%2520the%2520antiviral%2520effects%2520of%2520cytokines%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26spage%3D2255%26epage%3D2264%26doi%3D10.1128%2FJVI.74.5.2255-2264.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprinzl, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppensteiner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remouchamps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thasler, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejardin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikenwalder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1126/science.1243462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1243462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24557838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=1221-1228&author=J.+Luciforaauthor=Y.+C.+Xiaauthor=F.+Reisingerauthor=K.+Zhangauthor=D.+Stadlerauthor=X.+M.+Chengauthor=M.+F.+Sprinzlauthor=H.+Koppensteinerauthor=Z.+Makowskaauthor=T.+Volzauthor=C.+Remouchampsauthor=W.+M.+Chouauthor=W.+E.+Thaslerauthor=N.+Huserauthor=D.+Durantelauthor=T.+J.+Liangauthor=C.+Munkauthor=M.+H.+Heimauthor=J.+L.+Browningauthor=E.+Dejardinauthor=M.+Dandriauthor=M.+Schindlerauthor=M.+Heikenwalderauthor=U.+Protzer&title=Specific+and+nonhepatotoxic+degradation+of+nuclear+hepatitis+B+virus+cccDNA&doi=10.1126%2Fscience.1243462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA</span></div><div class="casAuthors">Lucifora, Julie; Xia, Yuchen; Reisinger, Florian; Zhang, Ke; Stadler, Daniela; Cheng, Xiaoming; Sprinzl, Martin F.; Koppensteiner, Herwig; Makowska, Zuzanna; Volz, Tassilo; Remouchamps, Caroline; Chou, Wen-Min; Thasler, Wolfgang E.; Hueser, Norbert; Durantel, David; Liang, T. Jake; Muenk, Carsten; Heim, Markus H.; Browning, Jeffrey L.; Dejardin, Emmanuel; Dandri, Maura; Schindler, Michael; Heikenwalder, Mathias; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6176</span>),
    <span class="NLM_cas:pages">1221-1228</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Current antiviral agents can control but not eliminate hepatitis B virus (HBV), because HBV establishes a stable nuclear covalently closed circular DNA (cccDNA).  Interferon-α treatment can clear HBV but is limited by systemic side effects.  The authors describe how interferon-α can induce specific degrdn. of the nuclear viral DNA without hepatotoxicity and propose lymphotoxin-β receptor activation as a therapeutic alternative.  Interferon-α and lymphotoxin-β receptor activation up-regulated APOBEC3A and APOBEC3B cytidine deaminases, resp., in HBV-infected cells, primary hepatocytes, and human liver needle biopsies.  HBV core protein mediated the interaction with nuclear cccDNA, resulting in cytidine deamination, apurinic/apyrimidinic site formation, and finally cccDNA degrdn. that prevented HBV reactivation.  Genomic DNA was not affected.  Thus, inducing nuclear deaminases-for example, by lymphotoxin-β receptor activation-allows the development of new therapeutics that, in combination with existing antivirals, may cure hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrONjt8Ppl67rVg90H21EOLACvtfcHk0li3DJZ1yBS-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVygsrY%253D&md5=18855f5a52c98d6167a7a8468d55e9ce</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243462%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%2BC.%26aulast%3DReisinger%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DStadler%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DX.%2BM.%26aulast%3DSprinzl%26aufirst%3DM.%2BF.%26aulast%3DKoppensteiner%26aufirst%3DH.%26aulast%3DMakowska%26aufirst%3DZ.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DRemouchamps%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DW.%2BM.%26aulast%3DThasler%26aufirst%3DW.%2BE.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DMunk%26aufirst%3DC.%26aulast%3DHeim%26aufirst%3DM.%2BH.%26aulast%3DBrowning%26aufirst%3DJ.%2BL.%26aulast%3DDejardin%26aufirst%3DE.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DHeikenwalder%26aufirst%3DM.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DSpecific%2520and%2520nonhepatotoxic%2520degradation%2520of%2520nuclear%2520hepatitis%2520B%2520virus%2520cccDNA%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D1221%26epage%3D1228%26doi%3D10.1126%2Fscience.1243462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span> </span><span class="NLM_article-title">Efficient hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">36128</span><span class="NLM_x">–</span> <span class="NLM_lpage">36138</span><span class="refDoi"> DOI: 10.1074/jbc.M301069200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1074%2Fjbc.M301069200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=36128-36138&author=J.+Beckauthor=M.+Nassal&title=Efficient+hsp90-independent+in+vitro+activation+by+Hsc70+and+Hsp40+of+duck+hepatitis+B+virus+reverse+transcriptase%2C+an+assumed+Hsp90+client+protein&doi=10.1074%2Fjbc.M301069200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M301069200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M301069200%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DNassal%26aufirst%3DM.%26atitle%3DEfficient%2520hsp90-independent%2520in%2520vitro%2520activation%2520by%2520Hsc70%2520and%2520Hsp40%2520of%2520duck%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%252C%2520an%2520assumed%2520Hsp90%2520client%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D36128%26epage%3D36138%26doi%3D10.1074%2Fjbc.M301069200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Hu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D.</span><span> </span><span class="NLM_article-title">Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">13122</span><span class="NLM_x">–</span> <span class="NLM_lpage">13131</span><span class="refDoi"> DOI: 10.1128/JVI.78.23.13122-13131.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.78.23.13122-13131.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15542664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=13122-13131&author=J.+M.+Huauthor=D.+Floresauthor=D.+Toftauthor=X.+T.+Wangauthor=D.+Nguyen&title=Requirement+of+heat+shock+protein+90+for+human+hepatitis+B+virus+reverse+transcriptase+function&doi=10.1128%2FJVI.78.23.13122-13131.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function</span></div><div class="casAuthors">Hu, Jianming; Flores, Dafna; Toft, David; Wang, Xingtai; Nguyen, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13122-13131</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The initiation of reverse transcription and nucleocapsid assembly in hepatitis B virus (HBV) depends on the specific recognition of an RNA signal (the packaging signal, ε) on the pregenomic RNA (pgRNA) by the viral reverse transcriptase (RT).  RT-ε interaction in the duck hepatitis B virus (DHBV) was recently shown to require the mol. chaperone complex, the heat shock protein 90 (Hsp90).  However, the requirement for RT-ε interaction in the human HBV has remained unknown due to the inability to obtain a purified RT protein active in specific ε binding.  We now report that Hsp90 is also required for HBV RT-ε interaction.  Inhibition of Hsp90 led to diminished HBV pgRNA packaging into nucleocapsids in cells, which depends on RT-ε interaction.  Furthermore, using truncated HBV RT proteins purified from bacteria and five purified Hsp90 chaperone factors, we have developed an in vitro RT-ε binding assay.  Our results demonstrate that Hsp90, in a dynamic process that was dependent on ATP hydrolysis, facilitated RT-ε interaction in HBV, as in DHBV.  Specific ε binding required sequences from both the amino-terminal terminal protein and the carboxy-terminal RT domain.  Only the cognate HBV ε, but not the DHBV ε, could bind the HBV RT proteins.  Furthermore, the internal bulge, but not the apical loop, of ε was required for RT binding.  The establishment of a defined in vitro reconstitution system has now paved the way for future biochem. and structural studies to elucidate the mechanisms of RT-ε interaction and chaperone activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaDLdMAlkfrVg90H21EOLACvtfcHk0lhtKhgdDtaydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtbbK&md5=d4f8f80600b0f78746539f760a21254e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.23.13122-13131.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.23.13122-13131.2004%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%2BM.%26aulast%3DFlores%26aufirst%3DD.%26aulast%3DToft%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DNguyen%26aufirst%3DD.%26atitle%3DRequirement%2520of%2520heat%2520shock%2520protein%252090%2520for%2520human%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%2520function%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D13122%26epage%3D13131%26doi%3D10.1128%2FJVI.78.23.13122-13131.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Wang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiswirth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span> </span><span class="NLM_article-title">Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2077</span><span class="refDoi"> DOI: 10.1128/AAC.01764-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01764-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2070-2077&author=Y.+P.+Wangauthor=F.+Liuauthor=H.+W.+Heauthor=Y.+X.+Hanauthor=Z.+G.+Pengauthor=B.+W.+Liauthor=X.+F.+Youauthor=D.+Q.+Songauthor=Z.+R.+Liauthor=L.+Y.+Yuauthor=S.+Cenauthor=B.+Hongauthor=C.+H.+Sunauthor=L.+X.+Zhaoauthor=B.+Kreiswirthauthor=D.+Perlinauthor=R.+G.+Shaoauthor=J.+D.+Jiang&title=Heat+stress+cognate+70+host+protein+as+a+potential+drug+target+against+drug+resistance+in+hepatitis+B+virus&doi=10.1128%2FAAC.01764-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.01764-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01764-09%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DPeng%26aufirst%3DZ.%2BG.%26aulast%3DLi%26aufirst%3DB.%2BW.%26aulast%3DYou%26aufirst%3DX.%2BF.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26aulast%3DLi%26aufirst%3DZ.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BY.%26aulast%3DCen%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DC.%2BH.%26aulast%3DZhao%26aufirst%3DL.%2BX.%26aulast%3DKreiswirth%26aufirst%3DB.%26aulast%3DPerlin%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DR.%2BG.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26atitle%3DHeat%2520stress%2520cognate%252070%2520host%2520protein%2520as%2520a%2520potential%2520drug%2520target%2520against%2520drug%2520resistance%2520in%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2070%26epage%3D2077%26doi%3D10.1128%2FAAC.01764-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Gao, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. Q.</span><span> </span><span class="NLM_article-title">Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">876</span><span class="refDoi"> DOI: 10.1021/jm101325h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101325h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=869-876&author=L.+M.+Gaoauthor=Y.+X.+Hanauthor=Y.+P.+Wangauthor=Y.+H.+Liauthor=Y.+Q.+Shanauthor=X.+Liauthor=Z.+G.+Pengauthor=C.+W.+Biauthor=T.+Zhangauthor=N.+N.+Duauthor=J.+D.+Jiangauthor=D.+Q.+Song&title=Design+and+synthesis+of+oxymatrine+analogues+overcoming+drug+resistance+in+hepatitis+B+virus+through+targeting+host+heat+stress+cognate+70&doi=10.1021%2Fjm101325h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Oxymatrine Analogs Overcoming Drug Resistance in Hepatitis B Virus through Targeting Host Heat Stress Cognate 70</span></div><div class="casAuthors">Gao, Li-Mei; Han, Yan-Xing; Wang, Yu-Ping; Li, Yu-Huan; Shan, Yong-Qiang; Li, Xin; Peng, Zong-Gen; Bi, Chong-Wen; Zhang, Tian; Du, Na-Na; Jiang, Jian-Dong; Song, Dan-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat-stress cognate 70 (Hsc70) is a host protein required for hepatitis B virus (HBV) replication, and oxymatrine I [R13 = H, R14 = H] suppresses Hsc70 expression.  Taking Hsc70 as a target against HBV, 22 analogs, such as oxysophocarpine I [R13R14 = bond] and II [R13 = OH, OMe, OEt, OCH2Ph, OCOPh, CH2NO2, NHMe, R14 = H; R13 = OCOMe, OCOCH2Cl, OCOCHClMe, OCOPh, OCOC6H3-4-F-3-NO2, OCO2Et, R14 = OH; R13 = R14 = OH, OMe, OCH2Ph, OCO2Et, OCOC6H3-4-F-3-NO2], of oxymatrine defined with substituents at positions 1, 13 and 14 were synthesized and evaluated for their activity on Hsc70 mRNA expression.  The SAR revealed that (i) the oxygen atom at the 1-position was not essential, (ii) increasing electron d. on the ring D reduced the activity, and (iii) introducing a proper substituent at the 13- and/or 14-position(s), esp. electron-withdrawing groups, might enhance the activity.  Among the analogs, II [R13 = OEt,R14 = H] with a 13-ethoxy substituent afforded an increased activity in respect to oxymatrine.  Importantly, it was active for either wild-type or lamivudine-resistant HBV, as its target is host Hsc70 but not viral enzymes.  LD50 of II [R13 = OEt,R14 = H] in mice was over 750 mg/kg in oral route.  II [R13 = OEt,R14 = H] was considered promising for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSX-G2d2bN4rVg90H21EOLACvtfcHk0lhGKq-aHDuqFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFOntg%253D%253D&md5=36465bf59f0d11ed49b80eff24cc2c55</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm101325h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101325h%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DL.%2BM.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DShan%26aufirst%3DY.%2BQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DZ.%2BG.%26aulast%3DBi%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DN.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520oxymatrine%2520analogues%2520overcoming%2520drug%2520resistance%2520in%2520hepatitis%2520B%2520virus%2520through%2520targeting%2520host%2520heat%2520stress%2520cognate%252070%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D869%26epage%3D876%26doi%3D10.1021%2Fjm101325h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span> </span><span class="NLM_article-title">Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1060</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1073/pnas.93.3.1060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.93.3.1060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=1060-1064&author=J.+Huauthor=C.+Seeger&title=Hsp90+is+required+for+the+activity+of+a+hepatitis+B+virus+reverse+transcriptase&doi=10.1073%2Fpnas.93.3.1060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.3.1060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.3.1060%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DSeeger%26aufirst%3DC.%26atitle%3DHsp90%2520is%2520required%2520for%2520the%2520activity%2520of%2520a%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D1060%26epage%3D1064%26doi%3D10.1073%2Fpnas.93.3.1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span> </span><span class="NLM_article-title">Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1093/emboj/16.1.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Femboj%2F16.1.59" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=59-68&author=J.+Huauthor=D.+O.+Toftauthor=C.+Seeger&title=Hepadnavirus+assembly+and+reverse+transcription+require+a+multi-component+chaperone+complex+which+is+incorporated+into+nucleocapsids&doi=10.1093%2Femboj%2F16.1.59"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.1.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.1.59%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DSeeger%26aufirst%3DC.%26atitle%3DHepadnavirus%2520assembly%2520and%2520reverse%2520transcription%2520require%2520a%2520multi-component%2520chaperone%2520complex%2520which%2520is%2520incorporated%2520into%2520nucleocapsids%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D59%26epage%3D68%26doi%3D10.1093%2Femboj%2F16.1.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Zhan, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. Z.</span><span> </span><span class="NLM_article-title">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1036</span><span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.drudis.2016.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1027-1036&author=M.+M.+Zhanauthor=X.+Q.+Huauthor=X.+X.+Liuauthor=B.+F.+Ruanauthor=J.+Xuauthor=C.+Z.+Liao&title=From+monoclonal+antibodies+to+small+molecules%3A+the+development+of+inhibitors+targeting+the+PD-1%2FPD-L1+pathway&doi=10.1016%2Fj.drudis.2016.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span></div><div class="casAuthors">Zhan, Mei-Miao; Hu, Xue-Qin; Liu, Xiu-Xiu; Ruan, Ban-Feng; Xu, Jun; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1027-1036</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made an extraordinary journey from bench to bedside.  Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer.  Here, we review the development of drugs targeting the PD-1/PD-L1 pathway.  We discuss the monoclonal antibodies (mAbs) approved or in clin. trials, peptides and patented small mols. developed against this pathway.  Such compds. have the potential to treat cancer as well as chronic virol. diseases.  We also detail PD-1/PD-L1 interactions, an understanding of which will be useful for the rational design of small-mol. therapeutics that disrupt the PD-1/PD-L1 pathway.  It is likely that more mAbs targeting the PD-1/PD-L1 pathway will be approved for the treatment of a range of cancers.  By contrast, it is likely to be more difficult to successfully develop small mols. or peptides and for them to reach the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsq7LUmul7bVg90H21EOLACvtfcHk0lhGKq-aHDuqFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D&md5=e7bfff84cb527571846c9d82a1d8accf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%2BM.%26aulast%3DHu%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DRuan%26aufirst%3DB.%2BF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%2BZ.%26atitle%3DFrom%2520monoclonal%2520antibodies%2520to%2520small%2520molecules%253A%2520the%2520development%2520of%2520inhibitors%2520targeting%2520the%2520PD-1%252FPD-L1%2520pathway%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1027%26epage%3D1036%26doi%3D10.1016%2Fj.drudis.2016.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Gibney, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span> </span><span class="NLM_article-title">Predictive biomarkers for checkpoint inhibitor-based immunotherapy</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">e542</span><span class="NLM_x">–</span> <span class="NLM_lpage">e551</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30406-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1470-2045%2816%2930406-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27924752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2gsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e542-e551&author=G.+T.+Gibneyauthor=L.+M.+Weinerauthor=M.+B.+Atkins&title=Predictive+biomarkers+for+checkpoint+inhibitor-based+immunotherapy&doi=10.1016%2FS1470-2045%2816%2930406-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive biomarkers for checkpoint inhibitor-based immunotherapy</span></div><div class="casAuthors">Gibney, Geoffrey T.; Weiner, Louis M.; Atkins, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e542-e551</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The clin. development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy.  Durable responses can be seen in patients with melanoma and other malignancies.  Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens.  The development of predictive biomarkers is needed to optimize patient benefit, minimise risk of toxicities, and guide combination approaches.  The greatest focus has been on tumor-cell PD-L1 expression.  Although PD-L1 positivity enriches for populations with clin. benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies.  In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumor-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochem.  Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterization of the immune tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1JKNhUHJEZbVg90H21EOLACvtfcHk0lg-Ntq8bFzYYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2gsL7M&md5=d3c67c04336efd1e86f6eaf38edf42d2</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930406-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930406-5%26sid%3Dliteratum%253Aachs%26aulast%3DGibney%26aufirst%3DG.%2BT.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26atitle%3DPredictive%2520biomarkers%2520for%2520checkpoint%2520inhibitor-based%2520immunotherapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3De542%26epage%3De551%26doi%3D10.1016%2FS1470-2045%2816%2930406-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Greil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutterer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleyer, L.</span><span> </span><span class="NLM_article-title">Reactivation of dormant anti-tumor immunity-a clinical perspective of therapeutic immune checkpoint modulation</span> <span class="citation_source-journal">Cell Commun. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.1186/s12964-016-0155-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1186%2Fs12964-016-0155-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=28100240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ntVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=5&author=R.+Greilauthor=E.+Huttererauthor=T.+N.+Hartmannauthor=L.+Pleyer&title=Reactivation+of+dormant+anti-tumor+immunity-a+clinical+perspective+of+therapeutic+immune+checkpoint+modulation&doi=10.1186%2Fs12964-016-0155-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation</span></div><div class="casAuthors">Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa; Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa; Greil Richard; Pleyer Lisa; Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cell communication and signaling : CCS</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In favor of their outgrowth, cancer cells must resist immune surveillance and edit the immune response.  Cancer immunoediting is characterized by fundamental changes in the cellular composition and the inflammatory cytokine profiles in the microenvironment of the primary tumor and metastatic niches, with an ever increasing complexity of interactions between tumor cells and the immune system.  Recent data suggest that genetic instability and immunoediting are not necessarily disparate processes.  Increasing mutational load may be associated with multiple neoepitopes expressed by the tumor cells and thus increased chances for the immune system to recognize and combat these cells.  At the same time the immune system is more and more suppressed and exhausted by this process.  Consequently, immune checkpoint modulation may have the potential to be most successful in genetically highly altered and usually extremely unfavorable types of cancer.  Moreover, the fact that epitopes recognized by the immune system are preferentially encoded by passenger gene mutations opens windows of synergy in targeting cancer-specific signaling pathways by small molecules simultaneously with antibodies modifying T-cell activation or exhaustion.This review covers some aspects of the current understanding of the immunological basis necessary to understand the rapidly developing therapeutic endeavours in cancer treatment, the clinical achievements made, and raises some burning questions for translational research in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmYYjLgPpERu2qxNLjzXe8fW6udTcc2eZaSnIQ2IKjH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ntVahuw%253D%253D&md5=89545b259ccf4e2485a1340f9c0a321b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs12964-016-0155-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-016-0155-9%26sid%3Dliteratum%253Aachs%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DHutterer%26aufirst%3DE.%26aulast%3DHartmann%26aufirst%3DT.%2BN.%26aulast%3DPleyer%26aufirst%3DL.%26atitle%3DReactivation%2520of%2520dormant%2520anti-tumor%2520immunity-a%2520clinical%2520perspective%2520of%2520therapeutic%2520immune%2520checkpoint%2520modulation%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2017%26volume%3D15%26spage%3D5%26doi%3D10.1186%2Fs12964-016-0155-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Barber, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wherry, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masopust, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, R.</span><span> </span><span class="NLM_article-title">Restoring function in exhausted CD8 T cells during chronic viral infection</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1038/nature04444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature04444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16382236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=682-687&author=D.+L.+Barberauthor=E.+J.+Wherryauthor=D.+Masopustauthor=B.+G.+Zhuauthor=J.+P.+Allisonauthor=A.+H.+Sharpeauthor=G.+J.+Freemanauthor=R.+Ahmed&title=Restoring+function+in+exhausted+CD8+T+cells+during+chronic+viral+infection&doi=10.1038%2Fnature04444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Restoring function in exhausted CD8 T cells during chronic viral infection</span></div><div class="casAuthors">Barber, Daniel L.; Wherry, E. John; Masopust, David; Zhu, Baogong; Allison, James P.; Sharpe, Arlene H.; Freeman, Gordon J.; Ahmed, Rafi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7077</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Functional impairment of antigen-specific T cells is a defining characteristic of many chronic infections, but the underlying mechanisms of T-cell dysfunction are not well understood.  To address this question, we analyzed genes expressed in functionally impaired virus-specific CD8 T cells present in mice chronically infected with lymphocytic choriomeningitis virus (LCMV), and compared these with the gene profile of functional memory CD8 T cells.  Here we report that PD-1 (programmed death 1; also known as Pdcd1) was selectively upregulated by the exhausted T cells, and that in vivo administration of antibodies that blocked the interaction of this inhibitory receptor with its ligand, PD-L1 (also known as B7-H1), enhanced T-cell responses.  Notably, we found that even in persistently infected mice that were lacking CD4 T-cell help, blockade of the PD-1/PD-L1 inhibitory pathway had a beneficial effect on the helpless' CD8 T cells, restoring their ability to undergo proliferation, secrete cytokines, kill infected cells and decrease viral load.  Blockade of the CTLA-4 (cytotoxic T-lymphocyte-assocd. protein 4) inhibitory pathway had no effect on either T-cell function or viral control.  These studies identify a specific mechanism of T-cell exhaustion and define a potentially effective immunol. strategy for the treatment of chronic viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrokjGzUXzvibVg90H21EOLACvtfcHk0lgBLlFLdICGuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyktL0%253D&md5=aa2ee550ea5d4eaa597f4f1337f48b1c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnature04444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04444%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DD.%2BL.%26aulast%3DWherry%26aufirst%3DE.%2BJ.%26aulast%3DMasopust%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DB.%2BG.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DAhmed%26aufirst%3DR.%26atitle%3DRestoring%2520function%2520in%2520exhausted%2520CD8%2520T%2520cells%2520during%2520chronic%2520viral%2520infection%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D682%26epage%3D687%26doi%3D10.1038%2Fnature04444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Day, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiepiela, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moodley, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePierres, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mncube, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duraiswamy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichbaum, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altfeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wherry, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coovadia, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulder, P. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B. D.</span><span> </span><span class="NLM_article-title">PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">443</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1038/nature05115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature05115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=350-354&author=C.+L.+Dayauthor=D.+E.+Kaufmannauthor=P.+Kiepielaauthor=J.+A.+Brownauthor=E.+S.+Moodleyauthor=S.+Reddyauthor=E.+W.+Mackeyauthor=J.+D.+Millerauthor=A.+J.+Leslieauthor=C.+DePierresauthor=Z.+Mncubeauthor=J.+Duraiswamyauthor=B.+G.+Zhuauthor=Q.+Eichbaumauthor=M.+Altfeldauthor=E.+J.+Wherryauthor=H.+M.+Coovadiaauthor=P.+J.+R.+Goulderauthor=P.+Klenermanauthor=R.+Ahmedauthor=G.+J.+Freemanauthor=B.+D.+Walker&title=PD-1+expression+on+HIV-specific+T+cells+is+associated+with+T-cell+exhaustion+and+disease+progression&doi=10.1038%2Fnature05115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnature05115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05115%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DC.%2BL.%26aulast%3DKaufmann%26aufirst%3DD.%2BE.%26aulast%3DKiepiela%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DMoodley%26aufirst%3DE.%2BS.%26aulast%3DReddy%26aufirst%3DS.%26aulast%3DMackey%26aufirst%3DE.%2BW.%26aulast%3DMiller%26aufirst%3DJ.%2BD.%26aulast%3DLeslie%26aufirst%3DA.%2BJ.%26aulast%3DDePierres%26aufirst%3DC.%26aulast%3DMncube%26aufirst%3DZ.%26aulast%3DDuraiswamy%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DB.%2BG.%26aulast%3DEichbaum%26aufirst%3DQ.%26aulast%3DAltfeld%26aufirst%3DM.%26aulast%3DWherry%26aufirst%3DE.%2BJ.%26aulast%3DCoovadia%26aufirst%3DH.%2BM.%26aulast%3DGoulder%26aufirst%3DP.%2BJ.%2BR.%26aulast%3DKlenerman%26aufirst%3DP.%26aulast%3DAhmed%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DWalker%26aufirst%3DB.%2BD.%26atitle%3DPD-1%2520expression%2520on%2520HIV-specific%2520T%2520cells%2520is%2520associated%2520with%2520T-cell%2520exhaustion%2520and%2520disease%2520progression%26jtitle%3DNature%26date%3D2006%26volume%3D443%26spage%3D350%26epage%3D354%26doi%3D10.1038%2Fnature05115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Zhang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F. S.</span><span> </span><span class="NLM_article-title">PD-1 up-regulation is correlated with HIV-specific memory CD8(+) T-cell exhaustion in typical progressors, but not in long-terrn nonprogressors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4671</span><span class="NLM_x">–</span> <span class="NLM_lpage">4678</span><span class="refDoi"> DOI: 10.1182/blood-2006-09-044826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1182%2Fblood-2006-09-044826" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4671-4678&author=J.+Y.+Zhangauthor=Z.+Zhangauthor=X.+C.+Wangauthor=J.+L.+Fuauthor=J.+X.+Yaoauthor=Y.+M.+Jiaoauthor=L.+G.+Chenauthor=H.+Zhangauthor=J.+N.+Weiauthor=L.+Jinauthor=M.+Shiauthor=G.+F.+Gaoauthor=H.+Wuauthor=F.+S.+Wang&title=PD-1+up-regulation+is+correlated+with+HIV-specific+memory+CD8%28%2B%29+T-cell+exhaustion+in+typical+progressors%2C+but+not+in+long-terrn+nonprogressors&doi=10.1182%2Fblood-2006-09-044826"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-09-044826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-09-044826%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%2BC.%26aulast%3DFu%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DJ.%2BX.%26aulast%3DJiao%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DJ.%2BN.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%2BS.%26atitle%3DPD-1%2520up-regulation%2520is%2520correlated%2520with%2520HIV-specific%2520memory%2520CD8%2528%252B%2529%2520T-cell%2520exhaustion%2520in%2520typical%2520progressors%252C%2520but%2520not%2520in%2520long-terrn%2520nonprogressors%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D4671%26epage%3D4678%26doi%3D10.1182%2Fblood-2006-09-044826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Trautmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janbazian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chomont, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimmig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessette, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulassel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delwart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepulveda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderas, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekaly, R. P.</span><span> </span><span class="NLM_article-title">Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span><span class="refDoi"> DOI: 10.1038/nm1482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnm1482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16917489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVChsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1198-1202&author=L.+Trautmannauthor=L.+Janbazianauthor=N.+Chomontauthor=E.+A.+Saidauthor=S.+Gimmigauthor=B.+Bessetteauthor=M.+R.+Boulasselauthor=E.+Delwartauthor=H.+Sepulvedaauthor=R.+S.+Balderasauthor=J.+P.+Routyauthor=E.+K.+Haddadauthor=R.+P.+Sekaly&title=Upregulation+of+PD-1+expression+on+HIV-specific+CD8%28%2B%29+T+cells+leads+to+reversible+immune+dysfunction&doi=10.1038%2Fnm1482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction</span></div><div class="casAuthors">Trautmann, Lydie; Janbazian, Loury; Chomont, Nicolas; Said, Elias A.; Gimmig, Sylvain; Bessette, Benoit; Boulassel, Mohamed-Rachid; Delwart, Eric; Sepulveda, Homero; Balderas, Robert S.; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L2, inhibits proliferation and cytokine prodn. mediated by antibodies to CD3 (refs. 5,6,7).  Blocking the PD-1-PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8+ T cells to undergo proliferation, cytokine prodn. and cytotoxic activity and, consequently, results in reduced viral load.  During chronic HIV infection, HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector mols. as well as an impaired capacity to proliferate.  Here, the authors found that PD-1 was upregulated on HIV-specific CD8+ T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine prodn. and proliferation of HIV-specific CD8+ T cells.  Notably, cytomegalovirus (CMV)-specific CD8+ T cells from the same donors did not upregulate PD-1 and maintained the prodn. of high levels of cytokines.  Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8+ T cells to survive and proliferate and led to an increased prodn. of cytokines and cytotoxic mols. in response to cognate antigen.  The accumulation of HIV-specific dysfunctional CD8+ T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8+ repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpozwd_OOIb_LVg90H21EOLACvtfcHk0lh0zKAgwEPc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVChsrjO&md5=e9403a4f16e5b8e19eea06d44987458a</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fnm1482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1482%26sid%3Dliteratum%253Aachs%26aulast%3DTrautmann%26aufirst%3DL.%26aulast%3DJanbazian%26aufirst%3DL.%26aulast%3DChomont%26aufirst%3DN.%26aulast%3DSaid%26aufirst%3DE.%2BA.%26aulast%3DGimmig%26aufirst%3DS.%26aulast%3DBessette%26aufirst%3DB.%26aulast%3DBoulassel%26aufirst%3DM.%2BR.%26aulast%3DDelwart%26aufirst%3DE.%26aulast%3DSepulveda%26aufirst%3DH.%26aulast%3DBalderas%26aufirst%3DR.%2BS.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DHaddad%26aufirst%3DE.%2BK.%26aulast%3DSekaly%26aufirst%3DR.%2BP.%26atitle%3DUpregulation%2520of%2520PD-1%2520expression%2520on%2520HIV-specific%2520CD8%2528%252B%2529%2520T%2520cells%2520leads%2520to%2520reversible%2520immune%2520dysfunction%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D1198%26epage%3D1202%26doi%3D10.1038%2Fnm1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Phillips, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chokshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoumov, N. V.</span><span> </span><span class="NLM_article-title">CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.4049/jimmunol.0902761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.4049%2Fjimmunol.0902761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=287-295&author=S.+Phillipsauthor=S.+Chokshiauthor=A.+Rivaauthor=A.+Evansauthor=R.+Williamsauthor=N.+V.+Naoumov&title=CD8%28%2B%29+T+cell+control+of+hepatitis+B+virus+replication%3A+direct+comparison+between+cytolytic+and+noncytolytic+functions&doi=10.4049%2Fjimmunol.0902761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902761%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DChokshi%26aufirst%3DS.%26aulast%3DRiva%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DNaoumov%26aufirst%3DN.%2BV.%26atitle%3DCD8%2528%252B%2529%2520T%2520cell%2520control%2520of%2520hepatitis%2520B%2520virus%2520replication%253A%2520direct%2520comparison%2520between%2520cytolytic%2520and%2520noncytolytic%2520functions%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D287%26epage%3D295%26doi%3D10.4049%2Fjimmunol.0902761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Immunobiology of hepatitis B virus infection</span> <span class="citation_source-journal">Hepatol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1111/hepr.12439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fhepr.12439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25331910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=179-189&author=M.+Isogawaauthor=Y.+Tanaka&title=Immunobiology+of+hepatitis+B+virus+infection&doi=10.1111%2Fhepr.12439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of hepatitis B virus infection</span></div><div class="casAuthors">Isogawa, Masanori; Tanaka, Yasuhito</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-189</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The adaptive immune response, particularly the virus-specific CD8+ T-cell response, is largely responsible for viral clearance and disease pathogenesis during hepatitis B virus (HBV) infection.  The HBV-specific CD8+ T-cell response is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focused in chronically infected patients.  The immunol. basis for this dichotomy is unclear.  A recent study using HBV transgenic mice and HBV-specific T-cell receptor transgenic mice suggests that intrahepatic antigen presentation by HBV pos. hepatocytes suppresses HBV-specific CD8+ T-cell responses through a co-inhibitory mol., programmed cell death 1 (PD-1).  In contrast, antigen presentation by activated professional antigen-presenting cells induces functional differentiation of HBV-specific CD8+ T cells.  These findings suggest that the outcome of T-cell priming is largely dependent on the nature of antigen-presenting cells.  Another study suggests that the timing of HBV-specific CD4+ T-cell priming regulates the magnitude of the HBV-specific CD8+ T-cell response.  Other factors that could regulate HBV-specific cellular immune responses are high viral loads, mutational epitope inactivation, T-cell receptor antagonism and infection of immunol. privileged tissues.  However, these pathways become apparent only in the setting of an ineffective cellular immune response, which is therefore the fundamental underlying cause.  Understanding the cellular and mol. mechanisms by which HBV evades host immune responses will eventually help develop new immunotherapeutic strategies designed to terminate chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmOqjGq3Ua5bVg90H21EOLACvtfcHk0lh0zKAgwEPc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKisL8%253D&md5=1f84853b83c084edd3d73461557f4c91</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12439%26sid%3Dliteratum%253Aachs%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DImmunobiology%2520of%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DHepatol.%2520Res.%26date%3D2015%26volume%3D45%26spage%3D179%26epage%3D189%26doi%3D10.1111%2Fhepr.12439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Peng, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span> </span><span class="NLM_article-title">PD-1 upregulation is associated with HBV specific T cell dysfunction in chronic hepatitis B patients</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1016/j.molimm.2007.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.molimm.2007.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17868872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Ghs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2008&pages=963-970&author=G.+P.+Pengauthor=S.+P.+Liauthor=W.+Wuauthor=X.+F.+Tanauthor=Y.+Q.+Chenauthor=Z.+Chen&title=PD-1+upregulation+is+associated+with+HBV+specific+T+cell+dysfunction+in+chronic+hepatitis+B+patients&doi=10.1016%2Fj.molimm.2007.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients</span></div><div class="casAuthors">Peng, Guoping; Li, Shuping; Wu, Wei; Tan, Xufei; Chen, Yiqiong; Chen, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Summary: Programmed death-1 (PD-1) is demonstrated to have an increased expression on antigen-specific T cells during chronic virus infections, and the blockage of PD-1/PD-ligand (PD-L1) pathway could restore the function of exhausted T cells.  We measured the PD-1 expression levels on HBV-specific CD8 T cells and investigated the role of PD-1/PD-L1 pathway in T-cell responses of patients with different HBV infection statuses.  Compared to the patients with convalescent acute hepatitis B, PD-1 expression on total CD8 T cells from chronic hepatitis B (CHB) patients was significantly upregulated, esp. on the HBV pentamer-pos. CD8 T cells.  And PD-L1, but not PD-L2, was also significantly upregulated on PBMC from CHB patients.  In CHB patients, HBV-specific T cells and cellular proliferation could be obsd. under the recombinant HBV-Ag stimulation in vitro, and blockade of PD-1 pathway significantly enhanced the IFN-gamma prodn. and cellular proliferation of PBMC.  Furthermore, PD-1 expression level on HBV-pentamers pos. CD8 T cells was pos. assocd. with plasma viral load in CHB patients.  Thus, PD-1 upregulation on HBV-specific CD8 T cells is engaged in the dysfunction of T cells and high viremia in CHB patients, and the antiviral T-cell responses could be improved by the blockade of this inhibitory PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx6HsAa_qqFbVg90H21EOLACvtfcHk0litYb_vwrGVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Ghs77F&md5=6bb202f1714a8e6b608b1a96ffb8384b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2007.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2007.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DG.%2BP.%26aulast%3DLi%26aufirst%3DS.%2BP.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DX.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DPD-1%2520upregulation%2520is%2520associated%2520with%2520HBV%2520specific%2520T%2520cell%2520dysfunction%2520in%2520chronic%2520hepatitis%2520B%2520patients%26jtitle%3DMol.%2520Immunol.%26date%3D2008%26volume%3D45%26spage%3D963%26epage%3D970%26doi%3D10.1016%2Fj.molimm.2007.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Sherman, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehanpati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daucher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarin, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, A.</span><span> </span><span class="NLM_article-title">Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir</span> <span class="citation_source-journal">AIDS Res. Hum. Retroviruses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1089/aid.2012.0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Faid.2012.0320" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=665-672&author=A.+C.+Shermanauthor=N.+Trehanpatiauthor=M.+Daucherauthor=R.+T.+Daveyauthor=H.+Masurauthor=S.+K.+Sarinauthor=S.+Kottililauthor=A.+Kohli&title=Augmentation+of+hepatitis+B+virus-specific+cellular+immunity+with+programmed+death+receptor-1%2Fprogrammed+death+receptor-L1+blockade+in+hepatitis+B+virus+and+HIV%2Fhepatitis+B+virus+coinfected+patients+treated+with+adefovir&doi=10.1089%2Faid.2012.0320"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0320%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DA.%2BC.%26aulast%3DTrehanpati%26aufirst%3DN.%26aulast%3DDaucher%26aufirst%3DM.%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DSarin%26aufirst%3DS.%2BK.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKohli%26aufirst%3DA.%26atitle%3DAugmentation%2520of%2520hepatitis%2520B%2520virus-specific%2520cellular%2520immunity%2520with%2520programmed%2520death%2520receptor-1%252Fprogrammed%2520death%2520receptor-L1%2520blockade%2520in%2520hepatitis%2520B%2520virus%2520and%2520HIV%252Fhepatitis%2520B%2520virus%2520coinfected%2520patients%2520treated%2520with%2520adefovir%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26spage%3D665%26epage%3D672%26doi%3D10.1089%2Faid.2012.0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooksley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puranik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chokshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoumov, N. V.</span><span> </span><span class="NLM_article-title">Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1002/hep.22419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.22419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=759-769&author=A.+Evansauthor=A.+Rivaauthor=H.+Cooksleyauthor=S.+Phillipsauthor=S.+Puranikauthor=A.+Nathwaniauthor=S.+Brettauthor=S.+Chokshiauthor=N.+V.+Naoumov&title=Programmed+death+1+expression+during+antiviral+treatment+of+chronic+hepatitis+B%3A+impact+of+hepatitis+B+e-antigen+seroconversion&doi=10.1002%2Fhep.22419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fhep.22419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22419%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DRiva%26aufirst%3DA.%26aulast%3DCooksley%26aufirst%3DH.%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DPuranik%26aufirst%3DS.%26aulast%3DNathwani%26aufirst%3DA.%26aulast%3DBrett%26aufirst%3DS.%26aulast%3DChokshi%26aufirst%3DS.%26aulast%3DNaoumov%26aufirst%3DN.%2BV.%26atitle%3DProgrammed%2520death%25201%2520expression%2520during%2520antiviral%2520treatment%2520of%2520chronic%2520hepatitis%2520B%253A%2520impact%2520of%2520hepatitis%2520B%2520e-antigen%2520seroconversion%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D759%26epage%3D769%26doi%3D10.1002%2Fhep.22419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möller, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glebe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span> </span><span class="NLM_article-title">Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003856</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1003856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.ppat.1003856" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1003856&author=J.+Liuauthor=E.+Zhangauthor=Z.+Y.+Maauthor=W.+M.+Wuauthor=A.+Kosinskaauthor=X.+Y.+Zhangauthor=I.+M%C3%B6llerauthor=P.+Seizauthor=D.+Glebeauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=M.+J.+Luauthor=M.+Roggendorf&title=Enhancing+virus-specific+immunity+in+vivo+by+combining+therapeutic+vaccination+and+PD-L1+blockade+in+chronic+hepadnaviral+infection&doi=10.1371%2Fjournal.ppat.1003856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003856%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DW.%2BM.%26aulast%3DKosinska%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DM%25C3%25B6ller%26aufirst%3DI.%26aulast%3DSeiz%26aufirst%3DP.%26aulast%3DGlebe%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DRoggendorf%26aufirst%3DM.%26atitle%3DEnhancing%2520virus-specific%2520immunity%2520in%2520vivo%2520by%2520combining%2520therapeutic%2520vaccination%2520and%2520PD-L1%2520blockade%2520in%2520chronic%2520hepadnaviral%2520infection%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26spage%3De1003856%26doi%3D10.1371%2Fjournal.ppat.1003856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saputelli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span> </span><span class="NLM_article-title">Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4277</span><span class="NLM_x">–</span> <span class="NLM_lpage">4288</span><span class="refDoi"> DOI: 10.1128/AAC.00473-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00473-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4277-4288&author=D.+Caiauthor=C.+Millsauthor=W.+Yuauthor=R.+Yanauthor=C.+E.+Aldrichauthor=J.+R.+Saputelliauthor=W.+S.+Masonauthor=X.+Xuauthor=J.-T.+Guoauthor=T.+M.+Blockauthor=A.+Cuconatiauthor=H.+Guo&title=Identification+of+disubstituted+sulfonamide+compounds+as+specific+inhibitors+of+hepatitis+B+virus+covalently+closed+circular+DNA+formation&doi=10.1128%2FAAC.00473-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FAAC.00473-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00473-12%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DAldrich%26aufirst%3DC.%2BE.%26aulast%3DSaputelli%26aufirst%3DJ.%2BR.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.-T.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520disubstituted%2520sulfonamide%2520compounds%2520as%2520specific%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520covalently%2520closed%2520circular%2520DNA%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4277%26epage%3D4288%26doi%3D10.1128%2FAAC.00473-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Carthew, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sontheimer, E. J.</span><span> </span><span class="NLM_article-title">Origins and mechanisms of miRNAs and siRNAs</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span><span class="refDoi"> DOI: 10.1016/j.cell.2009.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.cell.2009.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19239886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=642-655&author=R.+W.+Carthewauthor=E.+J.+Sontheimer&title=Origins+and+mechanisms+of+miRNAs+and+siRNAs&doi=10.1016%2Fj.cell.2009.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Origins and mechanisms of miRNAs and siRNAs</span></div><div class="casAuthors">Carthew, Richard W.; Sontheimer, Erik J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">642-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Over the last decade, ∼20-30 nucleotide RNA mols. have emerged as crit. regulators in the expression and function of eukaryotic genomes.  Two primary categories of these small RNAs, short interfering RNAs (siRNAs) and microRNAs (miRNAs), act in both somatic and germline lineages in a broad range of eukaryotic species to regulate endogenous genes and to defend the genome from invasive nucleic acids.  Recent advances have revealed unexpected diversity in their biogenesis pathways and the regulatory mechanisms that they access.  The understanding of siRNA- and miRNA-based regulation has direct implications for fundamental biol. as well as disease etiol. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3IZ-WDhiJbVg90H21EOLACvtfcHk0lhSgLlE1ccFnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFGksb0%253D&md5=0a21cafe31e6a3da5dc2399f109bcbc4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DCarthew%26aufirst%3DR.%2BW.%26aulast%3DSontheimer%26aufirst%3DE.%2BJ.%26atitle%3DOrigins%2520and%2520mechanisms%2520of%2520miRNAs%2520and%2520siRNAs%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D642%26epage%3D655%26doi%3D10.1016%2Fj.cell.2009.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Grimm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streetz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jopling, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, M. A.</span><span> </span><span class="NLM_article-title">Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">441</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1038/nature04791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature04791" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=537-541&author=D.+Grimmauthor=K.+L.+Streetzauthor=C.+L.+Joplingauthor=T.+A.+Stormauthor=K.+Pandeyauthor=C.+R.+Davisauthor=P.+Marionauthor=F.+Salazarauthor=M.+A.+Kay&title=Fatality+in+mice+due+to+oversaturation+of+cellular+microRNA%2Fshort+hairpin+RNA+pathways&doi=10.1038%2Fnature04791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnature04791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04791%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DD.%26aulast%3DStreetz%26aufirst%3DK.%2BL.%26aulast%3DJopling%26aufirst%3DC.%2BL.%26aulast%3DStorm%26aufirst%3DT.%2BA.%26aulast%3DPandey%26aufirst%3DK.%26aulast%3DDavis%26aufirst%3DC.%2BR.%26aulast%3DMarion%26aufirst%3DP.%26aulast%3DSalazar%26aufirst%3DF.%26aulast%3DKay%26aufirst%3DM.%2BA.%26atitle%3DFatality%2520in%2520mice%2520due%2520to%2520oversaturation%2520of%2520cellular%2520microRNA%252Fshort%2520hairpin%2520RNA%2520pathways%26jtitle%3DNature%26date%3D2006%26volume%3D441%26spage%3D537%26epage%3D541%26doi%3D10.1038%2Fnature04791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Sun, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M. H.</span><span> </span><span class="NLM_article-title">Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference</span> <span class="citation_source-journal">Hum. Gene Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1089/hum.2012.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Fhum.2012.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23829557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OisrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=739-750&author=C.+P.+Sunauthor=T.+H.+Wuauthor=C.+C.+Chenauthor=P.+Y.+Wuauthor=Y.+M.+Shihauthor=K.+Tsuneyamaauthor=M.+H.+Tao&title=Studies+of+efficacy+and+liver+toxicity+related+to+adeno-associated+virus-mediated+RNA+interference&doi=10.1089%2Fhum.2012.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Studies of Efficacy and Liver Toxicity Related to Adeno-Associated Virus-Mediated RNA Interference</span></div><div class="casAuthors">Sun, Cheng-Pu; Wu, Tzu-Hui; Chen, Chun-Chi; Wu, Ping-Yi; Shih, Yao-Ming; Tsuneyama, Koichi; Tao, Mi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">739-750</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Adeno-assocd. virus (AAV)-mediated RNA interference shows promise as a therapy for chronic hepatitis B virus (HBV) infection, but its low efficacy and hepatotoxicity pose major challenges.  We have generated AAV vectors contg. different promoters and a panel of HBV-specific short hairpin RNAs (shRNAs) to investigate factors that contribute to the efficacy and pathogenesis of AAV-mediated RNA interference.  HBV transgenic mice injected with high doses of AAV vectors contg. the U6 promoter produced abundant shRNAs, transiently inhibited HBV, but induced severe hepatotoxicity.  Sustained HBV suppression without liver toxicity can be achieved by lowering the dose of AAV-U6 vectors.  AAVs contg. the weaker H1 promoter did not cause liver injury, but their therapeutic efficacy was highly dependent on the sequence of the shRNA.  Mice treated with the toxic U6-promoter-driven shRNA showed little change in hepatic microRNA levels, but a dramatic increase in hepatic leukocytes and inflammatory cytokines and chemokines.  Hepatotoxicity was completely absent in immunodeficient mice and significantly alleviated in wild-type mice depleted of macrophages and granulocytes, suggesting that host inflammatory responses are the major cause of liver injury induced by the overexpressed shRNAs from AAV-U6 vectors.  Our results demonstrate that selection of a highly potent shRNA and control its expression level is crit. to achieve sustained HBV suppression without inducing inflammatory side effects.  Sun and colleagues generate a panel of AAV vectors contg. various promoters and hepatitis B virus (HBV)-specific short hairpin RNAs (shRNAs) to investigate factors that contribute to the efficacy and pathogenesis of AAV-mediated RNA interference.  They show that injecting HBV transgenic mice with high doses of AAV vectors contg. the U6 promoter produce abundant shRNAs, transiently inhibit HBV, but induce severe hepatotoxicity.  By contrast, AAVs contg. the weaker H1 promoter do not cause liver injury, but their therapeutic efficacy is highly dependent on the sequence of the shRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKFCUPhfZ4rVg90H21EOLACvtfcHk0liREQHS41VTqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OisrvL&md5=c75904536c3b64fc89e590e7febf5a98</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fhum.2012.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2012.239%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BP.%26aulast%3DWu%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DShih%26aufirst%3DY.%2BM.%26aulast%3DTsuneyama%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DM.%2BH.%26atitle%3DStudies%2520of%2520efficacy%2520and%2520liver%2520toxicity%2520related%2520to%2520adeno-associated%2520virus-mediated%2520RNA%2520interference%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2013%26volume%3D24%26spage%3D739%26epage%3D750%26doi%3D10.1089%2Fhum.2012.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Bobbin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, J. J.</span><span> </span><span class="NLM_article-title">RNA interference (RNAi)-based therapeutics: delivering on the promise?</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010715-103633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1146%2Fannurev-pharmtox-010715-103633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26738473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1SrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=103-22&author=M.+L.+Bobbinauthor=J.+J.+Rossi&title=RNA+interference+%28RNAi%29-based+therapeutics%3A+delivering+on+the+promise%3F&doi=10.1146%2Fannurev-pharmtox-010715-103633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?</span></div><div class="casAuthors">Bobbin, Maggie L.; Rossi, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-122</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A resurgence in clin. trials using RNA interference (RNAi) occurred in 2012.  Although there were initial difficulties in achieving efficacious results with RNAi without toxic side effects, advances in delivery and improved chem. made this resurgence possible.  More than 20 RNAi-based therapeutics are currently in clin. trials, and several of these are Phase III trials.  Continued pos. results from these trials have helped bolster further attempts to develop clin. relevant RNAi therapies.  With a wide variety of disease targets to choose from, the first RNAi therapeutic to be clin. approved is not far off.  This review covers recently established and completed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMjR4UbfY2prVg90H21EOLACvtfcHk0liREQHS41VTqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1SrsQ%253D%253D&md5=cfa02ab57293143b0c6f0b2e22cf5474</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010715-103633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010715-103633%26sid%3Dliteratum%253Aachs%26aulast%3DBobbin%26aufirst%3DM.%2BL.%26aulast%3DRossi%26aufirst%3DJ.%2BJ.%26atitle%3DRNA%2520interference%2520%2528RNAi%2529-based%2520therapeutics%253A%2520delivering%2520on%2520the%2520promise%253F%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D56%26spage%3D103%26epage%3D22%26doi%3D10.1146%2Fannurev-pharmtox-010715-103633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Ivacik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnot, P.</span><span> </span><span class="NLM_article-title">Countering hepatitis B virus infection using RNAi: how far are we from the clinic?</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1002/rmv.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Frmv.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21913277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=383-396&author=D.+Ivacikauthor=A.+Elyauthor=P.+Arbuthnot&title=Countering+hepatitis+B+virus+infection+using+RNAi%3A+how+far+are+we+from+the+clinic%3F&doi=10.1002%2Frmv.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Countering hepatitis B virus infection using RNAi: how far are we from the clinic?</span></div><div class="casAuthors">Ivacik, Dejana; Ely, Abdullah; Arbuthnot, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">383-396</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Globally, persistent HBV infection is a significant cause of public health problems.  Currently available HBV therapies have variable efficacy and there is a need to develop improved treatment to prevent cirrhosis and hepatocellular carcinoma.  Although RNA interference (RNAi)-based approaches have shown promise, accomplishing safe and sustained silencing by RNAi activators, as well as their efficient delivery to hepatocytes have hampered clin. translation of this very promising technol.  Expressed silencers may be produced in a sustained manner from stable DNA templates, which makes them suited to treatment of chronic HBV infection.  DNA expression cassettes can be incorporated into both viral and non-viral vectors, but in vivo delivery of these cassettes with non-viral vectors is currently inefficient.  Synthetic short interfering RNAs (siRNAs), which may be chem. modified to improve stability, specificity and efficacy, are more conveniently delivered to their cytoplasmic sites of action with synthetic non-viral vectors.  However, the short duration of action of this class of RNAi activator is a drawback for treatment of chronic HBV infection.  Despite the impressive progress that has been made in developing highly effective HBV gene silencers, challenges continue to face implementation of RNAi-based HBV therapy.  This review will discuss the current status of the topic and consider the developments that are required to advance RNAi-based HBV therapy to clin. application.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoORCuJxyJIxrVg90H21EOLACvtfcHk0lhJ13KUtmW5UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktLzF&md5=39c6e6e204bea3dc2a2b446ebeaadf89</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Frmv.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.705%26sid%3Dliteratum%253Aachs%26aulast%3DIvacik%26aufirst%3DD.%26aulast%3DEly%26aufirst%3DA.%26aulast%3DArbuthnot%26aufirst%3DP.%26atitle%3DCountering%2520hepatitis%2520B%2520virus%2520infection%2520using%2520RNAi%253A%2520how%2520far%2520are%2520we%2520from%2520the%2520clinic%253F%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2011%26volume%3D21%26spage%3D383%26epage%3D396%26doi%3D10.1002%2Frmv.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Haussecker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, M. A.</span><span> </span><span class="NLM_article-title">Drugging RNAi</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1070</span><span class="refDoi"> DOI: 10.1126/science.1252967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1252967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=1069-1070&author=D.+Hausseckerauthor=M.+A.+Kay&title=Drugging+RNAi&doi=10.1126%2Fscience.1252967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.1252967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1252967%26sid%3Dliteratum%253Aachs%26aulast%3DHaussecker%26aufirst%3DD.%26aulast%3DKay%26aufirst%3DM.%2BA.%26atitle%3DDrugging%2520RNAi%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D1069%26epage%3D1070%26doi%3D10.1126%2Fscience.1252967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Gish, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Given, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J. Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schluep, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=97-108&author=R.+G.+Gishauthor=M.+F.+Yuenauthor=H.+L.+Y.+Chanauthor=B.+D.+Givenauthor=C.+L.+Laiauthor=S.+A.+Locarniniauthor=J.+Y.+N.+Lauauthor=C.+I.+Wooddellauthor=T.+Schluepauthor=D.+L.+Lewis&title=Synthetic+RNAi+triggers+and+their+use+in+chronic+hepatitis+B+therapies+with+curative+intent&doi=10.1016%2Fj.antiviral.2015.06.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DGish%26aufirst%3DR.%2BG.%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DGiven%26aufirst%3DB.%2BD.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DLocarnini%26aufirst%3DS.%2BA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DSchluep%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DSynthetic%2520RNAi%2520triggers%2520and%2520their%2520use%2520in%2520chronic%2520hepatitis%2520B%2520therapies%2520with%2520curative%2520intent%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.antiviral.2015.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Wong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trubetskoy, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozema, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo</span> <span class="citation_source-journal">Nucleic Acid Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.1089/nat.2012.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Fnat.2012.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23181701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=380-390&author=S.+C.+Wongauthor=J.+J.+Kleinauthor=H.+L.+Hamiltonauthor=Q.+L.+Chuauthor=C.+L.+Freyauthor=V.+S.+Trubetskoyauthor=J.+Heggeauthor=D.+Wakefieldauthor=D.+B.+Rozemaauthor=D.+L.+Lewis&title=Co-injection+of+a+targeted%2C+reversibly+masked+endosomolytic+polymer+dramatically+improves+the+efficacy+of+cholesterol-conjugated+small+interfering+RNAs+in+vivo&doi=10.1089%2Fnat.2012.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo</span></div><div class="casAuthors">Wong, So C.; Klein, Jason J.; Hamilton, Holly L.; Chu, Qili; Frey, Christina L.; Trubetskoy, Vladimir S.; Hegge, Julia; Wakefield, Darren; Rozema, David B.; Lewis, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">380-390</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Effective in vivo delivery of small interfering (siRNA) has been a major obstacle in the development of RNA interference therapeutics.  One of the first attempts to overcome this obstacle utilized i.v. injection of cholesterol-conjugated siRNA (chol-siRNA).  Although studies in mice revealed target gene knockdown in the liver, delivery was relatively inefficient, requiring 3 daily injections of 50 mg/kg of chol-siRNA to obtain measurable redn. in gene expression.  Here we present a new delivery approach that increases the efficacy of the chol-siRNA over 500-fold and allows over 90% redn. in target gene expression in mice and, for the first time, high levels of gene knockdown in non-human primates.  This improved efficacy is achieved by the co-injection of a hepatocyte-targeted and reversibly masked endosomolytic polymer.  We show that knockdown is absolutely dependent on the presence of hepatocyte-targeting ligand on the polymer, the cognate hepatocyte receptor, and the cholesterol moiety of the siRNA.  Importantly, we provide evidence that this increase in efficacy is not dependent on interactions between the chol-siRNA with the polymer prior to injection or in the bloodstream.  The simplicity of the formulation and efficacy of this mode of siRNA delivery should prove beneficial in the use of siRNA as a therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfjeJYV0pmZbVg90H21EOLACvtfcHk0lhJ13KUtmW5UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLvO&md5=53530b2e7779300ce6eaf25afcdff12e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1089%2Fnat.2012.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2012.0389%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BC.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DChu%26aufirst%3DQ.%2BL.%26aulast%3DFrey%26aufirst%3DC.%2BL.%26aulast%3DTrubetskoy%26aufirst%3DV.%2BS.%26aulast%3DHegge%26aufirst%3DJ.%26aulast%3DWakefield%26aufirst%3DD.%26aulast%3DRozema%26aufirst%3DD.%2BB.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DCo-injection%2520of%2520a%2520targeted%252C%2520reversibly%2520masked%2520endosomolytic%2520polymer%2520dramatically%2520improves%2520the%2520efficacy%2520of%2520cholesterol-conjugated%2520small%2520interfering%2520RNAs%2520in%2520vivo%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2012%26volume%3D22%26spage%3D380%26epage%3D390%26doi%3D10.1089%2Fnat.2012.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozema, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegge, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oropeza, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehl, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahn-Hofmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadwiger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vornlocher, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1038/mt.2013.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fmt.2013.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23439496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=973-985&author=C.+I.+Wooddellauthor=D.+B.+Rozemaauthor=M.+Hossbachauthor=M.+Johnauthor=H.+L.+Hamiltonauthor=Q.+Chuauthor=J.+O.+Heggeauthor=J.+J.+Kleinauthor=D.+H.+Wakefieldauthor=C.+E.+Oropezaauthor=J.+Deckertauthor=I.+Roehlauthor=K.+Jahn-Hofmannauthor=P.+Hadwigerauthor=H.+P.+Vornlocherauthor=A.+McLachlanauthor=D.+L.+Lewis&title=Hepatocyte-targeted+RNAi+therapeutics+for+the+treatment+of+chronic+hepatitis+B+virus+infection&doi=10.1038%2Fmt.2013.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection</span></div><div class="casAuthors">Wooddell, Christine I.; Rozema, David B.; Hossbach, Markus; John, Matthias; Hamilton, Holly L.; Chu, Qili; Hegge, Julia O.; Klein, Jason J.; Wakefield, Darren H.; Oropeza, Claudia E.; Deckert, Jochen; Roehl, Ingo; Jahn-Hofmann, Kerstin; Hadwiger, Philipp; Vornlocher, Hans-Peter; McLachlan, Alan; Lewis, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-985</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B virus (HBV) infection in a fundamentally different manner than current therapies.  Using RNAi, it is possible to knock down expression of viral RNAs including the pregenomic RNA from which the replicative intermediates are derived, thus reducing viral load, and the viral proteins that result in disease and impact the immune system's ability to eliminate the virus.  We previously described the use of polymer-based Dynamic PolyConjugate (DPC) for the targeted delivery of siRNAs to hepatocytes.  Here, we first show in proof-of-concept studies that simple coinjection of a hepatocyte-targeted, N-acetylgalactosamine-conjugated melittin-like peptide (NAG-MLP) with a liver-tropic cholesterol-conjugated siRNA (chol-siRNA) targeting coagulation factor VII (F7) results in efficient F7 knockdown in mice and nonhuman primates without changes in clin. chem. or induction of cytokines.  Using transient and transgenic mouse models of HBV infection, we show that a single coinjection of NAG-MLP with potent chol-siRNAs targeting conserved HBV sequences resulted in multilog repression of viral RNA, proteins, and viral DNA with long duration of effect.  These results suggest that coinjection of NAG-MLP and chol-siHBVs holds great promise as a new therapeutic for patients chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUOFxUJIv1LVg90H21EOLACvtfcHk0ljCAh5UJxL0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegsL4%253D&md5=8154fe6812f5a931df54654c351cb5f4</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fmt.2013.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2013.31%26sid%3Dliteratum%253Aachs%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DRozema%26aufirst%3DD.%2BB.%26aulast%3DHossbach%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DHegge%26aufirst%3DJ.%2BO.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DWakefield%26aufirst%3DD.%2BH.%26aulast%3DOropeza%26aufirst%3DC.%2BE.%26aulast%3DDeckert%26aufirst%3DJ.%26aulast%3DRoehl%26aufirst%3DI.%26aulast%3DJahn-Hofmann%26aufirst%3DK.%26aulast%3DHadwiger%26aufirst%3DP.%26aulast%3DVornlocher%26aufirst%3DH.%2BP.%26aulast%3DMcLachlan%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DHepatocyte-targeted%2520RNAi%2520therapeutics%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D973%26epage%3D985%26doi%3D10.1038%2Fmt.2013.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Lanford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oropeza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Given, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">ARC-520 RNAi therapeutic reduces hepatitis B virus DNA, s antigen and e antigen in a chimpanzee with a very high viral titer</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">707A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=707A&author=R.+E.+Lanfordauthor=C.+I.+Wooddellauthor=D.+Chavezauthor=C.+Oropezaauthor=Q.+Chuauthor=H.+L.+Hamiltonauthor=A.+McLachlanauthor=B.+Givenauthor=C.+R.+Anzaloneauthor=D.+L.+Lewis&title=ARC-520+RNAi+therapeutic+reduces+hepatitis+B+virus+DNA%2C+s+antigen+and+e+antigen+in+a+chimpanzee+with+a+very+high+viral+titer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanford%26aufirst%3DR.%2BE.%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DOropeza%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DMcLachlan%26aufirst%3DA.%26aulast%3DGiven%26aufirst%3DB.%26aulast%3DAnzalone%26aufirst%3DC.%2BR.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DARC-520%2520RNAi%2520therapeutic%2520reduces%2520hepatitis%2520B%2520virus%2520DNA%252C%2520s%2520antigen%2520and%2520e%2520antigen%2520in%2520a%2520chimpanzee%2520with%2520a%2520very%2520high%2520viral%2520titer%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D707A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprague, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morskaya, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasperkovitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir-Stead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carito, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluri, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attarwala, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutabarat, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charisse, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchimanchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manoharan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyrzykiewicz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashmi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galil, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslett, P.</span><span> </span><span class="NLM_article-title">GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">224A</span><span class="NLM_x">–</span> <span class="NLM_lpage">225A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=224A-225A&author=L.+Sepp-Lorenzinoauthor=A.+G.+Spragueauthor=T.+Mayoauthor=T.+M.+Nguyenauthor=S.+S.+Morskayaauthor=H.+L.+Xuauthor=S.+Milsteinauthor=G.+Hinkleauthor=P.+Kasperkovitzauthor=R.+G.+Duncanauthor=N.+Keir-Steadauthor=B.+Caritoauthor=L.+Moranauthor=P.+Chaturvediauthor=K.+C.+Aluriauthor=H.+Attarwalaauthor=R.+M.+Hutabaratauthor=J.+Liuauthor=C.+Tranauthor=Q.+F.+Wangauthor=B.+S.+Brighamauthor=A.+Akincauthor=K.+B.+Charisseauthor=V.+Jadhavauthor=S.+Kuchimanchiauthor=M.+A.+Maierauthor=M.+Manoharanauthor=R.+Meyersauthor=T.+Wyrzykiewiczauthor=H.+Hashmiauthor=J.+Donovanauthor=T.+Mooneyauthor=D.+Freedmanauthor=T.+P.+Senguptaauthor=K.+Galilauthor=E.+Coakleyauthor=P.+Haslett&title=GalNAc-siRNA+conjugate+ALN-HBV+targets+a+highly+conserved%2C+pan-genotypic+X-orf+viral+site+and+mediates+profound+and+durable+HBsAg+silencing+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26aulast%3DSprague%26aufirst%3DA.%2BG.%26aulast%3DMayo%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DMorskaya%26aufirst%3DS.%2BS.%26aulast%3DXu%26aufirst%3DH.%2BL.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DHinkle%26aufirst%3DG.%26aulast%3DKasperkovitz%26aufirst%3DP.%26aulast%3DDuncan%26aufirst%3DR.%2BG.%26aulast%3DKeir-Stead%26aufirst%3DN.%26aulast%3DCarito%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DAluri%26aufirst%3DK.%2BC.%26aulast%3DAttarwala%26aufirst%3DH.%26aulast%3DHutabarat%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DQ.%2BF.%26aulast%3DBrigham%26aufirst%3DB.%2BS.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DCharisse%26aufirst%3DK.%2BB.%26aulast%3DJadhav%26aufirst%3DV.%26aulast%3DKuchimanchi%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DWyrzykiewicz%26aufirst%3DT.%26aulast%3DHashmi%26aufirst%3DH.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DFreedman%26aufirst%3DD.%26aulast%3DSengupta%26aufirst%3DT.%2BP.%26aulast%3DGalil%26aufirst%3DK.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DHaslett%26aufirst%3DP.%26atitle%3DGalNAc-siRNA%2520conjugate%2520ALN-HBV%2520targets%2520a%2520highly%2520conserved%252C%2520pan-genotypic%2520X-orf%2520viral%2520site%2520and%2520mediates%2520profound%2520and%2520durable%2520HBsAg%2520silencing%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D224A%26epage%3D225A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Maepa, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelofse, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnot, P.</span><span> </span><span class="NLM_article-title">Progress and prospects of anti-HBV gene therapy development</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">17589</span><span class="NLM_x">–</span> <span class="NLM_lpage">17610</span><span class="refDoi"> DOI: 10.3390/ijms160817589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3390%2Fijms160817589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26263978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVags7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=17589-17610&author=M.+B.+Maepaauthor=I.+Roelofseauthor=A.+Elyauthor=P.+Arbuthnot&title=Progress+and+prospects+of+anti-HBV+gene+therapy+development&doi=10.3390%2Fijms160817589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and prospects of anti-HBV gene therapy development</span></div><div class="casAuthors">Maepa, Mohube B.; Roelofse, Ilke; Ely, Abdullah; Arbuthnot, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">17589-17610</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Despite the availability of an effective vaccine against hepatitis B virus (HBV), chronic infection with the virus remains a major global health concern.  Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance.  This has prompted vigorous research on developing better drugs against chronic HBV infection.  Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive.  This has led to development of better HBV infection models and discovery of new drug candidates.  Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, esp. covalently closed circular DNA (cccDNA).  For the past few decades, nucleic acid-based therapy has emerged as an attractive alternative that may result in complete clearance of HBV in infected patients.  Several genetic anti-HBV strategies have been developed.  The most studied approaches include the use of antisense oligonucleotides, ribozymes, RNA interference effectors and gene editing tools.  This review will summarize recent developments and progress made in the use of gene therapy against HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokFxCwdEXC5rVg90H21EOLACvtfcHk0lhfkMb60ceZWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVags7g%253D&md5=b5e0a4ceeb2a8a954273d7d3e40b6a1f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3390%2Fijms160817589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160817589%26sid%3Dliteratum%253Aachs%26aulast%3DMaepa%26aufirst%3DM.%2BB.%26aulast%3DRoelofse%26aufirst%3DI.%26aulast%3DEly%26aufirst%3DA.%26aulast%3DArbuthnot%26aufirst%3DP.%26atitle%3DProgress%2520and%2520prospects%2520of%2520anti-HBV%2520gene%2520therapy%2520development%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D17589%26epage%3D17610%26doi%3D10.3390%2Fijms160817589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Goodarzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tewari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watabe, K.</span><span> </span><span class="NLM_article-title">Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3021</span><span class="NLM_x">–</span> <span class="NLM_lpage">3025</span><span class="refDoi"> DOI: 10.1099/0022-1317-71-12-3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1099%2F0022-1317-71-12-3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=2177093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlGlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1990&pages=3021-3025&author=G.+Goodarziauthor=S.+C.+Grossauthor=A.+Tewariauthor=K.+Watabe&title=Antisense+oligodeoxyribonucleotides+inhibit+the+expression+of+the+gene+for+hepatitis+B+virus+surface+antigen&doi=10.1099%2F0022-1317-71-12-3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen</span></div><div class="casAuthors">Goodarzi, Goodarz; Gross, Steven C.; Tewari, Arun; Watabe, Kounosuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3021-5</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    </div><div class="casAbstract">The effect of a series of antisense oligodeoxyribonucleotides [oligo(dN)] on the expression of the surface antigen (HBsAg) gene of human hepatitis B virus (HBV) was examd. in hepatocellular carcinoma cells contg. integrated HBV genomes.  Of a no. of antisense oligo(dN) tested, synthetic 15-mers directed at the cap site of mRNA and regions of the translational initiation site of the HBsAg gene were highly effective and inhibited viral gene expression by ≤96%.  The inhibition was specific for the HBsAg gene and appeared to be at the level of translation.  These results suggest a therapeutic potential for antisense oligo(dN) in the treatment of patients chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKna7HqQuae7Vg90H21EOLACvtfcHk0lhfkMb60ceZWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlGlsrc%253D&md5=7acc2415580754e3f798d943581e18b6</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-71-12-3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-71-12-3021%26sid%3Dliteratum%253Aachs%26aulast%3DGoodarzi%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DS.%2BC.%26aulast%3DTewari%26aufirst%3DA.%26aulast%3DWatabe%26aufirst%3DK.%26atitle%3DAntisense%2520oligodeoxyribonucleotides%2520inhibit%2520the%2520expression%2520of%2520the%2520gene%2520for%2520hepatitis%2520B%2520virus%2520surface%2520antigen%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D1990%26volume%3D71%26spage%3D3021%26epage%3D3025%26doi%3D10.1099%2F0022-1317-71-12-3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerin, J. L.</span><span> </span><span class="NLM_article-title">Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/0166-3542(95)00050-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2F0166-3542%2895%2900050-V" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=225-242&author=B.+E.+Korbaauthor=J.+L.+Gerin&title=Antisense+oligonucleotides+are+effective+inhibitors+of+hepatitis+B+virus+replication+in+vitro&doi=10.1016%2F0166-3542%2895%2900050-V"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2895%2900050-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252895%252900050-V%26sid%3Dliteratum%253Aachs%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DGerin%26aufirst%3DJ.%2BL.%26atitle%3DAntisense%2520oligonucleotides%2520are%2520effective%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D1995%26volume%3D28%26spage%3D225%26epage%3D242%26doi%3D10.1016%2F0166-3542%2895%2900050-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Nakazono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1297</span><span class="NLM_x">–</span> <span class="NLM_lpage">1303</span><span class="refDoi"> DOI: 10.1002/hep.510230601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.510230601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1996&pages=1297-1303&author=K.+Nakazonoauthor=Y.+Itoauthor=C.+H.+Wuauthor=G.+Y.+Wu&title=Inhibition+of+hepatitis+B+virus+replication+by+targeted+pretreatment+of+complexed+antisense+DNA+in+vitro&doi=10.1002%2Fhep.510230601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fhep.510230601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510230601%26sid%3Dliteratum%253Aachs%26aulast%3DNakazono%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DG.%2BY.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520targeted%2520pretreatment%2520of%2520complexed%2520antisense%2520DNA%2520in%2520vitro%26jtitle%3DHepatology%26date%3D1996%26volume%3D23%26spage%3D1297%26epage%3D1303%26doi%3D10.1002%2Fhep.510230601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Offensperger, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offensperger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teubner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igloi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerok, W.</span><span> </span><span class="NLM_article-title">In vivo inhibition of duck hepatitis B virus-replication and gene-expression by phosphorothioate modified antisense oligodeoxynucleotides</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1257</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=1257-1262&author=W.+B.+Offenspergerauthor=S.+Offenspergerauthor=E.+Walterauthor=K.+Teubnerauthor=G.+Igloiauthor=H.+E.+Blumauthor=W.+Gerok&title=In+vivo+inhibition+of+duck+hepatitis+B+virus-replication+and+gene-expression+by+phosphorothioate+modified+antisense+oligodeoxynucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOffensperger%26aufirst%3DW.%2BB.%26aulast%3DOffensperger%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DE.%26aulast%3DTeubner%26aufirst%3DK.%26aulast%3DIgloi%26aufirst%3DG.%26aulast%3DBlum%26aufirst%3DH.%2BE.%26aulast%3DGerok%26aufirst%3DW.%26atitle%3DIn%2520vivo%2520inhibition%2520of%2520duck%2520hepatitis%2520B%2520virus-replication%2520and%2520gene-expression%2520by%2520phosphorothioate%2520modified%2520antisense%2520oligodeoxynucleotides%26jtitle%3DEMBO%2520J.%26date%3D1993%26volume%3D12%26spage%3D1257%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span> </span><span class="NLM_article-title">Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">12436</span><span class="NLM_x">–</span> <span class="NLM_lpage">12439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=12436-12439&author=G.+Wuauthor=C.+H.+Wu&title=Specific+inhibition+of+hepatitis+B+viral+gene+expression+in+vitro+by+targeted+antisense+oligonucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DC.%2BH.%26atitle%3DSpecific%2520inhibition%2520of%2520hepatitis%2520B%2520viral%2520gene%2520expression%2520in%2520vitro%2520by%2520targeted%2520antisense%2520oligonucleotides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D12436%26epage%3D12439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Yao, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span> </span><span class="NLM_article-title">In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.1996.tb00076.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1365-2893.1996.tb00076.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=8736236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADyaK28zjs1GnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=19-22&author=Z.+Q.+Yaoauthor=Y.+X.+Zhouauthor=X.+M.+Fengauthor=C.+X.+Chenauthor=J.+Guo&title=In+vivo+inhibition+of+hepatitis+B+viral+gene+expression+by+antisense+phosphorothioate+oligodeoxynucleotides+in+athymic+nude+mice&doi=10.1111%2Fj.1365-2893.1996.tb00076.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice</span></div><div class="casAuthors">Yao Z; Zhou Y; Feng X; Chen C; Guo J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-22</span>
        ISSN:<span class="NLM_cas:issn">1352-0504</span>.
    </div><div class="casAbstract">Antisense oligodeoxynucleotides strategies have been used both to study normal gene function and to block gene expression therapeutically.  We have previously shown that a number of antisense oligonucleotides against hepatitis B virus (HBV) mRNA are able to inhibit viral gene expression in vitro.  Here we report the establishment of an animal model producing HBV markers in athymic nude mice and inhibition of HBV gene expression and replication by antisense DNA in vivo. 2.2.15 cells (Hep-G2 cell line transfected with HBV genomes) were injected subcutaneously (s.c.) into athymic BALB/c nude mice at a total cell number of 0.5-1 x 10(8) per mouse.  Transplanted tumours developed about 2 weeks after inoculation.  Hepatitis B surface and e antigens (HBsAg and HBeAg), as well as HBV DNA, could be detected in the circulation of tumour-bearing mice.  Hepatitis B surface antigen and hepatitis B core antigen (HBcAg) were demonstrated in tumour cells.  After 10 days of tumour growth, antisense phosphorothioate oligonucleotide, complementary to the cap site of the SP II promoter of HBV mRNA, were injected by infiltration into or around the tumour as a daily dose of 20 micrograms per gram body weight.  Treatment for a total of 10 days resulted in an effective inhibition of viral replication and gene expression.  These results suggest therapeutic potential for antisense oligomers in the treatment of patients who are chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7rczBYn8SAHtlzo9xastyfW6udTcc2eb_V2j2nPa3trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zjs1GnsA%253D%253D&md5=8f657e12f04ebf29458a224dacd9747e</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.1996.tb00076.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.1996.tb00076.x%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BX.%26aulast%3DFeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%26atitle%3DIn%2520vivo%2520inhibition%2520of%2520hepatitis%2520B%2520viral%2520gene%2520expression%2520by%2520antisense%2520phosphorothioate%2520oligodeoxynucleotides%2520in%2520athymic%2520nude%2520mice%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1996%26volume%3D3%26spage%3D19%26epage%3D22%26doi%3D10.1111%2Fj.1365-2893.1996.tb00076.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Yao, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Q.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus in vitro by antisense oligonucleotides</span> <span class="citation_source-journal">Acta Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=35-39&author=Z.+Q.+Yaoauthor=Y.+X.+Zhouauthor=J.+Guoauthor=Z.+H.+Fengauthor=X.+M.+Fengauthor=C.+X.+Chenauthor=J.+Z.+Jiaoauthor=S.+Q.+Wang&title=Inhibition+of+hepatitis+B+virus+in+vitro+by+antisense+oligonucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%2BH.%26aulast%3DFeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BX.%26aulast%3DJiao%26aufirst%3DJ.%2BZ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%2520by%2520antisense%2520oligonucleotides%26jtitle%3DActa%2520Virol.%26date%3D1996%26volume%3D40%26spage%3D35%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Sun, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D. R.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2011.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bbrc.2011.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=430-435&author=Z.+Sunauthor=W.+Q.+Xiangauthor=Y.+J.+Guoauthor=Z.+Chenauthor=W.+Liuauthor=D.+R.+Lu&title=Inhibition+of+hepatitis+B+virus+%28HBV%29+by+LNA-mediated+nuclear+interference+with+HBV+DNA+transcription&doi=10.1016%2Fj.bbrc.2011.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DW.%2BQ.%26aulast%3DGuo%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DD.%2BR.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520by%2520LNA-mediated%2520nuclear%2520interference%2520with%2520HBV%2520DNA%2520transcription%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D409%26spage%3D430%26epage%3D435%26doi%3D10.1016%2Fj.bbrc.2011.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Noordeen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilbert, A. R.</span><span> </span><span class="NLM_article-title">Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5306</span><span class="refDoi"> DOI: 10.1128/AAC.01005-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01005-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5299-5306&author=F.+Noordeenauthor=A.+Vaillantauthor=A.+R.+Jilbert&title=Nucleic+acid+polymers+prevent+the+establishment+of+duck+hepatitis+B+virus+infection+in+vivo&doi=10.1128%2FAAC.01005-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1128%2FAAC.01005-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01005-13%26sid%3Dliteratum%253Aachs%26aulast%3DNoordeen%26aufirst%3DF.%26aulast%3DVaillant%26aufirst%3DA.%26aulast%3DJilbert%26aufirst%3DA.%2BR.%26atitle%3DNucleic%2520acid%2520polymers%2520prevent%2520the%2520establishment%2520of%2520duck%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5299%26epage%3D5306%26doi%3D10.1128%2FAAC.01005-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Almahtab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0156667</span><span class="refDoi"> DOI: 10.1371/journal.pone.0156667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.pone.0156667" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0156667&author=M.+Almahtabauthor=M.+Bazinetauthor=A.+Vaillant&title=Safety+and+efficacy+of+nucleic+acid+polymers+in+monotherapy+and+combined+with+immunotherapy+in+treatment-naive+bangladeshi+patients+with+HBeAg%2B+chronic+hepatitis+B+infection&doi=10.1371%2Fjournal.pone.0156667"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0156667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0156667%26sid%3Dliteratum%253Aachs%26aulast%3DAlmahtab%26aufirst%3DM.%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520nucleic%2520acid%2520polymers%2520in%2520monotherapy%2520and%2520combined%2520with%2520immunotherapy%2520in%2520treatment-naive%2520bangladeshi%2520patients%2520with%2520HBeAg%252B%2520chronic%2520hepatitis%2520B%2520infection%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0156667%26doi%3D10.1371%2Fjournal.pone.0156667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantea, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebotarescu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojuhari, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimbei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer rep 2139 in caucasian patients with chronic HBV/HDV co-infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S257</span><span class="NLM_x">–</span> <span class="NLM_lpage">S258</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30148-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930148-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25463532" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S257-S258&author=M.+Bazinetauthor=V.+Panteaauthor=V.+Cebotarescuauthor=L.+Cojuhariauthor=P.+Jimbeiauthor=A.+Vaillant&title=Significant+reduction+of+HBsAg+and+HDV+RNA+by+the+nucleic+acid+polymer+rep+2139+in+caucasian+patients+with+chronic+HBV%2FHDV+co-infection&doi=10.1016%2FS0168-8278%2815%2930148-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930148-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930148-3%26sid%3Dliteratum%253Aachs%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DPantea%26aufirst%3DV.%26aulast%3DCebotarescu%26aufirst%3DV.%26aulast%3DCojuhari%26aufirst%3DL.%26aulast%3DJimbei%26aufirst%3DP.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DSignificant%2520reduction%2520of%2520HBsAg%2520and%2520HDV%2520RNA%2520by%2520the%2520nucleic%2520acid%2520polymer%2520rep%25202139%2520in%2520caucasian%2520patients%2520with%2520chronic%2520HBV%252FHDV%2520co-infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS257%26epage%3DS258%26doi%3D10.1016%2FS0168-8278%2815%2930148-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantea, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebotarescu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojuhari, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimbei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV/HDV co-infection</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fjvh.08_12424" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=5-6&author=M.+Bazinetauthor=V.+Panteaauthor=V.+Cebotarescuauthor=L.+Cojuhariauthor=P.+Jimbeiauthor=A.+Vaillant&title=REP+2139+monotherapy+and+combination+therapy+with+pegylated+interferon%3A+safety+and+potent+reduction+of+HBsAg+and+HDV+RNA+in+Caucasian+patients+with+chronic+HBV%2FHDV+co-infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1111%2Fjvh.08_12424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.08_12424%26sid%3Dliteratum%253Aachs%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DPantea%26aufirst%3DV.%26aulast%3DCebotarescu%26aufirst%3DV.%26aulast%3DCojuhari%26aufirst%3DL.%26aulast%3DJimbei%26aufirst%3DP.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DREP%25202139%2520monotherapy%2520and%2520combination%2520therapy%2520with%2520pegylated%2520interferon%253A%2520safety%2520and%2520potent%2520reduction%2520of%2520HBsAg%2520and%2520HDV%2520RNA%2520in%2520Caucasian%2520patients%2520with%2520chronic%2520HBV%252FHDV%2520co-infection%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2015%26volume%3D22%26spage%3D5%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Susman, E. D.</span><span> </span><span class="NLM_article-title">New agent shows promise in HBV/HDV co-infected patients</span> <span class="citation_source-journal">Oncol. Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1097/01.COT.0000467336.34244.7a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1097%2F01.COT.0000467336.34244.7a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=57-59&author=E.+D.+Susman&title=New+agent+shows+promise+in+HBV%2FHDV+co-infected+patients&doi=10.1097%2F01.COT.0000467336.34244.7a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1097%2F01.COT.0000467336.34244.7a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.COT.0000467336.34244.7a%26sid%3Dliteratum%253Aachs%26aulast%3DSusman%26aufirst%3DE.%2BD.%26atitle%3DNew%2520agent%2520shows%2520promise%2520in%2520HBV%252FHDV%2520co-infected%2520patients%26jtitle%3DOncol.%2520Times%26date%3D2015%26volume%3D37%26spage%3D57%26epage%3D59%26doi%3D10.1097%2F01.COT.0000467336.34244.7a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Newman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragg, G. M.</span><span> </span><span class="NLM_article-title">Natural products as sources of new drugs over the last 25 years</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1021/np068054v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np068054v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=461-477&author=D.+J.+Newmanauthor=G.+M.+Cragg&title=Natural+products+as+sources+of+new+drugs+over+the+last+25+years&doi=10.1021%2Fnp068054v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Products as Sources of New Drugs over the Last 25 Years</span></div><div class="casAuthors">Newman, David J.; Cragg, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-477</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">A review.  This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003.  In the case of all approved agents the time frame has been extended to include the 251/2 years from 01/1981 to 06/2006 for all diseases worldwide and from 1950 (earliest so far identified) to 06/2006 for all approved antitumor drugs worldwide.  We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions.  From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well.  Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 155 small mols., 73% are other than "S" (synthetic), with 47% actually being either natural products or directly derived therefrom.  In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the antiinfective area being dependent on natural products and their structures.  Although combinatorial chem. techniques have succeeded as methods of optimizing structures and have, in fact, been used in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compd. approved as a drug in this 25 plus year time frame.  We wish to draw the attention of readers to the rapidly evolving recognition that a significant no. of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpih5kusSUibVg90H21EOLACvtfcHk0lhkymY-v4b-NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKrsro%253D&md5=9fc0909750367ccd3b97589aaf087cdf</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fnp068054v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp068054v%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26atitle%3DNatural%2520products%2520as%2520sources%2520of%2520new%2520drugs%2520over%2520the%2520last%252025%2520years%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2007%26volume%3D70%26spage%3D461%26epage%3D477%26doi%3D10.1021%2Fnp068054v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Matsunaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamisuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, F.</span><span> </span><span class="NLM_article-title">Isolation and structure of vanitaracin A, a novel anti-hepatitis B virus compound from Talaromyces sp</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4325</span><span class="NLM_x">–</span> <span class="NLM_lpage">4328</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2015.07.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4325-4328&author=H.+Matsunagaauthor=S.+Kamisukiauthor=M.+Kanekoauthor=Y.+Yamaguchiauthor=T.+Takeuchiauthor=K.+Watashiauthor=F.+Sugawara&title=Isolation+and+structure+of+vanitaracin+A%2C+a+novel+anti-hepatitis+B+virus+compound+from+Talaromyces+sp&doi=10.1016%2Fj.bmcl.2015.07.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.067%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DH.%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DF.%26atitle%3DIsolation%2520and%2520structure%2520of%2520vanitaracin%2520A%252C%2520a%2520novel%2520anti-hepatitis%2520B%2520virus%2520compound%2520from%2520Talaromyces%2520sp%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4325%26epage%3D4328%26doi%3D10.1016%2Fj.bmcl.2015.07.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Zembower, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korba, B. E.</span><span> </span><span class="NLM_article-title">Robustaflavone, a potential non-nucleoside anti-hepatitis B agent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1016/S0166-3542(98)00033-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0166-3542%2898%2900033-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=81-88&author=D.+E.+Zembowerauthor=Y.+M.+Linauthor=M.+T.+Flavinauthor=F.+C.+Chenauthor=B.+E.+Korba&title=Robustaflavone%2C+a+potential+non-nucleoside+anti-hepatitis+B+agent&doi=10.1016%2FS0166-3542%2898%2900033-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2898%2900033-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252898%252900033-3%26sid%3Dliteratum%253Aachs%26aulast%3DZembower%26aufirst%3DD.%2BE.%26aulast%3DLin%26aufirst%3DY.%2BM.%26aulast%3DFlavin%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DF.%2BC.%26aulast%3DKorba%26aufirst%3DB.%2BE.%26atitle%3DRobustaflavone%252C%2520a%2520potential%2520non-nucleoside%2520anti-hepatitis%2520B%2520agent%26jtitle%3DAntiviral%2520Res.%26date%3D1998%26volume%3D39%26spage%3D81%26epage%3D88%26doi%3D10.1016%2FS0166-3542%2898%2900033-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 1: synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4647</span><span class="NLM_x">–</span> <span class="NLM_lpage">4650</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2008.07.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4647-4650&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=P.+Chengauthor=Y.+B.+Maauthor=X.+M.+Zhangauthor=F.+X.+Zhangauthor=J.+Zhouauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+1%3A+synthesis+of+alisol+A+derivatives%3A+a+new+class+of+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.bmcl.2008.07.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DF.%2BX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25201%253A%2520synthesis%2520of%2520alisol%2520A%2520derivatives%253A%2520a%2520new%2520class%2520of%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4647%26epage%3D4650%26doi%3D10.1016%2Fj.bmcl.2008.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">–</span> <span class="NLM_lpage">2153</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.02.122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2148-2153&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=J.+F.+Liuauthor=Y.+B.+Maauthor=R.+H.+Guoauthor=X.+M.+Zhangauthor=J.+Zhouauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+2%3A+synthesis+and+in+vitro+anti-hepatitis+B+virus+activities+of+alisol+A+derivatives&doi=10.1016%2Fj.bmcl.2009.02.122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.122%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DGuo%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25202%253A%2520synthesis%2520and%2520in%2520vitro%2520anti-hepatitis%2520B%2520virus%2520activities%2520of%2520alisol%2520A%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2148%26epage%3D2153%26doi%3D10.1016%2Fj.bmcl.2009.02.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6659</span><span class="NLM_x">–</span> <span class="NLM_lpage">6665</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.10.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6659-6665&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=Y.+B.+Maauthor=J.+F.+Liuauthor=R.+H.+Guoauthor=X.+M.+Zhangauthor=J.+Zhouauthor=W.+Niuauthor=F.+F.+Duauthor=L.+Liauthor=C.+Liauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+3%3A+preliminary+structure-activity+relationships+of+tetra-acylalisol+A+derivatives+as+potent+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.bmcl.2009.10.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DGuo%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25203%253A%2520preliminary%2520structure-activity%2520relationships%2520of%2520tetra-acylalisol%2520A%2520derivatives%2520as%2520potent%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6659%26epage%3D6665%26doi%3D10.1016%2Fj.bmcl.2009.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.2174/1573406410666140902111326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.2174%2F1573406410666140902111326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25181984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=165-179&author=L.+J.+Wangauthor=H.+Chenauthor=Y.+B.+Maauthor=X.+Y.+Huangauthor=C.+A.+Gengauthor=X.+M.+Zhangauthor=J.+J.+Chen&title=Design%2C+synthesis+and+biological+evaluation+of+caudatin+analogs+as+potent+hepatitis+B+virus+inhibitors&doi=10.2174%2F1573406410666140902111326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Biological Evaluation of Caudatin Analogs as Potent Hepatitis B Virus Inhibitors</span></div><div class="casAuthors">Wang, Li-Jun; Chen, Hao; Ma, Yun-Bao; Huang, Xiao-Yan; Geng, Chang-An; Zhang, Xue-Mei; Chen, Ji-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-179</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Thirty-nine caudatin analogs were designed and synthesized.  Their anti-hepatitis B virus (HBV) activities were evaluated in vitro.  Among them, twenty-three compds. showed much better anti-HBV activity than caudatin, and eleven compds. significantly inhibited the HBV DNA replication with IC50 values < 10 μM.  Interestingly, three compds. (22, 28, 29) exhibited excellent activity against the secretion of HBsAg (IC50 = 63.02 μM, 52.81 μM, 56.08 μM), HBeAg (IC50 = 204.80 μM, 173.51 μM, 70.39 μM), along with HBV DNA replication (IC50 = 24.55 μM, 5.69 μM, 8.23 μM) with lower cytotoxicity.  The structure-activity relationships (SARs) of these caudatin analogs were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8TkKglRdNorVg90H21EOLACvtfcHk0ljlg0OjgKrkTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislemtLk%253D&md5=559fd8d1314421001882f1074ee241e0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.2174%2F1573406410666140902111326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406410666140902111326%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DHuang%26aufirst%3DX.%2BY.%26aulast%3DGeng%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520caudatin%2520analogs%2520as%2520potent%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D11%26spage%3D165%26epage%3D179%26doi%3D10.2174%2F1573406410666140902111326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1038/nrd1468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs&doi=10.1038%2Fnrd1468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lgZqrJkZ0ZLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D673%26epage%3D683%26doi%3D10.1038%2Fnrd1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Mu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besusso, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J.</span><span> </span><span class="NLM_article-title">A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">17330</span><span class="NLM_x">–</span> <span class="NLM_lpage">17334</span><span class="refDoi"> DOI: 10.1074/jbc.C700079200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1074%2Fjbc.C700079200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=17330-17334&author=J.+J.+Muauthor=Y.+Wangauthor=H.+Luoauthor=M.+Lengauthor=J.+Zhangauthor=T.+Yangauthor=D.+Besussoauthor=S.+Y.+Jungauthor=J.+Qin&title=A+proteomic+analysis+of+ataxia+telangiectasia-mutated+%28ATM%29%2FATM-rad3-related+%28ATR%29+substrates+identifies+the+ubiquitin-proteasome+system+as+a+regulator+for+DNA+damage+checkpoints&doi=10.1074%2Fjbc.C700079200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C700079200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C700079200%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DLeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DBesusso%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DS.%2BY.%26aulast%3DQin%26aufirst%3DJ.%26atitle%3DA%2520proteomic%2520analysis%2520of%2520ataxia%2520telangiectasia-mutated%2520%2528ATM%2529%252FATM-rad3-related%2520%2528ATR%2529%2520substrates%2520identifies%2520the%2520ubiquitin-proteasome%2520system%2520as%2520a%2520regulator%2520for%2520DNA%2520damage%2520checkpoints%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D17330%26epage%3D17334%26doi%3D10.1074%2Fjbc.C700079200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Cellular DNA repair cofactors affecting hepatitis B virus infection and replication</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5059</span><span class="NLM_x">–</span> <span class="NLM_lpage">5065</span><span class="refDoi"> DOI: 10.3748/wjg.14.5059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.14.5059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18763290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyntLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5059-5065&author=F.+Zhaoauthor=N.+B.+Houauthor=T.+Songauthor=X.+Heauthor=Z.+R.+Zhengauthor=Q.+J.+Maauthor=L.+Liauthor=Y.+H.+Zhangauthor=H.+Zhong&title=Cellular+DNA+repair+cofactors+affecting+hepatitis+B+virus+infection+and+replication&doi=10.3748%2Fwjg.14.5059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular DNA repair cofactors affecting hepatitis B virus infection and replication</span></div><div class="casAuthors">Zhao, Fan; Hou, Ning-Bo; Song, Ting; He, Xiang; Zheng, Zi-Rui; Ma, Qing-Jun; Li, Li; Zhang, Yan-Hong; Zhong, Hui</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5059-5065</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">Aim: To investigate whether hepatitis B virus (HBV) infection activates DNA damage response and DNA repair cofactors inhibit HBV infection and replication.  Methods: Human hepatocyte cell line HL7702 was studied.  Immunoblotting was performed to test the expression of ataxia telangiectasia-mutated (ATM)-Rad3-related protein (ATR), p21 and the level of phosphorylation of Chk1, p53, H2AX, ATM in HBV-infected or non-infected-cells.  Special short RNAi oligos was transfected to induce transient ATR knockdown in HL7702.  ATR-ATM chem. inhibitors caffeine (CF) and theophylline (TP), or Chk1 inhibitor 7-hydroxystaurosporine (UCN01) was studied to det. whether they suppress cellular DNA damage response and MG132 inhibits proteasome.  Results: The ATR checkpoint pathway, responding to single-strand breaks in DNA, was activated in response to HBV infection.  ATR knockdown cells decreased the HBV DNA yields, implying that HBV infection and replication could activate and exploit the activated DNA damage response.  CF/TP or UCN01 reduced the HBV DNA yield by 70% and 80%, resp.  HBV abrogated the ATR-dependent DNA damage signaling pathway by degrading p21, and introduction of the p21 protein before HBV infection reduced the HBV DNA yield.  Consistent with this result, p21 accumulation after MG132 treatment also sharply decreased the HBV DNA yield.  Conclusion: HBV infection can be treated with therapeutic approaches targeting host cell proteins by inhibiting a cellular gene required for HBV replication or by restoring a response abrogated by HBV, thus providing a potential approach to the prevention and treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodPmt1AlprrVg90H21EOLACvtfcHk0lgZqrJkZ0ZLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyntLjO&md5=742b3515eab1868a297544d6686b66da</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3748%2Fwjg.14.5059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.14.5059%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DN.%2BB.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DZ.%2BR.%26aulast%3DMa%26aufirst%3DQ.%2BJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DCellular%2520DNA%2520repair%2520cofactors%2520affecting%2520hepatitis%2520B%2520virus%2520infection%2520and%2520replication%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2008%26volume%3D14%26spage%3D5059%26epage%3D5065%26doi%3D10.3748%2Fwjg.14.5059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Ataxia telangiectasia-mutated-rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6163</span><span class="NLM_x">–</span> <span class="NLM_lpage">6170</span><span class="refDoi"> DOI: 10.3748/wjg.14.6163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.14.6163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18985806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6163-6170&author=F.+Zhaoauthor=N.+B.+Houauthor=X.+L.+Yangauthor=X.+Heauthor=Y.+Liuauthor=Y.+H.+Zhangauthor=C.+W.+Weiauthor=T.+Songauthor=L.+Liauthor=Q.+J.+Maauthor=H.+Zhong&title=Ataxia+telangiectasia-mutated-rad3-related+DNA+damage+checkpoint+signaling+pathway+triggered+by+hepatitis+B+virus+infection&doi=10.3748%2Fwjg.14.6163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Ataxia telangiectasia-mutated-Rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection</span></div><div class="casAuthors">Zhao, Fan; Hou, Ning-Bo; Yang, Xiao-Li; He, Xiang; Liu, Yu; Zhang, Yan-Hong; Wei, Cong-Wen; Song, Ting; Li, Li; Ma, Qing-Jun; Zhong, Hui</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6163-6170</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">AIM: To explore whether acute cellular DNA damage response is induced upon hepatitis B virus (HBV) infection and the effects of the HBV infection.  METHODS: We incubated HL7702 hepatocytes with HBV-pos. serum, mimicking a natural HBV infection process.  We used immunoblotting to evaluate protein expression levels in HBV-infected cells or in non-infected cells; immunofluorescence to show ATR foci and Chk1 phosphorylation foci formation; flow cytometry to analyze the cell cycle and apoptosis; UV: (UV) radiation and ionizing radiation (IR)-treated cells to mimic DNA damage; and Trypan blue staining to count the viable cells.  RESULTS: We found that HBV infection induced an increased steady state of ATR protein and increased phosphorylation of multiple downstream targets including Chk1, p53 and H2AX.  In contrast to ATR and its target, the phosphorylated form of ATM at Ser-1981 and its downstream substrate Chk2 phosphorylation at Thr-68 did not visibly increase upon infection.  However, the level of Mre11 and p21 were reduced beginning at 0.5 h after HBV-pos. serum addn.  Also, HBV infection led to transient cell cycle arrest in the S and the G2 phases without accompanying increased apoptosis.  Research on cell survival changes upon radiation following HBV infection showed that survival of UV-treated host cells was greatly increased by HBV infection, owing to the reduced apoptosis.  Meanwhile, survival of IR-treated host cells was reduced by HBV infection.  CONCLUSION: HBV infection activates ATR DNA damage response to replication stress and abrogates the checkpoint signaling controlled by DNA damage response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquc0D0yKYIMbVg90H21EOLACvtfcHk0lgZqrJkZ0ZLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWnsr0%253D&md5=f10035404aa37b46d087804a157417a4</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.3748%2Fwjg.14.6163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.14.6163%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DN.%2BB.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DWei%26aufirst%3DC.%2BW.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DQ.%2BJ.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DAtaxia%2520telangiectasia-mutated-rad3-related%2520DNA%2520damage%2520checkpoint%2520signaling%2520pathway%2520triggered%2520by%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2008%26volume%3D14%26spage%3D6163%26epage%3D6170%26doi%3D10.3748%2Fwjg.14.6163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Zheng, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Inhibition of HBV replication by theophylline</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2010.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2010.12.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=149-155&author=Z.+R.+Zhengauthor=J.+Y.+Liauthor=J.+Sunauthor=T.+Songauthor=C.+W.+Weiauthor=Y.+H.+Zhangauthor=G.+R.+Raoauthor=G.+M.+Chenauthor=D.+C.+Liauthor=G.+M.+Yangauthor=B.+Hanauthor=S.+Weiauthor=C.+Caoauthor=H.+Zhong&title=Inhibition+of+HBV+replication+by+theophylline&doi=10.1016%2Fj.antiviral.2010.12.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2010.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2010.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%2BR.%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DRao%26aufirst%3DG.%2BR.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DLi%26aufirst%3DD.%2BC.%26aulast%3DYang%26aufirst%3DG.%2BM.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520HBV%2520replication%2520by%2520theophylline%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D89%26spage%3D149%26epage%3D155%26doi%3D10.1016%2Fj.antiviral.2010.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Fox, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saravolatz, L. D.</span><span> </span><span class="NLM_article-title">Nitazoxanide: a new thiazolide antiparasitic agent</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span><span class="refDoi"> DOI: 10.1086/428839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1086%2F428839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15791519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=1173-1180&author=L.+M.+Foxauthor=L.+D.+Saravolatz&title=Nitazoxanide%3A+a+new+thiazolide+antiparasitic+agent&doi=10.1086%2F428839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide: a new thiazolide antiparasitic agent</span></div><div class="casAuthors">Fox, LeAnne M.; Saravolatz, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1173-1180</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths.  It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects.  At present, there are no documented drug-drug interactions.  Nitazoxanide has been licensed for the treatment of Giardia intestinalis-induced diarrhea in patients ≥1 yr of age and Cryptosporidium-induced diarrhea in children aged 1-11 years.  At present, it is pending licensure for treatment of infection due to Cryptosporidium species in adults and for use in treating immunocompromised hosts.  It represents an important addn. to the antiparasitic arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk8xTuMMlYQrVg90H21EOLACvtfcHk0lgLjLcs4DPokQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVynsbw%253D&md5=9d1b8b6bfc962dd3ec3b3adbb13c451c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1086%2F428839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F428839%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DL.%2BM.%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26atitle%3DNitazoxanide%253A%2520a%2520new%2520thiazolide%2520antiparasitic%2520agent%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D40%26spage%3D1173%26epage%3D1180%26doi%3D10.1086%2F428839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Gilles, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, P. S.</span><span> </span><span class="NLM_article-title">Treatment of intestinal parasitic infections: a review of nitazoxanide</span> <span class="citation_source-journal">Trends Parasitol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1016/S1471-4922(01)02205-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1471-4922%2801%2902205-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11854075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD387itVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=95-97&author=H.+M.+Gillesauthor=P.+S.+Hoffman&title=Treatment+of+intestinal+parasitic+infections%3A+a+review+of+nitazoxanide&doi=10.1016%2FS1471-4922%2801%2902205-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of intestinal parasitic infections: a review of nitazoxanide</span></div><div class="casAuthors">Gilles Herbert M; Hoffman Paul S</div><div class="citationInfo"><span class="NLM_cas:title">Trends in parasitology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">95-7</span>
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIejC39IDdKCSm0e6ZOaemfW6udTcc2ebab_0ytQswcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itVarsw%253D%253D&md5=a022402051312fc038632cb60168b1a8</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2FS1471-4922%2801%2902205-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4922%252801%252902205-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilles%26aufirst%3DH.%2BM.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26atitle%3DTreatment%2520of%2520intestinal%2520parasitic%2520infections%253A%2520a%2520review%2520of%2520nitazoxanide%26jtitle%3DTrends%2520Parasitol.%26date%3D2002%26volume%3D18%26spage%3D95%26epage%3D97%26doi%3D10.1016%2FS1471-4922%2801%2902205-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeffe, E. B.</span><span> </span><span class="NLM_article-title">Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.2217/17460913.3.5.539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.2217%2F17460913.3.5.539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18811238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFGlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=539-545&author=J.+F.+Rossignolauthor=E.+B.+Keeffe&title=Thiazolides%3A+a+new+class+of+drugs+for+the+treatment+of+chronic+hepatitis+B+and+C&doi=10.2217%2F17460913.3.5.539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C</span></div><div class="casAuthors">Rossignol, Jean-Francois; Keeffe, Emmet B.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum.  The antiviral activity of nitazoxanide was discovered by serendipity in patients with AIDS who were treated for cryptosporidial diarrhea and had HBV or HCV co-infection.  In preliminary open-label studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss or seroconversion of hepatitis B e antigen in the majority of patients, as well as hepatitis B surface antigen in approx. a quarter of patients.  In Phase II studies of patients with chronic hepatitis C genotype 4, nitazoxanide combined with peginterferon alfa-2a, with or without ribavirin, increased the sustained virol. response rate to 79-80 vs. 50% with peginterferon plus ribavirin std. of care.  Randomized, controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 and patients with chronic hepatitis B are underway, and new second generation thiazolides are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOZh4gfIQvbVg90H21EOLACvtfcHk0litdvqSEygdPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFGlu7bK&md5=b360c87d45283cff3fe31469847fae5a</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2217%2F17460913.3.5.539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460913.3.5.539%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26atitle%3DThiazolides%253A%2520a%2520new%2520class%2520of%2520drugs%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520and%2520C%26jtitle%3DFuture%2520Microbiol.%26date%3D2008%26volume%3D3%26spage%3D539%26epage%3D545%26doi%3D10.2217%2F17460913.3.5.539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Rossignol, J. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayoub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M. S.</span><span> </span><span class="NLM_article-title">Treatment of diarrhea caused by cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1086/321008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1086%2F321008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11398117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Oiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2001&pages=103-106&author=J.+F.+A.+Rossignolauthor=A.+Ayoubauthor=M.+S.+Ayers&title=Treatment+of+diarrhea+caused+by+cryptosporidium+parvum%3A+a+prospective+randomized%2C+double-blind%2C+placebo-controlled+study+of+nitazoxanide&doi=10.1086%2F321008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of diarrhea caused by Cryptosporidium parvum: A prospective randomized, double-blind, placebo-controlled study of nitazoxanide</span></div><div class="casAuthors">Rossignol, Jean-Francois A.; Ayoub, Ayman; Ayers, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-106</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A prospective randomized, double-blind, placebo-controlled study was conducted in 50 adults and 50 children from the Nile delta of Egypt, to evaluate the efficacy of nitazoxanide in treating diarrhea caused by Cryptosporidium parvum.  Nitazoxanide was administered in 500-mg doses twice daily for 3 days in adults and adolescents, in 200-mg doses twice daily for 3 days in children aged 4-11 yr, and in 100-mg doses twice daily for 3 days in children aged 1-3 yr.  At 7 days after initiation of therapy, diarrhea had resolved in 39 (80%) of the 49 patients in the nitazoxanide treatment group, compared with 20 (41%) of 49 in the placebo group (P < .0001).  Diarrhea was resolved in most patients receiving nitazoxanide within 3 or 4 days of treatment initiation.  Nitazoxanide treatment reduced the duration of both diarrhea (P < .0001) and oocyst shedding (P < .0001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiYg7QprUqBrVg90H21EOLACvtfcHk0litdvqSEygdPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Oiu7g%253D&md5=08eb60fdda75f2a145502d06ce4707f4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1086%2F321008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F321008%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%2BA.%26aulast%3DAyoub%26aufirst%3DA.%26aulast%3DAyers%26aufirst%3DM.%2BS.%26atitle%3DTreatment%2520of%2520diarrhea%2520caused%2520by%2520cryptosporidium%2520parvum%253A%2520a%2520prospective%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520nitazoxanide%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D184%26spage%3D103%26epage%3D106%26doi%3D10.1086%2F321008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaye, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukerjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.08.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=56-63&author=B.+E.+Korbaauthor=A.+B.+Monteroauthor=K.+Farrarauthor=K.+Gayeauthor=S.+Mukerjeeauthor=M.+S.+Ayersauthor=J.+F.+Rossignol&title=Nitazoxanide%2C+tizoxanide+and+other+thiazolides+are+potent+inhibitors+of+hepatitis+B+virus+and+hepatitis+C+virus+replication&doi=10.1016%2Fj.antiviral.2007.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DMontero%26aufirst%3DA.%2BB.%26aulast%3DFarrar%26aufirst%3DK.%26aulast%3DGaye%26aufirst%3DK.%26aulast%3DMukerjee%26aufirst%3DS.%26aulast%3DAyers%26aufirst%3DM.%2BS.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DNitazoxanide%252C%2520tizoxanide%2520and%2520other%2520thiazolides%2520are%2520potent%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.antiviral.2007.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Elazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrig, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puglisi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1053/j.gastro.2009.07.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2009.07.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=1827-1835&author=M.+Elazarauthor=M.+Liuauthor=S.+A.+McKennaauthor=P.+Liuauthor=E.+A.+Gehrigauthor=J.+D.+Puglisiauthor=J.+F.+Rossignolauthor=J.+S.+Glenn&title=The+anti-hepatitis+C+agent+nitazoxanide+induces+phosphorylation+of+eukaryotic+initiation+factor+2alpha+via+protein+kinase+activated+by+double-stranded+RNA+activation&doi=10.1053%2Fj.gastro.2009.07.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.07.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.07.056%26sid%3Dliteratum%253Aachs%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGehrig%26aufirst%3DE.%2BA.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520anti-hepatitis%2520C%2520agent%2520nitazoxanide%2520induces%2520phosphorylation%2520of%2520eukaryotic%2520initiation%2520factor%25202alpha%2520via%2520protein%2520kinase%2520activated%2520by%2520double-stranded%2520RNA%2520activation%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D137%26spage%3D1827%26epage%3D1835%26doi%3D10.1053%2Fj.gastro.2009.07.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Mederacke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span> </span><span class="NLM_article-title">Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?</span> <span class="citation_source-journal">Ann. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19502665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=166-168&author=I.+Mederackeauthor=H.+Wedemeyer&title=Nitazoxanide+for+the+treatment+of+chronic+hepatitis+C+new+opportunities+but+new+challenges%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?</span></div><div class="casAuthors">Mederacke, Ingmar; Wedemeyer, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-168</span>CODEN:
                <span class="NLM_cas:coden">AHNEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1665-2681</span>.
    
            (<span class="NLM_cas:orgname">Mexican Association of Hepatology</span>)
        </div><div class="casAbstract">A review.  Background & Aims: Sustained virol. response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin.  The safety and efficacy of nitazoxanide plus peginterferon alfa-2a, with or without ribavirin, were evaluated in a randomized controlled trial at 2 centers in Egypt.  Methods: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given std. of care (peginterferon alfa-2a and ribavirin for 48 wk, n = 40), nitazoxanide monotherapy for 12 wk followed by nitazoxanide plus peginterferon alfa-2a for 36 wk (n = 28), or nitazoxanide monotherapy for 12 wk followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 wk (n = 28).  Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 μg) once weekly, and wt.-based ribavirin (1000-1200 mg/day).  Results: The percentages of rapid virol. response (RVR), defined as undetectable HCV RNA at week 4 of combination therapy, and SVR were significantly higher in patients given the triple therapy compared with the std. of care (64% vs 38%, P = .048; and 79% vs 50%, P = .023; resp.).  Patients given nitazoxanide plus peginterferon alfa-2a had intermediate rates of RVR (54%) and SVR (61%).  Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving ribavirin.  Conclusions: The combination of nitazoxanide, peginterferon alfa-2a, and ribavirin increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus ribavirin, without an increase in adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Pl_KmE2xpLVg90H21EOLACvtfcHk0lg-Wymcl15Xag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7jJ&md5=546e84ba509e0f715dc2fd5b77ae4137</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMederacke%26aufirst%3DI.%26aulast%3DWedemeyer%26aufirst%3DH.%26atitle%3DNitazoxanide%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520new%2520opportunities%2520but%2520new%2520challenges%253F%26jtitle%3DAnn.%2520Hepatol.%26date%3D2009%26volume%3D8%26spage%3D166%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Nitazoxanide: a first-in-class broad-spectrum antiviral agent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25108173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtleisL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=94-103&author=J.+F.+Rossignol&title=Nitazoxanide%3A+a+first-in-class+broad-spectrum+antiviral+agent&doi=10.1016%2Fj.antiviral.2014.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide: A first-in-class broad-spectrum antiviral agent</span></div><div class="casAuthors">Rossignol, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-103</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza.  A Phase 2b/3 clin. trial recently published in The Lancet Infectious Diseases found that oral administration of nitazoxanide 600 mg twice daily for five days reduced the duration of clin. symptoms and reduced viral shedding compared to placebo in persons with lab.-confirmed influenza.  The same study also suggested a potential benefit for subjects with influenza-like illness who did not have influenza or other documented respiratory viral infection.  From a chem. perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides.  These small-mol. drugs target host-regulated processes involved in viral replication.  Nitazoxanide is orally bioavailable and safe with extensive post-marketing experience involving more than 75 million adults and children.  A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clin. development for the treatment of influenza.  Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors.  It is synergistic with neuraminidase inhibitors, and combination therapy with oseltamivir is being studied in humans as part of ongoing Phase 3 clin. development.  Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, coronavirus, rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays.  Clin. trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C.  Ongoing and future clin. development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_XyG4B6HlO7Vg90H21EOLACvtfcHk0lg-Wymcl15Xag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtleisL%252FK&md5=12dd8a143876626fc31303da2c5f24c4</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DNitazoxanide%253A%2520a%2520first-in-class%2520broad-spectrum%2520antiviral%2520agent%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D94%26epage%3D103%26doi%3D10.1016%2Fj.antiviral.2014.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elfert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Gohary, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeffe, E. B.</span><span> </span><span class="NLM_article-title">Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">856</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span><span class="refDoi"> DOI: 10.1053/j.gastro.2008.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2008.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=856-862&author=J.+F.+Rossignolauthor=A.+Elfertauthor=Y.+El-Goharyauthor=E.+B.+Keeffe&title=Improved+virologic+response+in+chronic+hepatitis+C+genotype+4+treated+with+nitazoxanide%2C+peginterferon%2C+and+ribavirin&doi=10.1053%2Fj.gastro.2008.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DElfert%26aufirst%3DA.%26aulast%3DEl-Gohary%26aufirst%3DY.%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26atitle%3DImproved%2520virologic%2520response%2520in%2520chronic%2520hepatitis%2520C%2520genotype%25204%2520treated%2520with%2520nitazoxanide%252C%2520peginterferon%252C%2520and%2520ribavirin%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D136%26spage%3D856%26epage%3D862%26doi%3D10.1053%2Fj.gastro.2008.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Keeffe, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1805</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.3748/wjg.15.1805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.15.1805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19370775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsF2kur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1805-1808&author=E.+B.+Keeffeauthor=J.+F.+Rossignol&title=Treatment+of+chronic+viral+hepatitis+with+nitazoxanide+and+second+generation+thiazolides&doi=10.3748%2Fwjg.15.1805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides</span></div><div class="casAuthors">Keeffe, Emmet B.; Rossignol, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1805-1808</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum.  More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis C virus was recognized in in vitro systems.  These basic studies led to phase II clin. trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon, with or without ribavirin, in the treatment of chronic hepatitis C genotype 4.  The sustained virol. response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the std. of care with peginterferon plus ribavirin.  In very preliminary studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approx. a quarter of patients.  Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway, new second generation and controlled release thiazolides are being developed, and future studies of patients with chronic hepatitis B are planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqklsGnFYFTa7Vg90H21EOLACvtfcHk0lgr5p6QGFid1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsF2kur4%253D&md5=5c9d667204c617211719b7b107e3613b</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.3748%2Fwjg.15.1805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.15.1805%26sid%3Dliteratum%253Aachs%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DTreatment%2520of%2520chronic%2520viral%2520hepatitis%2520with%2520nitazoxanide%2520and%2520second%2520generation%2520thiazolides%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D15%26spage%3D1805%26epage%3D1808%26doi%3D10.3748%2Fwjg.15.1805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 42 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wuhong Chen, Feifei Liu, Qiliang Zhao, Xinna Ma, Dong Lu, Heng Li, Yanping Zeng, Xiankun Tong, Limin Zeng, Jia Liu, Li Yang, Jianping Zuo, <span class="NLM_string-name hlFld-ContribAuthor">Youhong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8134-8145. <a href="https://doi.org/10.1021/acs.jmedchem.0c00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPhthalazinone%252BDerivatives%252Bas%252BNovel%252BHepatitis%252BB%252BVirus%252BCapsid%252BInhibitors%26aulast%3DChen%26aufirst%3DWuhong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D21072020%26volume%3D63%26issue%3D15%26spage%3D8134%26epage%3D8145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
D. Huber, Dallas L. Pineda, Dandan Liu, Kelsey N. Boschert, Anna T. Gres, Jennifer J. Wolf, Emily M. Coonrod, Jing Tang, Thomas G. Laughlin, Qiongying Yang, Maritza N. Puray-Chavez, Juan Ji, Kamalendra Singh, Karen A. Kirby, Zhengqiang Wang, <span class="NLM_string-name hlFld-ContribAuthor">Stefan G. Sarafianos</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (5)
                                     , 750-758. <a href="https://doi.org/10.1021/acsinfecdis.8b00235" title="DOI URL">https://doi.org/10.1021/acsinfecdis.8b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.8b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.8b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DNovel%252BHepatitis%252BB%252BVirus%252BCapsid-Targeting%252BAntiviral%252BThat%252BAggregates%252BCore%252BParticles%252Band%252BInhibits%252BNuclear%252BEntry%252Bof%252BViral%252BCores%26aulast%3DHuber%26aufirst%3DAndrew%2BD.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D09092018%26date%3D14012019%26date%3D24122018%26volume%3D5%26issue%3D5%26spage%3D750%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Panagiotis Kondylis, Christopher J. Schlicksup, Sarah P. Katen, Lye Siang Lee, Adam Zlotnick, <span class="NLM_string-name hlFld-ContribAuthor">Stephen C. Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (5)
                                     , 769-777. <a href="https://doi.org/10.1021/acsinfecdis.8b00290" title="DOI URL">https://doi.org/10.1021/acsinfecdis.8b00290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.8b00290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.8b00290%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DEvolution%252Bof%252BIntermediates%252Bduring%252BCapsid%252BAssembly%252Bof%252BHepatitis%252BB%252BVirus%252Bwith%252BPhenylpropenamide-Based%252BAntivirals%26aulast%3DKondylis%26aufirst%3DPanagiotis%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28102018%26date%3D04022019%26date%3D07012019%26volume%3D5%26issue%3D5%26spage%3D769%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Li Yang, Feifei Liu, Xiankun Tong, Daniel Hoffmann, Jianping Zuo, <span class="NLM_string-name hlFld-ContribAuthor">Mengji Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (5)
                                     , 713-724. <a href="https://doi.org/10.1021/acsinfecdis.8b00337" title="DOI URL">https://doi.org/10.1021/acsinfecdis.8b00337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.8b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.8b00337%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DTreatment%252Bof%252BChronic%252BHepatitis%252BB%252BVirus%252BInfection%252BUsing%252BSmall%252BMolecule%252BModulators%252Bof%252BNucleocapsid%252BAssembly%25253A%252BRecent%252BAdvances%252Band%252BPerspectives%26aulast%3DYang%26aufirst%3DLi%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D29112018%26date%3D29032019%26date%3D21032019%26volume%3D5%26issue%3D5%26spage%3D713%26epage%3D724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yameng Pei, Chunting Wang, Haijing Ben, Lei Wang, Yao Ma, Qingyan Ma, Ye Xiang, Linqi Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Gang Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (5)
                                     , 778-787. <a href="https://doi.org/10.1021/acsinfecdis.9b00030" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00030%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDiscovery%252Bof%252BNew%252BHepatitis%252BB%252BVirus%252BCapsid%252BAssembly%252BModulators%252Bby%252Ban%252BOptimal%252BHigh-Throughput%252BCell-Based%252BAssay%26aulast%3DPei%26aufirst%3DYameng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23012019%26date%3D22022019%26date%3D14022019%26volume%3D5%26issue%3D5%26spage%3D778%26epage%3D787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Panagiotis Kondylis, Christopher J. Schlicksup, Nicholas E. Brunk, Jinsheng Zhou, Adam Zlotnick, <span class="NLM_string-name hlFld-ContribAuthor">Stephen C. Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Competition between Normative and Drug-Induced Virus Self-Assembly Observed with Single-Particle Methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (3)
                                     , 1251-1260. <a href="https://doi.org/10.1021/jacs.8b10131" title="DOI URL">https://doi.org/10.1021/jacs.8b10131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b10131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b10131%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCompetition%252Bbetween%252BNormative%252Band%252BDrug-Induced%252BVirus%252BSelf-Assembly%252BObserved%252Bwith%252BSingle-Particle%252BMethods%26aulast%3DKondylis%26aufirst%3DPanagiotis%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D18092018%26date%3D31122018%26date%3D11122018%26volume%3D141%26issue%3D3%26spage%3D1251%26epage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Panagiotis Kondylis, Christopher J. Schlicksup, Adam Zlotnick, <span class="NLM_string-name hlFld-ContribAuthor">Stephen C. Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Analytical Techniques to Characterize the Structure, Properties, and Assembly of Virus Capsids. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2019,</strong> <em>91 </em>
                                    (1)
                                     , 622-636. <a href="https://doi.org/10.1021/acs.analchem.8b04824" title="DOI URL">https://doi.org/10.1021/acs.analchem.8b04824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.8b04824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.8b04824%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DAnalytical%252BTechniques%252Bto%252BCharacterize%252Bthe%252BStructure%25252C%252BProperties%25252C%252Band%252BAssembly%252Bof%252BVirus%252BCapsids%26aulast%3DKondylis%26aufirst%3DPanagiotis%26date%3D2019%26date%3D2018%26date%3D03122018%26date%3D01112018%26volume%3D91%26issue%3D1%26spage%3D622%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Song Feng, Lu Gao, Xingchun Han, Taishan Hu, Yimin Hu, Haixia Liu, Andrew W. Thomas, Zhipeng Yan, Song Yang, John A. T. Young, Hongying Yun, Wei Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Hong C. Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2018,</strong> <em>4 </em>
                                    (3)
                                     , 257-277. <a href="https://doi.org/10.1021/acsinfecdis.7b00144" title="DOI URL">https://doi.org/10.1021/acsinfecdis.7b00144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.7b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.7b00144%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDiscovery%252Bof%252BSmall%252BMolecule%252BTherapeutics%252Bfor%252BTreatment%252Bof%252BChronic%252BHBV%252BInfection%26aulast%3DFeng%26aufirst%3DSong%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D04092017%26date%3D12022018%26date%3D25012018%26volume%3D4%26issue%3D3%26spage%3D257%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathália Alves Araújo  de Almeida</span>, <span class="hlFld-ContribAuthor ">Camilla Rodrigues de Almeida  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Jéssica Vasques  Raposo</span>, <span class="hlFld-ContribAuthor ">Vanessa Salete  de Paula</span>. </span><span class="cited-content_cbyCitation_article-title">Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 822. <a href="https://doi.org/10.3390/v13050822" title="DOI URL">https://doi.org/10.3390/v13050822</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13050822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13050822%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DImmunotherapy%252Band%252BGene%252BTherapy%252Bfor%252BOncoviruses%252BInfections%25253A%252BA%252BReview%26aulast%3Dde%2BAlmeida%26aufirst%3DNath%25C3%25A1lia%2BAlves%2BAra%25C3%25BAjo%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgia-Myrto  Prifti</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Moianos</span>, <span class="hlFld-ContribAuthor ">Erofili  Giannakopoulou</span>, <span class="hlFld-ContribAuthor ">Vasiliki  Pardali</span>, <span class="hlFld-ContribAuthor ">John  Tavis</span>, <span class="hlFld-ContribAuthor ">Grigoris  Zoidis</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Hepatitis B Treatment. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 417. <a href="https://doi.org/10.3390/ph14050417" title="DOI URL">https://doi.org/10.3390/ph14050417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14050417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14050417%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DRecent%252BAdvances%252Bin%252BHepatitis%252BB%252BTreatment%26aulast%3DPrifti%26aufirst%3DGeorgia-Myrto%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piet  Herdewijn</span>, <span class="hlFld-ContribAuthor ">Weijie  Gu</span>, <span class="hlFld-ContribAuthor ">Erik  Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Anti‐DNA Virus Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-41. <a href="https://doi.org/10.1002/0471266949.bmc237.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc237.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc237.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc237.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DAnti%2525E2%252580%252590DNA%252BVirus%252BAgents%26aulast%3DHerdewijn%26aufirst%3DPiet%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D41%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Ma</span>, <span class="hlFld-ContribAuthor ">Estrella  Frutos-Beltrán</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Luis  Menéndez-Arias</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (7)
                                     , 4514-4540. <a href="https://doi.org/10.1039/D0CS01084G" title="DOI URL">https://doi.org/10.1039/D0CS01084G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01084G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01084G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DMedicinal%252Bchemistry%252Bstrategies%252Bfor%252Bdiscovering%252Bantivirals%252Beffective%252Bagainst%252Bdrug-resistant%252Bviruses%26aulast%3DMa%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D7%26spage%3D4514%26epage%3D4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Jiacheng  Liu</span>, <span class="hlFld-ContribAuthor ">Yunwen  Wang</span>, <span class="hlFld-ContribAuthor ">Rui  Wu</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>, 116096. <a href="https://doi.org/10.1016/j.bmc.2021.116096" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116096%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BHBV%252Bcapsid%252Bassembly%252Bmodulators%252Bby%252Bstructure-based%252Bvirtual%252Bscreening%252Band%252Bbioassays%26aulast%3DWang%26aufirst%3DYuan%26date%3D2021%26volume%3D36%26spage%3D116096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo-Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Bei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yong-Fong  Yang</span>, <span class="hlFld-ContribAuthor ">Mao-Rong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2021,</strong> <em>27 </em>
                                    (8)
                                     , 666-676. <a href="https://doi.org/10.3748/wjg.v27.i8.666" title="DOI URL">https://doi.org/10.3748/wjg.v27.i8.666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v27.i8.666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v27.i8.666%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DNew%252Btherapeutic%252Boptions%252Bfor%252Bpersistent%252Blow-level%252Bviremia%252Bin%252Bpatients%252Bwith%252Bchronic%252Bhepatitis%252BB%252Bvirus%252Binfection%25253A%252BIncrease%252Bof%252Bentecavir%252Bdosage%26aulast%3DYin%26aufirst%3DGuo-Qing%26date%3D2021%26volume%3D27%26issue%3D8%26spage%3D666%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Farideh  Badichi Akher</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Fanie R.  Van Heerden</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of HEC72702 chirality on the selective inhibition of hepatitis B virus capsid dimer: A dynamics–structure–energetics perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (1)
                                     , 167-183. <a href="https://doi.org/10.1111/cbdd.13771" title="DOI URL">https://doi.org/10.1111/cbdd.13771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13771%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DImpact%252Bof%252BHEC72702%252Bchirality%252Bon%252Bthe%252Bselective%252Binhibition%252Bof%252Bhepatitis%252BB%252Bvirus%252Bcapsid%252Bdimer%25253A%252BA%252Bdynamics%2525E2%252580%252593structure%2525E2%252580%252593energetics%252Bperspective%26aulast%3DFarrokhzadeh%26aufirst%3DAbdolkarim%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D1%26spage%3D167%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Edeildo Ferreira  da Silva-Júnior</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">HIV-1 and HBV RNase H as Metal-Chelating Inhibitors: Discovery and Medicinal Chemistry Strategies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 585-602. <a href="https://doi.org/10.1007/978-3-030-71165-8_28" title="DOI URL">https://doi.org/10.1007/978-3-030-71165-8_28</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-71165-8_28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-71165-8_28%26sid%3Dliteratum%253Aachs%26atitle%3DHIV-1%252Band%252BHBV%252BRNase%252BH%252Bas%252BMetal-Chelating%252BInhibitors%25253A%252BDiscovery%252Band%252BMedicinal%252BChemistry%252BStrategies%26aulast%3DWei%26aufirst%3DFenju%26date%3D2021%26date%3D2021%26spage%3D585%26epage%3D602%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHuman%252BViruses%25253A%252BDiseases%25252C%252BTreatments%252Band%252BVaccines%26aulast%3DAhmad%26aufirst%3DShamim%2BI.%26date%3D2021%26volume%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhanfei  Chen</span>, <span class="hlFld-ContribAuthor ">Yiyin  Chen</span>, <span class="hlFld-ContribAuthor ">Lirong  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaoqian  Wang</span>, <span class="hlFld-ContribAuthor ">Nanhong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. </span><span class="cited-content_cbyCitation_journal-name">Journal for ImmunoTherapy of Cancer</span><span> <strong>2020,</strong> <em>8 </em>
                                    (2)
                                     , e001377. <a href="https://doi.org/10.1136/jitc-2020-001377" title="DOI URL">https://doi.org/10.1136/jitc-2020-001377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/jitc-2020-001377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fjitc-2020-001377%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520for%2520ImmunoTherapy%2520of%2520Cancer%26atitle%3D2%25252C5-dimethylcelecoxib%252Bimproves%252Bimmune%252Bmicroenvironment%252Bof%252Bhepatocellular%252Bcarcinoma%252Bby%252Bpromoting%252Bubiquitination%252Bof%252BHBx-induced%252BPD-L1%26aulast%3DChen%26aufirst%3DZhanfei%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D2%26spage%3De001377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen  Bak</span>, <span class="hlFld-ContribAuthor ">Jennifer T.  Miller</span>, <span class="hlFld-ContribAuthor ">Andrea  Noronha</span>, <span class="hlFld-ContribAuthor ">John  Tavis</span>, <span class="hlFld-ContribAuthor ">Emilio  Gallicchio</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Murelli</span>, <span class="hlFld-ContribAuthor ">Stuart F. J.  Le Grice</span>. </span><span class="cited-content_cbyCitation_article-title">3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus Minus-Strand DNA Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4434. <a href="https://doi.org/10.3390/molecules25194434" title="DOI URL">https://doi.org/10.3390/molecules25194434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194434%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3D3%25252C7-Dihydroxytropolones%252BInhibit%252BInitiation%252Bof%252BHepatitis%252BB%252BVirus%252BMinus-Strand%252BDNA%252BSynthesis%26aulast%3DBak%26aufirst%3DEllen%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Srinivasulu  Cherukupalli</span>, <span class="hlFld-ContribAuthor ">Waleed A.  Zalloum</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (9)
                                     , 715-721. <a href="https://doi.org/10.1080/13543776.2020.1801641" title="DOI URL">https://doi.org/10.1080/13543776.2020.1801641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1801641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1801641%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DDiscovery%252Band%252Boptimizing%252Bpolycyclic%252Bpyridone%252Bcompounds%252Bas%252Banti-HBV%252Bagents%26aulast%3DWei%26aufirst%3DFenju%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D9%26spage%3D715%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaku  Goto</span>, <span class="hlFld-ContribAuthor ">Hironori  Nishitsuji</span>, <span class="hlFld-ContribAuthor ">Masaya  Sugiyama</span>, <span class="hlFld-ContribAuthor ">Nao  Nishida</span>, <span class="hlFld-ContribAuthor ">Masashi  Mizokami</span>, <span class="hlFld-ContribAuthor ">Kunitada  Shimotohno</span>. </span><span class="cited-content_cbyCitation_article-title">Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (16)
                                     , 5661. <a href="https://doi.org/10.3390/ijms21165661" title="DOI URL">https://doi.org/10.3390/ijms21165661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21165661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21165661%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOrchestration%252Bof%252BIntracellular%252BCircuits%252Bby%252BG%252BProtein-Coupled%252BReceptor%252B39%252Bfor%252BHepatitis%252BB%252BVirus%252BProliferation%26aulast%3DGoto%26aufirst%3DKaku%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D16%26spage%3D5661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Gerasi</span>, <span class="hlFld-ContribAuthor ">Efseveia  Frakolaki</span>, <span class="hlFld-ContribAuthor ">Georgios  Papadakis</span>, <span class="hlFld-ContribAuthor ">Anna  Chalari</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Niki  Vassilaki</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103580. <a href="https://doi.org/10.1016/j.bioorg.2020.103580" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103580%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-HBV%252Bactivity%252Bevaluation%252Bof%252Bnew%252Bsubstituted%252Bimidazo%25255B4%25252C5-b%25255Dpyridines%26aulast%3DGerasi%26aufirst%3DMaria%26date%3D2020%26volume%3D98%26spage%3D103580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Lv</span>, <span class="hlFld-ContribAuthor ">Wenyan  Li</span>, <span class="hlFld-ContribAuthor ">Shuo  Wu</span>, <span class="hlFld-ContribAuthor ">Yunhe  Geng</span>, <span class="hlFld-ContribAuthor ">Apeng  Wang</span>, <span class="hlFld-ContribAuthor ">Lu  Yang</span>, <span class="hlFld-ContribAuthor ">Menghao  Huang</span>, <span class="hlFld-ContribAuthor ">Kushan  Chowdhury</span>, <span class="hlFld-ContribAuthor ">Yuhuan  Li</span>, <span class="hlFld-ContribAuthor ">Mingliang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (9)
                                     , 127103. <a href="https://doi.org/10.1016/j.bmcl.2020.127103" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127103%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAmino%252Bacid%252Bprodrugs%252Bof%252BNVR3-778%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Banti-HBV%252Bactivity%26aulast%3DLv%26aufirst%3DKai%26date%3D2020%26volume%3D30%26issue%3D9%26spage%3D127103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haitao  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Bin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinxin  Peng</span>, <span class="hlFld-ContribAuthor ">Qing  Xie</span>, <span class="hlFld-ContribAuthor ">Xieer  Liang</span>, <span class="hlFld-ContribAuthor ">Rong  Fan</span>, <span class="hlFld-ContribAuthor ">Carly  Conran</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yuan  Ji</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Sun</span>, <span class="hlFld-ContribAuthor ">Jidong  Jia</span>, <span class="hlFld-ContribAuthor ">Guiqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jinlin  Hou</span>, <span class="hlFld-ContribAuthor ">De-Ke  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">A missense variant in complement factor B (
              CFB
              ) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. </span><span class="cited-content_cbyCitation_journal-name">Alimentary Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>51 </em>
                                    (4)
                                     , 469-478. <a href="https://doi.org/10.1111/apt.15624" title="DOI URL">https://doi.org/10.1111/apt.15624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/apt.15624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fapt.15624%26sid%3Dliteratum%253Aachs%26jtitle%3DAlimentary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DA%252Bmissense%252Bvariant%252Bin%252Bcomplement%252Bfactor%252BB%252B%252528%252BCFB%252B%252529%252Bis%252Ba%252Bpotential%252Bpredictor%252Bof%252B24-week%252Boff-treatment%252Bresponse%252Bto%252BPegIFN%2525CE%2525B1%252Btherapy%252Bin%252BChinese%252BHBeAg-positive%252Bchronic%252Bhepatitis%252BB%252Bpatients%26aulast%3DChen%26aufirst%3DHaitao%26date%3D2020%26date%3D2020%26volume%3D51%26issue%3D4%26spage%3D469%26epage%3D478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Víctor Deioxes  Escandón-Felizzola</span>. </span><span class="cited-content_cbyCitation_article-title">Recomendaciones en el tratamiento actual de la infección crónica por el virus de la hepatitis B. </span><span class="cited-content_cbyCitation_journal-name">Hepatología</span><span> <strong>2020,</strong> <em> </em>, 36-54. <a href="https://doi.org/10.52784/27112330.114" title="DOI URL">https://doi.org/10.52784/27112330.114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.52784/27112330.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.52784%2F27112330.114%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatolog%25C3%25ADa%26atitle%3DRecomendaciones%252Ben%252Bel%252Btratamiento%252Bactual%252Bde%252Bla%252Binfecci%2525C3%2525B3n%252Bcr%2525C3%2525B3nica%252Bpor%252Bel%252Bvirus%252Bde%252Bla%252Bhepatitis%252BB%26aulast%3DEscand%25C3%25B3n-Felizzola%26aufirst%3DV%25C3%25ADctor%2BDeioxes%26date%3D2020%26date%3D2020%26spage%3D36%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Lv</span>, <span class="hlFld-ContribAuthor ">Shuo  Wu</span>, <span class="hlFld-ContribAuthor ">Wenyan  Li</span>, <span class="hlFld-ContribAuthor ">Yunhe  Geng</span>, <span class="hlFld-ContribAuthor ">Meng  Wu</span>, <span class="hlFld-ContribAuthor ">Jinming  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuhuan  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Gao</span>, <span class="hlFld-ContribAuthor ">Mingliang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-HBV activity of NVR3-778 derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103363. <a href="https://doi.org/10.1016/j.bioorg.2019.103363" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103363%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-HBV%252Bactivity%252Bof%252BNVR3-778%252Bderivatives%26aulast%3DLv%26aufirst%3DKai%26date%3D2020%26volume%3D94%26spage%3D103363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haitao  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Bin  Zhou</span>, <span class="hlFld-ContribAuthor ">Qing  Xie</span>, <span class="hlFld-ContribAuthor ">Xier  Liang</span>, <span class="hlFld-ContribAuthor ">Rong  Fan</span>, <span class="hlFld-ContribAuthor ">Carly  Conran</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yuan  Ji</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Sun</span>, <span class="hlFld-ContribAuthor ">Jidong  Jia</span>, <span class="hlFld-ContribAuthor ">Guiqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jinlin  Hou</span>, <span class="hlFld-ContribAuthor ">De-Ke  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. </span><span class="cited-content_cbyCitation_journal-name">Clinical Gastroenterology and Hepatology</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     , 196-204.e8. <a href="https://doi.org/10.1016/j.cgh.2019.04.044" title="DOI URL">https://doi.org/10.1016/j.cgh.2019.04.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cgh.2019.04.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cgh.2019.04.044%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Gastroenterology%2520and%2520Hepatology%26atitle%3DVariants%252Bin%252BSTAT4%252BAssociated%252BWith%252BCure%252Bof%252BChronic%252BHBV%252BInfection%252Bin%252BHBeAg-positive%252BPatients%252BTreated%252BWith%252BPegylated%252BInterferon-alpha%26aulast%3DChen%26aufirst%3DHaitao%26date%3D2020%26volume%3D18%26issue%3D1%26spage%3D196%26epage%3D204.e8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enzo  Tramontano</span>, <span class="hlFld-ContribAuthor ">Angela  Corona</span>, <span class="hlFld-ContribAuthor ">Luis  Menéndez-Arias</span>. </span><span class="cited-content_cbyCitation_article-title">Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2019,</strong> <em>171 </em>, 104613. <a href="https://doi.org/10.1016/j.antiviral.2019.104613" title="DOI URL">https://doi.org/10.1016/j.antiviral.2019.104613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2019.104613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2019.104613%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DRibonuclease%252BH%25252C%252Ban%252Bunexploited%252Btarget%252Bfor%252Bantiviral%252Bintervention%252Bagainst%252BHIV%252Band%252Bhepatitis%252BB%252Bvirus%26aulast%3DTramontano%26aufirst%3DEnzo%26date%3D2019%26volume%3D171%26spage%3D104613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingying  Qiu</span>, <span class="hlFld-ContribAuthor ">Wang  Chen</span>, <span class="hlFld-ContribAuthor ">Yinpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Qingqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Lihua  Yang</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Xiaoke  Gu</span>, <span class="hlFld-ContribAuthor ">Daoquan  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 41-49. <a href="https://doi.org/10.1016/j.ejmech.2019.05.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAssessment%252Bof%252Bquinazolinone%252Bderivatives%252Bas%252Bnovel%252Bnon-nucleoside%252Bhepatitis%252BB%252Bvirus%252Binhibitors%26aulast%3DQiu%26aufirst%3DJingying%26date%3D2019%26volume%3D176%26spage%3D41%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah M.  Lee</span>, <span class="hlFld-ContribAuthor ">Bubu A.  Banini</span>. </span><span class="cited-content_cbyCitation_article-title">Updates on Chronic HBV: Current Challenges and Future Goals. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Gastroenterology</span><span> <strong>2019,</strong> <em>17 </em>
                                    (2)
                                     , 271-291. <a href="https://doi.org/10.1007/s11938-019-00236-3" title="DOI URL">https://doi.org/10.1007/s11938-019-00236-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11938-019-00236-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11938-019-00236-3%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Gastroenterology%26atitle%3DUpdates%252Bon%252BChronic%252BHBV%25253A%252BCurrent%252BChallenges%252Band%252BFuture%252BGoals%26aulast%3DLee%26aufirst%3DHannah%2BM.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D271%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhavitavya  Nijampatnam</span>, <span class="hlFld-ContribAuthor ">Dennis C  Liotta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the development of HBV capsid assembly modulators. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 73-79. <a href="https://doi.org/10.1016/j.cbpa.2019.02.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdevelopment%252Bof%252BHBV%252Bcapsid%252Bassembly%252Bmodulators%26aulast%3DNijampatnam%26aufirst%3DBhavitavya%26date%3D2019%26volume%3D50%26spage%3D73%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li Ting  Song</span>, <span class="hlFld-ContribAuthor ">Rui Rui  Liu</span>, <span class="hlFld-ContribAuthor ">Hong Lin  Zhai</span>, <span class="hlFld-ContribAuthor ">Ya Jie  Meng</span>, <span class="hlFld-ContribAuthor ">Min  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archives of Biochemistry and Biophysics</span><span> <strong>2019,</strong> <em>663 </em>, 1-10. <a href="https://doi.org/10.1016/j.abb.2018.12.029" title="DOI URL">https://doi.org/10.1016/j.abb.2018.12.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.abb.2018.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.abb.2018.12.029%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Biochemistry%2520and%2520Biophysics%26atitle%3DMolecular%252Bmechanisms%252Bof%252Btetrahydropyrrolo%25255B1%25252C2-c%25255Dpyrimidines%252Bas%252BHBV%252Bcapsid%252Bassembly%252Binhibitors%26aulast%3DSong%26aufirst%3DLi%2BTing%26date%3D2019%26volume%3D663%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Tang</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Huber</span>, <span class="hlFld-ContribAuthor ">Dallas L.  Pineda</span>, <span class="hlFld-ContribAuthor ">Kelsey N.  Boschert</span>, <span class="hlFld-ContribAuthor ">Jennifer J.  Wolf</span>, <span class="hlFld-ContribAuthor ">Jayakanth  Kankanala</span>, <span class="hlFld-ContribAuthor ">Jiashu  Xie</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Sarafianos</span>, <span class="hlFld-ContribAuthor ">Zhengqiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 179-192. <a href="https://doi.org/10.1016/j.ejmech.2018.12.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D5-Aminothiophene-2%25252C4-dicarboxamide%252Banalogues%252Bas%252Bhepatitis%252BB%252Bvirus%252Bcapsid%252Bassembly%252Beffectors%26aulast%3DTang%26aufirst%3DJing%26date%3D2019%26volume%3D164%26spage%3D179%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Ferrari</span>, <span class="hlFld-ContribAuthor ">Stefan G. D.  Rüdiger</span>. </span><span class="cited-content_cbyCitation_article-title">Hsp90 Chaperone in Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 473-491. <a href="https://doi.org/10.1007/978-3-030-23158-3_21" title="DOI URL">https://doi.org/10.1007/978-3-030-23158-3_21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-23158-3_21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-23158-3_21%26sid%3Dliteratum%253Aachs%26atitle%3DHsp90%252BChaperone%252Bin%252BDisease%26aulast%3DFerrari%26aufirst%3DLuca%26date%3D2019%26date%3D2019%26spage%3D473%26epage%3D491%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHeat%252BShock%252BProtein%252B90%252Bin%252BHuman%252BDiseases%252Band%252BDisorders%26aulast%3DAsea%26aufirst%3DAlexzander%2BA.%2BA.%26date%3D2019%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun Hong  Yoo</span>, <span class="hlFld-ContribAuthor ">Jung Hyun  Kwon</span>. </span><span class="cited-content_cbyCitation_article-title">New Potential Therapies for Chronic Hepatitis B. </span><span class="cited-content_cbyCitation_journal-name">The Korean Journal of Gastroenterology</span><span> <strong>2019,</strong> <em>74 </em>
                                    (5)
                                     , 267. <a href="https://doi.org/10.4166/kjg.2019.74.5.267" title="DOI URL">https://doi.org/10.4166/kjg.2019.74.5.267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4166/kjg.2019.74.5.267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4166%2Fkjg.2019.74.5.267%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Korean%2520Journal%2520of%2520Gastroenterology%26atitle%3DNew%252BPotential%252BTherapies%252Bfor%252BChronic%252BHepatitis%252BB%26aulast%3DYoo%26aufirst%3DSun%2BHong%26date%3D2019%26volume%3D74%26issue%3D5%26spage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicky  Helsen</span>, <span class="hlFld-ContribAuthor ">Tom  Vervoort</span>, <span class="hlFld-ContribAuthor ">Joris  Vandenbossche</span>, <span class="hlFld-ContribAuthor ">Oliver  Lenz</span>, <span class="hlFld-ContribAuthor ">Mario  Monshouwer</span>, <span class="hlFld-ContribAuthor ">Frederik  Pauwels</span>, <span class="hlFld-ContribAuthor ">Jan  Snoeys</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2018,</strong> <em>62 </em>
                                    (11)
                                     <a href="https://doi.org/10.1128/AAC.01497-18" title="DOI URL">https://doi.org/10.1128/AAC.01497-18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01497-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01497-18%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DEffect%252Bof%252BPlasma%252BProtein%252BBinding%252Bon%252Bthe%252BAnti-Hepatitis%252BB%252BVirus%252BActivity%252Band%252BPharmacokinetic%252BProperties%252Bof%252BNVR%252B3-778%26aulast%3DHelsen%26aufirst%3DNicky%26date%3D2018%26volume%3D62%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uma S.  Singh</span>, <span class="hlFld-ContribAuthor ">Varughese A.  Mulamoottil</span>, <span class="hlFld-ContribAuthor ">Chung K.  Chu</span>. </span><span class="cited-content_cbyCitation_article-title">2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (3)
                                     , 977-1002. <a href="https://doi.org/10.1002/med.21490" title="DOI URL">https://doi.org/10.1002/med.21490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21490%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3D2%2525E2%252580%2525B2-Fluoro-6%2525E2%252580%2525B2-methylene%252Bcarbocyclic%252Badenosine%252Band%252Bits%252Bphosphoramidate%252Bprodrug%25253A%252BA%252Bnovel%252Banti-HBV%252Bagent%25252C%252Bactive%252Bagainst%252Bdrug-resistant%252BHBV%252Bmutants%26aulast%3DSingh%26aufirst%3DUma%2BS.%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D977%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauriane  Lecoq</span>, <span class="hlFld-ContribAuthor ">Shishan  Wang</span>, <span class="hlFld-ContribAuthor ">Thomas  Wiegand</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bressanelli</span>, <span class="hlFld-ContribAuthor ">Michael  Nassal</span>, <span class="hlFld-ContribAuthor ">Beat H.  Meier</span>, <span class="hlFld-ContribAuthor ">Anja  Böckmann</span>. </span><span class="cited-content_cbyCitation_article-title">Solid-state [13C–15N] NMR resonance assignment of hepatitis B virus core protein. </span><span class="cited-content_cbyCitation_journal-name">Biomolecular NMR Assignments</span><span> <strong>2018,</strong> <em>12 </em>
                                    (1)
                                     , 205-214. <a href="https://doi.org/10.1007/s12104-018-9810-y" title="DOI URL">https://doi.org/10.1007/s12104-018-9810-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12104-018-9810-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12104-018-9810-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecular%2520NMR%2520Assignments%26atitle%3DSolid-state%252B%25255B13C%2525E2%252580%25259315N%25255D%252BNMR%252Bresonance%252Bassignment%252Bof%252Bhepatitis%252BB%252Bvirus%252Bcore%252Bprotein%26aulast%3DLecoq%26aufirst%3DLauriane%26date%3D2018%26date%3D2018%26volume%3D12%26issue%3D1%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.  Lin</span>, <span class="hlFld-ContribAuthor ">W.  Zhuang</span>, <span class="hlFld-ContribAuthor ">X.H.  Chen</span>, <span class="hlFld-ContribAuthor ">C.  Huang</span>, <span class="hlFld-ContribAuthor ">X.D.  Lin</span>, <span class="hlFld-ContribAuthor ">Y.J.  Huang</span>, <span class="hlFld-ContribAuthor ">C.  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2018,</strong> <em>29 </em>
                                    (2)
                                     , 516-517. <a href="https://doi.org/10.1093/annonc/mdx694" title="DOI URL">https://doi.org/10.1093/annonc/mdx694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/annonc/mdx694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fannonc%2Fmdx694%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DIncrease%252Bof%252Bprogrammed%252Bdeath%252Bligand%252B1%252Bin%252Bnon-small-cell%252Blung%252Bcancers%252Bwith%252Bchronic%252Bhepatitis%252BB%26aulast%3DLin%26aufirst%3DG.%26date%3D2018%26volume%3D29%26issue%3D2%26spage%3D516%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher John  Schlicksup</span>, <span class="hlFld-ContribAuthor ">Joseph Che-Yen  Wang</span>, <span class="hlFld-ContribAuthor ">Samson  Francis</span>, <span class="hlFld-ContribAuthor ">Balasubramanian  Venkatakrishnan</span>, <span class="hlFld-ContribAuthor ">William W  Turner</span>, <span class="hlFld-ContribAuthor ">Michael  VanNieuwenhze</span>, <span class="hlFld-ContribAuthor ">Adam  Zlotnick</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2018,</strong> <em>7 </em><a href="https://doi.org/10.7554/eLife.31473" title="DOI URL">https://doi.org/10.7554/eLife.31473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.31473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.31473%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DHepatitis%252BB%252Bvirus%252Bcore%252Bprotein%252Ballosteric%252Bmodulators%252Bcan%252Bdistort%252Band%252Bdisrupt%252Bintact%252Bcapsids%26aulast%3DSchlicksup%26aufirst%3DChristopher%2BJohn%26date%3D2018%26date%3D2018%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Małgorzata  Patejko</span>, <span class="hlFld-ContribAuthor ">Wiktoria  Struck-Lewicka</span>, <span class="hlFld-ContribAuthor ">Danuta  Siluk</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Waszczuk-Jankowska</span>, <span class="hlFld-ContribAuthor ">Michał J.  Markuszewski</span>. </span><span class="cited-content_cbyCitation_article-title">Urinary Nucleosides and Deoxynucleosides. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-51. <a href="https://doi.org/10.1016/bs.acc.2017.10.001" title="DOI URL">https://doi.org/10.1016/bs.acc.2017.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.acc.2017.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.acc.2017.10.001%26sid%3Dliteratum%253Aachs%26atitle%3DUrinary%252BNucleosides%252Band%252BDeoxynucleosides%26aulast%3DPatejko%26aufirst%3DMa%25C5%2582gorzata%26date%3D2018%26spage%3D1%26epage%3D51%26pub%3DElsevier%26date%3D2018%26volume%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuye  Zhang</span>, <span class="hlFld-ContribAuthor ">Fusheng  Wang</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Current advances in the elimination of hepatitis B in China by 2030. </span><span class="cited-content_cbyCitation_journal-name">Frontiers of Medicine</span><span> <strong>2017,</strong> <em>11 </em>
                                    (4)
                                     , 490-501. <a href="https://doi.org/10.1007/s11684-017-0598-4" title="DOI URL">https://doi.org/10.1007/s11684-017-0598-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11684-017-0598-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11684-017-0598-4%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520of%2520Medicine%26atitle%3DCurrent%252Badvances%252Bin%252Bthe%252Belimination%252Bof%252Bhepatitis%252BB%252Bin%252BChina%252Bby%252B2030%26aulast%3DZhang%26aufirst%3DShuye%26date%3D2017%26date%3D2017%26volume%3D11%26issue%3D4%26spage%3D490%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Soriano</span>, <span class="hlFld-ContribAuthor ">Pablo  Barreiro</span>, <span class="hlFld-ContribAuthor ">Laura  Benitez</span>, <span class="hlFld-ContribAuthor ">Jose M.  Peña</span>, <span class="hlFld-ContribAuthor ">Carmen  de Mendoza</span>. </span><span class="cited-content_cbyCitation_article-title">New antivirals for the treatment of chronic hepatitis B. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (7)
                                     , 843-851. <a href="https://doi.org/10.1080/13543784.2017.1333105" title="DOI URL">https://doi.org/10.1080/13543784.2017.1333105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1333105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1333105%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DNew%252Bantivirals%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Bhepatitis%252BB%26aulast%3DSoriano%26aufirst%3DVincent%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D7%26spage%3D843%26epage%3D851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hepatitis B virus life cycle. The infectious HBV Dane particles attach to the cell surface HSPGs and bind to the putative HBV receptor, NTCP. Following viral particle endocytosis, the nucleocapsid is released into the cytoplasm from the endosome. The HBV partially double-stranded genomic rcDNA is then transported into the nucleus and is repaired to form cccDNA. Four distinct viral transcripts including pgRNA and preS1, preS2, and X RNAs are generated from cccDNA, which are responsible to produce all seven viral proteins. Viral polymerase and pgRNA are encapsulated through self-assembly of HBcAg to form the nascent nucleocapsid, within which the second-generation viral DNA is synthesized by reverse transcription catalyzed by viral polymerase using pgRNA as the template. The mature, rcDNA-containing nascent HBV nucleocapsid is either able to re-enter the nucleus for recycling or ready for secretion. After possible post-translational modifications within the endoplasmic reticulum and/or Golgi apparatus, the enveloped, mature viral particles are secreted out of the infected hepatocyte. A great number of noninfectious SVPs, which completely lack a functional nucleocapsid but display large number of different HBsAg proteins, are also secreted out of the hepatocyte. Every step of the HBV life cycle could potentially be a therapeutic target for treatment of HBV infection. cccDNA, covalently closed circular DNA; HBcAg, hepatitis B virus core antigen; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HBx, hepatitis B virus X protein; HSPG, heparan sulfate proteoglycan; NTCP, sodium taurocholate cotransporting polypeptide; pgRNA, pregenomic RNA; rcDNA, relaxed circular DNA; SVP, subviral particle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative hepatitis B virus entry inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative helioxanthin analogues as HBV viral transcription inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Approved nucleoside/nucleotide analogue drugs for treatment of HBV and representative newly developed nucleoside/nucleotide compounds targeting HBV reserve transcriptase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative HBV viral polymerase RNase H domain inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Heteroaryldihydropyrimidine (HAP) series of HBV viral nucleocapsid inhibitors. The IC<sub>50</sub> values are for suppression of HBV DNA in HepG2.2.15 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative phenylpropenamide (<b>28</b>, <b>29</b>) and sulfamoylbenzamide (<b>30</b>, <b>31</b>) series of inhibitors targeting viral nucleocapsid assembly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Distinct classes of HBV viral nucleocapsid modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compounds that disturb interactions between HBV core and surface proteins (<b>42</b>, <b>43</b>) and putative inhibitors of HBsAg secretion (<b>44</b>, <b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Distinct host targeting agents, cccDNA inhibitors, and nucleic acid polymer for treatment of HBV infection. <b>46</b>, TLR7 agonist; <b>47</b>, cIAP antagonists; <b>48</b>, Hsc70 inhibitor; <b>49</b>, Hsp90 inhibitor; <b>50</b> and <b>51</b>, putative cccDNA inhibitor; <b>53</b>, NAP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Natural products for treatment of HBV with respective antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/medium/jm-2016-01442y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Repositioned drugs as therapeutics for HBV infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.6b01442/20170804/images/large/jm-2016-01442y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01442&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 190 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lavanchy, D.</span><span> </span><span class="NLM_article-title">Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.2003.00487.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1046%2Fj.1365-2893.2003.00487.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=14996343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD2c7gs1Whug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=97-107&author=D.+Lavanchy&title=Hepatitis+B+virus+epidemiology%2C+disease+burden%2C+treatment%2C+and+current+and+emerging+prevention+and+control+measures&doi=10.1046%2Fj.1365-2893.2003.00487.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures</span></div><div class="casAuthors">Lavanchy D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn">1352-0504</span>.
    </div><div class="casAbstract">Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection.  The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year.  In Western countries, the disease is relatively rare and acquired primarily in adulthood, whereas in Asia and most of Africa, chronic HBV infection is common and usually acquired perinatally or in childhood.  More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality.  Safe and effective vaccines against HBV infection have been available since 1982.  The implementation of mass immunization programs, which have been recommended by the World Health Organization since 1991, have dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries.  However, not all countries have adopted these recommendations and there remains a large number of persons that were infected with HBV prior to the implementation of immunization programs.  Antiviral treatment is the only way to reduce morbidity and mortality from chronic HBV infection.  Conventional interferon alfa and lamivudine have been the primary treatments to date.  Conventional interferon alfa produces a durable response in a moderate proportion of patients but has undesirable side-effects and must be administered subcutaneously three times per week.  Lamivudine also produces a response in a modest proportion of patients and causes few side-effects.  However, prolonged treatment is often necessary to prevent relapse on cessation of therapy, and continuous treatment can lead to the development of lamivudine resistance.  Promising emerging new treatments include adefovir, entecavir and peginterferon alfa-2a (40 kDa).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDqr0BBatWzy6Ufuk_1xoTfW6udTcc2ebbHWAusYyp4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7gs1Whug%253D%253D&md5=1f147336e831e56548fce6fb08b6cbae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.2003.00487.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.2003.00487.x%26sid%3Dliteratum%253Aachs%26aulast%3DLavanchy%26aufirst%3DD.%26atitle%3DHepatitis%2520B%2520virus%2520epidemiology%252C%2520disease%2520burden%252C%2520treatment%252C%2520and%2520current%2520and%2520emerging%2520prevention%2520and%2520control%2520measures%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2004%26volume%3D11%26spage%3D97%26epage%3D107%26doi%3D10.1046%2Fj.1365-2893.2003.00487.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection: epidemiology and vaccination</span> <span class="citation_source-journal">Epidemiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1093/epirev/mxj009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Fepirev%2Fmxj009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16754644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=112-125&author=C.+W.+Shepardauthor=E.+P.+Simardauthor=L.+Finelliauthor=A.+E.+Fioreauthor=B.+P.+Bell&title=Hepatitis+B+virus+infection%3A+epidemiology+and+vaccination&doi=10.1093%2Fepirev%2Fmxj009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection: epidemiology and vaccination</span></div><div class="casAuthors">Shepard Colin W; Simard Edgar P; Finelli Lyn; Fiore Anthony E; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiologic reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-25</span>
        ISSN:<span class="NLM_cas:issn">0193-936X</span>.
    </div><div class="casAbstract">Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.  This comprehensive review of hepatitis B epidemiology and vaccines focuses on definitive and influential studies and highlights current trends, policies, and directions.  HBV can be transmitted vertically, through sexual or household contact, or by unsafe injections, but chronic infections acquired during infancy or childhood account for a disproportionately large share of worldwide morbidity and mortality.  Vaccination against HBV infection can be started at birth and provides long-term protection against infection in more than 90% of healthy people.  In the 1990s, many industrialized countries and a few less-developed countries implemented universal hepatitis B immunization and experienced measurable reductions in HBV-related disease.  For example, in Taiwan, the prevalence of chronic infection in children declined by more than 90%.  Many resource-poor nations have recently initiated universal hepatitis B immunization programs with assistance from the Global Alliance for Vaccines and Immunization.  Further progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2UhAXwGC9Lv9pSBfyDvp7fW6udTcc2eZXioKM6FlzO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D&md5=59540288bd15ae148dc1b162c798c94b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fepirev%2Fmxj009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fepirev%252Fmxj009%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DSimard%26aufirst%3DE.%2BP.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DFiore%26aufirst%3DA.%2BE.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DHepatitis%2520B%2520virus%2520infection%253A%2520epidemiology%2520and%2520vaccination%26jtitle%3DEpidemiol.%2520Rev.%26date%3D2006%26volume%3D28%26spage%3D112%26epage%3D125%26doi%3D10.1093%2Fepirev%2Fmxj009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Beasley, R. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus. The major etiology of hepatocellular carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1942</span><span class="NLM_x">–</span> <span class="NLM_lpage">1956</span><span class="refDoi"> DOI: 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1988&pages=1942-1956&author=R.+P.+Beasley&title=Hepatitis+B+virus.+The+major+etiology+of+hepatocellular+carcinoma&doi=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252819880515%252961%253A10%253C1942%253A%253AAID-CNCR2820611003%253E3.0.CO%253B2-J%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%2BP.%26atitle%3DHepatitis%2520B%2520virus.%2520The%2520major%2520etiology%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DCancer%26date%3D1988%26volume%3D61%26spage%3D1942%26epage%3D1956%26doi%3D10.1002%2F1097-0142%2819880515%2961%3A10%3C1942%3A%3AAID-CNCR2820611003%3E3.0.CO%3B2-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Michalak, T. I.</span><span> </span><span class="NLM_article-title">Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1034/j.1600-0528.2002.017406.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1034%2Fj.1600-0528.2002.017406.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10807510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD3cvgsVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2000&pages=98-111&author=T.+I.+Michalak&title=Occult+persistence+and+lymphotropism+of+hepadnaviral+infection%3A+insights+from+the+woodchuck+viral+hepatitis+model&doi=10.1034%2Fj.1600-0528.2002.017406.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model</span></div><div class="casAuthors">Michalak T I</div><div class="citationInfo"><span class="NLM_cas:title">Immunological reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-111</span>
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">Hepatitis B virus (HBV) is a major human pathogen that causes chronic infection and life-threatening liver diseases in millions of individuals.  While pathological and epidemiological consequences of clinically evident HBV infections are well recognized, there is no similar knowledge on an asymptomatic, silently progressing virus persistence.  Contrary to previous opinion, current evidence indicates that a serologically undetectable (occult) HBV carriage is a common outcome of recovery from symptomatic illness and that scanty amounts of the virus are carried by apparently healthy individuals for years after resolution of hepatitis B despite the presence of presumably protective antiviral antibodies.  Recent studies on this silent form of hepadnavirus carriage in an experimental woodchuck hepatitis virus (WHV) infection, which is considered to be the closest natural model of HBV disease, revealed that the life-long occult persistence of traces of pathogenic virus is an invariable consequence of recovery after hepadnaviral invasion and that this state always co-exists with a steady low-rate virus replication in both the liver and the lymphatic system.  Importantly, this serologically concealed infection can be accompanied by development of hepatocellular carcinoma in convalescent animals and is transmittable from mothers to offspring as an asymptomatic, indefinitely long infection which involves the lymphatic system but not always the liver.  This review focuses on the features of hepadnavirus occult persistence and its lymphotropism, and on what is currently understood about the contribution of the lymphatic system in maintaining hepadnavirus carriage based on insights provided by analysis of the woodchuck-WHV experimental system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpeS6vO_dxs_3jf77P2BG3fW6udTcc2eY3NLvHiucs7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvgsVanug%253D%253D&md5=341581a5b6c247cc816a1be5d9f782ee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-0528.2002.017406.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-0528.2002.017406.x%26sid%3Dliteratum%253Aachs%26aulast%3DMichalak%26aufirst%3DT.%2BI.%26atitle%3DOccult%2520persistence%2520and%2520lymphotropism%2520of%2520hepadnaviral%2520infection%253A%2520insights%2520from%2520the%2520woodchuck%2520viral%2520hepatitis%2520model%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D174%26spage%3D98%26epage%3D111%26doi%3D10.1034%2Fj.1600-0528.2002.017406.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bertoletti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, M. K.</span><span> </span><span class="NLM_article-title">Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span><span class="refDoi"> DOI: 10.1016/S0952-7915(00)00108-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0952-7915%2800%2900108-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10899021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=403-408&author=A.+Bertolettiauthor=M.+K.+Maini&title=Protection+or+damage%3A+a+dual+role+for+the+virus-specific+cytotoxic+T+lymphocyte+response+in+hepatitis+B+and+C+infection%3F&doi=10.1016%2FS0952-7915%2800%2900108-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?</span></div><div class="casAuthors">Bertoletti, Antonio; Maini, Mala K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-408</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 70 refs.  During infection with hepatitis B or C viruses, cytotoxic T lymphocytes (CTLs) have been implicated as both the mediators of protection and the principal effectors of liver pathol.  Recent studies have allowed an investigation of the relationship between virus-specific CTL responses, liver damage and viral replication.  In the presence of an efficient virus-specific CTL response, a scenario is emerging where inhibition of viral replication can be independent of liver pathol.  We discuss the possibility that an inadequate CTL response - unable to control viral replication - may contribute to liver pathol. not only directly but also via the recruitment of non-virus-specific T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXGd3dQL2XzrVg90H21EOLACvtfcHk0lgKRWog7f1jvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyltLo%253D&md5=a16f84e480753ae8abb58a09878c55d5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900108-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900108-4%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26atitle%3DProtection%2520or%2520damage%253A%2520a%2520dual%2520role%2520for%2520the%2520virus-specific%2520cytotoxic%2520T%2520lymphocyte%2520response%2520in%2520hepatitis%2520B%2520and%2520C%2520infection%253F%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D403%26epage%3D408%26doi%3D10.1016%2FS0952-7915%2800%2900108-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Urban, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span> </span><span class="NLM_article-title">The replication cycle of hepatitis B virus</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2009.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20056291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3c7gsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=282-284&author=S.+Urbanauthor=A.+Schulzeauthor=M.+Dandriauthor=J.+Petersen&title=The+replication+cycle+of+hepatitis+B+virus&doi=10.1016%2Fj.jhep.2009.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The replication cycle of hepatitis B virus</span></div><div class="casAuthors">Urban Stephan; Schulze Andreas; Dandri Maura; Petersen Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSRv8921fdzVQKX3ooHxWjfW6udTcc2eY3NLvHiucs7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7gsVKjsw%253D%253D&md5=dd8f42e871a5977c29cdbda891040946</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DA.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26atitle%3DThe%2520replication%2520cycle%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2010%26volume%3D52%26spage%3D282%26epage%3D284%26doi%3D10.1016%2Fj.jhep.2009.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Chan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, I. O. L.</span><span> </span><span class="NLM_article-title">Knock-down of hepatitis B virus x protein reduces the tumorigenicity of hepatocellular carcinoma cells</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">208</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span><span class="refDoi"> DOI: 10.1002/path.1901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fpath.1901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16353167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2006&pages=372-380&author=D.+W.+Chanauthor=I.+O.+L.+Ng&title=Knock-down+of+hepatitis+B+virus+x+protein+reduces+the+tumorigenicity+of+hepatocellular+carcinoma+cells&doi=10.1002%2Fpath.1901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells</span></div><div class="casAuthors">Chan, David Wai; Ng, Irene Oi-lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC) in Southeast Asia and Hong Kong.  Among the four proteins that are encoded by the HBV genome, HBV X (HBx) is the most potentially oncogenic factor.  It is known that HBx plays an important role in hepatocarcinogenesis, but the exact functions and mol. mechanisms of HBx in HCC are not well understood.  In this study, we constructed expression vectors for small hairpin RNAs (shRNA) against HBx and investigated their regulatory effects in PLC/PRF/5 HCC cells, which constitutively produce HBx.  Our data show that this tool of RNA interference (RNAi) could successfully reduce the HBx mRNA and protein levels by 50-95%.  RNAi targeting HBx in PLC/PRF/5 cells demonstrated significant redn. in cell proliferation, cell growth, anchorage-independent growth in soft agar, and tumor development in nude mice.  In addn., depletion of HBx expression increased cell sensitivity to TNFα-mediated and serum-free-induced apoptosis, and reduced the expression levels of C-myc and Bcl-XL.  These findings suggest that HBx plays an important role in tumorigenicity and anti-apoptotic mechanisms in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlXznU7d4Z7Vg90H21EOLACvtfcHk0lhzmt6-_Q_I0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOntbs%253D&md5=bed2e3bb6e052b258324282f91287813</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fpath.1901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1901%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DNg%26aufirst%3DI.%2BO.%2BL.%26atitle%3DKnock-down%2520of%2520hepatitis%2520B%2520virus%2520x%2520protein%2520reduces%2520the%2520tumorigenicity%2520of%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D208%26spage%3D372%26epage%3D380%26doi%3D10.1002%2Fpath.1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Cui, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span> </span><span class="NLM_article-title">The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1002/pmic.200500218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fpmic.200500218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=498-504&author=F.+Cuiauthor=Y.+L.+Wangauthor=J.+Wangauthor=K.+K.+Weiauthor=J.+Q.+Huauthor=F.+Liuauthor=H.+L.+Wangauthor=X.+H.+Zhaoauthor=X.+M.+Zhangauthor=X.+Yang&title=The+up-regulation+of+proteasome+subunits+and+lysosomal+proteases+in+hepatocellular+carcinomas+of+the+HBx+gene+knockin+transgenic+mice&doi=10.1002%2Fpmic.200500218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fpmic.200500218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpmic.200500218%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%2BK.%26aulast%3DHu%26aufirst%3DJ.%2BQ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DZhao%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DThe%2520up-regulation%2520of%2520proteasome%2520subunits%2520and%2520lysosomal%2520proteases%2520in%2520hepatocellular%2520carcinomas%2520of%2520the%2520HBx%2520gene%2520knockin%2520transgenic%2520mice%26jtitle%3DProteomics%26date%3D2006%26volume%3D6%26spage%3D498%26epage%3D504%26doi%3D10.1002%2Fpmic.200500218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Park, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D. Y.</span><span> </span><span class="NLM_article-title">iNOS promotes HBx-induced hepatocellular carcinoma via upregulation of JNK activation</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">244</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.04.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bbrc.2013.04.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=244-249&author=Y.+H.+Parkauthor=H.+J.+Shinauthor=S.+U.+Kimauthor=J.+M.+Kimauthor=J.+H.+Kimauthor=D.+H.+Bangauthor=K.+T.+Changauthor=B.+Y.+Kimauthor=D.+Y.+Yu&title=iNOS+promotes+HBx-induced+hepatocellular+carcinoma+via+upregulation+of+JNK+activation&doi=10.1016%2Fj.bbrc.2013.04.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.04.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.04.071%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DShin%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BU.%26aulast%3DKim%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DBang%26aufirst%3DD.%2BH.%26aulast%3DChang%26aufirst%3DK.%2BT.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DYu%26aufirst%3DD.%2BY.%26atitle%3DiNOS%2520promotes%2520HBx-induced%2520hepatocellular%2520carcinoma%2520via%2520upregulation%2520of%2520JNK%2520activation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D244%26epage%3D249%26doi%3D10.1016%2Fj.bbrc.2013.04.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. H.</span><span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e00049</span><span class="refDoi"> DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=e00049&author=H.+Yanauthor=G.+C.+Zhongauthor=G.+W.+Xuauthor=W.+H.+Heauthor=Z.+Y.+Jingauthor=Z.+C.+Gaoauthor=Y.+Huangauthor=Y.+H.+Qiauthor=B.+Pengauthor=H.+M.+Wangauthor=L.+R.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Q.+Gaoauthor=B.+J.+Renauthor=Y.+Y.+Sunauthor=T.+Caiauthor=X.+F.+Fengauthor=J.+H.+Suiauthor=W.+H.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0lhapkQUOxdtrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DHe%26aufirst%3DW.%2BH.%26aulast%3DJing%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DFu%26aufirst%3DL.%2BR.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%2BQ.%26aulast%3DRen%26aufirst%3DB.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%2BF.%26aulast%3DSui%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DeLife%26date%3D2012%26volume%3D1%26spage%3De00049%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Guidotti, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immunobiology and pathogenesis of viral hepatitis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1146/annurev.pathol.1.110304.100230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1146%2Fannurev.pathol.1.110304.100230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18039107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=23-61&author=L.+G.+Guidottiauthor=F.+V.+Chisari&title=Immunobiology+and+pathogenesis+of+viral+hepatitis&doi=10.1146%2Fannurev.pathol.1.110304.100230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology and pathogenesis of viral hepatitis</span></div><div class="casAuthors">Guidotti, Luca G.; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV) and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause persistent infection, cirrhosis, and liver cancer.  HBV and HCV are noncytopathic viruses and, thus, immunol. mediated events play an important role in the pathogenesis and outcome of these infections.  The adaptive immune response mediates virtually all of the liver disease assocd. with viral hepatitis.  However, it is becoming increasingly clear that antigen-nonspecific inflammatory cells exacerbate cytotoxic T lymphocyte (CTL)-induced immunopathol. and that platelets enhance the accumulation of CTLs in the liver.  Chronic hepatitis is characterized by an inefficient T cell response unable to completely clear HBV or HCV from the liver, which consequently sustains continuous cycles of low-level cell destruction.  Over long periods of time, recurrent immune-mediated liver damage contributes to the development of cirrhosis and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eRjyvjhbi7Vg90H21EOLACvtfcHk0lhapkQUOxdtrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D&md5=c740de97e8b1d52a3e3f9e3e7be3bd89</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100230%26sid%3Dliteratum%253Aachs%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmunobiology%2520and%2520pathogenesis%2520of%2520viral%2520hepatitis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D23%26epage%3D61%26doi%3D10.1146%2Fannurev.pathol.1.110304.100230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollicino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">Control of cccDNA function in hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2009.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19616338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=581-592&author=M.+Levreroauthor=T.+Pollicinoauthor=J.+Petersenauthor=L.+Belloniauthor=G.+Raimondoauthor=M.+Dandri&title=Control+of+cccDNA+function+in+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2009.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cccDNA function in hepatitis B virus infection</span></div><div class="casAuthors">Levrero, Massimo; Pollicino, Teresa; Petersen, Jorg; Belloni, Laura; Raimondo, Giovanni; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA (cccDNA), plays a key role in the life cycle of the virus and permits the persistence of infection.  Novel mol. techniques have opened new possibilities to investigate the organization and the activity of the cccDNA minichromosome in vivo, and recent advances have started to shed light on the complexity of the mechanisms controlling cccDNA function.  Nuclear cccDNA accumulates in hepatocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins.  Identification of the mol. mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic levels in the course of chronic hepatitis B (CH-B) infection may reveal new potential therapeutic targets for anti-HBV drugs and hence assist in the design of strategies aimed at silencing and eventually depleting the cccDNA reservoir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04ONkDq_te7Vg90H21EOLACvtfcHk0lhU6C_xvRlT9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D&md5=365616a92ba84ddc3cf7835162d3d900</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DPollicino%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DBelloni%26aufirst%3DL.%26aulast%3DRaimondo%26aufirst%3DG.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DControl%2520of%2520cccDNA%2520function%2520in%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D581%26epage%3D592%26doi%3D10.1016%2Fj.jhep.2009.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Dane, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M.</span><span> </span><span class="NLM_article-title">Virus like particles in serum of patients with Australia antigen associated hepatitis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1970</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span><span class="refDoi"> DOI: 10.1016/S0140-6736(70)90926-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0140-6736%2870%2990926-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=1970&pages=695-698&author=D.+S.+Daneauthor=C.+H.+Cameronauthor=M.+Briggs&title=Virus+like+particles+in+serum+of+patients+with+Australia+antigen+associated+hepatitis&doi=10.1016%2FS0140-6736%2870%2990926-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2870%2990926-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252870%252990926-8%26sid%3Dliteratum%253Aachs%26aulast%3DDane%26aufirst%3DD.%2BS.%26aulast%3DCameron%26aufirst%3DC.%2BH.%26aulast%3DBriggs%26aufirst%3DM.%26atitle%3DVirus%2520like%2520particles%2520in%2520serum%2520of%2520patients%2520with%2520Australia%2520antigen%2520associated%2520hepatitis%26jtitle%3DLancet%26date%3D1970%26volume%3D295%26spage%3D695%26epage%3D698%26doi%3D10.1016%2FS0140-6736%2870%2990926-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sells, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acs, G.</span><span> </span><span class="NLM_article-title">Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1009</span><span class="refDoi"> DOI: 10.1073/pnas.84.4.1005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.84.4.1005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=3029758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADyaL2sXhvV2qt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=1005-1009&author=M.+A.+Sellsauthor=M.+L.+Chenauthor=G.+Acs&title=Production+of+hepatitis+B+virus+particles+in+HepG2+cells+transfected+with+cloned+hepatitis+B+virus+DNA&doi=10.1073%2Fpnas.84.4.1005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA</span></div><div class="casAuthors">Sells, Mary Ann; Chen, Mei Ling; Acs, George</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The hepatoblastoma cell line Hep G2 was transfected with a plasmid carrying the gene that confers resistance to G418 and four 5'-3' tandem copies of the hepatitis B virus (HBV) genome positioned such that two dimers of the genomic DNA are 3'-3' with respect to one another.  Cells of one clone that grew in the presence of G418 produce high levels of hepatitis B e antigen and of hepatitis B surface antigen.  HBV DNA is carried by these cells as chromosomally integrated sequences and episomally as relaxed circular, covalently closed, and incomplete copies of the HBV genome.  Viral DNA was detected also in conditioned growth medium at the buoyant densities characteristic for infectious Dane and immature core particles.  Finally, HBV-specific components morphol. identical to the 22-nm spherical and filamentous hepatitis B surface antigen particles as well as 42-nm Dane particles were visualized by immunoelectron microscopic anal.  Therefore, the Hep G2 cell line can support the assembly and secretion not only of several of the replicative intermediates of HBV DNA but also of Dane-like particles.  This in vitro system can now be used to study the life cycle of HBV and the reaction of immunocompetent cells with cells carrying HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogbjqX6YU-W7Vg90H21EOLACvtfcHk0lhU6C_xvRlT9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvV2qt7c%253D&md5=27744d6955d4701586243f651c79ab1e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.84.4.1005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.84.4.1005%26sid%3Dliteratum%253Aachs%26aulast%3DSells%26aufirst%3DM.%2BA.%26aulast%3DChen%26aufirst%3DM.%2BL.%26aulast%3DAcs%26aufirst%3DG.%26atitle%3DProduction%2520of%2520hepatitis%2520B%2520virus%2520particles%2520in%2520HepG2%2520cells%2520transfected%2520with%2520cloned%2520hepatitis%2520B%2520virus%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1987%26volume%3D84%26spage%3D1005%26epage%3D1009%26doi%3D10.1073%2Fpnas.84.4.1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Schulze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1989</span><span class="NLM_x">–</span> <span class="NLM_lpage">2000</span><span class="refDoi"> DOI: 10.1128/JVI.01902-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.01902-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20007265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FktFCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=1989-2000&author=A.+Schulzeauthor=A.+Schieckauthor=Y.+Niauthor=W.+Mierauthor=S.+Urban&title=Fine+mapping+of+pre-s+sequence+requirements+for+hepatitis+B+virus+large+envelope+protein-mediated+receptor+interaction&doi=10.1128%2FJVI.01902-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction</span></div><div class="casAuthors">Schulze Andreas; Schieck Alexa; Ni Yi; Mier Walter; Urban Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1989-2000</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Previous studies showed that the N-terminal 75 amino acids of the pre-S1 domain of the hepatitis B virus (HBV) L protein are essential for HBV and hepatitis delta virus (HDV) infectivity.  Consistently, synthetic lipopeptides encompassing this sequence or only parts of it efficiently block HBV and HDV infection, presumably through specific interference with a cellular receptor.  Crucial for both virus infectivity and the inhibitory activity of the peptides are N-terminal myristoylation and a highly conserved motif within the N-terminal 48 amino acids.  To refine the sequence requirements, we synthesized a series of HBV pre-S1 peptides containing deletions, point mutations, d-amino acid exchanges, or genotype-specific sequence permutations.  Using the HepaRG cell line and a genotype D-derived virus, we determined the specific inhibitory activities of the peptides and found that (i) lipopeptides with an artificial consensus sequence inhibit HBV genotype D infection more potently than the corresponding genotype D peptides; (ii) point mutations, d-amino acid exchanges, or deletions introduced into the highly conserved part of the pre-S1 domain result in an almost complete loss of activity; and (iii) the flanking sequences comprising amino acids 2 to 8, 16 to 20, and, to a less pronounced extent, 34 to 48 gradually increase the inhibitory activity, while amino acids 21 to 33 behave indifferently.  Taken together, our data suggest that HBV pre-S1-mediated receptor interference and, thus, HBV receptor recognition form a highly specific process.  It requires an N-terminal acyl moiety and a highly conserved sequence that is present in primate but not rodent or avian hepadnaviruses, indicating different entry pathways for the different family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJx3HykmhMWEHdcurJClFcfW6udTcc2eZR5aOdNHbu57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FktFCjsg%253D%253D&md5=aa57d5c4025f31b8cd3ecd29163b32b8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FJVI.01902-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01902-09%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DA.%26aulast%3DSchieck%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DFine%2520mapping%2520of%2520pre-s%2520sequence%2520requirements%2520for%2520hepatitis%2520B%2520virus%2520large%2520envelope%2520protein-mediated%2520receptor%2520interaction%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D1989%26epage%3D2000%26doi%3D10.1128%2FJVI.01902-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Le Duff, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span> </span><span class="NLM_article-title">The pre-s1 and antigenic loop infectivity determinants of the hepatitis B Virus envelope proteins are functionally independent</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">12443</span><span class="NLM_x">–</span> <span class="NLM_lpage">12451</span><span class="refDoi"> DOI: 10.1128/JVI.01594-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.01594-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19759159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=12443-12451&author=Y.+Le+Duffauthor=M.+Blanchetauthor=C.+Sureau&title=The+pre-s1+and+antigenic+loop+infectivity+determinants+of+the+hepatitis+B+Virus+envelope+proteins+are+functionally+independent&doi=10.1128%2FJVI.01594-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent</span></div><div class="casAuthors">Le Duff, Yann; Blanchet, Matthieu; Sureau, Camille</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12443-12451</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) envelope proteins bear two determinants of viral entry: a receptor-binding site (RBS) in the pre-S1 domain of the large envelope protein and a conformation-dependent determinant, of unknown function, in the antigenic loop (AGL) of the small, middle, and large envelope proteins.  Using an in vitro infection assay consisting of susceptible HepaRG cells and the hepatitis delta virus (HDV) as a surrogate of HBV, we first investigated whether subelements of the pre-S1 determinant (amino acids 2 to 75), i.e., the N-terminal myristoyl anchor, subdomain 2-48 (RBS), and subdomain 49-75, were functionally separable.  In transcomplementation expts., coexpression of two distinct infectivity-deficient pre-S1 mutants at the surface of HDV virions failed to restore infectivity, indicating that the myristoyl anchor, the 2-48 RBS, and the 49-75 sequence, likely cooperate in cis at viral entry.  Furthermore, we showed that as much as 52% of total pre-S1 in the HDV envelope could bear infectivity-deficient lesions without affecting entry, indicating that a small no. of pre-S1 polypeptides-estd. at three to four per virion-is sufficient for infectivity.  We next investigated the AGL activity in the small or large envelope protein background (S- and L-AGL, resp.) and found that lesions in S-AGL were more deleterious to infectivity than in L-AGL, a difference that reflects the relative stoichiometry of the small and large envelope proteins in the viral envelope.  Finally, we showed that C147S, an AGL infectivity-deficient substitution, exerted a dominant-neg. effect on infectivity, likely reflecting an involvement of C147 in intermol. disulfide bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAVXOMSWDoEbVg90H21EOLACvtfcHk0lh4rF3iKrTXsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtLbM&md5=e29f64e8d0164e39b889d5f1c9856f4f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FJVI.01594-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01594-09%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDuff%26aufirst%3DY.%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26atitle%3DThe%2520pre-s1%2520and%2520antigenic%2520loop%2520infectivity%2520determinants%2520of%2520the%2520hepatitis%2520B%2520Virus%2520envelope%2520proteins%2520are%2520functionally%2520independent%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D12443%26epage%3D12451%26doi%3D10.1128%2FJVI.01594-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gripon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span><span class="refDoi"> DOI: 10.1128/JVI.79.3.1613-1622.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.79.3.1613-1622.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15650187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=1613-1622&author=P.+Griponauthor=I.+Cannieauthor=S.+Urban&title=Efficient+inhibition+of+hepatitis+B+virus+infection+by+acylated+peptides+derived+from+the+large+viral+surface+protein&doi=10.1128%2FJVI.79.3.1613-1622.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span></div><div class="casAuthors">Gripon, Philippe; Cannie, Isabelle; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1613-1622</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B virus (HBV) has prevented a mol. understanding of the early infection events of HBV.  We used the novel HBV-infectible cell line HepaRG and primary human hepatocytes to investigate the interference of infection by HBV envelope protein-derived peptides.  We found that a peptide consisting of the authentically myristoylated N-terminal 47 amino acids of the pre-S1 domain of the large viral envelope protein (L protein) specifically prevented HBV infection, with a 50% inhibitory concn. (IC50) of 8 nM.  The replacement of myristic acid with other hydrophobic moieties resulted in changes in the inhibitory activity, most notably by a decrease in the IC50 to picomolar concns. for longer unbranched fatty acids.  The obstruction of HepaRG cell susceptibility to HBV infection after short preincubation times with the peptides suggested that the peptides efficiently target and inactivate a receptor at the hepatocyte surface.  Our data both shed light on the mol. mechanism of HBV entry into hepatocytes and provide a basis for the development of potent hepadnaviral entry inhibitors as a novel therapeutic concept for the treatment of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ35R_8zOmS7Vg90H21EOLACvtfcHk0lh4rF3iKrTXsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D&md5=519a08a82ce4de9e5db5692cf2a5ae80</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.3.1613-1622.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.3.1613-1622.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGripon%26aufirst%3DP.%26aulast%3DCannie%26aufirst%3DI.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DEfficient%2520inhibition%2520of%2520hepatitis%2520B%2520virus%2520infection%2520by%2520acylated%2520peptides%2520derived%2520from%2520the%2520large%2520viral%2520surface%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D1613%26epage%3D1622%26doi%3D10.1128%2FJVI.79.3.1613-1622.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutgehetmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Weizsacker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nbt1389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnbt1389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=335-341&author=J.+Petersenauthor=M.+Dandriauthor=W.+Mierauthor=M.+Lutgehetmannauthor=T.+Volzauthor=F.+Von+Weizsackerauthor=U.+Haberkornauthor=L.+Fischerauthor=J.+Pollokauthor=B.+Erbesauthor=S.+Seitzauthor=S.+Urban&title=Prevention+of+hepatitis+B+virus+infection+in+vivo+by+entry+inhibitors+derived+from+the+large+envelope+protein&doi=10.1038%2Fnbt1389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1389%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DLutgehetmann%26aufirst%3DM.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DVon%2BWeizsacker%26aufirst%3DF.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DPollok%26aufirst%3DJ.%26aulast%3DErbes%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%2520by%2520entry%2520inhibitors%2520derived%2520from%2520the%2520large%2520envelope%2520protein%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Fnbt1389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lempp, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkongolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stindt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koniger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sultmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2013.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24361467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=1070-1083&author=Y.+Niauthor=F.+A.+Lemppauthor=S.+Mehrleauthor=S.+Nkongoloauthor=C.+Kaufmanauthor=M.+Falthauthor=J.+Stindtauthor=C.+Konigerauthor=M.+Nassalauthor=R.+Kubitzauthor=H.+Sultmannauthor=S.+Urban&title=Hepatitis+B+and+D+viruses+exploit+sodium+taurocholate+co-transporting+polypeptide+for+species-specific+entry+into+hepatocytes&doi=10.1053%2Fj.gastro.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes</span></div><div class="casAuthors">Ni, Yi; Lempp, Florian A.; Mehrle, Stefan; Nkongolo, Shirin; Kaufman, Christina; Falth, Maria; Stindt, Jan; Koniger, Christian; Nassal, Michael; Kubitz, Ralf; Sultmann, Holger; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1083.e6</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells.  We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.  To identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naive cells, which do not.  Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines.  We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.  Bioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochem. approach is a bona fide receptor for HBV and HDV.  NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein.  Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV.  Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with DMSO.  We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.  Human NTCP is a specific receptor for HBV and HDV.  NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies.  Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxfIdRSMiSbVg90H21EOLACvtfcHk0lhtVtmrYxKBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D&md5=9a6474af0ba645b685289066a35e972c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DFalth%26aufirst%3DM.%26aulast%3DStindt%26aufirst%3DJ.%26aulast%3DKoniger%26aufirst%3DC.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DHepatitis%2520B%2520and%2520D%2520viruses%2520exploit%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%2520for%2520species-specific%2520entry%2520into%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D1070%26epage%3D1083%26doi%3D10.1053%2Fj.gastro.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Blank, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carls, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2016.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27132172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=483-489&author=A.+Blankauthor=C.+Markertauthor=N.+Hohmannauthor=A.+Carlsauthor=G.+Mikusauthor=T.+Lehrauthor=A.+Alexandrovauthor=M.+Haagauthor=M.+Schwabauthor=S.+Urbanauthor=W.+E.+Haefeli&title=First-in-human+application+of+the+novel+hepatitis+B+and+hepatitis+D+virus+entry+inhibitor+myrcludex+B&doi=10.1016%2Fj.jhep.2016.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B</span></div><div class="casAuthors">Blank, Antje; Markert, Christoph; Hohmann, Nicolas; Carls, Alexandra; Mikus, Gerd; Lehr, Thorsten; Alexandrov, Alexander; Haag, Mathias; Schwab, Matthias; Urban, Stephan; Haefeli, Walter E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-489</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Myrcludex B is a first-in-class compd., which blocks entry of hepatitis B and D virus into hepatocytes in vitro and in animal models.  Based on the required preclin. data we aimed to translate this compd. into the first application in humans.Single ascending doses of myrcludex B, a 47 amino acid peptide, were administered up to 20 mg i.v. and 10 mg s.c. in a prospective open first-in-human, phase I clin. trial to 36 healthy volunteers.  Safety, tolerability and plasma concns. of myrcludex B were assessed and a pharmacokinetic model was derived.Myrcludex B was well tolerated and no serious or relevant AEs representing off-target effects, and no immunogenic effects were obsd. up to the highest applied dose of 20 mg (i.v.).  Myrcludex B showed dose-dependent pharmacokinetics, best described by a 2-compartment target-mediated drug disposition model.  Bioavailability of the s.c. application was large (85%).  Interindividual variability was moderate.  The pharmacokinetic model suggested that s.c. doses of 10 mg and above reach a target satn. of over 80% for at least 15 h.Myrcludex B showed excellent tolerability up to high doses.  Pharmacol. properties followed a 2-compartment target-mediated drug disposition model.  These findings are vital for planning of further multiple dose efficacy trials in patients.After showing antiviral activity in cell culture and animal models, myrcludex B, a new drug intended for the treatment of hepatitis B and D, has been administered the first time in humans.  Healthy volunteers received the drug i.v. and s.c. up to high doses (20 mg).  The drug was well tolerated and the characteristics of the drug detg. its way in the human body could be described.  These results will allow testing myrcludex B in hepatitis B and D patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoBJ0yS6pu7Vg90H21EOLACvtfcHk0lhtVtmrYxKBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2msrc%253D&md5=04a54ac56423c8692e19bd6baabff25b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DBlank%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DC.%26aulast%3DHohmann%26aufirst%3DN.%26aulast%3DCarls%26aufirst%3DA.%26aulast%3DMikus%26aufirst%3DG.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DHaag%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DFirst-in-human%2520application%2520of%2520the%2520novel%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520inhibitor%2520myrcludex%2520B%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D483%26epage%3D489%26doi%3D10.1016%2Fj.jhep.2016.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Nkongolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lempp, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser-Nobis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24295872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=723-731&author=S.+Nkongoloauthor=Y.+Niauthor=F.+A.+Lemppauthor=C.+Kaufmanauthor=T.+Lindnerauthor=K.+Esser-Nobisauthor=V.+Lohmannauthor=W.+Mierauthor=S.+Mehrleauthor=S.+Urban&title=Cyclosporin+A+inhibits+hepatitis+B+and+hepatitis+D+virus+entry+by+cyclophilin-independent+interference+with+the+NTCP+receptor&doi=10.1016%2Fj.jhep.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span></div><div class="casAuthors">Nkongolo, Shirin; Ni, Yi; Lempp, Florian A.; Kaufman, Christina; Lindner, Thomas; Esser-Nobis, Katharina; Lohmann, Volker; Mier, Walter; Mehrle, Stefan; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic hepatitis B and hepatitis D are global health problems caused by the human hepatitis B and hepatitis D virus.  The myristoylated preS1 domain of the large envelope protein mediates specific binding to hepatocytes by sodium taurocholate co-transporting polypeptide (NTCP).  NTCP is a bile salt transporter known to be inhibited by cyclosporin A.  This study aimed to characterize the effect of cyclosporin A on HBV/HDV infection.  HepaRG cells, primary human hepatocytes, and susceptible NTCP-expressing hepatoma cell lines were applied for infection expts.  The mode of action of cyclosporin A was studied by comparing the effect of different inhibitors, cyclophilin A/B/C-silenced cell lines as well as NTCP variants and mutants.  Bile salt transporter and HBV receptor functions were investigated by taurocholate uptake and quantification of HBVpreS binding.Cyclosporin A inhibited hepatitis B and D virus infections during and - less pronounced - prior to virus inoculation.  Binding of HBVpreS to NTCP was blocked by cyclosporin A concns. at 8 μM.  An NTCP variant deficient in HBVpreS binding but competent for bile salt transport showed resistance to cyclosporin A.  Silencing of cyclophilins A/B/C did not abrogate transporter and receptor inhibition.  In contrast, tacrolimus, a cyclophilin-independent calcineurin inhibitor, was inactive.HBV and HDV entry via sodium taurocholate co-transporting polypeptide is inhibited by cyclosporin A.  The interaction between the drug and the viral receptor is direct and overlaps with a functional binding site of the preS1 domain, which mediates viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTAVAhQe6_ErVg90H21EOLACvtfcHk0ljlCDmd8cx6xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D&md5=d8c7e3698ac926cd5c06a9e7e2c4717b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DEsser-Nobis%26aufirst%3DK.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DCyclosporin%2520A%2520inhibits%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520by%2520cyclophilin-independent%2520interference%2520with%2520the%2520NTCP%2520receptor%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D723%26epage%3D731%26doi%3D10.1016%2Fj.jhep.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sluder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagamori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroto-Esoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuhara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakita, T.</span><span> </span><span class="NLM_article-title">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1726</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1002/hep.26982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.26982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24375637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1726-1737&author=K.+Watashiauthor=A.+Sluderauthor=T.+Daitoauthor=S.+Matsunagaauthor=A.+Ryoauthor=S.+Nagamoriauthor=M.+Iwamotoauthor=S.+Nakajimaauthor=S.+Tsukudaauthor=K.+Borroto-Esodaauthor=M.+Sugiyamaauthor=Y.+Tanakaauthor=Y.+Kanaiauthor=H.+Kusuharaauthor=M.+Mizokamiauthor=T.+Wakita&title=Cyclosporin+A+and+its+analogs+inhibit+hepatitis+B+virus+entry+into+cultured+hepatocytes+through+targeting+a+membrane+transporter%2C+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1002%2Fhep.26982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span></div><div class="casAuthors">Watashi, Koichi; Sluder, Ann; Daito, Takuji; Matsunaga, Satoko; Ryo, Akihide; Nagamori, Shushi; Iwamoto, Masashi; Nakajima, Syo; Tsukuda, Senko; Borroto-Esoda, Katyna; Sugiyama, Masaya; Tanaka, Yasuhito; Kanai, Yoshikatsu; Kusuhara, Hiroyuki; Mizokami, Masashi; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1726-1737</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide.  Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clin. available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets.  Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes.  The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin.  Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP).  We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not.  A series of compds. targeting NTCP could inhibit HBV infection.  CsA inhibited the binding between NTCP and large envelope protein in vitro.  Evaluation of CsA analogs identified a compd. with higher anti-HBV potency, having a median inhibitory concn. <0.2 μM.  Conclusion: This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatol. 2014;59:1726-1737).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV21kvExmObVg90H21EOLACvtfcHk0ljlCDmd8cx6xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D&md5=d83ae63fbe3e8b827f9fbf5f6601b316</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fhep.26982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26982%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DBorroto-Esoda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DCyclosporin%2520A%2520and%2520its%2520analogs%2520inhibit%2520hepatitis%2520B%2520virus%2520entry%2520into%2520cultured%2520hepatocytes%2520through%2520targeting%2520a%2520membrane%2520transporter%252C%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1726%26epage%3D1737%26doi%3D10.1002%2Fhep.26982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Dong, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. E.</span><span> </span><span class="NLM_article-title">Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">–</span> <span class="NLM_lpage">1019</span><span class="refDoi"> DOI: 10.1021/mp300453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1008-1019&author=Z.+Q.+Dongauthor=S.+Ekinsauthor=J.+E.+Polli&title=Structure-activity+relationship+for+FDA+approved+drugs+as+inhibitors+of+the+human+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1021%2Fmp300453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP)</span></div><div class="casAuthors">Dong, Zhongqi; Ekins, Sean; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1019</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements.  The objectives of this study were (a) to identify FDA approved drugs that inhibit human NTCP, (b) to develop pharmacophore and Bayesian computational models for NTCP inhibition, and (c) to compare NTCP and ASBT transport inhibition requirements.  A series of NTCP inhibition studies were performed using FDA approved drugs, in concert with iterative computational model development.  Screening studies identified 27 drugs as novel NTCP inhibitors, including irbesartan (Ki = 11.9 μM) and ezetimibe (Ki = 25.0 μM).  The common feature pharmacophore indicated that two hydrophobes and one hydrogen bond acceptor were important for inhibition of NTCP.  From 72 drugs screened in vitro, a total of 31 drugs inhibited NTCP, while 51 drugs (i.e., more than half) inhibited ASBT.  Hence, while there was inhibitor overlap, ASBT unexpectedly was more permissive to drug inhibition than was NTCP, and this may be related to NTCP possessing fewer pharmacophore features.  Findings reflected that a combination of computational and in vitro approaches enriched the understanding of these poorly characterized transporters and yielded addnl. chem. probes for possible drug-transporter interaction detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGhpWyONrzbVg90H21EOLACvtfcHk0lixw4fo7AU7rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D&md5=0a0e0af7c8d1acb875ef8208c84f13c6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fmp300453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300453k%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%2BQ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DStructure-activity%2520relationship%2520for%2520FDA%2520approved%2520drugs%2520as%2520inhibitors%2520of%2520the%2520human%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1008%26epage%3D1019%26doi%3D10.1021%2Fmp300453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windisch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, W. S.</span><span> </span><span class="NLM_article-title">The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span><span class="refDoi"> DOI: 10.3851/IMP2965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2965" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=835-842&author=C.+Koauthor=W.+J.+Parkauthor=S.+Parkauthor=S.+Kimauthor=M.+P.+Windischauthor=W.+S.+Ryu&title=The+FDA-approved+drug+irbesartan+inhibits+HBV-infection+in+HepG2+cells+stably+expressing+sodium+taurocholate+co-transporting+polypeptide&doi=10.3851%2FIMP2965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3851%2FIMP2965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2965%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DW.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWindisch%26aufirst%3DM.%2BP.%26aulast%3DRyu%26aufirst%3DW.%2BS.%26atitle%3DThe%2520FDA-approved%2520drug%2520irbesartan%2520inhibits%2520HBV-infection%2520in%2520HepG2%2520cells%2520stably%2520expressing%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%26jtitle%3DAntiviral%2520Ther.%26date%3D2015%26volume%3D20%26spage%3D835%26epage%3D842%26doi%3D10.3851%2FIMP2965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Warner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">The new front-line in hepatitis B/D research: identification and blocking of a functional receptor</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1002/hep.26292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.26292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=9-12&author=N.+Warnerauthor=S.+Locarnini&title=The+new+front-line+in+hepatitis+B%2FD+research%3A+identification+and+blocking+of+a+functional+receptor&doi=10.1002%2Fhep.26292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fhep.26292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26292%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DN.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DThe%2520new%2520front-line%2520in%2520hepatitis%2520B%252FD%2520research%253A%2520identification%2520and%2520blocking%2520of%2520a%2520functional%2520receptor%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D9%26epage%3D12%26doi%3D10.1002%2Fhep.26292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23266293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=195-197&author=J.+Luciforaauthor=K.+Esserauthor=U.+Protzer&title=Ezetimibe+blocks+hepatitis+B+virus+infection+after+virus+uptake+into+hepatocytes&doi=10.1016%2Fj.antiviral.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span></div><div class="casAuthors">Lucifora, Julie; Esser, Knud; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current treatment of chronic hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases.  Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date.  Recently, entry of the hepatitis C virus (HCV) was shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, was shown to inhibit HCV infection.  We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG cells as a cell-culture infection model.  Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we obsd. no effect when the HBV viral genome was transduced via an adenoviral vector.  Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ1wQJ_RUkbVg90H21EOLACvtfcHk0lixw4fo7AU7rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D&md5=dcfca7855b8cacdad584203e23690f85</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DEsser%26aufirst%3DK.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DEzetimibe%2520blocks%2520hepatitis%2520B%2520virus%2520infection%2520after%2520virus%2520uptake%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D97%26spage%3D195%26epage%3D197%26doi%3D10.1016%2Fj.antiviral.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Blanchet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labonte, P.</span><span> </span><span class="NLM_article-title">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24717262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=111-115&author=M.+Blanchetauthor=C.+Sureauauthor=P.+Labonte&title=Use+of+FDA+approved+therapeutics+with+hNTCP+metabolic+inhibitory+properties+to+impair+the+HDV+lifecycle&doi=10.1016%2Fj.antiviral.2014.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span></div><div class="casAuthors">Blanchet, Matthieu; Sureau, Camille; Labonte, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-115</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Worldwide there are approx. 240 million individuals chronically infected with the hepatitis B virus (HBV), including 15-20 million coinfected with the hepatitis delta virus (HDV).  Treatments available today are not fully efficient and often assocd. to important side effects and development of drug resistance.  Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008).  Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV.  This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections.  Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line.  We demonstrate the potential of three FDA approved mols., irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uuuK9vPHVbVg90H21EOLACvtfcHk0lhg7ex1xtCNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D&md5=abe5262a9fa3fc4daaff030ae1a080c1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DP.%26atitle%3DUse%2520of%2520FDA%2520approved%2520therapeutics%2520with%2520hNTCP%2520metabolic%2520inhibitory%2520properties%2520to%2520impair%2520the%2520HDV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D111%26epage%3D115%26doi%3D10.1016%2Fj.antiviral.2014.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target</span> <span class="citation_source-journal">Drug Target Insights</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=9-18&author=K.+Watashiauthor=K.+Shimotohno&title=Cyclophilin+and+viruses%3A+cyclophilin+as+a+cofactor+for+viral+infection+and+possible+anti-viral+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DCyclophilin%2520and%2520viruses%253A%2520cyclophilin%2520as%2520a%2520cofactor%2520for%2520viral%2520infection%2520and%2520possible%2520anti-viral%2520target%26jtitle%3DDrug%2520Target%2520Insights%26date%3D2007%26volume%3D2%26spage%3D9%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Loor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenandy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, R.</span><span> </span><span class="NLM_article-title">Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 p-glycoprotein ABC transporter</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4598</span><span class="NLM_x">–</span> <span class="NLM_lpage">4612</span><span class="refDoi"> DOI: 10.1021/jm0109863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4598-4612&author=F.+Loorauthor=F.+O.+Tiberghienauthor=T.+Wenandyauthor=A.+Didierauthor=R.+Traber&title=Cyclosporins%3A+structure-activity+relationships+for+the+inhibition+of+the+human+MDR1+p-glycoprotein+ABC+transporter&doi=10.1021%2Fjm0109863"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm0109863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109863%26sid%3Dliteratum%253Aachs%26aulast%3DLoor%26aufirst%3DF.%26aulast%3DTiberghien%26aufirst%3DF.%2BO.%26aulast%3DWenandy%26aufirst%3DT.%26aulast%3DDidier%26aufirst%3DA.%26aulast%3DTraber%26aufirst%3DR.%26atitle%3DCyclosporins%253A%2520structure-activity%2520relationships%2520for%2520the%2520inhibition%2520of%2520the%2520human%2520MDR1%2520p-glycoprotein%2520ABC%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4598%26epage%3D4612%26doi%3D10.1021%2Fjm0109863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Xia, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S. S.</span><span> </span><span class="NLM_article-title">Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms</span> <span class="citation_source-journal">Hepatobiliary Pancreatic Dis. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15730912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=18-22&author=W.+L.+Xiaauthor=Y.+Shenauthor=S.+S.+Zheng&title=Inhibitory+effect+of+cyclosporine+A+on+hepatitis+B+virus+replication+in+vitro+and+its+possible+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms</span></div><div class="casAuthors">Xia, Wei-Liang; Shen, Yan; Zheng, Shu-Sen</div><div class="citationInfo"><span class="NLM_cas:title">Hepatobiliary & Pancreatic Diseases International</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-22</span>CODEN:
                <span class="NLM_cas:coden">HPDIAJ</span>;
        ISSN:<span class="NLM_cas:issn">1499-3872</span>.
    
            (<span class="NLM_cas:orgname">First Affiliated Hospital, Zhejiang University School of Medicine</span>)
        </div><div class="casAbstract">A review.  BACKGROUND: Hepatitis B related end-stage liver disease is recently acknowledged as one of the main indications for orthotopic liver transplantation (OLT).  However, the high recurrence rate of hepatitis B virus infection following transplantation is regarded as a major factor affecting the long-term survival of transplant recipients esp. in China.  Cyclosporine A (CsA), which is routinely used to prevent the allograft rejection, is reported to have the inhibitory activity on hepatitis B virus (HBV) replication in vitro.  In this paper, we review the inhibitory effect and its possible mechanisms of CsA on HBV replication in vitro.  DATA RESOURCES: An English-language literature search was conducted using MEDLINE (1990-2004) on cyclosporine A, hepatitis B virus, mitochondria, calcium and other related reports and review articles.  RESULTS: Hepatitis B x protein (HBx) is essential to HBV replication.  The cytosolic calcium signaling mediated by mitochondria and the Src kinase pathway were involved during HBx activation of HBV replication.  CsA inhibits the HBV replication in vitro by its binding to mitochondrial cyclophilin D, then blocking the mitochondria-mediated cytosolic calcium signaling.  The derivates of CsA also have the HBV replication inhibitory effect in vitro.  CONCLUSIONS: By interacting with mitochondria, preventing the release of intramitochondrial calcium, and then blocking the cytosolic calcium signaling, CsA inhibits the HBV replication in vitro.  The derivates of CsA also have this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsbBZ8LnoHSrVg90H21EOLACvtfcHk0lhg7ex1xtCNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWisrw%253D&md5=987868ed72067f9eefca9e891b9b6970</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%2BL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DS.%2BS.%26atitle%3DInhibitory%2520effect%2520of%2520cyclosporine%2520A%2520on%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vitro%2520and%2520its%2520possible%2520mechanisms%26jtitle%3DHepatobiliary%2520Pancreatic%2520Dis.%2520Int.%26date%3D2005%26volume%3D4%26spage%3D18%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Wang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Q.</span><span> </span><span class="NLM_article-title">Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2015&pages=140-146&author=X.+J.+Wangauthor=W.+Huauthor=T.+Y.+Zhangauthor=Y.+Y.+Maoauthor=N.+N.+Liuauthor=S.+Q.+Wang&title=Irbesartan%2C+an+FDA+approved+drug+for+hypertension+and+diabetic+nephropathy%2C+is+a+potent+inhibitor+for+hepatitis+B+virus+entry+by+disturbing+Na%2B-dependent+taurocholate+cotransporting+polypeptide+activity&doi=10.1016%2Fj.antiviral.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DT.%2BY.%26aulast%3DMao%26aufirst%3DY.%2BY.%26aulast%3DLiu%26aufirst%3DN.%2BN.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3DIrbesartan%252C%2520an%2520FDA%2520approved%2520drug%2520for%2520hypertension%2520and%2520diabetic%2520nephropathy%252C%2520is%2520a%2520potent%2520inhibitor%2520for%2520hepatitis%2520B%2520virus%2520entry%2520by%2520disturbing%2520Na%252B-dependent%2520taurocholate%2520cotransporting%2520polypeptide%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D120%26spage%3D140%26epage%3D146%26doi%3D10.1016%2Fj.antiviral.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span> </span><span class="NLM_article-title">(−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=100-111&author=H.+C.+Huangauthor=M.+H.+Taoauthor=T.+M.+Hungauthor=J.+C.+Chenauthor=Z.+J.+Linauthor=C.+Huang&title=%28%E2%88%92%29-Epigallocatechin-3-gallate+inhibits+entry+of+hepatitis+B+virus+into+hepatocytes&doi=10.1016%2Fj.antiviral.2014.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DTao%26aufirst%3DM.%2BH.%26aulast%3DHung%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DZ.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%26atitle%3D%2528%25E2%2588%2592%2529-Epigallocatechin-3-gallate%2520inhibits%2520entry%2520of%2520hepatitis%2520B%2520virus%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D111%26spage%3D100%26epage%3D111%26doi%3D10.1016%2Fj.antiviral.2014.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Yeo, H.; Austin, D. J.; Li, L.; Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Antiviral helioxanthin analogs</span>. U.S. Patent no. 7754718, Jul 13,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Yeo&author=D.+J.+Austin&author=L.+Li&author=Y.+C.+Cheng&title=Antiviral+helioxanthin+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DH.%26atitle%3DAntiviral%2520helioxanthin%2520analogs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Cheng, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">New targets and inhibitors of HBV replication to combat drug resistance</span> <span class="citation_source-journal">J. Clin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">S147</span><span class="NLM_x">–</span> <span class="NLM_lpage">S150</span><span class="refDoi"> DOI: 10.1016/S1386-6532(05)80026-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1386-6532%2805%2980026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16461217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2005&pages=S147-S150&author=Y.+C.+Chengauthor=C.+X.+Yingauthor=C.+H.+Leungauthor=Y.+Li&title=New+targets+and+inhibitors+of+HBV+replication+to+combat+drug+resistance&doi=10.1016%2FS1386-6532%2805%2980026-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">New targets and inhibitors of HBV replication to combat drug resistance</span></div><div class="casAuthors">Cheng, Yung-Chi; Ying, Chun-Xiao; Leung, Chung-Hang; Li, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S147-S150</span>CODEN:
                <span class="NLM_cas:coden">JCVIFB</span>;
        ISSN:<span class="NLM_cas:issn">1386-6532</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  All the approved chemotherapeutic drugs for the treatment of HBV hepatitis are nucleoside analogs targeting on HBV DNA polymerase.  Drugs targeting on other viral unique targets are needed.  A new class of chems. with novel action against HBV replication was discovered.  A brief description of their mode of action is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmAx8Mv2pCzLVg90H21EOLACvtfcHk0lgvQqgqH7NLdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGnu78%253D&md5=0ef8de832b8025c7fd088f2ca4cad080</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1386-6532%2805%2980026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1386-6532%252805%252980026-5%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%2BC.%26aulast%3DYing%26aufirst%3DC.%2BX.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DNew%2520targets%2520and%2520inhibitors%2520of%2520HBV%2520replication%2520to%2520combat%2520drug%2520resistance%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2005%26volume%3D34%26spage%3DS147%26epage%3DS150%26doi%3D10.1016%2FS1386-6532%2805%2980026-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ying, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robek, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">8526</span><span class="NLM_x">–</span> <span class="NLM_lpage">8531</span><span class="refDoi"> DOI: 10.1073/pnas.0609883104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0609883104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=8526-8531&author=C.+Yingauthor=Y.+Liauthor=C.+H.+Leungauthor=M.+D.+Robekauthor=Y.+C.+Cheng&title=Unique+antiviral+mechanism+discovered+in+anti-hepatitis+B+virus+research+with+a+natural+product+analogue&doi=10.1073%2Fpnas.0609883104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609883104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609883104%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DRobek%26aufirst%3DM.%2BD.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DUnique%2520antiviral%2520mechanism%2520discovered%2520in%2520anti-hepatitis%2520B%2520virus%2520research%2520with%2520a%2520natural%2520product%2520analogue%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D8526%26epage%3D8531%26doi%3D10.1073%2Fpnas.0609883104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yeo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullen, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutschman, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Synthesis and antiviral activity of helioxanthin analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1021/jm034265a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034265a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCitbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=534-546&author=H.+Yeoauthor=Y.+Liauthor=L.+Fuauthor=J.+L.+Zhuauthor=E.+A.+Gullenauthor=G.+E.+Dutschmanauthor=Y.+Leeauthor=R.+Chungauthor=E.+S.+Huangauthor=D.+J.+Austinauthor=Y.+C.+Cheng&title=Synthesis+and+antiviral+activity+of+helioxanthin+analogues&doi=10.1021%2Fjm034265a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antiviral Activity of Helioxanthin Analogues</span></div><div class="casAuthors">Yeo, Hosup; Li, Ying; Fu, Lei; Zhu, Ju-Liang; Gullen, Elizabeth A.; Dutschman, Ginger E.; Lee, Yashang; Chung, Raymond; Huang, Eng-Shang; Austin, David J.; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of natural product analogs based on helioxanthin, with particular attention to modification of the lactone ring and methylenedioxy group, were synthesized and evaluated for their antiviral activities.  Among them, lactam deriv. I and helioxanthin cyclic hydrazide II exhibited significant in vitro antiviral activity against hepatitis B virus (EC50 = 0.08 and 0.03 μM, resp.).  Compd. I showed the most potent antiviral activity against hepatitis C virus (55% inhibition at 1.0 μM).  An acid-hydrolyzed product of helioxanthin cyclic imide deriv. was found to exhibit broad-spectrum antiviral activity against hepatitis B virus (EC50 = 0.8 μM), herpes simplex virus type 1 (EC50 = 0.15 μM) and type 2 (EC50 < 0.1 μM), Epstein-Barr virus (EC50 = 9.0 μM), and cytomegalovirus (EC50 = 0.45 μM).  Helioxanthin lactam deriv. I also showed marked inhibition of herpes simplex virus type 1 (EC50 = 0.29 μM) and type 2 (EC50 = 0.16 μM).  The cyclic hydrazide deriv. of helioxanthin II and its brominated product exhibited moderately potent activities against human immunodeficiency virus (EC50 = 2.7 and 2.5 μM, resp.).  Collectively, these mols. represent a novel set of antiviral compds. with unique structural features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA1Xk5HKEMKLVg90H21EOLACvtfcHk0lgvQqgqH7NLdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCitbfK&md5=cd20af18bd272f6b1e8ea194ce66f596</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm034265a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034265a%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DGullen%26aufirst%3DE.%2BA.%26aulast%3DDutschman%26aufirst%3DG.%2BE.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DE.%2BS.%26aulast%3DAustin%26aufirst%3DD.%2BJ.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DSynthesis%2520and%2520antiviral%2520activity%2520of%2520helioxanthin%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D534%26epage%3D546%26doi%3D10.1021%2Fjm034265a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y. C.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1177/095632020501600305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1177%2F095632020501600305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16004082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=193-201&author=Y.+Liauthor=L.+Fuauthor=H.+Yeoauthor=J.+L.+Zhuauthor=C.+K.+Chouauthor=Y.+H.+Kouauthor=S.+F.+Yehauthor=E.+Gullenauthor=D.+Austinauthor=Y.+C.+Cheng&title=Inhibition+of+hepatitis+B+virus+gene+expression+and+replication+by+helioxanthin+and+its+derivative&doi=10.1177%2F095632020501600305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative</span></div><div class="casAuthors">Li, Ying; Fu, Lei; Yeo, Hosup; Zhu, Ju-Liang; Chou, Chen-Kung; Kou, Yueh-Hsiung; Yeh, Sheau-Farn; Gullen, Elizabeth; Austin, David; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-201</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection continues to be an important worldwide cause of morbidity and mortality.  All the currently approved therapeutic drugs have their limitations: interferon-α (IFN-α) has limited efficacy and a high incidence of adverse effects; nucleoside analogs are very efficient HBV DNA inhibitors, but resistance occurs eventually.  Therefore, it is important to develop new nonnucleoside/nucleotide agents with different modes of action that can be used for antiviral combination therapy.  Here, the authors report on a novel class of compds., helioxanthin and its deriv. 5-4-2, which had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 μM, resp.  The lamivudine-resistant HBV, L526M/M550V double mutant strain, was also sensitive to helioxanthin and 5-4-2.  This class of compds. not only inhibited HBV DNA, but also decreased HBV mRNA and HBV protein expression.  The EC50 of HBV DNA inhibition was consistent with the EC50 of HBV 3.5 Kb transcript inhibition, which was 1 and 0.09 μM for helioxanthin and 5-4-2 resp.  Western blot anal. of cell lysate from HepG2.2.15 cells showed that the core protein expression decreased in a dose-dependent manner after drug treatment.  In conclusion, helioxanthin and 5-4-2 are potentially unique new anti-HBV agents, which possess a different mechanism of action from existing therapeutic drugs.  Both compds. inhibited HBV RNA and protein expression in addn. to inhibiting HBV DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlCAqB4xiNNrVg90H21EOLACvtfcHk0ljyPYINjIa-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsrk%253D&md5=00e3b23f39429cb610227ffaefc812d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1177%2F095632020501600305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600305%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYeo%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DKou%26aufirst%3DY.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26aulast%3DGullen%26aufirst%3DE.%26aulast%3DAustin%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520gene%2520expression%2520and%2520replication%2520by%2520helioxanthin%2520and%2520its%2520derivative%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D193%26epage%3D201%26doi%3D10.1177%2F095632020501600305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Janmanchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhuang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of helioxanthin analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2163</span><span class="NLM_x">–</span> <span class="NLM_lpage">2176</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2012.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2163-2176&author=D.+Janmanchiauthor=C.+H.+Linauthor=J.+Y.+Hsiehauthor=Y.+P.+Tsengauthor=T.+A.+Chenauthor=H.+J.+Jhuangauthor=S.+F.+Yeh&title=Synthesis+and+biological+evaluation+of+helioxanthin+analogues&doi=10.1016%2Fj.bmc.2012.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DJanmanchi%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DHsieh%26aufirst%3DJ.%2BY.%26aulast%3DTseng%26aufirst%3DY.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BA.%26aulast%3DJhuang%26aufirst%3DH.%2BJ.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520helioxanthin%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2163%26epage%3D2176%26doi%3D10.1016%2Fj.bmc.2012.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Tseng, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janmanchi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S. F.</span><span> </span><span class="NLM_article-title">The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=206-214&author=Y.+P.+Tsengauthor=Y.+H.+Kuoauthor=C.+P.+Huauthor=K.+S.+Jengauthor=D.+Janmanchiauthor=C.+H.+Linauthor=C.+K.+Chouauthor=S.+F.+Yeh&title=The+role+of+helioxanthin+in+inhibiting+human+hepatitis+B+viral+replication+and+gene+expression+by+interfering+with+the+host+transcriptional+machinery+of+viral+promoters&doi=10.1016%2Fj.antiviral.2007.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DY.%2BP.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DHu%26aufirst%3DC.%2BP.%26aulast%3DJeng%26aufirst%3DK.%2BS.%26aulast%3DJanmanchi%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DYeh%26aufirst%3DS.%2BF.%26atitle%3DThe%2520role%2520of%2520helioxanthin%2520in%2520inhibiting%2520human%2520hepatitis%2520B%2520viral%2520replication%2520and%2520gene%2520expression%2520by%2520interfering%2520with%2520the%2520host%2520transcriptional%2520machinery%2520of%2520viral%2520promoters%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D206%26epage%3D214%26doi%3D10.1016%2Fj.antiviral.2007.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, R. W.</span><span> </span><span class="NLM_article-title">Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1720</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1715-1720&author=S.+K.+Ladnerauthor=M.+J.+Ottoauthor=C.+S.+Barkerauthor=K.+Zaifertauthor=G.+H.+Wangauthor=J.+T.+Guoauthor=C.+Seegerauthor=R.+W.+King&title=Inducible+expression+of+human+hepatitis+B+virus+%28HBV%29+in+stably+transfected+hepatoblastoma+cells%3A+a+novel+system+for+screening+potential+inhibitors+of+HBV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DBarker%26aufirst%3DC.%2BS.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DSeeger%26aufirst%3DC.%26aulast%3DKing%26aufirst%3DR.%2BW.%26atitle%3DInducible%2520expression%2520of%2520human%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520in%2520stably%2520transfected%2520hepatoblastoma%2520cells%253A%2520a%2520novel%2520system%2520for%2520screening%2520potential%2520inhibitors%2520of%2520HBV%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D1715%26epage%3D1720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span> </span><span class="NLM_article-title">Antiviral therapies and prospects for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">a021501</span><span class="refDoi"> DOI: 10.1101/cshperspect.a021501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1101%2Fcshperspect.a021501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25833942" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021501&author=F.+Zoulimauthor=D.+Durantel&title=Antiviral+therapies+and+prospects+for+a+cure+of+chronic+hepatitis+B&doi=10.1101%2Fcshperspect.a021501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021501%26sid%3Dliteratum%253Aachs%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520therapies%2520and%2520prospects%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021501%26doi%3D10.1101%2Fcshperspect.a021501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">You, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. K.</span><span> </span><span class="NLM_article-title">Update on hepatitis B virus infection</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">13293</span><span class="NLM_x">–</span> <span class="NLM_lpage">13305</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i37.13293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.v20.i37.13293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25309066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKntrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=13293-13305&author=C.+R.+Youauthor=S.+W.+Leeauthor=J.+W.+Jangauthor=S.+K.+Yoon&title=Update+on+hepatitis+B+virus+infection&doi=10.3748%2Fwjg.v20.i37.13293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Update on hepatitis B virus infection</span></div><div class="casAuthors">You, Chan Ran; Lee, Sung Won; Jang, Jeong Won; Yoon, Seung Kew</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">13293-13305</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic infection with hepatitis B virus (HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure.  Despite extensive research, the immunopathogenesis is not completely understood.  Viral persistence and clin. outcomes following HBV infection depend on viral factors and host factors; including genetic factors that det. a host's immune mechanisms.  The primary goal of chronic hepatitis B (CHB) treatment is to eradicate HBV or to at least maintain suppression of HBV replication.  Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve.  Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogs (NAs).  Although NAs are safe, effective and easily administered orally, their long-term use poses the risk of drug resistance.  Currently, international evidence-based guidelines have been developed to support physicians in managing CHB patients.  However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur.  In addn., as the currently available genotypic test for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virol. test to overcome this limitation is necessary.  Among the predictive factors assocd. with response to pegylated interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN.  Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients.  To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virol. response.  This review highlights recent advances in the understanding of the immunopathogenesis of HBV and currently available and developing treatment strategies against HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb4R2NC4R1obVg90H21EOLACvtfcHk0lhzKBklE7QYNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKntrbE&md5=bae4ee7caaed772318f0389455a409b2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i37.13293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i37.13293%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DJ.%2BW.%26aulast%3DYoon%26aufirst%3DS.%2BK.%26atitle%3DUpdate%2520on%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D13293%26epage%3D13305%26doi%3D10.3748%2Fwjg.v20.i37.13293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span> </span><span class="NLM_article-title">Combination therapy for chronic hepatitis B: simultaneous or sequential?</span> <span class="citation_source-journal">Am. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1111/j.1572-0241.2006.00997.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1572-0241.2006.00997.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17266690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVOms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=105-106&author=M.+F.+Yuenauthor=C.+L.+Lai&title=Combination+therapy+for+chronic+hepatitis+B%3A+simultaneous+or+sequential%3F&doi=10.1111%2Fj.1572-0241.2006.00997.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for chronic hepatitis B: simultaneous or sequential?</span></div><div class="casAuthors">Yuen, Man-Fung; Lai, Ching-Lung</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-106</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Various regimens of combination or sequential therapy using nucleoside/nucleotide analogs (NAs) and interferon-alfa (IFN-α) have been tried for the treatment of chronic hepatitis B.  To date, combination therapy of two NAs and of IFN-α and NAs fails to achieve extra viral suppression.  Sequential therapy with lamivudine followed by IFN-α seems to have better sustained virol. response.  However, the long-term beneficial effect of using this approach remains to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk8v-2Z8oF47Vg90H21EOLACvtfcHk0lhzKBklE7QYNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVOms7c%253D&md5=4605865f7b978e249cb8dc797df21bcf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2006.00997.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2006.00997.x%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DLai%26aufirst%3DC.%2BL.%26atitle%3DCombination%2520therapy%2520for%2520chronic%2520hepatitis%2520B%253A%2520simultaneous%2520or%2520sequential%253F%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2007%26volume%3D102%26spage%3D105%26epage%3D106%26doi%3D10.1111%2Fj.1572-0241.2006.00997.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Takamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohgo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venzon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashi-Kuwata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delino, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukenaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haraguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarafianos, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">4-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1024</span><span class="NLM_x">–</span> <span class="NLM_lpage">1036</span><span class="refDoi"> DOI: 10.1002/hep.27962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.27962" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1024-1036&author=Y.+Takamatsuauthor=Y.+Tanakaauthor=S.+Kohgoauthor=S.+Murakamiauthor=K.+Singhauthor=D.+Dasauthor=D.+J.+Venzonauthor=M.+Amanoauthor=N.+Higashi-Kuwataauthor=M.+Aokiauthor=N.+S.+Delinoauthor=S.+Hayashiauthor=S.+Takahashiauthor=Y.+Sukenagaauthor=K.+Haraguchiauthor=S.+G.+Sarafianosauthor=K.+Maedaauthor=H.+Mitsuya&title=4-modified+nucleoside+analogs%3A+potent+inhibitors+active+against+entecavir-resistant+hepatitis+B+virus&doi=10.1002%2Fhep.27962"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fhep.27962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27962%26sid%3Dliteratum%253Aachs%26aulast%3DTakamatsu%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKohgo%26aufirst%3DS.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DVenzon%26aufirst%3DD.%2BJ.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DHigashi-Kuwata%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DDelino%26aufirst%3DN.%2BS.%26aulast%3DHayashi%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DSukenaga%26aufirst%3DY.%26aulast%3DHaraguchi%26aufirst%3DK.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3D4-modified%2520nucleoside%2520analogs%253A%2520potent%2520inhibitors%2520active%2520against%2520entecavir-resistant%2520hepatitis%2520B%2520virus%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1024%26epage%3D1036%26doi%3D10.1002%2Fhep.27962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Li, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maag, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfredson, T.</span><span> </span><span class="NLM_article-title">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1002/jps.21047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fjps.21047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17696166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=1109-1134&author=F.+J.+Liauthor=H.+Maagauthor=T.+Alfredson&title=Prodrugs+of+nucleoside+analogues+for+improved+oral+absorption+and+tissue+targeting&doi=10.1002%2Fjps.21047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting</span></div><div class="casAuthors">Li Fujun; Maag Hans; Alfredson Tom</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1109-34</span>
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">Nucleoside analogues are widely used for the treatment of antiviral infections and anticancer chemotherapy.  However, many nucleoside analogues suffer from poor oral bioavailability due to their high polarity and low intestinal permeability.  In order to improve oral absorption of these polar drugs, prodrugs have been employed to increase lipophilicity by chemical modification of the parent.  Alternatively, prodrugs targeting transporters present in the intestine have been exploited to facilitate the transport of the nucleoside analogues.  Valacyclovir and valganciclovir are two successful valine ester prodrugs transported by the PepT1 transporter.  Recently, research efforts have focused on design of prodrugs for tissue specific delivery to improve efficacy and safety.  This review presents advances of prodrug approaches for improved oral absorption of nucleoside analogues and recent developments in tissue targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-KOBK65zide2qxNLjzXe8fW6udTcc2eYvaGVtYyONA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVCgtQ%253D%253D&md5=ed6aeaf75134be8bc9ef23a89b673b80</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjps.21047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21047%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%2BJ.%26aulast%3DMaag%26aufirst%3DH.%26aulast%3DAlfredson%26aufirst%3DT.%26atitle%3DProdrugs%2520of%2520nucleoside%2520analogues%2520for%2520improved%2520oral%2520absorption%2520and%2520tissue%2520targeting%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D1109%26epage%3D1134%26doi%3D10.1002%2Fjps.21047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Painter, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trost, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampert, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De-Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beadle, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostetler, K. Y.</span><span> </span><span class="NLM_article-title">Evaluation of hexadecyloxypropyl-9-R-2-(phosphonomethoxy)propyl adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3505</span><span class="NLM_x">–</span> <span class="NLM_lpage">3509</span><span class="refDoi"> DOI: 10.1128/AAC.00460-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00460-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3505-3509&author=G.+R.+Painterauthor=M.+R.+Almondauthor=L.+C.+Trostauthor=B.+M.+Lampertauthor=J.+Neytsauthor=E.+De-Clercqauthor=B.+E.+Korbaauthor=K.+A.+Aldernauthor=J.+R.+Beadleauthor=K.+Y.+Hostetler&title=Evaluation+of+hexadecyloxypropyl-9-R-2-%28phosphonomethoxy%29propyl+adenine%2C+CMX157%2C+as+a+potential+treatment+for+human+immunodeficiency+virus+type+1+and+hepatitis+B+virus+infections&doi=10.1128%2FAAC.00460-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.00460-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00460-07%26sid%3Dliteratum%253Aachs%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DAlmond%26aufirst%3DM.%2BR.%26aulast%3DTrost%26aufirst%3DL.%2BC.%26aulast%3DLampert%26aufirst%3DB.%2BM.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe-Clercq%26aufirst%3DE.%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DAldern%26aufirst%3DK.%2BA.%26aulast%3DBeadle%26aufirst%3DJ.%2BR.%26aulast%3DHostetler%26aufirst%3DK.%2BY.%26atitle%3DEvaluation%2520of%2520hexadecyloxypropyl-9-R-2-%2528phosphonomethoxy%2529propyl%2520adenine%252C%2520CMX157%252C%2520as%2520a%2520potential%2520treatment%2520for%2520human%2520immunodeficiency%2520virus%2520type%25201%2520and%2520hepatitis%2520B%2520virus%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3505%26epage%3D3509%26doi%3D10.1128%2FAAC.00460-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Murakami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babusis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span> </span><span class="NLM_article-title">Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3569</span><span class="refDoi"> DOI: 10.1128/AAC.00128-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00128-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25870059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFCqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3563-3569&author=E.+Murakamiauthor=T.+Wangauthor=Y.+Parkauthor=J.+Haoauthor=E.+I.+Lepistauthor=D.+Babusisauthor=A.+S.+Ray&title=Implications+of+efficient+hepatic+delivery+by+tenofovir+alafenamide+%28GS-7340%29+for+hepatitis+B+virus+therapy&doi=10.1128%2FAAC.00128-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B Virus therapy</span></div><div class="casAuthors">Murakami, Eisuke; Wang, Ting; Park, Yeojin; Hao, Jia; Lepist, Eve-Irene; Babusis, Darius; Ray, Adrian S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3563-3569</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tenofovir alafenamide (TAF) is a prodrug of tenofovir (TFV) currently in clin. evaluation for treatment for HIV and hepatitis B virus (HBV) infections.  Since the target tissue for HBV is the liver, the hepatic delivery and metab. of TAF in primary human hepatocytes in vitro and in dogs in vivo were evaluated here.  Incubation of primary human hepatocytes with TAF resulted in high levels of the pharmacol. active metabolite tenofovir diphosphate (TFV-DP), which persisted in the cell with a half life of > 24 h.  In addn. to passive permeability, studies of transfected cell lines suggest that the hepatic uptake of TAF is also facilitated by the org. anion-transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3, resp.).  In order to inhibit HBV reverse transcriptase, TAF must be converted to the pharmacol. active form, TFV-DP.  While cathepsin A is known to be the major enzyme hydrolyzing TAF in cells targeted by HIV, including lymphocytes and macrophages, TAF was primarily hydrolyzed by carboxylesterase 1 (CES1) in primary human hepatocytes, with cathepsin A making a small contribution.  Following oral administration of TAF to dogs for 7 days, TAF was rapidly absorbed.  The appearance of the major metabolite TFV in plasma was accompanied by a rapid decline in circulating TAF.  Consistent with the in vitro data, high and persistent levels of TFV-DP were obsd. in dog livers.  Notably, higher liver TFV-DP levels were obsd. after administration of TAF than those given TDF.  These results support the clin. testing of once-daily low-dose TAF for the treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeY0bOfccxebVg90H21EOLACvtfcHk0lhnWQNiFCaI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFCqur4%253D&md5=f09a7f5420215dd0a626aedf57933be6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FAAC.00128-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00128-15%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DLepist%26aufirst%3DE.%2BI.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DRay%26aufirst%3DA.%2BS.%26atitle%3DImplications%2520of%2520efficient%2520hepatic%2520delivery%2520by%2520tenofovir%2520alafenamide%2520%2528GS-7340%2529%2520for%2520hepatitis%2520B%2520virus%2520therapy%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3563%26epage%3D3569%26doi%3D10.1128%2FAAC.00128-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span> </span><span class="NLM_article-title">Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2014.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25450717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFCjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=533-540&author=K.+Agarwalauthor=S.+K.+Fungauthor=T.+T.+Nguyenauthor=W.+Chengauthor=E.+Sicardauthor=S.+D.+Ryderauthor=J.+F.+Flahertyauthor=E.+Lawsonauthor=S.+Zhaoauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=E.+J.+Ganeauthor=G.+R.+Foster&title=Twenty-eight+day+safety%2C+antiviral+activity%2C+and+pharmacokinetics+of+tenofovir+alafenamide+for+treatment+of+chronic+hepatitis+B+infection&doi=10.1016%2Fj.jhep.2014.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection</span></div><div class="casAuthors">Agarwal, Kosh; Fung, Scott K.; Nguyen, Tuan T.; Cheng, Wendy; Sicard, Eric; Ryder, Stephen D.; Flaherty, John F.; Lawson, Eileen; Zhao, Sally; Subramanian, G. Mani; McHutchison, John G.; Gane, Edward J.; Foster, Graham R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug to hepatocytes at reduced systemic tenofovir exposures.  Non-cirrhotic, treatment-na.ovrddot.ive subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 wk.51 subjects were randomized and all completed study treatment.  Groups were generally well matched (67% male, 57% Asian, 53% HBeAg-neg., mean HBV DNA approx. 6.0 log10 IU/mL) with HBV genotypes reflective of the population.  No subject experienced an adverse event that was serious or severe (grade 3/4).  Across the tenofovir alafenamide groups, similar mean changes in serum HBV DNA were found at Week 4 (-2.81, -2.55, -2.19, and -2.76 log10 IU/mL for the 8, 25, 40, and 120 mg groups, resp.) which were also comparable to the control (-2.68 log10 IU/mL for tenofovir disoproxil fumarate 300 mg).  Kinetics of viral decline were also similar among groups.  Tenofovir alafenamide pharmacokinetics were linear and proportional to the dose; doses ≤25 mg were assocd. with ≥92% redns. in mean tenofovir area under the curve relative to tenofovir disoproxil fumarate 300 mg.  Tenofovir alafenamide was safe and well tolerated; declines in HBV DNA were similar to tenofovir disoproxil fumarate at all doses evaluated.  Tenofovir alafenamide 25 mg has been selected for further hepatitis B clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKrJztqILtfbVg90H21EOLACvtfcHk0liJ0sY0Y7mmUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFCjsr0%253D&md5=da729a4b4fe0b19430e2dbe14282bc9a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DFung%26aufirst%3DS.%2BK.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DSicard%26aufirst%3DE.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DFlaherty%26aufirst%3DJ.%2BF.%26aulast%3DLawson%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26atitle%3DTwenty-eight%2520day%2520safety%252C%2520antiviral%2520activity%252C%2520and%2520pharmacokinetics%2520of%2520tenofovir%2520alafenamide%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D533%26epage%3D540%26doi%3D10.1016%2Fj.jhep.2014.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Tavis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michailidis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurora, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parniak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarafianos, S. G.</span><span> </span><span class="NLM_article-title">The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003125</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1003125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.ppat.1003125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23349632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVOrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003125&author=J.+E.+Tavisauthor=X.+H.+Chengauthor=Y.+Huauthor=M.+Tottenauthor=F.+Caoauthor=E.+Michailidisauthor=R.+Auroraauthor=M.+J.+Meyersauthor=E.+J.+Jacobsenauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=The+hepatitis+B+virus+ribonuclease+H+is+sensitive+to+inhibitors+of+the+human+immunodeficiency+virus+ribonuclease+H+and+integrase+enzymes&doi=10.1371%2Fjournal.ppat.1003125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes</span></div><div class="casAuthors">Tavis, John E.; Cheng, Xiaohong; Hu, Yuan; Totten, Michael; Cao, Feng; Michailidis, Eleftherios; Aurora, Rajeev; Meyers, Marvin J.; Jacobsen, E. Jon; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1003125</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects.  The profound suppression of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of extinction.  Consequently, more patients could be cured by suppressing HBV replication further using a new drug in combination with the nucleos(t)ide analogs.  The HBV RNase H (RNAseH) is a logical drug target because it is the second of only two viral enzymes that are essential for viral replication, but it has not been exploited, primarily because it is very difficult to produce active enzyme.  To address this difficulty, we expressed HBV genotype D and H RNAseHs in E. coli and enriched the enzymes by nickel-affinity chromatog.  HBV RNAseH activity in the enriched lysates was characterized in prepn. for drug screening.  Twenty-one candidate HBV RNAseH inhibitors were identified using chem. structureactivity analyses based on inhibitors of the HIV RNAseH and integrase.  Twelve anti-RNAseH and anti-integrase compds. inhibited the HBV RNAseH at 10 μM, the best compds. had low micromolar IC50 values against the RNAseH and one compd. inhibited HBV replication in tissue culture at 10 μM.  Recombinant HBV genotype D RNAseH was more sensitive to inhibition than genotype H.  This study demonstrates that recombinant HBV RNAseH suitable for low-throughput antiviral drug screening has been produced.  The high percentage of compds. developed against the HIV RNAseH and integrase that were active against the HBV RNAseH indicates that the extensive drug design efforts against these HIV enzymes can guide anti-HBV RNAseH drug discovery.  Finally, differential inhibition of HBV genotype D and H RNAseHs indicates that viral genetic variability will be a factor during drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoFFUjTDO7rVg90H21EOLACvtfcHk0liJ0sY0Y7mmUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVOrsbg%253D&md5=f7841946904e4fe9ae6cc7a7b4502de5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003125%26sid%3Dliteratum%253Aachs%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTotten%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DF.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DAurora%26aufirst%3DR.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DThe%2520hepatitis%2520B%2520virus%2520ribonuclease%2520H%2520is%2520sensitive%2520to%2520inhibitors%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520ribonuclease%2520H%2520and%2520integrase%2520enzymes%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26spage%3De1003125%26doi%3D10.1371%2Fjournal.ppat.1003125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Lu, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomonosova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Grice, S. F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Erasmo, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suyabatmaz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murelli, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1079</span><span class="refDoi"> DOI: 10.1128/AAC.04617-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.04617-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25451058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Kqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1070-1079&author=G.+F.+Luauthor=E.+Lomonosovaauthor=X.+H.+Chengauthor=E.+A.+Moranauthor=M.+J.+Meyersauthor=S.+F.+J.+Le+Griceauthor=C.+J.+Thomasauthor=J.+K.+Jiangauthor=C.+Meckauthor=D.+R.+Hirschauthor=M.+P.+D%E2%80%99Erasmoauthor=D.+M.+Suyabatmazauthor=R.+P.+Murelliauthor=J.+E.+Tavis&title=Hydroxylated+tropolones+inhibit+hepatitis+B+virus+replication+by+blocking+viral+ribonuclease+H+activity&doi=10.1128%2FAAC.04617-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity</span></div><div class="casAuthors">Lu, Gaofeng; Lomonosova, Elena; Cheng, Xiaohong; Moran, Eileen A.; Meyers, Marvin J.; Le Grice, Stuart F. J.; Thomas, Craig J.; Jiang, Jian-kang; Meck, Christine; Hirsch, Danielle R.; D'Erasmo, Michael P.; Suyabatmaz, Duygu M.; Murelli, Ryan P.; Tavis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1070-1079, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) remains a major human pathogen despite the development of both antiviral drugs and a vaccine, in part because the current therapies do not suppress HBV replication far enough to eradicate the virus.  Here, we screened 51 troponoid compds. for their ability to suppress HBV RNaseH activity and HBV replication based on the activities of α-hydroxytropolones against HIV RNaseH, with the goal of detg. whether the tropolone pharmacophore may be a promising scaffold for anti-HBV drug development.  Thirteen compds. inhibited HBV RNaseH, with the best 50% inhibitory concn. (IC50) being 2.3 μM.  Similar inhibition patterns were obsd. against HBV genotype D and C RNaseHs, implying limited genotype specificity.  Six of 10 compds. tested against HBV replication in culture suppressed replication via blocking of viral RNaseH activity, with the best 50% effective concn. (EC50) being 0.34 μM.  Eighteen compds. inhibited recombinant human RNaseH1, and moderate cytotoxicity was obsd. for all compds. (50% cytotoxic concn. [CC50] = 25 to 79 μM).  Therapeutic indexes ranged from 3.8 to 94.  Efficient inhibition required an intact α-hydroxytropolone moiety plus one or more short appendages on the tropolone ring, but a wide variety of constituents were permissible.  These data indicate that troponoids and specifically α-hydroxytropolones are promising lead candidates for development as anti-HBV drugs, providing that toxicity can be minimized.  Potential anti-RNaseH drugs are envisioned to be employed in combination with the existing nucleos(t)ide analogs to suppress HBV replication far enough to block genomic maintenance, with the goal of eradicating infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpknK2lLWuF87Vg90H21EOLACvtfcHk0lj6O7NXnEDKvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Kqsrg%253D&md5=ad57f43a17b6aaf4a68a5912a7e72c1e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1128%2FAAC.04617-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04617-14%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%2BF.%26aulast%3DLomonosova%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DMoran%26aufirst%3DE.%2BA.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DLe%2BGrice%26aufirst%3DS.%2BF.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DMeck%26aufirst%3DC.%26aulast%3DHirsch%26aufirst%3DD.%2BR.%26aulast%3DD%25E2%2580%2599Erasmo%26aufirst%3DM.%2BP.%26aulast%3DSuyabatmaz%26aufirst%3DD.%2BM.%26aulast%3DMurelli%26aufirst%3DR.%2BP.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DHydroxylated%2520tropolones%2520inhibit%2520hepatitis%2520B%2520virus%2520replication%2520by%2520blocking%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1070%26epage%3D1079%26doi%3D10.1128%2FAAC.04617-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Beta-thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2013.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2013.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2013&pages=221-229&author=Y.+Huauthor=X.+H.+Chengauthor=F.+Caoauthor=A.+L.+Huangauthor=J.+E.+Tavis&title=Beta-thujaplicinol+inhibits+hepatitis+B+virus+replication+by+blocking+the+viral+ribonuclease+H+activity&doi=10.1016%2Fj.antiviral.2013.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DCao%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DA.%2BL.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DBeta-thujaplicinol%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520blocking%2520the%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D99%26spage%3D221%26epage%3D229%26doi%3D10.1016%2Fj.antiviral.2013.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Cai, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomonosova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavis, J. E.</span><span> </span><span class="NLM_article-title">Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24858512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=48-55&author=C.+W.+Caiauthor=E.+Lomonosovaauthor=E.+A.+Moranauthor=X.+H.+Chengauthor=K.+B.+Patelauthor=F.+Baillyauthor=P.+Cotelleauthor=M.+J.+Meyersauthor=J.+E.+Tavis&title=Hepatitis+B+virus+replication+is+blocked+by+a+2-hydroxyisoquinoline-1%2C3%282H%2C4H%29-dione+%28HID%29+inhibitor+of+the+viral+ribonuclease+H+activity&doi=10.1016%2Fj.antiviral.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity</span></div><div class="casAuthors">Cai, Catherine W.; Lomonosova, Elena; Moran, Eileen A.; Cheng, Xiaohong; Patel, Kunjan B.; Bailly, Fabrice; Cotelle, Philippe; Meyers, Marvin J.; Tavis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-55</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog drugs profoundly suppress Hepatitis B virus (HBV) replication but rarely cure the infection, so therapy is usually life-long.  The nucleos(t)ide analogs inhibit the viral DNA polymerase and often push HBV to the brink of extinction, so it may be possible to eradicate HBV by suppressing HBV replication further.  The HBV RNase H (RNaseH) is a logical new drug target because it is the second of only two viral enzymes essential for viral replication.  We recently developed a low throughput screening pipeline for inhibitors of the HBV RNaseH and viral replication.  Here, we screened a series of twenty-three nitrogen-based polyoxygenated heterocycles including sixteen 2-hydroxyisoquinoline-1,3(2H,4H)-dione derivs. for anti-HBV RNaseH activity.  Nine compds. inhibited the HBV RNaseH, but activity was marginal for eight of them.  Compd. #1 [2-hydroxyisoquinoline-1,3(2H,4H)-dione, HID] was the best hit with an IC50 of 28.1 μM and an EC50 of 4.2 μM.  It preferentially suppressed accumulation of the viral plus-polarity DNA strand in replication inhibition assays, indicating that replication was blocked due to suppression of HBV RNaseH activity.  It had a CC50 of 75 μM, yielding a therapeutic index of ∼18.  The EC50 value was 7-fold lower than the IC50, possibly due to cellular retention or metab. of the compd., or higher affinity for the full-length enzyme than the recombinant form used for screening.  These data indicate that the 2-hydroxyisoquinoline-1,3(2H,4H)-diones will have different structure-activity relationships for the HBV and HIV RNaseHs.  Therefore, HID compds. may provide a foundation for development of more effective RNaseH inhibitors of HBV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJVUWhOxXkALVg90H21EOLACvtfcHk0lj6O7NXnEDKvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGqsrnE&md5=790a7c0b6496897f62a68cbcfc747135</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DC.%2BW.%26aulast%3DLomonosova%26aufirst%3DE.%26aulast%3DMoran%26aufirst%3DE.%2BA.%26aulast%3DCheng%26aufirst%3DX.%2BH.%26aulast%3DPatel%26aufirst%3DK.%2BB.%26aulast%3DBailly%26aufirst%3DF.%26aulast%3DCotelle%26aufirst%3DP.%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DTavis%26aufirst%3DJ.%2BE.%26atitle%3DHepatitis%2520B%2520virus%2520replication%2520is%2520blocked%2520by%2520a%25202-hydroxyisoquinoline-1%252C3%25282H%252C4H%2529-dione%2520%2528HID%2529%2520inhibitor%2520of%2520the%2520viral%2520ribonuclease%2520H%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D108%26spage%3D48%26epage%3D55%26doi%3D10.1016%2Fj.antiviral.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Bruss, V.</span><span> </span><span class="NLM_article-title">Envelopment of the hepatitis B virus nucleocapsid</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1016/j.virusres.2004.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.virusres.2004.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15567498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVantLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2004&pages=199-209&author=V.+Bruss&title=Envelopment+of+the+hepatitis+B+virus+nucleocapsid&doi=10.1016%2Fj.virusres.2004.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Envelopment of the hepatitis B virus nucleocapsid</span></div><div class="casAuthors">Bruss, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis B virus (HBV) is an enveloped DNA virus with an icosahedral capsid replicating via reverse transcription.  The crystal structure of the capsid is known.  It has a diam. of 36 nm and is formed by one protein species (C protein).  The viral envelope contains three different coterminal proteins (S, M, and L proteins) spanning the membrane several times.  These proteins are not only released from infected cells as components of the viral envelope but in 10,000-fold excess as subviral lipoprotein particles with a diam. of 22 nm contg. no capsid.  Assembly of the capsid occurs in the cytosol and results in packaging of a 3.5 kb RNA mol. together with viral and cellular factors.  This newly formed capsid cannot be enveloped.  Rather, synthesis of the viral DNA genome in the lumen of the capsid by reverse transcription is required to induce a budding competent state.  Envelopment then takes place at an intracellular membrane of the pre-Golgi compartment.  The S and the L protein, but not the M protein, is required for this process.  The L protein forms two different transmembrane topologies.  The isoform exposing the N-terminal part at the cytosolic side of the membrane is essential for budding.  In this domain, a 22 amino acid (aa) long linear stretch has been mapped genetically to play a vital role in the morphogenetic process.  This domain probably mediates the contact to the capsid.  A second matrix domain was mapped to the cytosolic loop of the S protein.  A similar genetic approach identified two small areas on the capsid surface, which might interact with the envelope proteins during envelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxadiOhpcOhLVg90H21EOLACvtfcHk0liS_ruKK9ivSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVantLnO&md5=b5355066968d9553b30d27d3dd48e307</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2004.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2004.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DV.%26atitle%3DEnvelopment%2520of%2520the%2520hepatitis%2520B%2520virus%2520nucleocapsid%26jtitle%3DVirus%2520Res.%26date%3D2004%26volume%3D106%26spage%3D199%26epage%3D209%26doi%3D10.1016%2Fj.virusres.2004.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Chain, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span> </span><span class="NLM_article-title">Variability and conservation in hepatitis B virus core protein</span> <span class="citation_source-journal">BMC Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1186/1471-2180-5-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1186%2F1471-2180-5-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15649330" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1-14&author=B.+M.+Chainauthor=R.+Myers&title=Variability+and+conservation+in+hepatitis+B+virus+core+protein&doi=10.1186%2F1471-2180-5-33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1471-2180-5-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2180-5-33%26sid%3Dliteratum%253Aachs%26aulast%3DChain%26aufirst%3DB.%2BM.%26aulast%3DMyers%26aufirst%3DR.%26atitle%3DVariability%2520and%2520conservation%2520in%2520hepatitis%2520B%2520virus%2520core%2520protein%26jtitle%3DBMC%2520Microbiol.%26date%3D2005%26volume%3D5%26spage%3D1%26epage%3D14%26doi%3D10.1186%2F1471-2180-5-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Zlotnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewellyn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S.</span><span> </span><span class="NLM_article-title">Core protein: a pleiotropic keystone in the HBV lifecycle</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26129969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=82-93&author=A.+Zlotnickauthor=B.+Venkatakrishnanauthor=Z.+N.+Tanauthor=E.+Lewellynauthor=W.+Turnerauthor=S.+Francis&title=Core+protein%3A+a+pleiotropic+keystone+in+the+HBV+lifecycle&doi=10.1016%2Fj.antiviral.2015.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Core protein: A pleiotropic keystone in the HBV lifecycle</span></div><div class="casAuthors">Zlotnick, Adam; Venkatakrishnan, Balasubramanian; Tan, Zhenning; Lewellyn, Eric; Turner, William; Francis, Samson</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-93</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B Virus (HBV) is a small virus whose genome has only four open reading frames.  We argue that the simplicity of the virion correlates with a complexity of functions for viral proteins.  We focus on the HBV core protein (Cp), a small (183 residue) protein that self-assembles to form the viral capsid.  However, its functions are a little more complicated than that.  In an infected cell Cp modulates almost every step of the viral lifecycle.  Cp is bound to nuclear viral DNA and affects its epigenetics.  Cp correlates with RNA specificity.  Cp assembles specifically on a reverse transcriptase-viral RNA complex or, apparently, nothing at all.  Indeed Cp has been one of the model systems for investigation of virus self-assembly.  Cp participates in regulation of reverse transcription.  Cp signals completion of reverse transcription to support virus secretion.  Cp carries both nuclear localization signals and HBV surface antigen (HBsAg) binding sites; both of these functions appear to be regulated by contents of the capsid.  Cp can be targeted by antivirals - while self-assembly is the most accessible of Cp activities, we argue that it makes sense to engage the broader spectrum of Cp function.  This article forms part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyafN5HJZSQLVg90H21EOLACvtfcHk0liS_ruKK9ivSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM&md5=e1bd58b97219cb54136dbb2db2fadb70</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DZ.%2BN.%26aulast%3DLewellyn%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DS.%26atitle%3DCore%2520protein%253A%2520a%2520pleiotropic%2520keystone%2520in%2520the%2520HBV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D82%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2015.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagelschur, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruebsamen-Waigmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlfeil, S.</span><span> </span><span class="NLM_article-title">Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/S0166-3542(01)00216-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0166-3542%2801%2900216-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12062392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=69-78&author=O.+Weberauthor=K.+H.+Schlemmerauthor=E.+Hartmannauthor=I.+Hagelschurauthor=A.+Paessensauthor=E.+Graefauthor=K.+Deresauthor=S.+Goldmannauthor=U.+Niewoehnerauthor=J.+Stoltefussauthor=D.+Haebichauthor=H.+Ruebsamen-Waigmannauthor=S.+Wohlfeil&title=Inhibition+of+human+hepatitis+B+virus+%28HBV%29+by+a+novel+non-nucleosidic+compound+in+a+transgenic+mouse+model&doi=10.1016%2FS0166-3542%2801%2900216-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model</span></div><div class="casAuthors">Weber, O.; Schlemmer, K.-H.; Hartmann, E.; Hagelschuer, Ina; Paessens, A.; Graef, E.; Deres, K.; Goldmann, S.; Niewoehner, U.; Stoltefuss, J.; Haebich, D.; Ruebsamen-Waigmann, H.; Wohlfeil, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-78</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">BAY 41-4109 is a member of a class of heteroaryl-pyrimidines that was recently identified as potent inhibitors of human hepatitis B virus (HBV) replication.  We have investigated the antiviral activity of BAY 41-4109 (Me (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylate) in HBV-transgenic mice (Tg [HBV1.3 fsX-3'5']).  Bay 41-4109 was administered per os using different schedules (b.i.d. or t.i.d. for up to 28 days) and dosages ranging from 3 to 30 mg/kg.  The compd. reduced viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC.  In contrast to 3TC-treated mice, we found a redn. of cytoplasmic hepatitis B virus core antigen (HBcAg) in liver sections of BAY 41-4109-treated mice, which indicated a different mode of action.  Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concns.  We conclude that BAY 41-4109 is a new anti-HBV drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj4XpaXvzGrVg90H21EOLACvtfcHk0lgbAZID3iVPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVShsLg%253D&md5=bae520cd731096858f86f4ce28674231</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2801%2900216-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252801%252900216-9%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHartmann%26aufirst%3DE.%26aulast%3DHagelschur%26aufirst%3DI.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DNiewoehner%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRuebsamen-Waigmann%26aufirst%3DH.%26aulast%3DWohlfeil%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520human%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520by%2520a%2520novel%2520non-nucleosidic%2520compound%2520in%2520a%2520transgenic%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2002%26volume%3D54%26spage%3D69%26epage%3D78%26doi%3D10.1016%2FS0166-3542%2801%2900216-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacker, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewohner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koletzki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masantschek, R. N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubsamen-Waigmann, H.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.1126/science.1077215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1077215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12574631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=893-896&author=K.+Deresauthor=C.+H.+Schroderauthor=A.+Paessensauthor=S.+Goldmannauthor=H.+J.+Hackerauthor=O.+Weberauthor=T.+Kramerauthor=U.+Niewohnerauthor=U.+Pleissauthor=J.+Stoltefussauthor=E.+Graefauthor=D.+Koletzkiauthor=R.+N.+A.+Masantschekauthor=A.+Reimannauthor=R.+Jaegerauthor=R.+Grossauthor=B.+Beckermannauthor=K.+H.+Schlemmerauthor=D.+Haebichauthor=H.+Rubsamen-Waigmann&title=Inhibition+of+hepatitis+B+virus+replication+by+drug-induced+depletion+of+nucleocapsids&doi=10.1126%2Fscience.1077215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids</span></div><div class="casAuthors">Deres, Karl; Schroeder, Claus H.; Paessens, Arnold; Goldmann, Siegfried; Hacker, Hans Joerg; Weber, Olaf; Kraemer, Thomas; Niewoehner, Ulrich; Pleiss, Ulrich; Stoltefuss, Juergen; Graef, Erwin; Koletzki, Diana; Masantschek, Ralf N. A.; Reimann, Anja; Jaeger, Rainer; Gro, Rainer; Beckermann, Bernhard; Schlemmer, Karl-Heinz; Haebich, Dieter; Ruebsamen-Waigmann, Helga</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5608</span>),
    <span class="NLM_cas:pages">893-896</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major cause of liver disease.  Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy.  However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors.  Potent new antiviral compds. suitable for monotherapy or combination therapy are highly desired.  We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity.  These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlJUFASSEhLVg90H21EOLACvtfcHk0lgbAZID3iVPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D&md5=a5e74b45d335f74ba17ec9fe4d31e24b</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1126%2Fscience.1077215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1077215%26sid%3Dliteratum%253Aachs%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DSchroder%26aufirst%3DC.%2BH.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DHacker%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DKoletzki%26aufirst%3DD.%26aulast%3DMasantschek%26aufirst%3DR.%2BN.%2BA.%26aulast%3DReimann%26aufirst%3DA.%26aulast%3DJaeger%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DBeckermann%26aufirst%3DB.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRubsamen-Waigmann%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520drug-induced%2520depletion%2520of%2520nucleocapsids%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D893%26epage%3D896%26doi%3D10.1126%2Fscience.1077215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Stray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">BAY 41–4109 has multiple effects on Hepatitis B virus capsid assembly</span> <span class="citation_source-journal">J. Mol. Recognit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1002/jmr.801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fjmr.801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17006877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=542-548&author=S.+J.+Strayauthor=A.+Zlotnick&title=BAY+41%E2%80%934109+has+multiple+effects+on+Hepatitis+B+virus+capsid+assembly&doi=10.1002%2Fjmr.801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Recognition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JMORE4</span>;
        ISSN:<span class="NLM_cas:issn">0952-3499</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Here we report the effect of a heteroaryldihydropyrimidine (HAP) antiviral compd., BAY 41-4109, on Hepatitis B virus (HBV) capsid assembly and on preformed HBV capsids.  The HBV capsid is an icosahedral complex of 120 capsid protein dimers.  BAY41-4109 inhibits virus prodn. in vivo by a mechanism that targets the viral capsid.  We found that BAY 41-4109 was able to both accelerate and misdirect capsid assembly in vitro.  As little as one HAP mol. for every five HBV dimers was sufficient to induce formation of non-capsid polymers.  Unlike the related mol. HAP-1, no stable assembly intermediates were obsd. in assembly reactions with BAY 41-4109, indicating that accelerated assembly by BAY 41-4109 was still kinetically regulated by the nucleation rate.  Preformed capsids were stabilized by BAY 41-4109, up to a ratio of one inhibitor mol. per two dimers.  However, at BAY 41-4109:dimer ratios of 1:1 and greater, capsids were destabilized to yield very large noncapsid polymers.  These data suggest the existence of two functionally distinguishable classes of drug-binding sites on HBV capsids.  Occupation of the first class of site stabilizes capsid, while binding at the second class requires or induces structural changes that cannot be tolerated without destabilizing the capsid.  Our data suggest that HAP compds. may inhibit virus replication by inducing assembly inappropriately and, when in excess, by misdirecting assembly decreasing the stability of normal capsids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorOaQz7SajJrVg90H21EOLACvtfcHk0lgbAZID3iVPig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D&md5=15c132fcc380b09f691561adf737fbd3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjmr.801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.801%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DBAY%252041%25E2%2580%25934109%2520has%2520multiple%2520effects%2520on%2520Hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2006%26volume%3D19%26spage%3D542%26epage%3D548%26doi%3D10.1002%2Fjmr.801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Stray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">8138</span><span class="NLM_x">–</span> <span class="NLM_lpage">8143</span><span class="refDoi"> DOI: 10.1073/pnas.0409732102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0409732102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15928089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsV2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=8138-8143&author=S.+J.+Strayauthor=C.+R.+Bourneauthor=S.+Punnaauthor=W.+G.+Lewisauthor=M.+G.+Finnauthor=A.+Zlotnick&title=A+heteroaryldihydropyrimidine+activates+and+can+misdirect+hepatitis+B+virus+capsid+assembly&doi=10.1073%2Fpnas.0409732102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Bourne, Christina R.; Punna, Sreenivas; Lewis, Warren G.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8138-8143</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heteroaryldihydropyrimidines (HAPs) are a new class of antivirals inhibiting prodn. of hepatitis B virus (HBV) virions in tissue culture.  Here, we examine the effect of a representative HAP mol., Me 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP-1), on the in vitro assembly of HBV capsid protein (Cp).  HAP-1 enhances the rate and extent of Cp assembly over a broad concn. range.  Aberrant particles, dominated by hexagonal arrays of Cp, were obsd. from assembly reactions with high HAP-1 concns.  HAP-1 also led to dissocn. of metastable HBV capsids, overcoming a kinetic barrier to dissocn. by scavenging Cp and redirecting its assembly into hexamer-rich structures.  Thus, HAP drugs act as allosteric effectors that induce an assembly-active state and, at high concn., preferentially stabilize noncapsid polymers of Cp.  HAP compds. may have multiple effects in vivo stemming from inappropriate assembly of Cp.  These results show that activating and deregulating virus assembly may be a powerful general approach for antiviral therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IO3o_Hqhk7Vg90H21EOLACvtfcHk0ljBCvyj7d76Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsV2msbc%253D&md5=30abe296011a5e771047ce4fdc0343a8</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0409732102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0409732102%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DPunna%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DW.%2BG.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DA%2520heteroaryldihydropyrimidine%2520activates%2520and%2520can%2520misdirect%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D8138%26epage%3D8143%26doi%3D10.1073%2Fpnas.0409732102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span> </span><span class="NLM_article-title">The novel compound Z060228 inhibits assembly of the HBV capsid</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.1016/j.lfs.2015.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.lfs.2015.04.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2015&pages=1-7&author=H.+Guanauthor=G.+Zhaoauthor=W.+Chenauthor=G.+Wuauthor=H.+Liuauthor=X.+Jiangauthor=S.+Liauthor=L.+L.+Wang&title=The+novel+compound+Z060228+inhibits+assembly+of+the+HBV+capsid&doi=10.1016%2Fj.lfs.2015.04.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2015.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2015.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BL.%26atitle%3DThe%2520novel%2520compound%2520Z060228%2520inhibits%2520assembly%2520of%2520the%2520HBV%2520capsid%26jtitle%3DLife%2520Sci.%26date%3D2015%26volume%3D133%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.lfs.2015.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. S.</span><span> </span><span class="NLM_article-title">In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.3851/IMP2152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=793-803&author=X.+Y.+Wangauthor=Z.+M.+Weiauthor=G.+Y.+Wuauthor=J.+H.+Wangauthor=Y.+J.+Zhangauthor=J.+Liauthor=H.+H.+Zhangauthor=X.+W.+Xieauthor=X.+Wangauthor=Z.+H.+Wangauthor=L.+Weiauthor=Y.+Wangauthor=H.+S.+Chen&title=In+vitro+inhibition+of+HBV+replication+by+a+novel+compound%2C+GLS4%2C+and+its+efficacy+against+adefovir-dipivoxil-resistant+HBV+mutations&doi=10.3851%2FIMP2152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3851%2FIMP2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2152%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DZ.%2BM.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DXie%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%2BS.%26atitle%3DIn%2520vitro%2520inhibition%2520of%2520HBV%2520replication%2520by%2520a%2520novel%2520compound%252C%2520GLS4%252C%2520and%2520its%2520efficacy%2520against%2520adefovir-dipivoxil-resistant%2520HBV%2520mutations%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D793%26epage%3D803%26doi%3D10.3851%2FIMP2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baydo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abendroth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O. A.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">15196</span><span class="NLM_x">–</span> <span class="NLM_lpage">15201</span><span class="refDoi"> DOI: 10.1073/pnas.1513803112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1513803112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26598693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15196-15201&author=K.+Klumppauthor=A.+M.+Lamauthor=C.+Lukacsauthor=R.+Vogelauthor=S.+P.+Renauthor=C.+Espirituauthor=R.+Baydoauthor=K.+Atkinsauthor=J.+Abendrothauthor=G.+C.+Liaoauthor=A.+Efimovauthor=G.+Hartmanauthor=O.+A.+Flores&title=High-resolution+crystal+structure+of+a+hepatitis+B+virus+replication+inhibitor+bound+to+the+viral+core+protein&doi=10.1073%2Fpnas.1513803112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span></div><div class="casAuthors">Klumpp, Klaus; Lam, Angela M.; Lukacs, Christine; Vogel, Robert; Ren, Suping; Espiritu, Christine; Baydo, Ruth; Atkins, Kateri; Abendroth, Jan; Liao, Guochun; Efimov, Andrey; Hartman, George; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15196-15201</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery.  We report the first, to our knowledge, high-resoln. crystal structure of an antiviral compd. bound to the HBV core protein.  The compd. NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C.  NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability.  The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions detd. by crystallog.  The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxV-odPonGbVg90H21EOLACvtfcHk0lipqSCZ-glq0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK&md5=bf487dda7165d1637fad0ebab8f46142</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1513803112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1513803112%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%2BP.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DBaydo%26aufirst%3DR.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DG.%2BC.%26aulast%3DEfimov%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520a%2520hepatitis%2520B%2520virus%2520replication%2520inhibitor%2520bound%2520to%2520the%2520viral%2520core%2520protein%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D15196%26epage%3D15201%26doi%3D10.1073%2Fpnas.1513803112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Yang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">A new series of HAPs as anti-HBV agents targeting at capsid assembly</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4247</span><span class="NLM_x">–</span> <span class="NLM_lpage">4249</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2014.07.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4247-4249&author=X.+Y.+Yangauthor=X.+Q.+Xuauthor=H.+Guanauthor=L.+L.+Wangauthor=Q.+Wuauthor=G.+M.+Zhaoauthor=S.+Li&title=A+new+series+of+HAPs+as+anti-HBV+agents+targeting+at+capsid+assembly&doi=10.1016%2Fj.bmcl.2014.07.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.032%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DX.%2BQ.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DG.%2BM.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DA%2520new%2520series%2520of%2520HAPs%2520as%2520anti-HBV%2520agents%2520targeting%2520at%2520capsid%2520assembly%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4247%26epage%3D4249%26doi%3D10.1016%2Fj.bmcl.2014.07.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.10.119" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=299-301&author=X.+Zhuauthor=G.+Zhaoauthor=X.+Zhouauthor=X.+Xuauthor=G.+Xiaauthor=Z.+Zhengauthor=L.+Wangauthor=X.+Yangauthor=S.+Li&title=2%2C4-Diaryl-4%2C6%2C7%2C8-tetrahydroquinazolin-5%281H%29-one+derivatives+as+anti-HBV+agents+targeting+at+capsid+assembly&doi=10.1016%2Fj.bmcl.2009.10.119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.119%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26atitle%3D2%252C4-Diaryl-4%252C6%252C7%252C8-tetrahydroquinazolin-5%25281H%2529-one%2520derivatives%2520as%2520anti-HBV%2520agents%2520targeting%2520at%2520capsid%2520assembly%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D299%26epage%3D301%26doi%3D10.1016%2Fj.bmcl.2009.10.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Qiu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7651</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&author=Z.+Qiuauthor=X.+Linauthor=M.+Zhouauthor=Y.+Liuauthor=W.+Zhuauthor=W.+Chenauthor=W.+Zhangauthor=L.+Guoauthor=H.+Liuauthor=G.+Wuauthor=M.+Huangauthor=M.+Jiangauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+Qiuauthor=S.+Zhongauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Wang, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naduthambi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4642</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2011.05.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4642-4647&author=P.+Y.+Wangauthor=D.+Naduthambiauthor=R.+T.+Mosleyauthor=C.+R.+Niuauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Phenylpropenamide+derivatives%3A+anti-hepatitis+B+virus+activity+of+the+Z+isomer%2C+SAR+and+the+search+for+novel+analogs&doi=10.1016%2Fj.bmcl.2011.05.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.077%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%2BY.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DNiu%26aufirst%3DC.%2BR.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPhenylpropenamide%2520derivatives%253A%2520anti-hepatitis%2520B%2520virus%2520activity%2520of%2520the%2520Z%2520isomer%252C%2520SAR%2520and%2520the%2520search%2520for%2520novel%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4642%26epage%3D4647%26doi%3D10.1016%2Fj.bmcl.2011.05.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">King, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span> </span><span class="NLM_article-title">Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (−)beta-L-2′,3′-dideoxy-3′-thiacytidine</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3179</span><span class="NLM_x">–</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3179-3186&author=R.+W.+Kingauthor=S.+K.+Ladnerauthor=T.+J.+Millerauthor=K.+Zaifertauthor=R.+B.+Perniauthor=S.+C.+Conwayauthor=M.+J.+Otto&title=Inhibition+of+human+hepatitis+B+virus+replication+by+AT-61%2C+a+phenylpropenamide+derivative%2C+alone+and+in+combination+with+%28%E2%88%92%29beta-L-2%E2%80%B2%2C3%E2%80%B2-dideoxy-3%E2%80%B2-thiacytidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DR.%2BW.%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DMiller%26aufirst%3DT.%2BJ.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DConway%26aufirst%3DS.%2BC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26atitle%3DInhibition%2520of%2520human%2520hepatitis%2520B%2520virus%2520replication%2520by%2520AT-61%252C%2520a%2520phenylpropenamide%2520derivative%252C%2520alone%2520and%2520in%2520combination%2520with%2520%2528%25E2%2588%2592%2529beta-L-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxy-3%25E2%2580%25B2-thiacytidine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3179%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladner, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaifert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, R. W.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2687</span><span class="NLM_x">–</span> <span class="NLM_lpage">2690</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00544-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0960-894X%2800%2900544-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11128652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotlantbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2687-2690&author=R.+B.+Perniauthor=S.+C.+Conwayauthor=S.+K.+Ladnerauthor=K.+Zaifertauthor=M.+J.+Ottoauthor=R.+W.+King&title=Phenylpropenamide+derivatives+as+inhibitors+of+hepatitis+B+virus+replication&doi=10.1016%2FS0960-894X%2800%2900544-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives as inhibitors of Hepatitis B virus replication</span></div><div class="casAuthors">Perni, R. B.; Conway, S. C.; Ladner, S. K.; Zaifert, K.; Otto, M. J.; King, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2687-2690</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A non-nucleoside class of compds. that inhibits the replication of hepatitis B virus (HBV) in cell culture has been discovered.  A series of substituted analogs of phenylpropenamide has been prepd. and evaluated in the HepAD38 cellular assay.  Structure-activity relationships of this series are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZcKEPcrqkbVg90H21EOLACvtfcHk0lj29jhFX4bOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotlantbw%253D&md5=4c3ee48f05dc8bee0724ba928d89f8a1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900544-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900544-8%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DConway%26aufirst%3DS.%2BC.%26aulast%3DLadner%26aufirst%3DS.%2BK.%26aulast%3DZaifert%26aufirst%3DK.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DKing%26aufirst%3DR.%2BW.%26atitle%3DPhenylpropenamide%2520derivatives%2520as%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520replication%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2687%26epage%3D2690%26doi%3D10.1016%2FS0960-894X%2800%2900544-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Delaney, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Painter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3057</span><span class="NLM_x">–</span> <span class="NLM_lpage">3060</span><span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12183271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&author=W.+E.+Delaneyauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span></div><div class="casAuthors">Delaney, William E., IV; Edwards, Ros; Colledge, Danni; Shaw, Tim; Furman, Phil; Painter, George; Locarnini, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3057-3060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The phenylpropenamide derivs. AT-61 and AT-130 are nonnucleoside analog inhibitors of hepatitis B virus (HBV) replication.  They inhibited the replication of wild-type HBV with 50% inhibitory concns. of 21.2±9.5 and 2.40±0.92 μM, resp., compared to 0.064±0.020 μM lamivudine.  There were no significant differences in sensitivity between wild-type and nucleoside analog-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UNW_6bFxUrVg90H21EOLACvtfcHk0lhwD7UQ0WSHCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D&md5=ffb8ff070fda879480d93597468cbd9b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlejohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S. A.</span><span> </span><span class="NLM_article-title">The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17709147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOgtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=168-177&author=J.+J.+Feldauthor=D.+Colledgeauthor=V.+Sozziauthor=R.+Edwardsauthor=M.+Littlejohnauthor=S.+A.+Locarnini&title=The+phenylpropenamide+derivative+AT-130+blocks+HBV+replication+at+the+level+of+viral+RNA+packaging&doi=10.1016%2Fj.antiviral.2007.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging</span></div><div class="casAuthors">Feld, J. J.; Colledge, D.; Sozzi, V.; Edwards, R.; Littlejohn, M.; Locarnini, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-177</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nucleos(t)ide analog antiviral therapy for chronic hepatitis B has proven to be effective in the short term but the frequent development of resistance limits its clin. utility.  Agents targeting other stages of viral replication are needed in order to develop improved combination therapies.  The phenylpropenamide derivs. AT-61 and AT-130 have been shown to inhibit HBV replication in vitro, but the mechanism of action of these compds. remains undefined.  The aim of this study was to det. the mechanism of action of AT-130, a nonnucleoside inhibitor of HBV in several in vitro models of replication.  These studies found that AT-130 inhibited HBV DNA replication in hepatoma cells but had no effect on viral DNA polymerase activity or core protein translation.  Total HBV RNA prodn. was also unaffected in the presence of the drug while the amt. of encapsidated RNA was significantly reduced, thereby inhibiting subsequent viral reverse transcription.  These studies have established that the inhibition of HBV genome replication by a nonnucleoside analog acting at the level of viral encapsidation and packaging is a potentially useful strategy for future therapeutic drug development in the management of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGXzYFUdjuOrVg90H21EOLACvtfcHk0lhwD7UQ0WSHCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOgtb3K&md5=d8989ca5da33e96859f3de9f87f38872</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DSozzi%26aufirst%3DV.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DLittlejohn%26aufirst%3DM.%26aulast%3DLocarnini%26aufirst%3DS.%2BA.%26atitle%3DThe%2520phenylpropenamide%2520derivative%2520AT-130%2520blocks%2520HBV%2520replication%2520at%2520the%2520level%2520of%2520viral%2520RNA%2520packaging%26jtitle%3DAntiviral%2520Res.%26date%3D2007%26volume%3D76%26spage%3D168%26epage%3D177%26doi%3D10.1016%2Fj.antiviral.2007.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Katen, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirapu, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1125</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1021/cb100275b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100275b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1125-1136&author=S.+P.+Katenauthor=S.+R.+Chirapuauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Trapping+of+hepatitis+B+virus+capsid+assembly+intermediates+by+phenylpropenamide+assembly+accelerators&doi=10.1021%2Fcb100275b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of Hepatitis B Virus Capsid Assembly Intermediates by Phenylpropenamide Assembly Accelerators</span></div><div class="casAuthors">Katen, Sarah P.; Chirapu, Srinivas Reddy; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1125-1136</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the biol. self-assembly process of virus capsids is key to understanding the viral life cycle, as well as serving as a platform for the design of assembly-based antiviral drugs.  Here we identify and characterize the phenylpropenamide family of small mols., known to have antiviral activity in vivo, as assembly effectors of the hepatitis B virus (HBV) capsid.  We have found two representative phenylpropenamides to be assembly accelerators, increasing the rate of assembly with only modest increases in the stability of the HBV capsids; these data provide a phys.-chem. basis for their antiviral activity.  Unlike previously described HBV assembly effectors, the phenylpropenamides do not misdirect assembly; rather, the accelerated reactions proceed on-path to produce morphol. normal capsids.  However, capsid assembly in the presence of phenylpropenamides is characterized by kinetic trapping of assembly intermediates.  These traps resolve under conditions close to physiol., but we found that trapped intermediates persist under conditions that favor phenylpropenamide binding and strong core protein-protein interactions.  The phenylpropenamides serve as chem. probes of the HBV capsid assembly pathway by trapping on-path assembly intermediates, illustrating the governing influence of reaction kinetics on capsid assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0sU96uRbhi7Vg90H21EOLACvtfcHk0lhwD7UQ0WSHCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku7jL&md5=90a8728ca9cc6bb2ff3acf47694e0d50</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fcb100275b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100275b%26sid%3Dliteratum%253Aachs%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DChirapu%26aufirst%3DS.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DTrapping%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%2520intermediates%2520by%2520phenylpropenamide%2520assembly%2520accelerators%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2010%26volume%3D5%26spage%3D1125%26epage%3D1136%26doi%3D10.1021%2Fcb100275b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Cole, A. G.</span><span> </span><span class="NLM_article-title">Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1016/j.coph.2016.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.coph.2016.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27636324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWksLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=131-137&author=A.+G.+Cole&title=Modulators+of+HBV+capsid+assembly+as+an+approach+to+treating+hepatitis+B+virus+infection&doi=10.1016%2Fj.coph.2016.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection</span></div><div class="casAuthors">Cole, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-137</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for a cure for hepatitis B virus infection extends beyond interferon and the existing polymerase inhibitors, and targets different aspects of the virus life cycle to develop agents that operate by alternative mechanisms.  Examples of small mols. that disrupt the encapsidation of pgRNA have been known for some time, but recent advances in the understanding of nucleocapsid formation, how compds. interact with core protein, and the development of drug-like mols. have recently progressed the study of capsid assembly modulators to proof of concept in the clinic with respect to redn. of viral load in chronic HBV patients.  Interference with HBV capsid assembly is thus a legitimate approach to treating HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsPSq66Ons2rVg90H21EOLACvtfcHk0ljqxZgU-hGSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWksLbF&md5=9ed4b04d1c497ecf976b40a1b62a52f7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%2BG.%26atitle%3DModulators%2520of%2520HBV%2520capsid%2520assembly%2520as%2520an%2520approach%2520to%2520treating%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D131%26epage%3D137%26doi%3D10.1016%2Fj.coph.2016.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0ljqxZgU-hGSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Katen, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirapu, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1406</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span><span class="refDoi"> DOI: 10.1016/j.str.2013.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.str.2013.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23871485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCgs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1406-1416&author=S.+P.+Katenauthor=Z.+N.+Tanauthor=S.+R.+Chirapuauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Assembly-directed+antivirals+differentially+bind+quasiequivalent+pockets+to+modify+hepatitis+B+virus+capsid+tertiary+and+quaternary+structure&doi=10.1016%2Fj.str.2013.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly-Directed Antivirals Differentially Bind Quasiequivalent Pockets to Modify Hepatitis B Virus Capsid Tertiary and Quaternary Structure</span></div><div class="casAuthors">Katen, Sarah P.; Tan, Zhenning; Chirapu, Srinivas Reddy; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1406-1416</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a major cause of liver disease.  Assembly of the HBV capsid is a crit. step in virus prodn. and an attractive target for new antiviral therapies.  We detd. the structure of HBV capsid in complex with AT-130, a member of the phenylpropenamide family of assembly effectors.  AT-130 causes tertiary and quaternary structural changes but does not disrupt capsid structure.  AT-130 binds a hydrophobic pocket that also accommodates the previously characterized heteroaryldihydropyrimidine compds. but favors a unique quasiequivalent location on the capsid surface.  Thus, this pocket is a promiscuous drug-binding site and a likely target for different assembly effectors with a broad range of mechanisms of activity.  That AT-130 successfully decreases virus prodn. by increasing capsid assembly rate without disrupting capsid structure delineates a paradigm in antiviral design, that disrupting reaction timing is a viable strategy for assembly effectors of HBV and other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZur3DCpnS3LVg90H21EOLACvtfcHk0ljqxZgU-hGSqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCgs7fF&md5=bb515fd504fb69f82755409c4c8f2079</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2013.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2013.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DTan%26aufirst%3DZ.%2BN.%26aulast%3DChirapu%26aufirst%3DS.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DAssembly-directed%2520antivirals%2520differentially%2520bind%2520quasiequivalent%2520pockets%2520to%2520modify%2520hepatitis%2520B%2520virus%2520capsid%2520tertiary%2520and%2520quaternary%2520structure%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D1406%26epage%3D1416%26doi%3D10.1016%2Fj.str.2013.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Campagna, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6931</span><span class="NLM_x">–</span> <span class="NLM_lpage">6942</span><span class="refDoi"> DOI: 10.1128/JVI.00582-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00582-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23576513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=6931-6942&author=M.+R.+Campagnaauthor=F.+Liuauthor=R.+C.+Maoauthor=C.+Millsauthor=D.+W.+Caiauthor=F.+Guoauthor=X.+S.+Zhaoauthor=H.+Yeauthor=A.+Cuconatiauthor=H.+T.+Guoauthor=J.+H.+Changauthor=X.+D.+Xuauthor=T.+M.+Blockauthor=J.+T.+Guo&title=Sulfamoylbenzamide+derivatives+inhibit+the+assembly+of+hepatitis+B+virus+nucleocapsids&doi=10.1128%2FJVI.00582-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span></div><div class="casAuthors">Campagna, Matthew R.; Liu, Fei; Mao, Richeng; Mills, Courtney; Cai, Dawei; Guo, Fang; Zhao, Xuesen; Ye, Hong; Cuconati, Andrea; Guo, Haitao; Chang, Jinhong; Xu, Xiaodong; Block, Timothy M.; Guo, Ju-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6931-6942</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos(t)ide analog viral DNA polymerase inhibitors.  However, neither pegIFN-α nor nucleos(t)ide analogs are capable of reliably curing the viral infection.  In order to develop novel antiviral drugs against HBV, we established a cell-based screening assay by using an immortalized mouse hepatocyte-derived stable cell line supporting a high level of HBV replication in a tetracycline-inducible manner.  Screening of a library consisting of 26,900 small mols. led to the discovery of a series of sulfamoylbenzamide (SBA) derivs. that significantly reduced the amt. of cytoplasmic HBV DNA.  Structure-activity relationship studies have thus far identified a group of fluorine-substituted SBAs with submicromolar antiviral activity against HBV in human hepatoma cells.  Mechanistic analyses reveal that the compds. dose dependently inhibit the formation of pregenomic RNA (pgRNA)-contg. nucleocapsids of HBV but not other animal hepadnaviruses, such as woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV).  Moreover, heterologous genetic complementation studies of capsid protein, DNA polymerase, and pgRNA between HBV and WHV suggest that HBV capsid protein confers sensitivity to the SBAs.  In summary, SBAs represent a novel chem. entity with superior activity and a unique antiviral mechanism and are thus warranted for further development as novel antiviral therapeutics for the treatment of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNUsTkQKVBQbVg90H21EOLACvtfcHk0lgKcefL1Uy33Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D&md5=80cd9d05d889ecf1bd2f6c28f7946bcf</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FJVI.00582-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00582-13%26sid%3Dliteratum%253Aachs%26aulast%3DCampagna%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DR.%2BC.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DD.%2BW.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%2BS.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%2BT.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BD.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DSulfamoylbenzamide%2520derivatives%2520inhibit%2520the%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520nucleocapsids%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D6931%26epage%3D6942%26doi%3D10.1128%2FJVI.00582-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Hartman, G. D.; Flores, O. A.</span><span> </span><span class="NLM_article-title">Hepatitis B antivial agents</span>. PCT Int. Appl. WO 2013096744 A1, Jun 27,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+D.+Hartman&author=O.+A.+Flores&title=Hepatitis+B+antivial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DHepatitis%2520B%2520antivial%2520agents%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span> </span><span class="NLM_article-title">P0640: effect of the combination of the HBV core inhibitor NVR 3–778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG2.2.15 cells</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S559</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30845-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930845-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S559&author=A.+Lamauthor=C.+Espirituauthor=O.+Floresauthor=G.+Hartmanauthor=K.+Klumpp&title=P0640%3A+effect+of+the+combination+of+the+HBV+core+inhibitor+NVR+3%E2%80%93778+with+nucleoside+analogs+or+other+HBV+core+inhibitors+on+the+inhibition+of+HBV+DNA+replication+in+HepG2.2.15+cells&doi=10.1016%2FS0168-8278%2815%2930845-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930845-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930845-X%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DP0640%253A%2520effect%2520of%2520the%2520combination%2520of%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203%25E2%2580%2593778%2520with%2520nucleoside%2520analogs%2520or%2520other%2520HBV%2520core%2520inhibitors%2520on%2520the%2520inhibition%2520of%2520HBV%2520DNA%2520replication%2520in%2520HepG2.2.15%2520cells%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS559%26doi%3D10.1016%2FS0168-8278%2815%2930845-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allweiss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetgehetman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">High antiviral activity of the HBV core inhibitor NVR 3–778 in the humanized UPA/SCID mouse model</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S250</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30134-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930134-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25281864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S250&author=K.+Klumppauthor=T.+Shimadaauthor=L.+Allweissauthor=T.+Volzauthor=M.+Luetgehetmanauthor=O.+Floresauthor=G.+Hartmanauthor=A.+Lamauthor=M.+Dandri&title=High+antiviral+activity+of+the+HBV+core+inhibitor+NVR+3%E2%80%93778+in+the+humanized+UPA%2FSCID+mouse+model&doi=10.1016%2FS0168-8278%2815%2930134-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930134-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930134-3%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DAllweiss%26aufirst%3DL.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DLuetgehetman%26aufirst%3DM.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DA.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DHigh%2520antiviral%2520activity%2520of%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203%25E2%2580%2593778%2520in%2520the%2520humanized%2520UPA%252FSCID%2520mouse%2520model%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS250%26doi%3D10.1016%2FS0168-8278%2815%2930134-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by the HBV core inhibitor NVR 3-778</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">223A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=223A&author=A.+Lamauthor=S.+P.+Renauthor=R.+Vogelauthor=C.+Espirituauthor=M.+Kellyauthor=V.+Lauauthor=G.+D.+Hartmanauthor=L.+Floresauthor=K.+Klumpp&title=Inhibition+of+hepatitis+B+virus+replication+by+the+HBV+core+inhibitor+NVR+3-778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DS.%2BP.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DV.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520the%2520HBV%2520core%2520inhibitor%2520NVR%25203-778%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D223A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. A.</span><span> </span><span class="NLM_article-title">Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV coreInhibitor</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1279A&author=E.+J.+Ganeauthor=C.+Schwabeauthor=K.+Walkerauthor=L.+Floresauthor=G.+D.+Hartmanauthor=K.+Klumppauthor=S.+Liawauthor=N.+A.+Brown&title=Phase+1a+safety+and+pharmacokinetics+of+NVR+3-778%2C+a+potential+first-in-class+HBV+coreInhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%2BA.%26atitle%3DPhase%25201a%2520safety%2520and%2520pharmacokinetics%2520of%2520NVR%25203-778%252C%2520a%2520potential%2520first-in-class%2520HBV%2520coreInhibitor%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1279A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weilert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span> </span><span class="NLM_article-title">Phase 1b efficacy and safety of NVR 3-778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385A</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1385A-1386A&author=M.+F.+Yuenauthor=D.+J.+Kimauthor=F.+Weilertauthor=H.+L.+Y.+Chanauthor=J.+P.+Lalezariauthor=S.+G.+Hwangauthor=T.+T.+Nguyenauthor=S.+Liawauthor=N.+Brownauthor=K.+Klumppauthor=L.+Floresauthor=G.+D.+Hartmanauthor=E.+J.+Gane&title=Phase+1b+efficacy+and+safety+of+NVR+3-778%2C+a+first-in-class+HBV+core+inhibitor%2C+in+HBeAg-positive+patients+with+chronic+HBV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DWeilert%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DFlores%26aufirst%3DL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26atitle%3DPhase%25201b%2520efficacy%2520and%2520safety%2520of%2520NVR%25203-778%252C%2520a%2520first-in-class%2520HBV%2520core%2520inhibitor%252C%2520in%2520HBeAg-positive%2520patients%2520with%2520chronic%2520HBV%2520infection%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1385A%26epage%3D1386A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1002/cmdc.200800136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fcmdc.200800136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1316-1321&author=H.+J.+Chenauthor=W.+L.+Wangauthor=G.+F.+Wangauthor=L.+P.+Shiauthor=M.+Guauthor=Y.+D.+Renauthor=L.+F.+Houauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=X.+G.+Zhongauthor=W.+Tangauthor=J.+P.+Zuoauthor=F.+J.+Nan&title=Rational+design+and+synthesis+of+2%2C2-bisheterocycle+tandem+derivatives+as+non-nucleoside+hepatitis+B+virus+inhibitors&doi=10.1002%2Fcmdc.200800136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800136%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DRen%26aufirst%3DY.%2BD.%26aulast%3DHou%26aufirst%3DL.%2BF.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DZhong%26aufirst%3DX.%2BG.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%25202%252C2-bisheterocycle%2520tandem%2520derivatives%2520as%2520non-nucleoside%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2008%26volume%3D3%26spage%3D1316%26epage%3D1321%26doi%3D10.1002%2Fcmdc.200800136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+P.+Shiauthor=H.+J.+Chenauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=Y.+M.+Zhangauthor=W.+L.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=Y.+H.+Haoauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=W.+Tangauthor=F.+J.+Nanauthor=J.+P.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0lhW_3-o061jEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Cho, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, G.</span><span> </span><span class="NLM_article-title">2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1111/jvh.12214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fjvh.12214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24372792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=843-852&author=M.+H.+Choauthor=H.+Jeongauthor=Y.+S.+Kimauthor=J.+W.+Kimauthor=G.+Jung&title=2-Amino-N-%282%2C6-dichloropyridin-3-yl%29acetamide+derivatives+as+a+novel+class+of+HBV+capsid+assembly+inhibitor&doi=10.1111%2Fjvh.12214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor</span></div><div class="casAuthors">Cho, M. H.; Jeong, H.; Kim, Y. S.; Kim, J.-W.; Jung, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : Capsid structure is crucial for the maturation and maintenance of the stable hepatitis B virion.  Therefore, chems. that inhibit capsid assembly might potentially act as potent antiviral compds.  However, only a few chems. are known to block the capsid assembly process and further viral proliferation.  In this study, we present a novel family of capsid assembly inhibitors that act against hepatitis B virus (HBV).  Based on X-ray crystallog. data of the HBV core protein (Cp), we built dimer and hexamer structural models to be used in library searches.  Several chems. in the 2-amino-N-(2,6-dichloropyridin-3-yl)acetamide family were predicted to have high affinity for the groove structure in Cp.  Using in vitro assembly and the HepG2.2.15 cell culture test, we verified that these chems. demonstrated inhibitory effects on capsid assembly.  Furthermore, we investigated the combinatorial effects of these assembly inhibitor chems. with lamivudine and revealed that, in combination, they have synergistic inhibitory effects on decreasing viral concn.  We propose that these inhibitors could be utilized as an effective combination treatment against HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUuUFPBCmP7Vg90H21EOLACvtfcHk0li_tVwRTR2_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegsrjP&md5=8ea975bf569a0ba1a79e2b88017e6950</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12214%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DM.%2BH.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DJung%26aufirst%3DG.%26atitle%3D2-Amino-N-%25282%252C6-dichloropyridin-3-yl%2529acetamide%2520derivatives%2520as%2520a%2520novel%2520class%2520of%2520HBV%2520capsid%2520assembly%2520inhibitor%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26spage%3D843%26epage%3D852%26doi%3D10.1111%2Fjvh.12214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7061</span><span class="NLM_x">–</span> <span class="NLM_lpage">7072</span><span class="refDoi"> DOI: 10.1128/AAC.01558-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01558-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=7061-7072&author=Y.+J.+Wangauthor=D.+Luauthor=Y.+B.+Xuauthor=W.+Q.+Xingauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=L.+Yangauthor=W.+Tangauthor=Y.+H.+Huauthor=J.+P.+Zuo&title=A+novel+pyridazinone+derivative+inhibits+hepatitis+B+virus+replication+by+inducing+genome-free+capsid+formation&doi=10.1128%2FAAC.01558-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1128%2FAAC.01558-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01558-15%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%2BB.%26aulast%3DXing%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%2BH.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DA%2520novel%2520pyridazinone%2520derivative%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D7061%26epage%3D7072%26doi%3D10.1128%2FAAC.01558-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Hartman, G. D.; Kuduk, S.</span><span> </span><span class="NLM_article-title">Azepane derivatives and methods of treating hepatitis B infections</span>. U.S. Pat. Appl. 20150132258 A1, May 14,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+D.+Hartman&author=S.+Kuduk&title=Azepane+derivatives+and+methods+of+treating+hepatitis+B+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartman%26aufirst%3DG.%2BD.%26atitle%3DAzepane%2520derivatives%2520and%2520methods%2520of%2520treating%2520hepatitis%2520B%2520infections%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Zlotnick, A.; Li, L. C.; Turner, W. J.; Francis, S.</span><span> </span><span class="NLM_article-title">Hepatitis B viral assembly effector</span>. PCT Int. Appl. WO 2015057945 A1, Apr 23,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Zlotnick&author=L.+C.+Li&author=W.+J.+Turner&author=S.+Francis&title=Hepatitis+B+viral+assembly+effector"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DHepatitis%2520B%2520viral%2520assembly%2520effector%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Vandyck, K. V.; Wim, G.; Raboisson; Pierre, J. M. B.</span><span> </span><span class="NLM_article-title">Fused bicyclic sulfamoyl derivatives for the treatment of hepatitis B</span>. PCT Int. Appl. WO 2014033167, Mar 6,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+V.+Vandyck&author=G.+Wim&author=+Raboisson&author=J.+M.+B.+Pierre&title=Fused+bicyclic+sulfamoyl+derivatives+for+the+treatment+of+hepatitis+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVandyck%26aufirst%3DK.%2BV.%26atitle%3DFused%2520bicyclic%2520sulfamoyl%2520derivatives%2520for%2520the%2520treatment%2520of%2520hepatitis%2520B%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Turner, W. W. A.; Lee, D.; Maag, H.; Zlotnick, A.</span><span> </span><span class="NLM_article-title">Hepatitis B core protein allosteric modulators</span>. PCT Int. Appl. WO 2015138895, Sep 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+W.+A.+Turner&author=D.+Lee&author=H.+Maag&author=A.+Zlotnick&title=Hepatitis+B+core+protein+allosteric+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DW.%2BW.%2BA.%26atitle%3DHepatitis%2520B%2520core%2520protein%2520allosteric%2520modulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Asif-Ullah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. G.</span><span> </span><span class="NLM_article-title">Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2006.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2006.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=85-90&author=M.+Asif-Ullahauthor=K.+J.+Choiauthor=K.+I.+Choiauthor=Y.+J.+Jeongauthor=Y.+G.+Yu&title=Identification+of+compounds+that+inhibit+the+interaction+between+core+and+surface+protein+of+hepatitis+B+virus&doi=10.1016%2Fj.antiviral.2006.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2006.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2006.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAsif-Ullah%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DK.%2BJ.%26aulast%3DChoi%26aufirst%3DK.%2BI.%26aulast%3DJeong%26aufirst%3DY.%2BJ.%26aulast%3DYu%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520compounds%2520that%2520inhibit%2520the%2520interaction%2520between%2520core%2520and%2520surface%2520protein%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DAntiviral%2520Res.%26date%3D2006%26volume%3D70%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.antiviral.2006.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Hadziyannis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadziyannis, S. J.</span><span> </span><span class="NLM_article-title">Quantitative HBsAg titer as predictor of response to therapy</span> <span class="citation_source-journal">Curr. Hepat. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1007/s11901-009-0024-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1007%2Fs11901-009-0024-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=169-172&author=E.+Hadziyannisauthor=D.+Vassilopoulosauthor=S.+J.+Hadziyannis&title=Quantitative+HBsAg+titer+as+predictor+of+response+to+therapy&doi=10.1007%2Fs11901-009-0024-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2Fs11901-009-0024-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11901-009-0024-8%26sid%3Dliteratum%253Aachs%26aulast%3DHadziyannis%26aufirst%3DE.%26aulast%3DVassilopoulos%26aufirst%3DD.%26aulast%3DHadziyannis%26aufirst%3DS.%2BJ.%26atitle%3DQuantitative%2520HBsAg%2520titer%2520as%2520predictor%2520of%2520response%2520to%2520therapy%26jtitle%3DCurr.%2520Hepat.%2520Rep.%26date%3D2009%26volume%3D8%26spage%3D169%26epage%3D172%26doi%3D10.1007%2Fs11901-009-0024-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinot-Peignoux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piratvisuth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillmann, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Hepatitis B surface antigen quantification: why and how to use it in 2011-A core group report</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1016/j.jhep.2011.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2011.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21718667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC3MbitFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1121-1131&author=H.+L.+Y.+Chanauthor=A.+Thompsonauthor=M.+Martinot-Peignouxauthor=T.+Piratvisuthauthor=M.+Cornbergauthor=M.+R.+Brunettoauthor=H.+L.+Tillmannauthor=J.+H.+Kaoauthor=J.+D.+Jiaauthor=H.+Wedemeyerauthor=S.+Locarniniauthor=H.+L.+A.+Janssenauthor=P.+Marcellin&title=Hepatitis+B+surface+antigen+quantification%3A+why+and+how+to+use+it+in+2011-A+core+group+report&doi=10.1016%2Fj.jhep.2011.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report</span></div><div class="casAuthors">Chan Henry Lik-Yuen; Thompson Alex; Martinot-Peignoux Michelle; Piratvisuth Teerha; Cornberg Markus; Brunetto Maurizia Rossana; Tillmann Hans L; Kao Jia-Horng; Jia Ji-Dong; Wedemeyer Heiner; Locarnini Stephen; Janssen Harry L A; Marcellin Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1121-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome.  The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B.  HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies.  Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients.  Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients.  The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment.  On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders.  The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection.  A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term.  There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment.  In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4Ym-TR-Q2esRAV4D_Ins_fW6udTcc2eZebitm4fUahrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbitFShsg%253D%253D&md5=025b70ddfc809716d6d24c534ae3b334</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DMartinot-Peignoux%26aufirst%3DM.%26aulast%3DPiratvisuth%26aufirst%3DT.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DTillmann%26aufirst%3DH.%2BL.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DJia%26aufirst%3DJ.%2BD.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DLocarnini%26aufirst%3DS.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DHepatitis%2520B%2520surface%2520antigen%2520quantification%253A%2520why%2520and%2520how%2520to%2520use%2520it%2520in%25202011-A%2520core%2520group%2520report%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D55%26spage%3D1121%26epage%3D1131%26doi%3D10.1016%2Fj.jhep.2011.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span> </span><span class="NLM_article-title">HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2646</span><span class="refDoi"> DOI: 10.1016/j.molimm.2009.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.molimm.2009.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19501403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Omu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=2640-2646&author=Y.+Xuauthor=Y.+Huauthor=B.+Shiauthor=X.+Zhangauthor=J.+Wangauthor=Z.+Zhangauthor=F.+Shenauthor=Q.+Zhangauthor=S.+Sunauthor=Z.+Yuan&title=HBsAg+inhibits+TLR9-mediated+activation+and+IFN-alpha+production+in+plasmacytoid+dendritic+cells&doi=10.1016%2Fj.molimm.2009.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">HBsAg inhibits TLR9-mediated activation and IFN-α production in plasmacytoid dendritic cells</span></div><div class="casAuthors">Xu, Yongfen; Hu, Yunwen; Shi, Bisheng; Zhang, Xiaonan; Wang, Jiefei; Zhang, Zhanqing; Shen, Fang; Zhang, Qin; Sun, Shuhui; Yuan, Zhenghong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2640-2646</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Plasmacytoid dendritic cells (pDCs), the professional producers of type I interferons (IFN-α/β), play a pivotal role in innate and adaptive immune responses against viral infections.  Although functional impairment of circulating pDCs in chronic hepatitis B (CHB) patients has been reported previously, the mechanism responsible for these defects remains unclear.  The authors hypothesize that HBsAg circulating in high amts. during HBV infection may interact with pDC and contribute to pDC dysfunction.  In support of this hypothesis the authors show that pDCs treated with HBsAg secreted much less IFN-α than control pDCs.  Furthermore, suppression is specific for TLR9, with no effects upon TLR7-mediated IFN-α secretion.  HBsAg inhibited TLR9-mediated IRF-7 expression and nuclear translocation, which are important for induction of IFN-α gene transcription.  HBsAg up-regulated the SOCS-1 expression and bound to BDCA-2 receptors on the plasma membrane of pDCs, resulting in the inhibition of the IFN-α prodn.  In conclusion, the above data suggested that HBsAg may directly interfere with the function of pDC through HBsAg-mediated upregulation of SOCS-1 expression and BDCA-2 ligation, which could partially explain how HBV evades the immune system to establish a persistent infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfplXW2jsQA7Vg90H21EOLACvtfcHk0lhSuP-izv6fIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Omu7s%253D&md5=67a6c0d6ccc02ce8f56e29edbf962bb5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2009.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2009.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DZ.%26atitle%3DHBsAg%2520inhibits%2520TLR9-mediated%2520activation%2520and%2520IFN-alpha%2520production%2520in%2520plasmacytoid%2520dendritic%2520cells%26jtitle%3DMol.%2520Immunol.%26date%3D2009%26volume%3D46%26spage%3D2640%26epage%3D2646%26doi%3D10.1016%2Fj.molimm.2009.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Dougherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simsek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span> </span><span class="NLM_article-title">A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4427</span><span class="NLM_x">–</span> <span class="NLM_lpage">4437</span><span class="refDoi"> DOI: 10.1128/AAC.00541-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00541-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=4427-4437&author=A.+M.+Doughertyauthor=H.+Guoauthor=G.+Westbyauthor=Y.+Liuauthor=E.+Simsekauthor=J.+T.+Guoauthor=A.+Mehtaauthor=P.+Nortonauthor=B.+Guauthor=T.+Blockauthor=A.+Cuconati&title=A+substituted+tetrahydro-tetrazolo-pyrimidine+is+a+specific+and+novel+inhibitor+of+hepatitis+B+virus+surface+antigen+secretion&doi=10.1128%2FAAC.00541-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FAAC.00541-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00541-07%26sid%3Dliteratum%253Aachs%26aulast%3DDougherty%26aufirst%3DA.%2BM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWestby%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSimsek%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DNorton%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DB.%26aulast%3DBlock%26aufirst%3DT.%26aulast%3DCuconati%26aufirst%3DA.%26atitle%3DA%2520substituted%2520tetrahydro-tetrazolo-pyrimidine%2520is%2520a%2520specific%2520and%2520novel%2520inhibitor%2520of%2520hepatitis%2520B%2520virus%2520surface%2520antigen%2520secretion%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D4427%26epage%3D4437%26doi%3D10.1128%2FAAC.00541-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clearfield, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrey, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motter, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5660</span><span class="NLM_x">–</span> <span class="NLM_lpage">5670</span><span class="refDoi"> DOI: 10.1021/jm200696v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200696v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5660-5670&author=W.+Yuauthor=G.+Goddardauthor=E.+Clearfieldauthor=C.+Millsauthor=T.+Xiaoauthor=H.+Guoauthor=J.+D.+Morreyauthor=N.+E.+Motterauthor=K.+Zhaoauthor=T.+M.+Blockauthor=A.+Cuconatiauthor=X.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+triazolo-pyrimidine+derivatives+as+novel+inhibitors+of+hepatitis+B+virus+surface+antigen+%28HBsAg%29+secretion&doi=10.1021%2Fjm200696v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm200696v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200696v%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGoddard%26aufirst%3DG.%26aulast%3DClearfield%26aufirst%3DE.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMorrey%26aufirst%3DJ.%2BD.%26aulast%3DMotter%26aufirst%3DN.%2BE.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520triazolo-pyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520surface%2520antigen%2520%2528HBsAg%2529%2520secretion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5660%26epage%3D5670%26doi%3D10.1021%2Fjm200696v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robek, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Toll-like receptor signaling inhibits hepatitis B virus replication in vivo</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">7269</span><span class="NLM_x">–</span> <span class="NLM_lpage">7272</span><span class="refDoi"> DOI: 10.1128/JVI.79.11.7269-7272.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.79.11.7269-7272.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15890966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=7269-7272&author=M.+Isogawaauthor=M.+D.+Robekauthor=Y.+Furuichiauthor=F.+V.+Chisari&title=Toll-like+receptor+signaling+inhibits+hepatitis+B+virus+replication+in+vivo&doi=10.1128%2FJVI.79.11.7269-7272.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor signaling inhibits hepatitis B virus replication in vivo</span></div><div class="casAuthors">Isogawa, Masanori; Robek, Michael D.; Furuichi, Yoshihiro; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7269-7272</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Toll-like receptors (TLR) play a key role in innate immunity.  To examine the ability of diverse TLRs to modulate hepatitis B virus (HBV) replication, HBV transgenic mice received a single i.v. injection of ligands specific for TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9.  All of the ligands except for TLR2 inhibited HBV replication in the liver noncytopathically within 24 h in a α/β interferon-dependent manner.  The ability of these TLR ligands to induce antiviral cytokines at the site of HBV replication suggests that TLR activation could represent a powerful and novel therapeutic strategy for the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogjxi1EvUpKrVg90H21EOLACvtfcHk0ljpkw3Z7YKs3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKgtr0%253D&md5=6761f9d0a746a06c3c4b67044e1721f6</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.11.7269-7272.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.11.7269-7272.2005%26sid%3Dliteratum%253Aachs%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DRobek%26aufirst%3DM.%2BD.%26aulast%3DFuruichi%26aufirst%3DY.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DToll-like%2520receptor%2520signaling%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D7269%26epage%3D7272%26doi%3D10.1128%2FJVI.79.11.7269-7272.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Vincent, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zannetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainaut, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemin, I.</span><span> </span><span class="NLM_article-title">Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26315</span><span class="refDoi"> DOI: 10.1371/journal.pone.0026315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.pone.0026315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26315&author=I.+E.+Vincentauthor=C.+Zannettiauthor=J.+Luciforaauthor=H.+Norderauthor=U.+Protzerauthor=P.+Hainautauthor=F.+Zoulimauthor=M.+Tommasinoauthor=C.+Trepoauthor=U.+Hasanauthor=I.+Chemin&title=Hepatitis+B+virus+impairs+TLR9+expression+and+function+in+plasmacytoid+dendritic+cells&doi=10.1371%2Fjournal.pone.0026315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0026315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0026315%26sid%3Dliteratum%253Aachs%26aulast%3DVincent%26aufirst%3DI.%2BE.%26aulast%3DZannetti%26aufirst%3DC.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DNorder%26aufirst%3DH.%26aulast%3DProtzer%26aufirst%3DU.%26aulast%3DHainaut%26aufirst%3DP.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DTommasino%26aufirst%3DM.%26aulast%3DTrepo%26aufirst%3DC.%26aulast%3DHasan%26aufirst%3DU.%26aulast%3DChemin%26aufirst%3DI.%26atitle%3DHepatitis%2520B%2520virus%2520impairs%2520TLR9%2520expression%2520and%2520function%2520in%2520plasmacytoid%2520dendritic%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26315%26doi%3D10.1371%2Fjournal.pone.0026315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Koumbi, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastassiadou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machaira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafetzis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papaevangelou, V.</span><span> </span><span class="NLM_article-title">Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers</span> <span class="citation_source-journal">Clin. Vaccine Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1085</span><span class="refDoi"> DOI: 10.1128/CVI.00074-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FCVI.00074-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=20463102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1079-1085&author=L.+J.+Koumbiauthor=N.+G.+Papadopoulosauthor=V.+Anastassiadouauthor=M.+Machairaauthor=D.+A.+Kafetzisauthor=V.+Papaevangelou&title=Dendritic+cells+in+uninfected+infants+born+to+hepatitis+B+virus-positive+mothers&doi=10.1128%2FCVI.00074-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers</span></div><div class="casAuthors">Koumbi, Lemonica J.; Papadopoulos, Nikolaos, G.; Anastassiadou, Vassiliki; Machaira, Maria; Kafetzis, Dimitris A.; Papaevangelou, Vassiliki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Vaccine Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1079-1085</span>CODEN:
                <span class="NLM_cas:coden">CVILA6</span>;
        ISSN:<span class="NLM_cas:issn">1556-679X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Plasmacytoid dendritic cells (pDCs) play a central role in antiviral immunity, detecting viruses via Toll-like receptors (TLR) and producing in response vast amts. of type I interferons (IFNs).  Hepatitis B virus (HBV) causes chronic infection after vertical transmission.  This study investigated whether an HBV-infected maternal environment might influence DC nos. and pDC function in uninfected infants.  Blood was collected from inactive HBsAg carrier and control mothers and their infants at birth and 1 and 6 mo of age.  HBV DNA was measured in maternal and neonatal perinatal sera using real-time PCR.  The circulating frequencies of myeloid DCs (mDCs) and pDCs were detd. in the babies by flow cytometry.  Peripheral blood mononuclear cells (PBMCs) and cord blood pDCs were stimulated with resiquimod, and alpha interferon (IFN-α) prodn. and the pDC phenotype were assessed.  The effect of the common-cold virus, rhinovirus (RV), on resiquimod stimulation was also detd. HBV DNA was detected in 62.3% of the mothers and 41% of their infants.  DC nos. and pDC functions were similar between subjects and controls and were not correlated with maternal or neonatal viremia.  RV infection did not induce pDC maturation until the age of 6 mo, and it reduced TLR7-dependent resiquimod-induced IFN- prodn. similarly in both groups. Although the DC system is immature at birth, DCs of uninfected neonates of HBV-pos. mothers are competent to initiate and maintain T-cell responses.  RV is a weak inducer of IFN-α prodn. until the age of 6 mo and inhibits IFN-α responses triggered by the TLR7 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1armtC5dqVLVg90H21EOLACvtfcHk0lgOMGuN5REiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGit74%253D&md5=9212ef305a5454b54ad9466e36c8277c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1128%2FCVI.00074-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCVI.00074-10%26sid%3Dliteratum%253Aachs%26aulast%3DKoumbi%26aufirst%3DL.%2BJ.%26aulast%3DPapadopoulos%26aufirst%3DN.%2BG.%26aulast%3DAnastassiadou%26aufirst%3DV.%26aulast%3DMachaira%26aufirst%3DM.%26aulast%3DKafetzis%26aufirst%3DD.%2BA.%26aulast%3DPapaevangelou%26aufirst%3DV.%26atitle%3DDendritic%2520cells%2520in%2520uninfected%2520infants%2520born%2520to%2520hepatitis%2520B%2520virus-positive%2520mothers%26jtitle%3DClin.%2520Vaccine%2520Immunol.%26date%3D2010%26volume%3D17%26spage%3D1079%26epage%3D1085%26doi%3D10.1128%2FCVI.00074-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Shim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, G.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 facilitates formation of the HBV capsid via interacting with the HBV core protein dimers</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">410</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1016/j.virol.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.virol.2010.11.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2011&pages=161-169&author=H.+Y.+Shimauthor=X.+Quanauthor=Y.+S.+Yiauthor=G.+Jung&title=Heat+shock+protein+90+facilitates+formation+of+the+HBV+capsid+via+interacting+with+the+HBV+core+protein+dimers&doi=10.1016%2Fj.virol.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DShim%26aufirst%3DH.%2BY.%26aulast%3DQuan%26aufirst%3DX.%26aulast%3DYi%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DG.%26atitle%3DHeat%2520shock%2520protein%252090%2520facilitates%2520formation%2520of%2520the%2520HBV%2520capsid%2520via%2520interacting%2520with%2520the%2520HBV%2520core%2520protein%2520dimers%26jtitle%3DVirology%26date%3D2011%26volume%3D410%26spage%3D161%26epage%3D169%26doi%3D10.1016%2Fj.virol.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span> </span><span class="NLM_article-title">STING agonists induce an innate antiviral immune response against hepatitis B virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span><span class="refDoi"> DOI: 10.1128/AAC.04321-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.04321-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1273-1281&author=F.+Guoauthor=Y.+Hanauthor=X.+Zhaoauthor=J.+Wangauthor=F.+Liuauthor=C.+Xuauthor=L.+Weiauthor=J.+D.+Jiangauthor=T.+M.+Blockauthor=J.+T.+Guoauthor=J.+Chang&title=STING+agonists+induce+an+innate+antiviral+immune+response+against+hepatitis+B+virus&doi=10.1128%2FAAC.04321-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1128%2FAAC.04321-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04321-14%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DChang%26aufirst%3DJ.%26atitle%3DSTING%2520agonists%2520induce%2520an%2520innate%2520antiviral%2520immune%2520response%2520against%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1273%26epage%3D1281%26doi%3D10.1128%2FAAC.04321-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Baumert, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrier, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span> </span><span class="NLM_article-title">Host-targeting agents for treatment of hepatitis B virus infection</span> <span class="citation_source-journal">Curr. Opin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.coviro.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.coviro.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26262886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=41-46&author=T.+F.+Baumertauthor=E.+R.+Verrierauthor=M.+Nassalauthor=R.+T.+Chungauthor=M.+B.+Zeisel&title=Host-targeting+agents+for+treatment+of+hepatitis+B+virus+infection&doi=10.1016%2Fj.coviro.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Host-targeting agents for treatment of hepatitis B virus infection</span></div><div class="casAuthors">Baumert, Thomas F.; Verrier, Eloi R.; Nassal, Michael; Chung, Raymond T.; Zeisel, Mirjam B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infection is a major cause of chronic liver disease, including liver cirrhosis, liver failure and hepatocellular carcinoma (HCC) - the second leading and fastest rising cause of cancer death world-wide.  While de novo infection can be efficiently prevented by vaccination and chronic infection can be controlled using antivirals targeting the viral polymerase, the development of efficient antiviral strategies to eliminate the virus and thus to cure infection remains a key unmet medical need.  The recent progress in the development of robust infectious HBV cell culture models now enables the investigation of the full viral life cycle, including a more detailed study of the mol. mechanisms of virus-host interactions responsible for viral persistence.  The understanding of these virus-host interactions will be instrumental for the development of curative treatments.  Host-dependency factors have recently emerged as promising candidates to treat and prevent infection by various pathogens.  This review focuses on the potential of host-targeting agents (HTAs) as novel antivirals to treat and cure HBV infection.  These include HTAs that inhibit de novo and re-infection, synthesis and spread of cc-cDNA as well as development of immune-based approaches eliminating or curing infected hepatocytes, including the eradication of viral cc-cDNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYl0SYCgrHVrVg90H21EOLACvtfcHk0lhtpd-HzMNl5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7fP&md5=ede8bc8ef59438814df31e158abad292</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DVerrier%26aufirst%3DE.%2BR.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26atitle%3DHost-targeting%2520agents%2520for%2520treatment%2520of%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2015%26volume%3D14%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fj.coviro.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.07.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=152-159&author=J.+Changauthor=J.+T.+Guo&title=Treatment+of+chronic+hepatitis+B+with+pattern+recognition+receptor+agonists%3A+current+status+and+potential+for+a+cure&doi=10.1016%2Fj.antiviral.2015.07.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520B%2520with%2520pattern%2520recognition%2520receptor%2520agonists%253A%2520current%2520status%2520and%2520potential%2520for%2520a%2520cure%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D152%26epage%3D159%26doi%3D10.1016%2Fj.antiviral.2015.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span> </span><span class="NLM_article-title">Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways</span> <span class="citation_source-journal">Cell. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">–</span> <span class="NLM_lpage">1637</span><span class="refDoi"> DOI: 10.1111/j.1462-5822.2009.01353.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1462-5822.2009.01353.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19573162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOisLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1624-1637&author=X.+Zhangauthor=Z.+Mengauthor=S.+Qiuauthor=Y.+Xuauthor=D.+Yangauthor=J.+F.+Schlaakauthor=M.+Roggendorfauthor=M.+Lu&title=Lipopolysaccharide-induced+innate+immune+responses+in+primary+hepatocytes+downregulates+woodchuck+hepatitis+virus+replication+via+interferon-independent+pathways&doi=10.1111%2Fj.1462-5822.2009.01353.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways</span></div><div class="casAuthors">Zhang, Xiaoyong; Meng, Zhongji; Qiu, Song; Xu, Yang; Yang, Dongliang; Schlaak, Joerg F.; Roggendorf, Michael; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1624-1637</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Our previous studies have shown that Toll-like receptor (TLR) ligands, Poly I:C and lipopolysaccharide (LPS), are able to activate non-parenchymal liver cells and trigger the prodn. of interferon (IFN) to inhibit hepatitis B virus replication in vivo and in vitro.  However, little is known about TLR-mediated cellular responses in primary hepatocytes.  By the model of woodchuck hepatitis virus (WHV) infected primary woodchuck hepatocytes (PWHs), Poly I:C and LPS stimulation resulted in upregulation of cellular antiviral genes and relevant TLRs mRNA expression resp.  LPS stimulation led to a pronounced redn. of WHV replicative intermediates without a significant IFN induction.  Poly I:C transfection resulted in the prodn. of IFN and a highly increased expression of antiviral genes in PWHs and slight inhibitory effect on WHV replication.  LPS could activate nuclear factor kappa B, MAPK and PI-3k/Akt pathways in PWHs.  Further, inhibitors of MAPK-ERK and PI-3k/Akt pathways, but not that of IFN signalling pathway, were able to block the antiviral effect of LPS.  These results indicate that IFN-independent pathways which activated by LPS are able to downregulate hepadnaviral replication in hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokYTWEzEEIvLVg90H21EOLACvtfcHk0lhtpd-HzMNl5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOisLzJ&md5=01f5d14af0dbabbc998a7b8bfbf6eee9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2009.01353.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2009.01353.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DLipopolysaccharide-induced%2520innate%2520immune%2520responses%2520in%2520primary%2520hepatocytes%2520downregulates%2520woodchuck%2520hepatitis%2520virus%2520replication%2520via%2520interferon-independent%2520pathways%26jtitle%3DCell.%2520Microbiol.%26date%3D2009%26volume%3D11%26spage%3D1624%26epage%3D1637%26doi%3D10.1111%2Fj.1462-5822.2009.01353.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span> </span><span class="NLM_article-title">Role of toll-like receptor 2 in the immune response against hepadnaviral infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">522</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2012.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=22617154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=522-528&author=X.+Zhangauthor=Z.+Maauthor=H.+Liuauthor=J.+Liuauthor=Z.+Mengauthor=R.+Broeringauthor=D.+Yangauthor=J.+F.+Schlaakauthor=M.+Roggendorfauthor=M.+Lu&title=Role+of+toll-like+receptor+2+in+the+immune+response+against+hepadnaviral+infection&doi=10.1016%2Fj.jhep.2012.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Toll-like receptor 2 in the immune response against hepadnaviral infection</span></div><div class="casAuthors">Zhang, Xiaoyong; Ma, Zhiyong; Liu, Hongyan; Liu, Jia; Meng, Zhongji; Broering, Ruth; Yang, Dongliang; Schlaak, Joerg F.; Roggendorf, Michael; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">522-528</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: The Toll-like receptor 2 (TLR2) has recently been recognized to play an important role in the pathogenesis of chronic hepatitis B virus (HBV) infection.  In the present study, we examd. the role of TLR2 in hepadnaviral infection in hepatoma cell lines and the woodchuck model.  Methods: The expression of TLR2 and pro-inflammatory cytokines was quantified by real time RT-PCR.  TLR2-assocd. signaling pathways in hepatocytes were examd. by Western blot.  HBV replication and gene expression were assessed by Southern blot, Northern blot and specific ELISA, resp.  Results: TLR2 ligands activated NF-κB, PI3K/Akt, and different arms of MAPK signaling pathways and induced the prodn. of pro-inflammatory cytokines in hepatocytes.  TLR2-mediated innate immune responses led to redn. of HBV/woodchuck hepatitis virus (WHV) replication and gene expression in HepG2.2.15 cells and primary woodchuck hepatocytes.  Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, resp.  In the woodchuck model, relatively low levels of TLR2 expression were found in peripheral blood mononuclear cells (PBMCs) and in liver tissues from chronic WHV carriers.  TLR2 expression in PBMCs was inversely correlated with WHV DNA titers in acute WHV infection and in entecavir-treated chronic WHV carriers.  Conclusions: These data suggest that hepatocytes play an active role in TLR2-mediated antiviral responses during hepadnaviral infection.  The mutual inhibition of HBV replication and TLR2 signaling represents an important aspect of HBV infection and should be considered in the new therapeutic concept against chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4u9PCys4aa7Vg90H21EOLACvtfcHk0lijIjyqdvegYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrzK&md5=49f9185fce2a355f8dfa2bcaa0a52542</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DBroering%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DRole%2520of%2520toll-like%2520receptor%25202%2520in%2520the%2520immune%2520response%2520against%2520hepadnaviral%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D522%26epage%3D528%26doi%3D10.1016%2Fj.jhep.2012.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span> </span><span class="NLM_article-title">Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">10421</span><span class="NLM_x">–</span> <span class="NLM_lpage">10431</span><span class="refDoi"> DOI: 10.1128/JVI.00996-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.00996-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24920792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yktrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=10421-10431&author=J.+Wuauthor=S.+Huangauthor=X.+Zhaoauthor=M.+Chenauthor=Y.+Linauthor=Y.+Xiaauthor=C.+Sunauthor=X.+Yangauthor=J.+Wangauthor=Y.+Guoauthor=J.+Songauthor=E.+Zhangauthor=B.+Wangauthor=X.+Zhengauthor=J.+F.+Schlaakauthor=M.+Luauthor=D.+Yang&title=Poly%28I%3AC%29+treatment+leads+to+interferon-dependent+clearance+of+hepatitis+B+virus+in+a+hydrodynamic+injection+mouse+model&doi=10.1128%2FJVI.00996-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model</span></div><div class="casAuthors">Wu, Jun; Huang, Shunmei; Zhao, Xiaoli; Chen, Mingfa; Lin, Yong; Xia, Youchen; Sun, Chan; Yang, Xuecheng; Wang, Junzhong; Guo, Yan; Song, Jingjiao; Zhang, Ejuan; Wang, Baoju; Zheng, Xin; Schlaak, Joerg F.; Lu, Mengji; Yang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10421-10431, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We have previously shown that poly(I:C) activates murine hepatic cells to produce interferon (IFN) and suppresses hepatitis B virus (HBV) replication in vitro.  Therefore, we addressed whether poly(I:C) is able to induce the clearance of HBV in vivo.  The chronic HBV replication mouse model was established by the hydrodynamic injection (HI) of pAAV-HBV1.2 into the tail veins of wild-type and IFN-α/βR-, IFN-γ-, and CXCR3-deficient C57BL/6 mice.  Fourteen days post-HI of pAAV-HBV1.2, mice were administered poly(I:C) by i.p. injection, i.m. injection, or HI.  Only treatment of poly(I:C) by HI led to HBV clearance in wild-type C57BL/6 mice.  Serum HBsAg disappeared within 40 days postinfection (dpi) in mice that received poly(I:C) by HI, and this was accompanied by the appearance of anti-HBs antibodies.  HBV-specific T-cell and antibody responses were significantly enhanced by HI of poly(I:C).  HBV replication intermediates and HBcAg-pos. hepatocytes were eliminated in the liver.  HI of poly(I:C) induced the prodn. of IFNs in mice and enhanced the levels of cytokines, IFN-stimulated genes, and T-cell markers in the liver.  Importantly, poly(I:C)-induced HBV clearance was impaired in IFN-α/βR-, IFN-γ-, and CXCR3-deficient mice, indicating that the induction of type I IFN and the stimulation and recruitment of T cells into the liver are essential for HBV clearance in this model.  Taken together, the application of poly(I:C) by HI into the liver enhances innate and adaptive immune responses and leads to HBV clearance in an HBV mouse model, implicating the potential of intrahepatic Toll-like receptor 3 (TLR3) activation for the treatment of chronic hepatitis B patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3OMxRsoQOLVg90H21EOLACvtfcHk0lijIjyqdvegYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yktrjF&md5=7d063d4c2b61ff3d8da276df3edf431a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1128%2FJVI.00996-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00996-14%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DD.%26atitle%3DPoly%2528I%253AC%2529%2520treatment%2520leads%2520to%2520interferon-dependent%2520clearance%2520of%2520hepatitis%2520B%2520virus%2520in%2520a%2520hydrodynamic%2520injection%2520mouse%2520model%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D10421%26epage%3D10431%26doi%3D10.1128%2FJVI.00996-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span> </span><span class="NLM_article-title">Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication</span> <span class="citation_source-journal">Zhonghua Ganzangbing Zazhi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">838</span><span class="NLM_x">–</span> <span class="NLM_lpage">842</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12isbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=838-842&author=J.+Wuauthor=M.+F.+Chenauthor=Y.+C.+Xiaauthor=Y.+Guoauthor=Y.+Linauthor=C.+Sunauthor=C.+Y.+Zhangauthor=Y.+Chenauthor=S.+P.+Liuauthor=Y.+H.+Haoauthor=M.+J.+Luauthor=J.+F.+Schlaakauthor=D.+L.+Yang&title=Toll-like+receptor+dependent+innate+immune+responses+by+primary+mouse+hepatocytes+and+its+control+of+HBV+replication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication</span></div><div class="casAuthors">Wu, Jun; Chen, Mingfa; Xia, Youchen; Guo, Yan; Lin, Yong; Sun, Chan; Zhang, Chunyan; Chen, Yan; Liu, Shenpei; Hao, Youhua; Lu, Mengji; Schlaak, Jorg F.; Yang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua Ganzangbing Zazhi</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">838-842</span>CODEN:
                <span class="NLM_cas:coden">ZGZZFE</span>;
        ISSN:<span class="NLM_cas:issn">1007-3418</span>.
    
            (<span class="NLM_cas:orgname">Chongqing Yike Daxue, Dier Linchuang Xueyuan</span>)
        </div><div class="casAbstract">This report aimed to investigate the Toll-like receptor (TLR) signaling pathways and induced antiviral activity in hepatocytes.  We isolated primary hepatocytes from wild-type C57BL/6 mice and examd. the expression of TLR by real-time RT-PCR.  Hepatocytes were stimulated with TLR 1-9 agonists and the supernatants were harvested.  The secretion of cytokines was tested by ELISA.  The antiviral effectors in supernatants were assayed via virus protection assay (in EMCV system) and the control of HBV replication was assessed via Southern blotting (in HBV system).  We demonstrated that hepatocytes expressed TLR1-9.  In accordance with these TLR expression profiles, hepatocytes responded to all TLR ligands by producing inflammatory cytokines (TNF-α or IL-6), to TLR-1, -3, -7 and -9 ligands by producing type I IFN (IFN-α or IFN-β).  Only TLR 3 and TLR 7 agonists could stimulate the prodn. of high amts. of antiviral mediators by hepatocytes in virus protection assay.  By contrast, supernatants from TLR1, -3 and -4 directly stimulated hepatocytes and TLR 3, -7 and -9 transfected hepatocytes were able to potently suppress HBV replication.  Primary hepatocytes display a unique TLR signaling pathway and can control HBV replication after stimulation by TLR agonists in mice.  It may be helpful for the development of TLR-based therapeutic approaches against hepatotropism virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHkJmZGBAInrVg90H21EOLACvtfcHk0lijIjyqdvegYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12isbfM&md5=97a4d000c28f301fd33cc12b9ebb1a87</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DM.%2BF.%26aulast%3DXia%26aufirst%3DY.%2BC.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%2BP.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DToll-like%2520receptor%2520dependent%2520innate%2520immune%2520responses%2520by%2520primary%2520mouse%2520hepatocytes%2520and%2520its%2520control%2520of%2520HBV%2520replication%26jtitle%3DZhonghua%2520Ganzangbing%2520Zazhi%26date%3D2011%26volume%3D19%26spage%3D838%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groothuismink, Z. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruijne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotho, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Vliet, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Wetering de Rooij, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de-Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span> </span><span class="NLM_article-title">Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via toll-like receptor 7</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.3851/IMP2023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=657-667&author=A.+Boonstraauthor=B.+S.+Liuauthor=Z.+M.+A.+Groothuisminkauthor=J.+F.+Bergmannauthor=J.+de+Bruijneauthor=D.+M.+Hothoauthor=B.+E.+Hansenauthor=A.+A.+van+Vlietauthor=J.+V.+van+de+Wetering+de+Rooijauthor=S.+P.+Fletcherauthor=L.+A.+Baumanauthor=M.+Rahimyauthor=J.+R.+Applemanauthor=J.+L.+Freddoauthor=H.+W.+Reesinkauthor=R.+J.+de-Knegtauthor=H.+L.+A.+Janssen&title=Potent+immune+activation+in+chronic+hepatitis+C+patients+upon+administration+of+an+oral+inducer+of+endogenous+interferons+that+acts+via+toll-like+receptor+7&doi=10.3851%2FIMP2023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3851%2FIMP2023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2023%26sid%3Dliteratum%253Aachs%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DB.%2BS.%26aulast%3DGroothuismink%26aufirst%3DZ.%2BM.%2BA.%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DHotho%26aufirst%3DD.%2BM.%26aulast%3DHansen%26aufirst%3DB.%2BE.%26aulast%3Dvan%2BVliet%26aufirst%3DA.%2BA.%26aulast%3Dvan%2Bde%2BWetering%2Bde%2BRooij%26aufirst%3DJ.%2BV.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DBauman%26aufirst%3DL.%2BA.%26aulast%3DRahimy%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3Dde-Knegt%26aufirst%3DR.%2BJ.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26atitle%3DPotent%2520immune%2520activation%2520in%2520chronic%2520hepatitis%2520C%2520patients%2520upon%2520administration%2520of%2520an%2520oral%2520inducer%2520of%2520endogenous%2520interferons%2520that%2520acts%2520via%2520toll-like%2520receptor%25207%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D657%26epage%3D667%26doi%3D10.3851%2FIMP2023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Bergmann, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bruijne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotho, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van-Vliet, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van-de-Wetering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, H. L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H. W.</span><span> </span><span class="NLM_article-title">Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2011.04745.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1365-2036.2011.04745.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21707679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=443-453&author=J.+F.+Bergmannauthor=J.+de+Bruijneauthor=D.+M.+Hothoauthor=R.+J.+de+Knegtauthor=A.+Boonstraauthor=C.+J.+Weeginkauthor=A.+A.+van-Vlietauthor=J.+van-de-Weteringauthor=S.+P.+Fletcherauthor=L.+A.+Baumanauthor=M.+Rahimyauthor=J.+R.+Applemanauthor=J.+L.+Freddoauthor=H.+L.+A.+Janssenauthor=H.+W.+Reesink&title=Randomised+clinical+trial%3A+anti-viral+activity+of+ANA773%2C+an+oral+inducer+of+endogenous+interferons+acting+via+TLR7%2C+in+chronic+HCV&doi=10.1111%2Fj.1365-2036.2011.04745.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV</span></div><div class="casAuthors">Bergmann, J. F.; de Bruijne, J.; Hotho, D. M.; de Knegt, R. J.; Boonstra, A.; Weegink, C. J.; van Vliet, A. A.; van de Wetering, J.; Fletcher, S. P.; Bauman, L. A.; Rahimy, M.; Appleman, J. R.; Freddo, J. L.; Janssen, H. L. A.; Reesink, H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-453</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The ANA773 is an oral prodrug of a small-mol. toll-like receptor (TLR)7 agonist.  Preclin. and healthy volunteer clin. studies with ANA773 have demonstrated induction of endogenous interferon-α (IFN-α) of multiple subtypes, which supports the potential utility in the treatment of chronic hepatitis C virus (HCV) infection.  Aim: To examine safety, tolerability, pharmacodynamics, pharmacokinetics and anti-viral activity of ANA773.  Methods: The ANA773 was investigated in a double-blind, placebo-controlled study in 34 patients chronically infected with HCV of any genotype.  Patients were treatment-naive or had relapsed following previous interferon-based treatment.  This dose escalation study was composed of four dose groups (800, 1200, 1600 and 2000 mg).  In each group, six to eight patients received ANA773 and two received placebo.  Patients were dosed with ANA773 every-other-day for either 28 days (800, 1200 or 1600 mg) or 10 days (2000 mg).  Results: Mild to moderate adverse events were reported, with an increase in frequency and intensity with increasing dose.  No serious AEs were reported and there were no early discontinuations.  There were dose-related increases in various markers of IFN-α response.  The mean max. change in serum HCV RNA level from baseline was -0.34, -0.29, -0.40, -0.97 and -1.26 log10 in the placebo, 800, 1200, 1600 and 2000 mg cohorts, resp.  At the 2000 mg dose, ANA773 significantly (P = 0.037) reduced serum HCV RNA levels (range: 0.14 to -3.10 log10).  Conclusion: The ANA773 was generally well tolerated and resulted in a dose-related IFN-dependent response leading to a significant decrease in serum HCV RNA levels in the 2000 mg dose group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsKL6ETdoGvbVg90H21EOLACvtfcHk0lhVRn8iCPXbxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjtLfI&md5=62c9aba2d263f87170d4b45673fad597</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2011.04745.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2011.04745.x%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DHotho%26aufirst%3DD.%2BM.%26aulast%3Dde%2BKnegt%26aufirst%3DR.%2BJ.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DWeegink%26aufirst%3DC.%2BJ.%26aulast%3Dvan-Vliet%26aufirst%3DA.%2BA.%26aulast%3Dvan-de-Wetering%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DBauman%26aufirst%3DL.%2BA.%26aulast%3DRahimy%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26atitle%3DRandomised%2520clinical%2520trial%253A%2520anti-viral%2520activity%2520of%2520ANA773%252C%2520an%2520oral%2520inducer%2520of%2520endogenous%2520interferons%2520acting%2520via%2520TLR7%252C%2520in%2520chronic%2520HCV%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D34%26spage%3D443%26epage%3D453%26doi%3D10.1111%2Fj.1365-2036.2011.04745.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Kurimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sajiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5501</span><span class="NLM_x">–</span> <span class="NLM_lpage">5508</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.09.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2003.09.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5501-5508&author=A.+Kurimotoauthor=T.+Oginoauthor=S.+Ichiiauthor=Y.+Isobeauthor=M.+Tobeauthor=H.+Ogitaauthor=H.+Takakuauthor=H.+Sajikiauthor=K.+Hirotaauthor=H.+Kawakami&title=Synthesis+and+structure-activity+relationships+of+2-amino-8-hydroxyadenines+as+orally+active+interferon+inducing+agents&doi=10.1016%2Fj.bmc.2003.09.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.09.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.09.032%26sid%3Dliteratum%253Aachs%26aulast%3DKurimoto%26aufirst%3DA.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DIchii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DOgita%26aufirst%3DH.%26aulast%3DTakaku%26aufirst%3DH.%26aulast%3DSajiki%26aufirst%3DH.%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25202-amino-8-hydroxyadenines%2520as%2520orally%2520active%2520interferon%2520inducing%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5501%26epage%3D5508%26doi%3D10.1016%2Fj.bmc.2003.09.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Kurimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichii, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sajiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, H.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/j.bmc.2003.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmc.2003.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=14980621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFWht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1091-1099&author=A.+Kurimotoauthor=T.+Oginoauthor=S.+Ichiiauthor=Y.+Isobeauthor=M.+Tobeauthor=H.+Ogitaauthor=H.+Takakuauthor=H.+Sajikiauthor=K.+Hirotaauthor=H.+Kawakami&title=Synthesis+and+evaluation+of+2-substituted+8-hydroxyadenines+as+potent+interferon+inducers+with+improved+oral+bioavailabilities&doi=10.1016%2Fj.bmc.2003.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities</span></div><div class="casAuthors">Kurimoto, Ayumu; Ogino, Tetsuhiro; Ichii, Shinji; Isobe, Yoshiaki; Tobe, Masanori; Ogita, Haruhisa; Takaku, Haruo; Sajiki, Hironao; Hirota, Kosaku; Kawakami, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1091-1099</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In order to create novel compds. which possess potent interferon (IFN) inducing activities with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various alkoxy or alkylthio moieties at the adenine C(2)-position, were synthesized and evaluated.  The introduction of hydrophobic groups was not considered to be effective for potentiating the IFN-inducing activity, but several compds. having hydrophilic groups were effective.  Among the compds. tested, compd. I induced IFN from the dosage of 0.03 mg/kg, which was approx. 100-fold more potent than that of Imiquimod, and showed an excellent oral bioavailability (F=40%) which was 10-fold improved over the lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqY8-Ou6UMlbVg90H21EOLACvtfcHk0lhVRn8iCPXbxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFWht7g%253D&md5=7786077b1ccac729aaaa96ec4254c1cf</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DKurimoto%26aufirst%3DA.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DIchii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26aulast%3DTobe%26aufirst%3DM.%26aulast%3DOgita%26aufirst%3DH.%26aulast%3DTakaku%26aufirst%3DH.%26aulast%3DSajiki%26aufirst%3DH.%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25202-substituted%25208-hydroxyadenines%2520as%2520potent%2520interferon%2520inducers%2520with%2520improved%2520oral%2520bioavailabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D1091%26epage%3D1099%26doi%3D10.1016%2Fj.bmc.2003.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Roethle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadden, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrvatin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graupe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duatschek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span> </span><span class="NLM_article-title">Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7324</span><span class="NLM_x">–</span> <span class="NLM_lpage">7333</span><span class="refDoi"> DOI: 10.1021/jm400815m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400815m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7324-7333&author=P.+A.+Roethleauthor=R.+M.+McFaddenauthor=H.+Yangauthor=P.+Hrvatinauthor=H.+Huiauthor=M.+Graupeauthor=B.+Gallagherauthor=J.+Chaoauthor=J.+Hesselgesserauthor=P.+Duatschekauthor=J.+Zhengauthor=B.+Luauthor=D.+B.+Tumasauthor=J.+Perryauthor=R.+L.+Halcomb&title=Identification+and+optimization+of+pteridinone+toll-like+receptor+7+%28TLR7%29+agonists+for+the+oral+treatment+of+viral+hepatitis&doi=10.1021%2Fjm400815m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span></div><div class="casAuthors">Roethle, Paul A.; McFadden, Ryan M.; Yang, Hong; Hrvatin, Paul; Hui, Hon; Graupe, Michael; Gallagher, Brian; Chao, Jessica; Hesselgesser, Joseph; Duatschek, Paul; Zheng, Jim; Lu, Bing; Tumas, Daniel B.; Perry, Jason; Halcomb, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7324-7333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620 (I).  Analogs were optimized for the immunomodulatory activity and selectivity vs. other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α).  In addn., physicochem. properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties.  GS-9620 is currently in clin. evaluation for the treatment of chronic hepatitis B (HBV) infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2wrWq68pK7Vg90H21EOLACvtfcHk0lhq4BwHjFmOaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL&md5=753aa20b0d0f9b16eb3a1d205fbe0a30</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm400815m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400815m%26sid%3Dliteratum%253Aachs%26aulast%3DRoethle%26aufirst%3DP.%2BA.%26aulast%3DMcFadden%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHrvatin%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DGraupe%26aufirst%3DM.%26aulast%3DGallagher%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DDuatschek%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520pteridinone%2520toll-like%2520receptor%25207%2520%2528TLR7%2529%2520agonists%2520for%2520the%2520oral%2520treatment%2520of%2520viral%2520hepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7324%26epage%3D7333%26doi%3D10.1021%2Fjm400815m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Jurk, M. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="refDoi"> DOI: 10.1038/ni0602-499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fni0602-499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=12032557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=499&author=M.+H.+F.+Jurkauthor=F.+Heilauthor=J.+Vollmerauthor=C.+Schetterauthor=A.+M.+Kriegauthor=H.+Wagnerauthor=G.+Lipfordauthor=S.+Bauer&title=Human+TLR7+or+TLR8+independently+confer+responsiveness+to+the+antiviral+compound+R-848&doi=10.1038%2Fni0602-499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848</span></div><div class="casAuthors">Jurk, Marion; Heil, Florian; Vollmer, Joerg; Schetter, Christian; Krieg, Arthur M.; Wagner, Hermann; Lipford, Grayson; Bauer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">In their quest to identify ligands for TLRs, the authors found that the antiviral immunostimulant drug imidazoquinoline resiquimod R-848 induced NF-κB activation in HEK293 cells transfected with human TLR8 in a dose-dependent manner.  The results of the study showed that both human TLR7 and TLR* can independently mediate recognition of the same antiviral compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonRoNyuBI4w7Vg90H21EOLACvtfcHk0lhq4BwHjFmOaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFOmsLo%253D&md5=f8d7a53ffd849013dba07c33807ccc8f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fni0602-499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni0602-499%26sid%3Dliteratum%253Aachs%26aulast%3DJurk%26aufirst%3DM.%2BH.%2BF.%26aulast%3DHeil%26aufirst%3DF.%26aulast%3DVollmer%26aufirst%3DJ.%26aulast%3DSchetter%26aufirst%3DC.%26aulast%3DKrieg%26aufirst%3DA.%2BM.%26aulast%3DWagner%26aufirst%3DH.%26aulast%3DLipford%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DHuman%2520TLR7%2520or%2520TLR8%2520independently%2520confer%2520responsiveness%2520to%2520the%2520antiviral%2520compound%2520R-848%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D499%26doi%3D10.1038%2Fni0602-499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Lanford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavedoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodara, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasky, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosdick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfgang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span> </span><span class="NLM_article-title">GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">1508</span><span class="NLM_x">–</span> <span class="NLM_lpage">1517</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2013.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2013&pages=1508-1517&author=R.+E.+Lanfordauthor=B.+Guerraauthor=D.+Chavezauthor=L.+Giavedoniauthor=V.+L.+Hodaraauthor=K.+M.+Braskyauthor=A.+Fosdickauthor=C.+R.+Freyauthor=J.+Zhengauthor=G.+Wolfgangauthor=R.+L.+Halcombauthor=D.+B.+Tumas&title=GS-9620%2C+an+oral+agonist+of+Toll-like+receptor-7%2C+induces+prolonged+suppression+of+hepatitis+B+virus+in+chronically+infected+chimpanzees&doi=10.1053%2Fj.gastro.2013.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLanford%26aufirst%3DR.%2BE.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DGiavedoni%26aufirst%3DL.%26aulast%3DHodara%26aufirst%3DV.%2BL.%26aulast%3DBrasky%26aufirst%3DK.%2BM.%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DWolfgang%26aufirst%3DG.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DGS-9620%252C%2520an%2520oral%2520agonist%2520of%2520Toll-like%2520receptor-7%252C%2520induces%2520prolonged%2520suppression%2520of%2520hepatitis%2520B%2520virus%2520in%2520chronically%2520infected%2520chimpanzees%26jtitle%3DGastroenterology%26date%3D2013%26volume%3D144%26spage%3D1508%26epage%3D1517%26doi%3D10.1053%2Fj.gastro.2013.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Fosdick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfgang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumas, D. B.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1124/jpet.113.207878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1124%2Fjpet.113.207878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24133297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=96-105&author=A.+Fosdickauthor=J.+Zhengauthor=S.+Pflanzauthor=C.+R.+Freyauthor=J.+Hesselgesserauthor=R.+L.+Halcombauthor=G.+Wolfgangauthor=D.+B.+Tumas&title=Pharmacokinetic+and+pharmacodynamic+properties+of+GS-9620%2C+a+novel+toll-like+receptor+7+agonist%2C+demonstrate+interferon-stimulated+gene+induction+without+detectable+serum+interferon+at+low+oral+doses&doi=10.1124%2Fjpet.113.207878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses</span></div><div class="casAuthors">Fosdick, Abigail; Zheng, Jim; Pflanz, Stefan; Frey, Christian R.; Hesselgesser, Joseph; Halcomb, Randall L.; Wolfgang, Grushenka; Tumas, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-mol. agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects assocd. with current systemic interferon-a (IFN-α) therapies.  We characterized the pharmacodynamic response of GS-9620 in CD-1 mice and cynomolgus monkeys following i.v. or oral administration and showed that GS-9620 induces the prodn. of select chemokines and cytokines, including IFN-α and interferon-stimulated genes (ISGs).  It is noteworthy that we also demonstrated that, in animals and healthy human volunteers, oral administration of GS-9620 can induce a type I interferon-dependent antiviral innate immune response, as measured by whole-blood mRNA of the ISGs 2'5'-oligoadenylate synthetase 1 (OAS1) and myxovirus resistance 1 (MX1), without the induction of detectable systemic IFN-α, i.e., a presystemic response.  Addnl., presystemic induction of hepatic OAS1 and MX1 mRNA was obsd. in CD-1 mice in the absence of detectable systemic IFN-α.  We propose that the mechanism of this presystemic response is likely its high intestinal absorption, which facilitates localized activation of TLR7, probably in plasmacytoid dendritic cells at the level of gut-assocd. lymphoid tissue and/or the liver.  This localized response is further supported by data that indicate only minimal contributions of systemic immune stimulation to the overall pharmacodynamic response to orally administered GS-9620.  These data demonstrate that GS-9620 can induce an antiviral innate immune response without inducing a systemic IFN-α response and thus suggest the therapeutic potential of this approach in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGLt0m-dYGx7Vg90H21EOLACvtfcHk0lii6zb8l4dVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKjurw%253D&md5=002591f8338f6bfacaaa13be4297cf87</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207878%26sid%3Dliteratum%253Aachs%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26aulast%3DWolfgang%26aufirst%3DG.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520properties%2520of%2520GS-9620%252C%2520a%2520novel%2520toll-like%2520receptor%25207%2520agonist%252C%2520demonstrate%2520interferon-stimulated%2520gene%2520induction%2520without%2520detectable%2520serum%2520interferon%2520at%2520low%2520oral%2520doses%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fjpet.113.207878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visvanathan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorak, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. J.</span><span> </span><span class="NLM_article-title">The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.jhep.2015.02.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25733157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=320-328&author=E.+J.+Ganeauthor=Y.-S.+Limauthor=S.+C.+Gordonauthor=K.+Visvanathanauthor=E.+Sicardauthor=R.+N.+Fedorakauthor=S.+Robertsauthor=B.+Massettoauthor=Z.+Yeauthor=S.+Pflanzauthor=K.+L.+Garrisonauthor=A.+Gaggarauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=S.+Kottililauthor=B.+Freilichauthor=C.+S.+Coffinauthor=W.+Chengauthor=Y.+J.+Kim&title=The+oral+toll-like+receptor-7+agonist+GS-9620+in+patients+with+chronic+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2015.02.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection</span></div><div class="casAuthors">Gane, Edward J.; Lim, Young-Suk; Gordon, Stuart C.; Visvanathan, Kumar; Sicard, Eric; Fedorak, Richard N.; Roberts, Stuart; Massetto, Benedetta; Ye, Zhishen; Pflanz, Stefan; Garrison, Kimberly L.; Gaggar, Anuj; Mani Subramanian, G.; McHutchison, John G.; Kottilil, Shyamasundaran; Freilich, Bradley; Coffin, Carla S.; Cheng, Wendy; Kim, Yoon Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-328</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GS-9620 is an oral agonist of toll-like receptor 7, a pattern-recognition receptor whose activation results in innate and adaptive immune stimulation.  We evaluated the safety, pharmacokinetics, and pharmacodynamics of GS-9620 in patients with chronic hepatitis B.  In two double-blind, phase 1b trials of identical design, 49 treatment-naive and 51 virol. suppressed patients were randomized 5:1 to receive GS-9620 (at doses of 0.3 mg, 1 mg, 2 mg, 4 mg) or placebo as a single dose or as two doses seven days apart.  Pharmacodynamic assessment included evaluation of peripheral mRNA expression of interferon-stimulated gene 15 (ISG15), serum interferon gamma-induced protein 10 and serum interferon (IFN)-alpha.  Overall, 74% of patients were male and 75% were HBeAg neg. at baseline.  No subject discontinued treatment due to adverse events.  Fifty-eight percent experienced ≥1 adverse event, all of which were mild to moderate in severity.  The most common adverse event was headache.  No clin. significant changes in HBsAg or HBV DNA levels were obsd.  Overall, a transient dose-dependent induction of peripheral ISG15 gene expression was obsd. peaking within 48 h of dosing followed by return to baseline levels within seven days.  Higher GS-9620 dose, HBeAg pos. status, and low HBsAg level at baseline were independently assocd. with greater probability of ISG15 response.  Most patients (88%) did not show detectable levels of serum IFN-alpha at any time point.  Oral GS-9620 was safe, well tolerated, and assocd. with induction of peripheral ISG15 prodn. in the absence of significant systemic IFN-alpha levels or related symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdIo77Po2by7Vg90H21EOLACvtfcHk0lii6zb8l4dVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslCnurc%253D&md5=51aa5f91d1002dc228abf96a93602791</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DLim%26aufirst%3DY.-S.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DVisvanathan%26aufirst%3DK.%26aulast%3DSicard%26aufirst%3DE.%26aulast%3DFedorak%26aufirst%3DR.%2BN.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DGarrison%26aufirst%3DK.%2BL.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DCoffin%26aufirst%3DC.%2BS.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26atitle%3DThe%2520oral%2520toll-like%2520receptor-7%2520agonist%2520GS-9620%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D320%26epage%3D328%26doi%3D10.1016%2Fj.jhep.2015.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruener, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflanz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massetto, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">708</span><span class="refDoi"> DOI: 10.3851/IMP2845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3851%2FIMP2845" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=699-708&author=E.+Lawitzauthor=D.+Gruenerauthor=T.+Marburyauthor=J.+Hillauthor=L.+Websterauthor=D.+Hassmanauthor=A.+H.+Nguyenauthor=S.+Pflanzauthor=E.+Mogalianauthor=A.+Gaggarauthor=B.+Massettoauthor=G.+M.+Subramanianauthor=J.+G.+McHutchisonauthor=I.+M.+Jacobsonauthor=B.+Freilichauthor=M.+Rodriguez-Torres&title=Safety%2C+pharmacokinetics+and+pharmacodynamics+of+the+oral+toll-like+receptor+7+agonist+GS-9620+in+treatment-naive+patients+with+chronic+hepatitis+C&doi=10.3851%2FIMP2845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3851%2FIMP2845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2845%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGruener%26aufirst%3DD.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DA.%2BH.%26aulast%3DPflanz%26aufirst%3DS.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DMassetto%26aufirst%3DB.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520the%2520oral%2520toll-like%2520receptor%25207%2520agonist%2520GS-9620%2520in%2520treatment-naive%2520patients%2520with%2520chronic%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Ther.%26date%3D2015%26volume%3D20%26spage%3D699%26epage%3D708%26doi%3D10.3851%2FIMP2845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Kawai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akira, S.</span><span> </span><span class="NLM_article-title">Antiviral signaling through pattern recognition receptors</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span><span class="refDoi"> DOI: 10.1093/jb/mvm032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Fjb%2Fmvm032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17190786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltF2it7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2007&pages=137-145&author=T.+Kawaiauthor=S.+Akira&title=Antiviral+signaling+through+pattern+recognition+receptors&doi=10.1093%2Fjb%2Fmvm032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral signaling through pattern recognition receptors</span></div><div class="casAuthors">Kawai, Taro; Akira, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-145</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">A review.  Viral infection is detected by the host innate immune system.  Innate immune cells such as dendritic cells and macrophages detect nucleic acids derived from viruses through pattern recognition receptors (PRRs).  Viral recognition by PRRs initiates the activation of signaling pathways that lead to prodn. of type I interferon and inflammatory cytokines, which are important for the elimination of viruses.  Two types of PRRs that recognize viral nucleic acids, Toll-like receptors (TLR) and RIG-I-like RNA helicases (RLH), have been identified.  Of the TLRs, TLR3 recognizes viral double-stranded (ds) RNA, TLR7 and human TLR8 identify viral single-stranded (ss) RNA and TLR9 detects viral DNA.  TLRs are located in endosomal compartments, whereas RLH are present in the cytoplasm where they detect viral dsRNA or ssRNA.  Here the authors review the role of TLRs and RLHs in the antiviral innate immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjoRNXj3KSbLVg90H21EOLACvtfcHk0lhL1Ji0TjVs-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltF2it7w%253D&md5=823993e4611230830fe639ed23ef6534</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1093%2Fjb%2Fmvm032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjb%252Fmvm032%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DAkira%26aufirst%3DS.%26atitle%3DAntiviral%2520signaling%2520through%2520pattern%2520recognition%2520receptors%26jtitle%3DJ.%2520Biochem.%26date%3D2007%26volume%3D141%26spage%3D137%26epage%3D145%26doi%3D10.1093%2Fjb%2Fmvm032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trippler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczeponek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlaak, J. F.</span><span> </span><span class="NLM_article-title">Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1769</span><span class="NLM_x">–</span> <span class="NLM_lpage">1778</span><span class="refDoi"> DOI: 10.1002/hep.21897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.21897" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=1769-1778&author=J.+Wuauthor=M.+Luauthor=Z.+Mengauthor=M.+Tripplerauthor=R.+Broeringauthor=A.+Szczeponekauthor=F.+Kruxauthor=U.+Dittmerauthor=M.+Roggendorfauthor=G.+Gerkenauthor=J.+F.+Schlaak&title=Toll-like+receptor-mediated+control+of+HBV+replication+by+nonparenchymal+liver+cells+in+mice&doi=10.1002%2Fhep.21897"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1002%2Fhep.21897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21897%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DTrippler%26aufirst%3DM.%26aulast%3DBroering%26aufirst%3DR.%26aulast%3DSzczeponek%26aufirst%3DA.%26aulast%3DKrux%26aufirst%3DF.%26aulast%3DDittmer%26aufirst%3DU.%26aulast%3DRoggendorf%26aufirst%3DM.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DSchlaak%26aufirst%3DJ.%2BF.%26atitle%3DToll-like%2520receptor-mediated%2520control%2520of%2520HBV%2520replication%2520by%2520nonparenchymal%2520liver%2520cells%2520in%2520mice%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D1769%26epage%3D1778%26doi%3D10.1002%2Fhep.21897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althage, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immune effectors required for hepatitis B virus clearance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">798</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span><span class="refDoi"> DOI: 10.1073/pnas.0913498107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.0913498107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=798-802&author=P.+L.+Yangauthor=A.+Althageauthor=J.+Chungauthor=H.+Maierauthor=S.+Wielandauthor=M.+Isogawaauthor=F.+V.+Chisari&title=Immune+effectors+required+for+hepatitis+B+virus+clearance&doi=10.1073%2Fpnas.0913498107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0913498107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0913498107%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DAlthage%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DWieland%26aufirst%3DS.%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmune%2520effectors%2520required%2520for%2520hepatitis%2520B%2520virus%2520clearance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D798%26epage%3D802%26doi%3D10.1073%2Fpnas.0913498107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Ebert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stutz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojaimi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baschuk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachbur, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torresi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, M.</span><span> </span><span class="NLM_article-title">Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5797</span><span class="NLM_x">–</span> <span class="NLM_lpage">5802</span><span class="refDoi"> DOI: 10.1073/pnas.1502390112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1502390112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25902529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5797-5802&author=G.+Ebertauthor=S.+Prestonauthor=C.+Allisonauthor=J.+Cooneyauthor=J.+G.+Toeauthor=M.+D.+Stutzauthor=S.+Ojaimiauthor=H.+W.+Scottauthor=N.+Baschukauthor=U.+Nachburauthor=J.+Torresiauthor=R.+Chinauthor=D.+Colledgeauthor=X.+Liauthor=N.+Warnerauthor=P.+Revillauthor=S.+Bowdenauthor=J.+Silkeauthor=C.+G.+Begleyauthor=M.+Pellegrini&title=Cellular+inhibitor+of+apoptosis+proteins+prevent+clearance+of+hepatitis+B+virus&doi=10.1073%2Fpnas.1502390112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus</span></div><div class="casAuthors">Ebert, Gregor; Preston, Simon; Allison, Cody; Cooney, James; Toe, Jesse G.; Stutz, Michael D.; Ojaimi, Samar; Scott, Hamish W.; Baschuk, Nikola; Nachbur, Ueli; Torresi, Joseph; Chin, Ruth; Colledge, Danielle; Li, Xin; Warner, Nadia; Revill, Peter; Bowden, Scott; Silke, John; Begley, C. Glenn; Pellegrini, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5797-5802</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) infection can result in a spectrum of outcomes from immune-mediated control to disease progression, cirrhosis, and liver cancer.  The host mol. pathways that influence and contribute to these outcomes need to be defined.  Using an immunocompetent mouse model of chronic HBV infection, we identified some of the host cellular and mol. factors that impact on infection outcomes.  Here, we show that cellular inhibitor of apoptosis proteins (cIAPs) attenuate TNF signaling during hepatitis B infection, and they restrict the death of infected hepatocytes, thus allowing viral persistence.  Animals with a liver-specific cIAP1 and total cIAP2 deficiency efficiently control HBV infection compared with WT mice.  This phenotype was partly recapitulated in mice that were deficient in cIAP2 alone.  These results indicate that antagonizing the function of cIAPs may promote the clearance of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5MHwS37sJbVg90H21EOLACvtfcHk0lhL1Ji0TjVs-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLg%253D&md5=098384720ec928dc72c3b0c41bb88d02</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502390112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502390112%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DG.%26aulast%3DPreston%26aufirst%3DS.%26aulast%3DAllison%26aufirst%3DC.%26aulast%3DCooney%26aufirst%3DJ.%26aulast%3DToe%26aufirst%3DJ.%2BG.%26aulast%3DStutz%26aufirst%3DM.%2BD.%26aulast%3DOjaimi%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DH.%2BW.%26aulast%3DBaschuk%26aufirst%3DN.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DTorresi%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DN.%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DBowden%26aufirst%3DS.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DBegley%26aufirst%3DC.%2BG.%26aulast%3DPellegrini%26aufirst%3DM.%26atitle%3DCellular%2520inhibitor%2520of%2520apoptosis%2520proteins%2520prevent%2520clearance%2520of%2520hepatitis%2520B%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5797%26epage%3D5802%26doi%3D10.1073%2Fpnas.1502390112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Ebert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stutz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojaimi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baschuk, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachbur, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torresi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, M.</span><span> </span><span class="NLM_article-title">Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">5803</span><span class="NLM_x">–</span> <span class="NLM_lpage">5808</span><span class="refDoi"> DOI: 10.1073/pnas.1502400112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.1502400112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25902530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5803-5808&author=G.+Ebertauthor=C.+Allisonauthor=S.+Prestonauthor=J.+Cooneyauthor=J.+G.+Toeauthor=M.+D.+Stutzauthor=S.+Ojaimiauthor=N.+Baschukauthor=U.+Nachburauthor=J.+Torresiauthor=J.+Silkeauthor=C.+G.+Begleyauthor=M.+Pellegrini&title=Eliminating+hepatitis+B+by+antagonizing+cellular+inhibitors+of+apoptosis&doi=10.1073%2Fpnas.1502400112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis</span></div><div class="casAuthors">Ebert, Gregor; Allison, Cody; Preston, Simon; Cooney, James; Toe, Jesse G.; Stutz, Michael D.; Ojaimi, Samar; Baschuk, Nikola; Nachbur, Ueli; Torresi, Joseph; Silke, John; Begley, C. Glenn; Pellegrini, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5803-5808</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We have shown that cellular inhibitor of apoptosis proteins (cIAPs) impair clearance of hepatitis B virus (HBV) infection by preventing TNF-mediated killing/death of infected cells.  A key question, with profound therapeutic implications, is whether this finding can be translated to the development of drugs that promote elimination of infected cells.  Drug inhibitors of cIAPs were developed as cancer therapeutics to promote TNF-mediated tumor killing.  These drugs are also known as Smac mimetics, because they mimic the action of the endogenous protein Smac/Diablo that antagonizes cIAP function.  Here, we show using an immunocompetent mouse model of chronic HBV infection that birinapant and other Smac mimetics are able to rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hepatocytes contg. HBV core antigen.  The efficacy of Smac mimetics in treating HBV infection is dependent on their chem., host CD4+ T cells, and TNF.  Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA prodn. in HBV-infected animals.  These results indicate that birinapant and other Smac mimetics may have efficacy in treating HBV infection and perhaps, other intracellular infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6fFsKqFdCAbVg90H21EOLACvtfcHk0lhL1Ji0TjVs-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOrsLk%253D&md5=dd522bba71dfdeba3f9804c680745f78</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502400112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502400112%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DG.%26aulast%3DAllison%26aufirst%3DC.%26aulast%3DPreston%26aufirst%3DS.%26aulast%3DCooney%26aufirst%3DJ.%26aulast%3DToe%26aufirst%3DJ.%2BG.%26aulast%3DStutz%26aufirst%3DM.%2BD.%26aulast%3DOjaimi%26aufirst%3DS.%26aulast%3DBaschuk%26aufirst%3DN.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DTorresi%26aufirst%3DJ.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DBegley%26aufirst%3DC.%2BG.%26aulast%3DPellegrini%26aufirst%3DM.%26atitle%3DEliminating%2520hepatitis%2520B%2520by%2520antagonizing%2520cellular%2520inhibitors%2520of%2520apoptosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5803%26epage%3D5808%26doi%3D10.1073%2Fpnas.1502400112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">McClary, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guidotti, L. G.</span><span> </span><span class="NLM_article-title">Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2255</span><span class="NLM_x">–</span> <span class="NLM_lpage">2264</span><span class="refDoi"> DOI: 10.1128/JVI.74.5.2255-2264.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.74.5.2255-2264.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10666256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtF2kt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2255-2264&author=H.+McClaryauthor=R.+Kochauthor=F.+V.+Chisariauthor=L.+G.+Guidotti&title=Relative+sensitivity+of+hepatitis+B+virus+and+other+hepatotropic+viruses+to+the+antiviral+effects+of+cytokines&doi=10.1128%2FJVI.74.5.2255-2264.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines</span></div><div class="casAuthors">McClary, Heike; Koch, Rick; Chisari, Francis V.; Guidotti, Luca G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2255-2264</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The authors have previously shown that hepatitis B virus (HBV) replication is inhibited noncytopathically in the livers of transgenic mice following injection of HBV-specific cytotoxic T lymphocytes (CTLs) or infection with unrelated hepatotropic viruses, including lymphocytic choriomeningitis virus (LCMV) and adenovirus.  These effects are mediated by gamma interferon (IFNγ), tumor necrosis factor alpha (TNFα), and IFNα/β.  In the present study, the authors crossed HBV transgenic mice with mice genetically deficient for IFNγ (IFNγKO), the TNFα receptor (TNFαRKO), or the IFNα/β receptor (IFNα/βRKO) to det. the relative contribution of each cytokine to the antiviral effects obsd. in each of these systems.  Interestingly, the authors showed that HBV replicates in unmanipulated IFNγKO and IFNα/βRKO mice at levels higher than those obsd. in control mice, implying that baseline levels of these cytokines control HBV replication in the absence of inflammation.  The authors also showed that IFNγ mediates most of the antiviral effect of the CTLs while IFNα/β is primarily responsible for the early inhibitory effect of LCMV and adenovirus on HBV replication.  In addn., the authors showed that the hepatic induction of IFNα/β obsd. after injection of poly(I·C) is sufficient to inhibit HBV replication and that a similar antiviral effect is achieved by systemic administration of very high doses of IFNα.  The authors also compared the relative sensitivity of LCMV and adenovirus to control by IFNγ, TNFα, or IFNα/β in these animals.  Importantly, IFNα/βRKO mice, and to a lesser extent IFNγKO mice, showed higher hepatic levels of LCMV RNA and adenovirus DNA and RNA than control mice, underscoring the importance of both interferons in controlling these other viral infections as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTeQxPXCUCIrVg90H21EOLACvtfcHk0lhGYkEtbVkyQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtF2kt7g%253D&md5=a7a856dc10b170399536a70e3b916af7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.5.2255-2264.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.5.2255-2264.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMcClary%26aufirst%3DH.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26atitle%3DRelative%2520sensitivity%2520of%2520hepatitis%2520B%2520virus%2520and%2520other%2520hepatotropic%2520viruses%2520to%2520the%2520antiviral%2520effects%2520of%2520cytokines%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26spage%3D2255%26epage%3D2264%26doi%3D10.1128%2FJVI.74.5.2255-2264.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprinzl, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppensteiner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remouchamps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thasler, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejardin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikenwalder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1228</span><span class="refDoi"> DOI: 10.1126/science.1243462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1243462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=24557838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=1221-1228&author=J.+Luciforaauthor=Y.+C.+Xiaauthor=F.+Reisingerauthor=K.+Zhangauthor=D.+Stadlerauthor=X.+M.+Chengauthor=M.+F.+Sprinzlauthor=H.+Koppensteinerauthor=Z.+Makowskaauthor=T.+Volzauthor=C.+Remouchampsauthor=W.+M.+Chouauthor=W.+E.+Thaslerauthor=N.+Huserauthor=D.+Durantelauthor=T.+J.+Liangauthor=C.+Munkauthor=M.+H.+Heimauthor=J.+L.+Browningauthor=E.+Dejardinauthor=M.+Dandriauthor=M.+Schindlerauthor=M.+Heikenwalderauthor=U.+Protzer&title=Specific+and+nonhepatotoxic+degradation+of+nuclear+hepatitis+B+virus+cccDNA&doi=10.1126%2Fscience.1243462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA</span></div><div class="casAuthors">Lucifora, Julie; Xia, Yuchen; Reisinger, Florian; Zhang, Ke; Stadler, Daniela; Cheng, Xiaoming; Sprinzl, Martin F.; Koppensteiner, Herwig; Makowska, Zuzanna; Volz, Tassilo; Remouchamps, Caroline; Chou, Wen-Min; Thasler, Wolfgang E.; Hueser, Norbert; Durantel, David; Liang, T. Jake; Muenk, Carsten; Heim, Markus H.; Browning, Jeffrey L.; Dejardin, Emmanuel; Dandri, Maura; Schindler, Michael; Heikenwalder, Mathias; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6176</span>),
    <span class="NLM_cas:pages">1221-1228</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Current antiviral agents can control but not eliminate hepatitis B virus (HBV), because HBV establishes a stable nuclear covalently closed circular DNA (cccDNA).  Interferon-α treatment can clear HBV but is limited by systemic side effects.  The authors describe how interferon-α can induce specific degrdn. of the nuclear viral DNA without hepatotoxicity and propose lymphotoxin-β receptor activation as a therapeutic alternative.  Interferon-α and lymphotoxin-β receptor activation up-regulated APOBEC3A and APOBEC3B cytidine deaminases, resp., in HBV-infected cells, primary hepatocytes, and human liver needle biopsies.  HBV core protein mediated the interaction with nuclear cccDNA, resulting in cytidine deamination, apurinic/apyrimidinic site formation, and finally cccDNA degrdn. that prevented HBV reactivation.  Genomic DNA was not affected.  Thus, inducing nuclear deaminases-for example, by lymphotoxin-β receptor activation-allows the development of new therapeutics that, in combination with existing antivirals, may cure hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrONjt8Ppl67rVg90H21EOLACvtfcHk0lhGYkEtbVkyQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVygsrY%253D&md5=18855f5a52c98d6167a7a8468d55e9ce</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243462%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%2BC.%26aulast%3DReisinger%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DStadler%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DX.%2BM.%26aulast%3DSprinzl%26aufirst%3DM.%2BF.%26aulast%3DKoppensteiner%26aufirst%3DH.%26aulast%3DMakowska%26aufirst%3DZ.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DRemouchamps%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DW.%2BM.%26aulast%3DThasler%26aufirst%3DW.%2BE.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DMunk%26aufirst%3DC.%26aulast%3DHeim%26aufirst%3DM.%2BH.%26aulast%3DBrowning%26aufirst%3DJ.%2BL.%26aulast%3DDejardin%26aufirst%3DE.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DHeikenwalder%26aufirst%3DM.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DSpecific%2520and%2520nonhepatotoxic%2520degradation%2520of%2520nuclear%2520hepatitis%2520B%2520virus%2520cccDNA%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D1221%26epage%3D1228%26doi%3D10.1126%2Fscience.1243462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassal, M.</span><span> </span><span class="NLM_article-title">Efficient hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">36128</span><span class="NLM_x">–</span> <span class="NLM_lpage">36138</span><span class="refDoi"> DOI: 10.1074/jbc.M301069200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1074%2Fjbc.M301069200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=36128-36138&author=J.+Beckauthor=M.+Nassal&title=Efficient+hsp90-independent+in+vitro+activation+by+Hsc70+and+Hsp40+of+duck+hepatitis+B+virus+reverse+transcriptase%2C+an+assumed+Hsp90+client+protein&doi=10.1074%2Fjbc.M301069200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M301069200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M301069200%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DNassal%26aufirst%3DM.%26atitle%3DEfficient%2520hsp90-independent%2520in%2520vitro%2520activation%2520by%2520Hsc70%2520and%2520Hsp40%2520of%2520duck%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%252C%2520an%2520assumed%2520Hsp90%2520client%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D36128%26epage%3D36138%26doi%3D10.1074%2Fjbc.M301069200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Hu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D.</span><span> </span><span class="NLM_article-title">Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">13122</span><span class="NLM_x">–</span> <span class="NLM_lpage">13131</span><span class="refDoi"> DOI: 10.1128/JVI.78.23.13122-13131.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FJVI.78.23.13122-13131.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15542664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=13122-13131&author=J.+M.+Huauthor=D.+Floresauthor=D.+Toftauthor=X.+T.+Wangauthor=D.+Nguyen&title=Requirement+of+heat+shock+protein+90+for+human+hepatitis+B+virus+reverse+transcriptase+function&doi=10.1128%2FJVI.78.23.13122-13131.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function</span></div><div class="casAuthors">Hu, Jianming; Flores, Dafna; Toft, David; Wang, Xingtai; Nguyen, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13122-13131</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The initiation of reverse transcription and nucleocapsid assembly in hepatitis B virus (HBV) depends on the specific recognition of an RNA signal (the packaging signal, ε) on the pregenomic RNA (pgRNA) by the viral reverse transcriptase (RT).  RT-ε interaction in the duck hepatitis B virus (DHBV) was recently shown to require the mol. chaperone complex, the heat shock protein 90 (Hsp90).  However, the requirement for RT-ε interaction in the human HBV has remained unknown due to the inability to obtain a purified RT protein active in specific ε binding.  We now report that Hsp90 is also required for HBV RT-ε interaction.  Inhibition of Hsp90 led to diminished HBV pgRNA packaging into nucleocapsids in cells, which depends on RT-ε interaction.  Furthermore, using truncated HBV RT proteins purified from bacteria and five purified Hsp90 chaperone factors, we have developed an in vitro RT-ε binding assay.  Our results demonstrate that Hsp90, in a dynamic process that was dependent on ATP hydrolysis, facilitated RT-ε interaction in HBV, as in DHBV.  Specific ε binding required sequences from both the amino-terminal terminal protein and the carboxy-terminal RT domain.  Only the cognate HBV ε, but not the DHBV ε, could bind the HBV RT proteins.  Furthermore, the internal bulge, but not the apical loop, of ε was required for RT binding.  The establishment of a defined in vitro reconstitution system has now paved the way for future biochem. and structural studies to elucidate the mechanisms of RT-ε interaction and chaperone activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxaDLdMAlkfrVg90H21EOLACvtfcHk0ljnBeZWB6He0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVaqtbbK&md5=d4f8f80600b0f78746539f760a21254e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.23.13122-13131.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.23.13122-13131.2004%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%2BM.%26aulast%3DFlores%26aufirst%3DD.%26aulast%3DToft%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DNguyen%26aufirst%3DD.%26atitle%3DRequirement%2520of%2520heat%2520shock%2520protein%252090%2520for%2520human%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%2520function%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D13122%26epage%3D13131%26doi%3D10.1128%2FJVI.78.23.13122-13131.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Wang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiswirth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span> </span><span class="NLM_article-title">Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2077</span><span class="refDoi"> DOI: 10.1128/AAC.01764-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01764-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2070-2077&author=Y.+P.+Wangauthor=F.+Liuauthor=H.+W.+Heauthor=Y.+X.+Hanauthor=Z.+G.+Pengauthor=B.+W.+Liauthor=X.+F.+Youauthor=D.+Q.+Songauthor=Z.+R.+Liauthor=L.+Y.+Yuauthor=S.+Cenauthor=B.+Hongauthor=C.+H.+Sunauthor=L.+X.+Zhaoauthor=B.+Kreiswirthauthor=D.+Perlinauthor=R.+G.+Shaoauthor=J.+D.+Jiang&title=Heat+stress+cognate+70+host+protein+as+a+potential+drug+target+against+drug+resistance+in+hepatitis+B+virus&doi=10.1128%2FAAC.01764-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.01764-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01764-09%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DPeng%26aufirst%3DZ.%2BG.%26aulast%3DLi%26aufirst%3DB.%2BW.%26aulast%3DYou%26aufirst%3DX.%2BF.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26aulast%3DLi%26aufirst%3DZ.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BY.%26aulast%3DCen%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DC.%2BH.%26aulast%3DZhao%26aufirst%3DL.%2BX.%26aulast%3DKreiswirth%26aufirst%3DB.%26aulast%3DPerlin%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DR.%2BG.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26atitle%3DHeat%2520stress%2520cognate%252070%2520host%2520protein%2520as%2520a%2520potential%2520drug%2520target%2520against%2520drug%2520resistance%2520in%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2070%26epage%3D2077%26doi%3D10.1128%2FAAC.01764-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Gao, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. Q.</span><span> </span><span class="NLM_article-title">Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">876</span><span class="refDoi"> DOI: 10.1021/jm101325h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101325h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=869-876&author=L.+M.+Gaoauthor=Y.+X.+Hanauthor=Y.+P.+Wangauthor=Y.+H.+Liauthor=Y.+Q.+Shanauthor=X.+Liauthor=Z.+G.+Pengauthor=C.+W.+Biauthor=T.+Zhangauthor=N.+N.+Duauthor=J.+D.+Jiangauthor=D.+Q.+Song&title=Design+and+synthesis+of+oxymatrine+analogues+overcoming+drug+resistance+in+hepatitis+B+virus+through+targeting+host+heat+stress+cognate+70&doi=10.1021%2Fjm101325h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Oxymatrine Analogs Overcoming Drug Resistance in Hepatitis B Virus through Targeting Host Heat Stress Cognate 70</span></div><div class="casAuthors">Gao, Li-Mei; Han, Yan-Xing; Wang, Yu-Ping; Li, Yu-Huan; Shan, Yong-Qiang; Li, Xin; Peng, Zong-Gen; Bi, Chong-Wen; Zhang, Tian; Du, Na-Na; Jiang, Jian-Dong; Song, Dan-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat-stress cognate 70 (Hsc70) is a host protein required for hepatitis B virus (HBV) replication, and oxymatrine I [R13 = H, R14 = H] suppresses Hsc70 expression.  Taking Hsc70 as a target against HBV, 22 analogs, such as oxysophocarpine I [R13R14 = bond] and II [R13 = OH, OMe, OEt, OCH2Ph, OCOPh, CH2NO2, NHMe, R14 = H; R13 = OCOMe, OCOCH2Cl, OCOCHClMe, OCOPh, OCOC6H3-4-F-3-NO2, OCO2Et, R14 = OH; R13 = R14 = OH, OMe, OCH2Ph, OCO2Et, OCOC6H3-4-F-3-NO2], of oxymatrine defined with substituents at positions 1, 13 and 14 were synthesized and evaluated for their activity on Hsc70 mRNA expression.  The SAR revealed that (i) the oxygen atom at the 1-position was not essential, (ii) increasing electron d. on the ring D reduced the activity, and (iii) introducing a proper substituent at the 13- and/or 14-position(s), esp. electron-withdrawing groups, might enhance the activity.  Among the analogs, II [R13 = OEt,R14 = H] with a 13-ethoxy substituent afforded an increased activity in respect to oxymatrine.  Importantly, it was active for either wild-type or lamivudine-resistant HBV, as its target is host Hsc70 but not viral enzymes.  LD50 of II [R13 = OEt,R14 = H] in mice was over 750 mg/kg in oral route.  II [R13 = OEt,R14 = H] was considered promising for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSX-G2d2bN4rVg90H21EOLACvtfcHk0ljnBeZWB6He0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFOntg%253D%253D&md5=36465bf59f0d11ed49b80eff24cc2c55</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm101325h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101325h%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DL.%2BM.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DShan%26aufirst%3DY.%2BQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DZ.%2BG.%26aulast%3DBi%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DN.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520oxymatrine%2520analogues%2520overcoming%2520drug%2520resistance%2520in%2520hepatitis%2520B%2520virus%2520through%2520targeting%2520host%2520heat%2520stress%2520cognate%252070%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D869%26epage%3D876%26doi%3D10.1021%2Fjm101325h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span> </span><span class="NLM_article-title">Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1060</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1073/pnas.93.3.1060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1073%2Fpnas.93.3.1060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=1060-1064&author=J.+Huauthor=C.+Seeger&title=Hsp90+is+required+for+the+activity+of+a+hepatitis+B+virus+reverse+transcriptase&doi=10.1073%2Fpnas.93.3.1060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.3.1060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.3.1060%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DSeeger%26aufirst%3DC.%26atitle%3DHsp90%2520is%2520required%2520for%2520the%2520activity%2520of%2520a%2520hepatitis%2520B%2520virus%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D1060%26epage%3D1064%26doi%3D10.1073%2Fpnas.93.3.1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, C.</span><span> </span><span class="NLM_article-title">Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1093/emboj/16.1.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1093%2Femboj%2F16.1.59" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=59-68&author=J.+Huauthor=D.+O.+Toftauthor=C.+Seeger&title=Hepadnavirus+assembly+and+reverse+transcription+require+a+multi-component+chaperone+complex+which+is+incorporated+into+nucleocapsids&doi=10.1093%2Femboj%2F16.1.59"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.1.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.1.59%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DSeeger%26aufirst%3DC.%26atitle%3DHepadnavirus%2520assembly%2520and%2520reverse%2520transcription%2520require%2520a%2520multi-component%2520chaperone%2520complex%2520which%2520is%2520incorporated%2520into%2520nucleocapsids%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D59%26epage%3D68%26doi%3D10.1093%2Femboj%2F16.1.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Zhan, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. Z.</span><span> </span><span class="NLM_article-title">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1036</span><span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.drudis.2016.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1027-1036&author=M.+M.+Zhanauthor=X.+Q.+Huauthor=X.+X.+Liuauthor=B.+F.+Ruanauthor=J.+Xuauthor=C.+Z.+Liao&title=From+monoclonal+antibodies+to+small+molecules%3A+the+development+of+inhibitors+targeting+the+PD-1%2FPD-L1+pathway&doi=10.1016%2Fj.drudis.2016.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span></div><div class="casAuthors">Zhan, Mei-Miao; Hu, Xue-Qin; Liu, Xiu-Xiu; Ruan, Ban-Feng; Xu, Jun; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1027-1036</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made an extraordinary journey from bench to bedside.  Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer.  Here, we review the development of drugs targeting the PD-1/PD-L1 pathway.  We discuss the monoclonal antibodies (mAbs) approved or in clin. trials, peptides and patented small mols. developed against this pathway.  Such compds. have the potential to treat cancer as well as chronic virol. diseases.  We also detail PD-1/PD-L1 interactions, an understanding of which will be useful for the rational design of small-mol. therapeutics that disrupt the PD-1/PD-L1 pathway.  It is likely that more mAbs targeting the PD-1/PD-L1 pathway will be approved for the treatment of a range of cancers.  By contrast, it is likely to be more difficult to successfully develop small mols. or peptides and for them to reach the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsq7LUmul7bVg90H21EOLACvtfcHk0lh1ikqVqPdzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D&md5=e7bfff84cb527571846c9d82a1d8accf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%2BM.%26aulast%3DHu%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DRuan%26aufirst%3DB.%2BF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%2BZ.%26atitle%3DFrom%2520monoclonal%2520antibodies%2520to%2520small%2520molecules%253A%2520the%2520development%2520of%2520inhibitors%2520targeting%2520the%2520PD-1%252FPD-L1%2520pathway%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1027%26epage%3D1036%26doi%3D10.1016%2Fj.drudis.2016.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Gibney, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, M. B.</span><span> </span><span class="NLM_article-title">Predictive biomarkers for checkpoint inhibitor-based immunotherapy</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">e542</span><span class="NLM_x">–</span> <span class="NLM_lpage">e551</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30406-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1470-2045%2816%2930406-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=27924752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2gsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e542-e551&author=G.+T.+Gibneyauthor=L.+M.+Weinerauthor=M.+B.+Atkins&title=Predictive+biomarkers+for+checkpoint+inhibitor-based+immunotherapy&doi=10.1016%2FS1470-2045%2816%2930406-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive biomarkers for checkpoint inhibitor-based immunotherapy</span></div><div class="casAuthors">Gibney, Geoffrey T.; Weiner, Louis M.; Atkins, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e542-e551</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The clin. development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy.  Durable responses can be seen in patients with melanoma and other malignancies.  Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens.  The development of predictive biomarkers is needed to optimize patient benefit, minimise risk of toxicities, and guide combination approaches.  The greatest focus has been on tumor-cell PD-L1 expression.  Although PD-L1 positivity enriches for populations with clin. benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies.  In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumor-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochem.  Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterization of the immune tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1JKNhUHJEZbVg90H21EOLACvtfcHk0lh1ikqVqPdzuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2gsL7M&md5=d3c67c04336efd1e86f6eaf38edf42d2</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930406-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930406-5%26sid%3Dliteratum%253Aachs%26aulast%3DGibney%26aufirst%3DG.%2BT.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26atitle%3DPredictive%2520biomarkers%2520for%2520checkpoint%2520inhibitor-based%2520immunotherapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3De542%26epage%3De551%26doi%3D10.1016%2FS1470-2045%2816%2930406-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Greil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutterer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleyer, L.</span><span> </span><span class="NLM_article-title">Reactivation of dormant anti-tumor immunity-a clinical perspective of therapeutic immune checkpoint modulation</span> <span class="citation_source-journal">Cell Commun. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.1186/s12964-016-0155-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1186%2Fs12964-016-0155-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=28100240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ntVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=5&author=R.+Greilauthor=E.+Huttererauthor=T.+N.+Hartmannauthor=L.+Pleyer&title=Reactivation+of+dormant+anti-tumor+immunity-a+clinical+perspective+of+therapeutic+immune+checkpoint+modulation&doi=10.1186%2Fs12964-016-0155-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation</span></div><div class="casAuthors">Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa; Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa; Greil Richard; Pleyer Lisa; Greil Richard; Hutterer Evelyn; Hartmann Tanja Nicole; Pleyer Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cell communication and signaling : CCS</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In favor of their outgrowth, cancer cells must resist immune surveillance and edit the immune response.  Cancer immunoediting is characterized by fundamental changes in the cellular composition and the inflammatory cytokine profiles in the microenvironment of the primary tumor and metastatic niches, with an ever increasing complexity of interactions between tumor cells and the immune system.  Recent data suggest that genetic instability and immunoediting are not necessarily disparate processes.  Increasing mutational load may be associated with multiple neoepitopes expressed by the tumor cells and thus increased chances for the immune system to recognize and combat these cells.  At the same time the immune system is more and more suppressed and exhausted by this process.  Consequently, immune checkpoint modulation may have the potential to be most successful in genetically highly altered and usually extremely unfavorable types of cancer.  Moreover, the fact that epitopes recognized by the immune system are preferentially encoded by passenger gene mutations opens windows of synergy in targeting cancer-specific signaling pathways by small molecules simultaneously with antibodies modifying T-cell activation or exhaustion.This review covers some aspects of the current understanding of the immunological basis necessary to understand the rapidly developing therapeutic endeavours in cancer treatment, the clinical achievements made, and raises some burning questions for translational research in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmYYjLgPpERu2qxNLjzXe8fW6udTcc2ea6y9g9mxyserntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ntVahuw%253D%253D&md5=89545b259ccf4e2485a1340f9c0a321b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs12964-016-0155-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-016-0155-9%26sid%3Dliteratum%253Aachs%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DHutterer%26aufirst%3DE.%26aulast%3DHartmann%26aufirst%3DT.%2BN.%26aulast%3DPleyer%26aufirst%3DL.%26atitle%3DReactivation%2520of%2520dormant%2520anti-tumor%2520immunity-a%2520clinical%2520perspective%2520of%2520therapeutic%2520immune%2520checkpoint%2520modulation%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2017%26volume%3D15%26spage%3D5%26doi%3D10.1186%2Fs12964-016-0155-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Barber, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wherry, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masopust, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, R.</span><span> </span><span class="NLM_article-title">Restoring function in exhausted CD8 T cells during chronic viral infection</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1038/nature04444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature04444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16382236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=682-687&author=D.+L.+Barberauthor=E.+J.+Wherryauthor=D.+Masopustauthor=B.+G.+Zhuauthor=J.+P.+Allisonauthor=A.+H.+Sharpeauthor=G.+J.+Freemanauthor=R.+Ahmed&title=Restoring+function+in+exhausted+CD8+T+cells+during+chronic+viral+infection&doi=10.1038%2Fnature04444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Restoring function in exhausted CD8 T cells during chronic viral infection</span></div><div class="casAuthors">Barber, Daniel L.; Wherry, E. John; Masopust, David; Zhu, Baogong; Allison, James P.; Sharpe, Arlene H.; Freeman, Gordon J.; Ahmed, Rafi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7077</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Functional impairment of antigen-specific T cells is a defining characteristic of many chronic infections, but the underlying mechanisms of T-cell dysfunction are not well understood.  To address this question, we analyzed genes expressed in functionally impaired virus-specific CD8 T cells present in mice chronically infected with lymphocytic choriomeningitis virus (LCMV), and compared these with the gene profile of functional memory CD8 T cells.  Here we report that PD-1 (programmed death 1; also known as Pdcd1) was selectively upregulated by the exhausted T cells, and that in vivo administration of antibodies that blocked the interaction of this inhibitory receptor with its ligand, PD-L1 (also known as B7-H1), enhanced T-cell responses.  Notably, we found that even in persistently infected mice that were lacking CD4 T-cell help, blockade of the PD-1/PD-L1 inhibitory pathway had a beneficial effect on the helpless' CD8 T cells, restoring their ability to undergo proliferation, secrete cytokines, kill infected cells and decrease viral load.  Blockade of the CTLA-4 (cytotoxic T-lymphocyte-assocd. protein 4) inhibitory pathway had no effect on either T-cell function or viral control.  These studies identify a specific mechanism of T-cell exhaustion and define a potentially effective immunol. strategy for the treatment of chronic viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrokjGzUXzvibVg90H21EOLACvtfcHk0lj_SKonl1NsPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyktL0%253D&md5=aa2ee550ea5d4eaa597f4f1337f48b1c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnature04444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04444%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DD.%2BL.%26aulast%3DWherry%26aufirst%3DE.%2BJ.%26aulast%3DMasopust%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DB.%2BG.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DAhmed%26aufirst%3DR.%26atitle%3DRestoring%2520function%2520in%2520exhausted%2520CD8%2520T%2520cells%2520during%2520chronic%2520viral%2520infection%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D682%26epage%3D687%26doi%3D10.1038%2Fnature04444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Day, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiepiela, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moodley, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePierres, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mncube, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duraiswamy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichbaum, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altfeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wherry, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coovadia, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulder, P. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B. D.</span><span> </span><span class="NLM_article-title">PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">443</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1038/nature05115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature05115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=350-354&author=C.+L.+Dayauthor=D.+E.+Kaufmannauthor=P.+Kiepielaauthor=J.+A.+Brownauthor=E.+S.+Moodleyauthor=S.+Reddyauthor=E.+W.+Mackeyauthor=J.+D.+Millerauthor=A.+J.+Leslieauthor=C.+DePierresauthor=Z.+Mncubeauthor=J.+Duraiswamyauthor=B.+G.+Zhuauthor=Q.+Eichbaumauthor=M.+Altfeldauthor=E.+J.+Wherryauthor=H.+M.+Coovadiaauthor=P.+J.+R.+Goulderauthor=P.+Klenermanauthor=R.+Ahmedauthor=G.+J.+Freemanauthor=B.+D.+Walker&title=PD-1+expression+on+HIV-specific+T+cells+is+associated+with+T-cell+exhaustion+and+disease+progression&doi=10.1038%2Fnature05115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnature05115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05115%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DC.%2BL.%26aulast%3DKaufmann%26aufirst%3DD.%2BE.%26aulast%3DKiepiela%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DMoodley%26aufirst%3DE.%2BS.%26aulast%3DReddy%26aufirst%3DS.%26aulast%3DMackey%26aufirst%3DE.%2BW.%26aulast%3DMiller%26aufirst%3DJ.%2BD.%26aulast%3DLeslie%26aufirst%3DA.%2BJ.%26aulast%3DDePierres%26aufirst%3DC.%26aulast%3DMncube%26aufirst%3DZ.%26aulast%3DDuraiswamy%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DB.%2BG.%26aulast%3DEichbaum%26aufirst%3DQ.%26aulast%3DAltfeld%26aufirst%3DM.%26aulast%3DWherry%26aufirst%3DE.%2BJ.%26aulast%3DCoovadia%26aufirst%3DH.%2BM.%26aulast%3DGoulder%26aufirst%3DP.%2BJ.%2BR.%26aulast%3DKlenerman%26aufirst%3DP.%26aulast%3DAhmed%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DWalker%26aufirst%3DB.%2BD.%26atitle%3DPD-1%2520expression%2520on%2520HIV-specific%2520T%2520cells%2520is%2520associated%2520with%2520T-cell%2520exhaustion%2520and%2520disease%2520progression%26jtitle%3DNature%26date%3D2006%26volume%3D443%26spage%3D350%26epage%3D354%26doi%3D10.1038%2Fnature05115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Zhang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F. S.</span><span> </span><span class="NLM_article-title">PD-1 up-regulation is correlated with HIV-specific memory CD8(+) T-cell exhaustion in typical progressors, but not in long-terrn nonprogressors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4671</span><span class="NLM_x">–</span> <span class="NLM_lpage">4678</span><span class="refDoi"> DOI: 10.1182/blood-2006-09-044826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1182%2Fblood-2006-09-044826" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4671-4678&author=J.+Y.+Zhangauthor=Z.+Zhangauthor=X.+C.+Wangauthor=J.+L.+Fuauthor=J.+X.+Yaoauthor=Y.+M.+Jiaoauthor=L.+G.+Chenauthor=H.+Zhangauthor=J.+N.+Weiauthor=L.+Jinauthor=M.+Shiauthor=G.+F.+Gaoauthor=H.+Wuauthor=F.+S.+Wang&title=PD-1+up-regulation+is+correlated+with+HIV-specific+memory+CD8%28%2B%29+T-cell+exhaustion+in+typical+progressors%2C+but+not+in+long-terrn+nonprogressors&doi=10.1182%2Fblood-2006-09-044826"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-09-044826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-09-044826%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%2BC.%26aulast%3DFu%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DJ.%2BX.%26aulast%3DJiao%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DJ.%2BN.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%2BS.%26atitle%3DPD-1%2520up-regulation%2520is%2520correlated%2520with%2520HIV-specific%2520memory%2520CD8%2528%252B%2529%2520T-cell%2520exhaustion%2520in%2520typical%2520progressors%252C%2520but%2520not%2520in%2520long-terrn%2520nonprogressors%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D4671%26epage%3D4678%26doi%3D10.1182%2Fblood-2006-09-044826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Trautmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janbazian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chomont, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimmig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessette, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulassel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delwart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepulveda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderas, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekaly, R. P.</span><span> </span><span class="NLM_article-title">Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span><span class="refDoi"> DOI: 10.1038/nm1482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnm1482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=16917489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVChsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1198-1202&author=L.+Trautmannauthor=L.+Janbazianauthor=N.+Chomontauthor=E.+A.+Saidauthor=S.+Gimmigauthor=B.+Bessetteauthor=M.+R.+Boulasselauthor=E.+Delwartauthor=H.+Sepulvedaauthor=R.+S.+Balderasauthor=J.+P.+Routyauthor=E.+K.+Haddadauthor=R.+P.+Sekaly&title=Upregulation+of+PD-1+expression+on+HIV-specific+CD8%28%2B%29+T+cells+leads+to+reversible+immune+dysfunction&doi=10.1038%2Fnm1482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction</span></div><div class="casAuthors">Trautmann, Lydie; Janbazian, Loury; Chomont, Nicolas; Said, Elias A.; Gimmig, Sylvain; Bessette, Benoit; Boulassel, Mohamed-Rachid; Delwart, Eric; Sepulveda, Homero; Balderas, Robert S.; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L2, inhibits proliferation and cytokine prodn. mediated by antibodies to CD3 (refs. 5,6,7).  Blocking the PD-1-PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8+ T cells to undergo proliferation, cytokine prodn. and cytotoxic activity and, consequently, results in reduced viral load.  During chronic HIV infection, HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector mols. as well as an impaired capacity to proliferate.  Here, the authors found that PD-1 was upregulated on HIV-specific CD8+ T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine prodn. and proliferation of HIV-specific CD8+ T cells.  Notably, cytomegalovirus (CMV)-specific CD8+ T cells from the same donors did not upregulate PD-1 and maintained the prodn. of high levels of cytokines.  Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8+ T cells to survive and proliferate and led to an increased prodn. of cytokines and cytotoxic mols. in response to cognate antigen.  The accumulation of HIV-specific dysfunctional CD8+ T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8+ repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpozwd_OOIb_LVg90H21EOLACvtfcHk0ljNa6FDC6UtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVChsrjO&md5=e9403a4f16e5b8e19eea06d44987458a</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fnm1482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1482%26sid%3Dliteratum%253Aachs%26aulast%3DTrautmann%26aufirst%3DL.%26aulast%3DJanbazian%26aufirst%3DL.%26aulast%3DChomont%26aufirst%3DN.%26aulast%3DSaid%26aufirst%3DE.%2BA.%26aulast%3DGimmig%26aufirst%3DS.%26aulast%3DBessette%26aufirst%3DB.%26aulast%3DBoulassel%26aufirst%3DM.%2BR.%26aulast%3DDelwart%26aufirst%3DE.%26aulast%3DSepulveda%26aufirst%3DH.%26aulast%3DBalderas%26aufirst%3DR.%2BS.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DHaddad%26aufirst%3DE.%2BK.%26aulast%3DSekaly%26aufirst%3DR.%2BP.%26atitle%3DUpregulation%2520of%2520PD-1%2520expression%2520on%2520HIV-specific%2520CD8%2528%252B%2529%2520T%2520cells%2520leads%2520to%2520reversible%2520immune%2520dysfunction%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D1198%26epage%3D1202%26doi%3D10.1038%2Fnm1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Phillips, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chokshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoumov, N. V.</span><span> </span><span class="NLM_article-title">CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.4049/jimmunol.0902761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.4049%2Fjimmunol.0902761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=287-295&author=S.+Phillipsauthor=S.+Chokshiauthor=A.+Rivaauthor=A.+Evansauthor=R.+Williamsauthor=N.+V.+Naoumov&title=CD8%28%2B%29+T+cell+control+of+hepatitis+B+virus+replication%3A+direct+comparison+between+cytolytic+and+noncytolytic+functions&doi=10.4049%2Fjimmunol.0902761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902761%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DChokshi%26aufirst%3DS.%26aulast%3DRiva%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DNaoumov%26aufirst%3DN.%2BV.%26atitle%3DCD8%2528%252B%2529%2520T%2520cell%2520control%2520of%2520hepatitis%2520B%2520virus%2520replication%253A%2520direct%2520comparison%2520between%2520cytolytic%2520and%2520noncytolytic%2520functions%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D287%26epage%3D295%26doi%3D10.4049%2Fjimmunol.0902761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Isogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Immunobiology of hepatitis B virus infection</span> <span class="citation_source-journal">Hepatol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1111/hepr.12439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fhepr.12439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25331910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=179-189&author=M.+Isogawaauthor=Y.+Tanaka&title=Immunobiology+of+hepatitis+B+virus+infection&doi=10.1111%2Fhepr.12439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of hepatitis B virus infection</span></div><div class="casAuthors">Isogawa, Masanori; Tanaka, Yasuhito</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-189</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The adaptive immune response, particularly the virus-specific CD8+ T-cell response, is largely responsible for viral clearance and disease pathogenesis during hepatitis B virus (HBV) infection.  The HBV-specific CD8+ T-cell response is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focused in chronically infected patients.  The immunol. basis for this dichotomy is unclear.  A recent study using HBV transgenic mice and HBV-specific T-cell receptor transgenic mice suggests that intrahepatic antigen presentation by HBV pos. hepatocytes suppresses HBV-specific CD8+ T-cell responses through a co-inhibitory mol., programmed cell death 1 (PD-1).  In contrast, antigen presentation by activated professional antigen-presenting cells induces functional differentiation of HBV-specific CD8+ T cells.  These findings suggest that the outcome of T-cell priming is largely dependent on the nature of antigen-presenting cells.  Another study suggests that the timing of HBV-specific CD4+ T-cell priming regulates the magnitude of the HBV-specific CD8+ T-cell response.  Other factors that could regulate HBV-specific cellular immune responses are high viral loads, mutational epitope inactivation, T-cell receptor antagonism and infection of immunol. privileged tissues.  However, these pathways become apparent only in the setting of an ineffective cellular immune response, which is therefore the fundamental underlying cause.  Understanding the cellular and mol. mechanisms by which HBV evades host immune responses will eventually help develop new immunotherapeutic strategies designed to terminate chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmOqjGq3Ua5bVg90H21EOLACvtfcHk0ljNa6FDC6UtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKisL8%253D&md5=1f84853b83c084edd3d73461557f4c91</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12439%26sid%3Dliteratum%253Aachs%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DImmunobiology%2520of%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DHepatol.%2520Res.%26date%3D2015%26volume%3D45%26spage%3D179%26epage%3D189%26doi%3D10.1111%2Fhepr.12439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Peng, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span> </span><span class="NLM_article-title">PD-1 upregulation is associated with HBV specific T cell dysfunction in chronic hepatitis B patients</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1016/j.molimm.2007.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.molimm.2007.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=17868872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Ghs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2008&pages=963-970&author=G.+P.+Pengauthor=S.+P.+Liauthor=W.+Wuauthor=X.+F.+Tanauthor=Y.+Q.+Chenauthor=Z.+Chen&title=PD-1+upregulation+is+associated+with+HBV+specific+T+cell+dysfunction+in+chronic+hepatitis+B+patients&doi=10.1016%2Fj.molimm.2007.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients</span></div><div class="casAuthors">Peng, Guoping; Li, Shuping; Wu, Wei; Tan, Xufei; Chen, Yiqiong; Chen, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Summary: Programmed death-1 (PD-1) is demonstrated to have an increased expression on antigen-specific T cells during chronic virus infections, and the blockage of PD-1/PD-ligand (PD-L1) pathway could restore the function of exhausted T cells.  We measured the PD-1 expression levels on HBV-specific CD8 T cells and investigated the role of PD-1/PD-L1 pathway in T-cell responses of patients with different HBV infection statuses.  Compared to the patients with convalescent acute hepatitis B, PD-1 expression on total CD8 T cells from chronic hepatitis B (CHB) patients was significantly upregulated, esp. on the HBV pentamer-pos. CD8 T cells.  And PD-L1, but not PD-L2, was also significantly upregulated on PBMC from CHB patients.  In CHB patients, HBV-specific T cells and cellular proliferation could be obsd. under the recombinant HBV-Ag stimulation in vitro, and blockade of PD-1 pathway significantly enhanced the IFN-gamma prodn. and cellular proliferation of PBMC.  Furthermore, PD-1 expression level on HBV-pentamers pos. CD8 T cells was pos. assocd. with plasma viral load in CHB patients.  Thus, PD-1 upregulation on HBV-specific CD8 T cells is engaged in the dysfunction of T cells and high viremia in CHB patients, and the antiviral T-cell responses could be improved by the blockade of this inhibitory PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx6HsAa_qqFbVg90H21EOLACvtfcHk0ljNa6FDC6UtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Ghs77F&md5=6bb202f1714a8e6b608b1a96ffb8384b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2007.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2007.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DG.%2BP.%26aulast%3DLi%26aufirst%3DS.%2BP.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DX.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DPD-1%2520upregulation%2520is%2520associated%2520with%2520HBV%2520specific%2520T%2520cell%2520dysfunction%2520in%2520chronic%2520hepatitis%2520B%2520patients%26jtitle%3DMol.%2520Immunol.%26date%3D2008%26volume%3D45%26spage%3D963%26epage%3D970%26doi%3D10.1016%2Fj.molimm.2007.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Sherman, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehanpati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daucher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarin, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, A.</span><span> </span><span class="NLM_article-title">Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir</span> <span class="citation_source-journal">AIDS Res. Hum. Retroviruses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1089/aid.2012.0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Faid.2012.0320" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=665-672&author=A.+C.+Shermanauthor=N.+Trehanpatiauthor=M.+Daucherauthor=R.+T.+Daveyauthor=H.+Masurauthor=S.+K.+Sarinauthor=S.+Kottililauthor=A.+Kohli&title=Augmentation+of+hepatitis+B+virus-specific+cellular+immunity+with+programmed+death+receptor-1%2Fprogrammed+death+receptor-L1+blockade+in+hepatitis+B+virus+and+HIV%2Fhepatitis+B+virus+coinfected+patients+treated+with+adefovir&doi=10.1089%2Faid.2012.0320"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0320%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DA.%2BC.%26aulast%3DTrehanpati%26aufirst%3DN.%26aulast%3DDaucher%26aufirst%3DM.%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DSarin%26aufirst%3DS.%2BK.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKohli%26aufirst%3DA.%26atitle%3DAugmentation%2520of%2520hepatitis%2520B%2520virus-specific%2520cellular%2520immunity%2520with%2520programmed%2520death%2520receptor-1%252Fprogrammed%2520death%2520receptor-L1%2520blockade%2520in%2520hepatitis%2520B%2520virus%2520and%2520HIV%252Fhepatitis%2520B%2520virus%2520coinfected%2520patients%2520treated%2520with%2520adefovir%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26spage%3D665%26epage%3D672%26doi%3D10.1089%2Faid.2012.0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooksley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puranik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chokshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoumov, N. V.</span><span> </span><span class="NLM_article-title">Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1002/hep.22419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.22419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=759-769&author=A.+Evansauthor=A.+Rivaauthor=H.+Cooksleyauthor=S.+Phillipsauthor=S.+Puranikauthor=A.+Nathwaniauthor=S.+Brettauthor=S.+Chokshiauthor=N.+V.+Naoumov&title=Programmed+death+1+expression+during+antiviral+treatment+of+chronic+hepatitis+B%3A+impact+of+hepatitis+B+e-antigen+seroconversion&doi=10.1002%2Fhep.22419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fhep.22419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22419%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DA.%26aulast%3DRiva%26aufirst%3DA.%26aulast%3DCooksley%26aufirst%3DH.%26aulast%3DPhillips%26aufirst%3DS.%26aulast%3DPuranik%26aufirst%3DS.%26aulast%3DNathwani%26aufirst%3DA.%26aulast%3DBrett%26aufirst%3DS.%26aulast%3DChokshi%26aufirst%3DS.%26aulast%3DNaoumov%26aufirst%3DN.%2BV.%26atitle%3DProgrammed%2520death%25201%2520expression%2520during%2520antiviral%2520treatment%2520of%2520chronic%2520hepatitis%2520B%253A%2520impact%2520of%2520hepatitis%2520B%2520e-antigen%2520seroconversion%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D759%26epage%3D769%26doi%3D10.1002%2Fhep.22419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möller, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glebe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggendorf, M.</span><span> </span><span class="NLM_article-title">Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1003856</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1003856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.ppat.1003856" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1003856&author=J.+Liuauthor=E.+Zhangauthor=Z.+Y.+Maauthor=W.+M.+Wuauthor=A.+Kosinskaauthor=X.+Y.+Zhangauthor=I.+M%C3%B6llerauthor=P.+Seizauthor=D.+Glebeauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=M.+J.+Luauthor=M.+Roggendorf&title=Enhancing+virus-specific+immunity+in+vivo+by+combining+therapeutic+vaccination+and+PD-L1+blockade+in+chronic+hepadnaviral+infection&doi=10.1371%2Fjournal.ppat.1003856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003856%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DW.%2BM.%26aulast%3DKosinska%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DM%25C3%25B6ller%26aufirst%3DI.%26aulast%3DSeiz%26aufirst%3DP.%26aulast%3DGlebe%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DRoggendorf%26aufirst%3DM.%26atitle%3DEnhancing%2520virus-specific%2520immunity%2520in%2520vivo%2520by%2520combining%2520therapeutic%2520vaccination%2520and%2520PD-L1%2520blockade%2520in%2520chronic%2520hepadnaviral%2520infection%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26spage%3De1003856%26doi%3D10.1371%2Fjournal.ppat.1003856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saputelli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span> </span><span class="NLM_article-title">Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4277</span><span class="NLM_x">–</span> <span class="NLM_lpage">4288</span><span class="refDoi"> DOI: 10.1128/AAC.00473-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.00473-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4277-4288&author=D.+Caiauthor=C.+Millsauthor=W.+Yuauthor=R.+Yanauthor=C.+E.+Aldrichauthor=J.+R.+Saputelliauthor=W.+S.+Masonauthor=X.+Xuauthor=J.-T.+Guoauthor=T.+M.+Blockauthor=A.+Cuconatiauthor=H.+Guo&title=Identification+of+disubstituted+sulfonamide+compounds+as+specific+inhibitors+of+hepatitis+B+virus+covalently+closed+circular+DNA+formation&doi=10.1128%2FAAC.00473-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FAAC.00473-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00473-12%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DAldrich%26aufirst%3DC.%2BE.%26aulast%3DSaputelli%26aufirst%3DJ.%2BR.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.-T.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520disubstituted%2520sulfonamide%2520compounds%2520as%2520specific%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520covalently%2520closed%2520circular%2520DNA%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4277%26epage%3D4288%26doi%3D10.1128%2FAAC.00473-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Carthew, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sontheimer, E. J.</span><span> </span><span class="NLM_article-title">Origins and mechanisms of miRNAs and siRNAs</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span><span class="refDoi"> DOI: 10.1016/j.cell.2009.01.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.cell.2009.01.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19239886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=642-655&author=R.+W.+Carthewauthor=E.+J.+Sontheimer&title=Origins+and+mechanisms+of+miRNAs+and+siRNAs&doi=10.1016%2Fj.cell.2009.01.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Origins and mechanisms of miRNAs and siRNAs</span></div><div class="casAuthors">Carthew, Richard W.; Sontheimer, Erik J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">642-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Over the last decade, ∼20-30 nucleotide RNA mols. have emerged as crit. regulators in the expression and function of eukaryotic genomes.  Two primary categories of these small RNAs, short interfering RNAs (siRNAs) and microRNAs (miRNAs), act in both somatic and germline lineages in a broad range of eukaryotic species to regulate endogenous genes and to defend the genome from invasive nucleic acids.  Recent advances have revealed unexpected diversity in their biogenesis pathways and the regulatory mechanisms that they access.  The understanding of siRNA- and miRNA-based regulation has direct implications for fundamental biol. as well as disease etiol. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3IZ-WDhiJbVg90H21EOLACvtfcHk0lg1nwITlLe_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFGksb0%253D&md5=0a21cafe31e6a3da5dc2399f109bcbc4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.01.035%26sid%3Dliteratum%253Aachs%26aulast%3DCarthew%26aufirst%3DR.%2BW.%26aulast%3DSontheimer%26aufirst%3DE.%2BJ.%26atitle%3DOrigins%2520and%2520mechanisms%2520of%2520miRNAs%2520and%2520siRNAs%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D642%26epage%3D655%26doi%3D10.1016%2Fj.cell.2009.01.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Grimm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streetz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jopling, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, M. A.</span><span> </span><span class="NLM_article-title">Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">441</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1038/nature04791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnature04791" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=537-541&author=D.+Grimmauthor=K.+L.+Streetzauthor=C.+L.+Joplingauthor=T.+A.+Stormauthor=K.+Pandeyauthor=C.+R.+Davisauthor=P.+Marionauthor=F.+Salazarauthor=M.+A.+Kay&title=Fatality+in+mice+due+to+oversaturation+of+cellular+microRNA%2Fshort+hairpin+RNA+pathways&doi=10.1038%2Fnature04791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnature04791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04791%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DD.%26aulast%3DStreetz%26aufirst%3DK.%2BL.%26aulast%3DJopling%26aufirst%3DC.%2BL.%26aulast%3DStorm%26aufirst%3DT.%2BA.%26aulast%3DPandey%26aufirst%3DK.%26aulast%3DDavis%26aufirst%3DC.%2BR.%26aulast%3DMarion%26aufirst%3DP.%26aulast%3DSalazar%26aufirst%3DF.%26aulast%3DKay%26aufirst%3DM.%2BA.%26atitle%3DFatality%2520in%2520mice%2520due%2520to%2520oversaturation%2520of%2520cellular%2520microRNA%252Fshort%2520hairpin%2520RNA%2520pathways%26jtitle%3DNature%26date%3D2006%26volume%3D441%26spage%3D537%26epage%3D541%26doi%3D10.1038%2Fnature04791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Sun, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M. H.</span><span> </span><span class="NLM_article-title">Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference</span> <span class="citation_source-journal">Hum. Gene Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1089/hum.2012.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Fhum.2012.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23829557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OisrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=739-750&author=C.+P.+Sunauthor=T.+H.+Wuauthor=C.+C.+Chenauthor=P.+Y.+Wuauthor=Y.+M.+Shihauthor=K.+Tsuneyamaauthor=M.+H.+Tao&title=Studies+of+efficacy+and+liver+toxicity+related+to+adeno-associated+virus-mediated+RNA+interference&doi=10.1089%2Fhum.2012.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Studies of Efficacy and Liver Toxicity Related to Adeno-Associated Virus-Mediated RNA Interference</span></div><div class="casAuthors">Sun, Cheng-Pu; Wu, Tzu-Hui; Chen, Chun-Chi; Wu, Ping-Yi; Shih, Yao-Ming; Tsuneyama, Koichi; Tao, Mi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Human Gene Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">739-750</span>CODEN:
                <span class="NLM_cas:coden">HGTHE3</span>;
        ISSN:<span class="NLM_cas:issn">1043-0342</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Adeno-assocd. virus (AAV)-mediated RNA interference shows promise as a therapy for chronic hepatitis B virus (HBV) infection, but its low efficacy and hepatotoxicity pose major challenges.  We have generated AAV vectors contg. different promoters and a panel of HBV-specific short hairpin RNAs (shRNAs) to investigate factors that contribute to the efficacy and pathogenesis of AAV-mediated RNA interference.  HBV transgenic mice injected with high doses of AAV vectors contg. the U6 promoter produced abundant shRNAs, transiently inhibited HBV, but induced severe hepatotoxicity.  Sustained HBV suppression without liver toxicity can be achieved by lowering the dose of AAV-U6 vectors.  AAVs contg. the weaker H1 promoter did not cause liver injury, but their therapeutic efficacy was highly dependent on the sequence of the shRNA.  Mice treated with the toxic U6-promoter-driven shRNA showed little change in hepatic microRNA levels, but a dramatic increase in hepatic leukocytes and inflammatory cytokines and chemokines.  Hepatotoxicity was completely absent in immunodeficient mice and significantly alleviated in wild-type mice depleted of macrophages and granulocytes, suggesting that host inflammatory responses are the major cause of liver injury induced by the overexpressed shRNAs from AAV-U6 vectors.  Our results demonstrate that selection of a highly potent shRNA and control its expression level is crit. to achieve sustained HBV suppression without inducing inflammatory side effects.  Sun and colleagues generate a panel of AAV vectors contg. various promoters and hepatitis B virus (HBV)-specific short hairpin RNAs (shRNAs) to investigate factors that contribute to the efficacy and pathogenesis of AAV-mediated RNA interference.  They show that injecting HBV transgenic mice with high doses of AAV vectors contg. the U6 promoter produce abundant shRNAs, transiently inhibit HBV, but induce severe hepatotoxicity.  By contrast, AAVs contg. the weaker H1 promoter do not cause liver injury, but their therapeutic efficacy is highly dependent on the sequence of the shRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKFCUPhfZ4rVg90H21EOLACvtfcHk0lg1nwITlLe_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OisrvL&md5=c75904536c3b64fc89e590e7febf5a98</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1089%2Fhum.2012.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fhum.2012.239%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%2BP.%26aulast%3DWu%26aufirst%3DT.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DShih%26aufirst%3DY.%2BM.%26aulast%3DTsuneyama%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DM.%2BH.%26atitle%3DStudies%2520of%2520efficacy%2520and%2520liver%2520toxicity%2520related%2520to%2520adeno-associated%2520virus-mediated%2520RNA%2520interference%26jtitle%3DHum.%2520Gene%2520Ther.%26date%3D2013%26volume%3D24%26spage%3D739%26epage%3D750%26doi%3D10.1089%2Fhum.2012.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Bobbin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, J. J.</span><span> </span><span class="NLM_article-title">RNA interference (RNAi)-based therapeutics: delivering on the promise?</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010715-103633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1146%2Fannurev-pharmtox-010715-103633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26738473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1SrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=103-22&author=M.+L.+Bobbinauthor=J.+J.+Rossi&title=RNA+interference+%28RNAi%29-based+therapeutics%3A+delivering+on+the+promise%3F&doi=10.1146%2Fannurev-pharmtox-010715-103633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?</span></div><div class="casAuthors">Bobbin, Maggie L.; Rossi, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-122</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A resurgence in clin. trials using RNA interference (RNAi) occurred in 2012.  Although there were initial difficulties in achieving efficacious results with RNAi without toxic side effects, advances in delivery and improved chem. made this resurgence possible.  More than 20 RNAi-based therapeutics are currently in clin. trials, and several of these are Phase III trials.  Continued pos. results from these trials have helped bolster further attempts to develop clin. relevant RNAi therapies.  With a wide variety of disease targets to choose from, the first RNAi therapeutic to be clin. approved is not far off.  This review covers recently established and completed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMjR4UbfY2prVg90H21EOLACvtfcHk0lhduFGDwXJVJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1SrsQ%253D%253D&md5=cfa02ab57293143b0c6f0b2e22cf5474</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010715-103633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010715-103633%26sid%3Dliteratum%253Aachs%26aulast%3DBobbin%26aufirst%3DM.%2BL.%26aulast%3DRossi%26aufirst%3DJ.%2BJ.%26atitle%3DRNA%2520interference%2520%2528RNAi%2529-based%2520therapeutics%253A%2520delivering%2520on%2520the%2520promise%253F%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D56%26spage%3D103%26epage%3D22%26doi%3D10.1146%2Fannurev-pharmtox-010715-103633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Ivacik, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnot, P.</span><span> </span><span class="NLM_article-title">Countering hepatitis B virus infection using RNAi: how far are we from the clinic?</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1002/rmv.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Frmv.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=21913277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=383-396&author=D.+Ivacikauthor=A.+Elyauthor=P.+Arbuthnot&title=Countering+hepatitis+B+virus+infection+using+RNAi%3A+how+far+are+we+from+the+clinic%3F&doi=10.1002%2Frmv.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Countering hepatitis B virus infection using RNAi: how far are we from the clinic?</span></div><div class="casAuthors">Ivacik, Dejana; Ely, Abdullah; Arbuthnot, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">383-396</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Globally, persistent HBV infection is a significant cause of public health problems.  Currently available HBV therapies have variable efficacy and there is a need to develop improved treatment to prevent cirrhosis and hepatocellular carcinoma.  Although RNA interference (RNAi)-based approaches have shown promise, accomplishing safe and sustained silencing by RNAi activators, as well as their efficient delivery to hepatocytes have hampered clin. translation of this very promising technol.  Expressed silencers may be produced in a sustained manner from stable DNA templates, which makes them suited to treatment of chronic HBV infection.  DNA expression cassettes can be incorporated into both viral and non-viral vectors, but in vivo delivery of these cassettes with non-viral vectors is currently inefficient.  Synthetic short interfering RNAs (siRNAs), which may be chem. modified to improve stability, specificity and efficacy, are more conveniently delivered to their cytoplasmic sites of action with synthetic non-viral vectors.  However, the short duration of action of this class of RNAi activator is a drawback for treatment of chronic HBV infection.  Despite the impressive progress that has been made in developing highly effective HBV gene silencers, challenges continue to face implementation of RNAi-based HBV therapy.  This review will discuss the current status of the topic and consider the developments that are required to advance RNAi-based HBV therapy to clin. application.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoORCuJxyJIxrVg90H21EOLACvtfcHk0lhduFGDwXJVJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktLzF&md5=39c6e6e204bea3dc2a2b446ebeaadf89</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Frmv.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.705%26sid%3Dliteratum%253Aachs%26aulast%3DIvacik%26aufirst%3DD.%26aulast%3DEly%26aufirst%3DA.%26aulast%3DArbuthnot%26aufirst%3DP.%26atitle%3DCountering%2520hepatitis%2520B%2520virus%2520infection%2520using%2520RNAi%253A%2520how%2520far%2520are%2520we%2520from%2520the%2520clinic%253F%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2011%26volume%3D21%26spage%3D383%26epage%3D396%26doi%3D10.1002%2Frmv.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Haussecker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, M. A.</span><span> </span><span class="NLM_article-title">Drugging RNAi</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1070</span><span class="refDoi"> DOI: 10.1126/science.1252967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1126%2Fscience.1252967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=1069-1070&author=D.+Hausseckerauthor=M.+A.+Kay&title=Drugging+RNAi&doi=10.1126%2Fscience.1252967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.1252967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1252967%26sid%3Dliteratum%253Aachs%26aulast%3DHaussecker%26aufirst%3DD.%26aulast%3DKay%26aufirst%3DM.%2BA.%26atitle%3DDrugging%2520RNAi%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D1069%26epage%3D1070%26doi%3D10.1126%2Fscience.1252967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Gish, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Given, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J. Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schluep, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2015.06.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=97-108&author=R.+G.+Gishauthor=M.+F.+Yuenauthor=H.+L.+Y.+Chanauthor=B.+D.+Givenauthor=C.+L.+Laiauthor=S.+A.+Locarniniauthor=J.+Y.+N.+Lauauthor=C.+I.+Wooddellauthor=T.+Schluepauthor=D.+L.+Lewis&title=Synthetic+RNAi+triggers+and+their+use+in+chronic+hepatitis+B+therapies+with+curative+intent&doi=10.1016%2Fj.antiviral.2015.06.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DGish%26aufirst%3DR.%2BG.%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DGiven%26aufirst%3DB.%2BD.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DLocarnini%26aufirst%3DS.%2BA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DSchluep%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DSynthetic%2520RNAi%2520triggers%2520and%2520their%2520use%2520in%2520chronic%2520hepatitis%2520B%2520therapies%2520with%2520curative%2520intent%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.antiviral.2015.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Wong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trubetskoy, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozema, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo</span> <span class="citation_source-journal">Nucleic Acid Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.1089/nat.2012.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1089%2Fnat.2012.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23181701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=380-390&author=S.+C.+Wongauthor=J.+J.+Kleinauthor=H.+L.+Hamiltonauthor=Q.+L.+Chuauthor=C.+L.+Freyauthor=V.+S.+Trubetskoyauthor=J.+Heggeauthor=D.+Wakefieldauthor=D.+B.+Rozemaauthor=D.+L.+Lewis&title=Co-injection+of+a+targeted%2C+reversibly+masked+endosomolytic+polymer+dramatically+improves+the+efficacy+of+cholesterol-conjugated+small+interfering+RNAs+in+vivo&doi=10.1089%2Fnat.2012.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo</span></div><div class="casAuthors">Wong, So C.; Klein, Jason J.; Hamilton, Holly L.; Chu, Qili; Frey, Christina L.; Trubetskoy, Vladimir S.; Hegge, Julia; Wakefield, Darren; Rozema, David B.; Lewis, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acid Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">380-390</span>CODEN:
                <span class="NLM_cas:coden">NATUCU</span>;
        ISSN:<span class="NLM_cas:issn">2159-3337</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Effective in vivo delivery of small interfering (siRNA) has been a major obstacle in the development of RNA interference therapeutics.  One of the first attempts to overcome this obstacle utilized i.v. injection of cholesterol-conjugated siRNA (chol-siRNA).  Although studies in mice revealed target gene knockdown in the liver, delivery was relatively inefficient, requiring 3 daily injections of 50 mg/kg of chol-siRNA to obtain measurable redn. in gene expression.  Here we present a new delivery approach that increases the efficacy of the chol-siRNA over 500-fold and allows over 90% redn. in target gene expression in mice and, for the first time, high levels of gene knockdown in non-human primates.  This improved efficacy is achieved by the co-injection of a hepatocyte-targeted and reversibly masked endosomolytic polymer.  We show that knockdown is absolutely dependent on the presence of hepatocyte-targeting ligand on the polymer, the cognate hepatocyte receptor, and the cholesterol moiety of the siRNA.  Importantly, we provide evidence that this increase in efficacy is not dependent on interactions between the chol-siRNA with the polymer prior to injection or in the bloodstream.  The simplicity of the formulation and efficacy of this mode of siRNA delivery should prove beneficial in the use of siRNA as a therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfjeJYV0pmZbVg90H21EOLACvtfcHk0ljPfHIb-_rNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLvO&md5=53530b2e7779300ce6eaf25afcdff12e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1089%2Fnat.2012.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fnat.2012.0389%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BC.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DChu%26aufirst%3DQ.%2BL.%26aulast%3DFrey%26aufirst%3DC.%2BL.%26aulast%3DTrubetskoy%26aufirst%3DV.%2BS.%26aulast%3DHegge%26aufirst%3DJ.%26aulast%3DWakefield%26aufirst%3DD.%26aulast%3DRozema%26aufirst%3DD.%2BB.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DCo-injection%2520of%2520a%2520targeted%252C%2520reversibly%2520masked%2520endosomolytic%2520polymer%2520dramatically%2520improves%2520the%2520efficacy%2520of%2520cholesterol-conjugated%2520small%2520interfering%2520RNAs%2520in%2520vivo%26jtitle%3DNucleic%2520Acid%2520Ther.%26date%3D2012%26volume%3D22%26spage%3D380%26epage%3D390%26doi%3D10.1089%2Fnat.2012.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozema, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegge, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oropeza, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehl, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahn-Hofmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadwiger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vornlocher, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection</span> <span class="citation_source-journal">Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1038/mt.2013.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fmt.2013.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=23439496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=973-985&author=C.+I.+Wooddellauthor=D.+B.+Rozemaauthor=M.+Hossbachauthor=M.+Johnauthor=H.+L.+Hamiltonauthor=Q.+Chuauthor=J.+O.+Heggeauthor=J.+J.+Kleinauthor=D.+H.+Wakefieldauthor=C.+E.+Oropezaauthor=J.+Deckertauthor=I.+Roehlauthor=K.+Jahn-Hofmannauthor=P.+Hadwigerauthor=H.+P.+Vornlocherauthor=A.+McLachlanauthor=D.+L.+Lewis&title=Hepatocyte-targeted+RNAi+therapeutics+for+the+treatment+of+chronic+hepatitis+B+virus+infection&doi=10.1038%2Fmt.2013.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection</span></div><div class="casAuthors">Wooddell, Christine I.; Rozema, David B.; Hossbach, Markus; John, Matthias; Hamilton, Holly L.; Chu, Qili; Hegge, Julia O.; Klein, Jason J.; Wakefield, Darren H.; Oropeza, Claudia E.; Deckert, Jochen; Roehl, Ingo; Jahn-Hofmann, Kerstin; Hadwiger, Philipp; Vornlocher, Hans-Peter; McLachlan, Alan; Lewis, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-985</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B virus (HBV) infection in a fundamentally different manner than current therapies.  Using RNAi, it is possible to knock down expression of viral RNAs including the pregenomic RNA from which the replicative intermediates are derived, thus reducing viral load, and the viral proteins that result in disease and impact the immune system's ability to eliminate the virus.  We previously described the use of polymer-based Dynamic PolyConjugate (DPC) for the targeted delivery of siRNAs to hepatocytes.  Here, we first show in proof-of-concept studies that simple coinjection of a hepatocyte-targeted, N-acetylgalactosamine-conjugated melittin-like peptide (NAG-MLP) with a liver-tropic cholesterol-conjugated siRNA (chol-siRNA) targeting coagulation factor VII (F7) results in efficient F7 knockdown in mice and nonhuman primates without changes in clin. chem. or induction of cytokines.  Using transient and transgenic mouse models of HBV infection, we show that a single coinjection of NAG-MLP with potent chol-siRNAs targeting conserved HBV sequences resulted in multilog repression of viral RNA, proteins, and viral DNA with long duration of effect.  These results suggest that coinjection of NAG-MLP and chol-siHBVs holds great promise as a new therapeutic for patients chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUOFxUJIv1LVg90H21EOLACvtfcHk0ljPfHIb-_rNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegsL4%253D&md5=8154fe6812f5a931df54654c351cb5f4</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fmt.2013.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2013.31%26sid%3Dliteratum%253Aachs%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DRozema%26aufirst%3DD.%2BB.%26aulast%3DHossbach%26aufirst%3DM.%26aulast%3DJohn%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DHegge%26aufirst%3DJ.%2BO.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DWakefield%26aufirst%3DD.%2BH.%26aulast%3DOropeza%26aufirst%3DC.%2BE.%26aulast%3DDeckert%26aufirst%3DJ.%26aulast%3DRoehl%26aufirst%3DI.%26aulast%3DJahn-Hofmann%26aufirst%3DK.%26aulast%3DHadwiger%26aufirst%3DP.%26aulast%3DVornlocher%26aufirst%3DH.%2BP.%26aulast%3DMcLachlan%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DHepatocyte-targeted%2520RNAi%2520therapeutics%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D973%26epage%3D985%26doi%3D10.1038%2Fmt.2013.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Lanford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooddell, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oropeza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Given, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. L.</span><span> </span><span class="NLM_article-title">ARC-520 RNAi therapeutic reduces hepatitis B virus DNA, s antigen and e antigen in a chimpanzee with a very high viral titer</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">707A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=707A&author=R.+E.+Lanfordauthor=C.+I.+Wooddellauthor=D.+Chavezauthor=C.+Oropezaauthor=Q.+Chuauthor=H.+L.+Hamiltonauthor=A.+McLachlanauthor=B.+Givenauthor=C.+R.+Anzaloneauthor=D.+L.+Lewis&title=ARC-520+RNAi+therapeutic+reduces+hepatitis+B+virus+DNA%2C+s+antigen+and+e+antigen+in+a+chimpanzee+with+a+very+high+viral+titer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanford%26aufirst%3DR.%2BE.%26aulast%3DWooddell%26aufirst%3DC.%2BI.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DOropeza%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DHamilton%26aufirst%3DH.%2BL.%26aulast%3DMcLachlan%26aufirst%3DA.%26aulast%3DGiven%26aufirst%3DB.%26aulast%3DAnzalone%26aufirst%3DC.%2BR.%26aulast%3DLewis%26aufirst%3DD.%2BL.%26atitle%3DARC-520%2520RNAi%2520therapeutic%2520reduces%2520hepatitis%2520B%2520virus%2520DNA%252C%2520s%2520antigen%2520and%2520e%2520antigen%2520in%2520a%2520chimpanzee%2520with%2520a%2520very%2520high%2520viral%2520titer%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D707A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Sepp-Lorenzino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprague, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morskaya, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasperkovitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir-Stead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carito, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluri, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attarwala, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutabarat, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charisse, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchimanchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manoharan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyrzykiewicz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashmi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galil, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslett, P.</span><span> </span><span class="NLM_article-title">GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">224A</span><span class="NLM_x">–</span> <span class="NLM_lpage">225A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=224A-225A&author=L.+Sepp-Lorenzinoauthor=A.+G.+Spragueauthor=T.+Mayoauthor=T.+M.+Nguyenauthor=S.+S.+Morskayaauthor=H.+L.+Xuauthor=S.+Milsteinauthor=G.+Hinkleauthor=P.+Kasperkovitzauthor=R.+G.+Duncanauthor=N.+Keir-Steadauthor=B.+Caritoauthor=L.+Moranauthor=P.+Chaturvediauthor=K.+C.+Aluriauthor=H.+Attarwalaauthor=R.+M.+Hutabaratauthor=J.+Liuauthor=C.+Tranauthor=Q.+F.+Wangauthor=B.+S.+Brighamauthor=A.+Akincauthor=K.+B.+Charisseauthor=V.+Jadhavauthor=S.+Kuchimanchiauthor=M.+A.+Maierauthor=M.+Manoharanauthor=R.+Meyersauthor=T.+Wyrzykiewiczauthor=H.+Hashmiauthor=J.+Donovanauthor=T.+Mooneyauthor=D.+Freedmanauthor=T.+P.+Senguptaauthor=K.+Galilauthor=E.+Coakleyauthor=P.+Haslett&title=GalNAc-siRNA+conjugate+ALN-HBV+targets+a+highly+conserved%2C+pan-genotypic+X-orf+viral+site+and+mediates+profound+and+durable+HBsAg+silencing+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSepp-Lorenzino%26aufirst%3DL.%26aulast%3DSprague%26aufirst%3DA.%2BG.%26aulast%3DMayo%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DMorskaya%26aufirst%3DS.%2BS.%26aulast%3DXu%26aufirst%3DH.%2BL.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DHinkle%26aufirst%3DG.%26aulast%3DKasperkovitz%26aufirst%3DP.%26aulast%3DDuncan%26aufirst%3DR.%2BG.%26aulast%3DKeir-Stead%26aufirst%3DN.%26aulast%3DCarito%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DAluri%26aufirst%3DK.%2BC.%26aulast%3DAttarwala%26aufirst%3DH.%26aulast%3DHutabarat%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DQ.%2BF.%26aulast%3DBrigham%26aufirst%3DB.%2BS.%26aulast%3DAkinc%26aufirst%3DA.%26aulast%3DCharisse%26aufirst%3DK.%2BB.%26aulast%3DJadhav%26aufirst%3DV.%26aulast%3DKuchimanchi%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DM.%2BA.%26aulast%3DManoharan%26aufirst%3DM.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DWyrzykiewicz%26aufirst%3DT.%26aulast%3DHashmi%26aufirst%3DH.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DFreedman%26aufirst%3DD.%26aulast%3DSengupta%26aufirst%3DT.%2BP.%26aulast%3DGalil%26aufirst%3DK.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DHaslett%26aufirst%3DP.%26atitle%3DGalNAc-siRNA%2520conjugate%2520ALN-HBV%2520targets%2520a%2520highly%2520conserved%252C%2520pan-genotypic%2520X-orf%2520viral%2520site%2520and%2520mediates%2520profound%2520and%2520durable%2520HBsAg%2520silencing%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D224A%26epage%3D225A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Maepa, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelofse, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnot, P.</span><span> </span><span class="NLM_article-title">Progress and prospects of anti-HBV gene therapy development</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">17589</span><span class="NLM_x">–</span> <span class="NLM_lpage">17610</span><span class="refDoi"> DOI: 10.3390/ijms160817589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3390%2Fijms160817589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=26263978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVags7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=17589-17610&author=M.+B.+Maepaauthor=I.+Roelofseauthor=A.+Elyauthor=P.+Arbuthnot&title=Progress+and+prospects+of+anti-HBV+gene+therapy+development&doi=10.3390%2Fijms160817589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and prospects of anti-HBV gene therapy development</span></div><div class="casAuthors">Maepa, Mohube B.; Roelofse, Ilke; Ely, Abdullah; Arbuthnot, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">17589-17610</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Despite the availability of an effective vaccine against hepatitis B virus (HBV), chronic infection with the virus remains a major global health concern.  Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance.  This has prompted vigorous research on developing better drugs against chronic HBV infection.  Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive.  This has led to development of better HBV infection models and discovery of new drug candidates.  Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, esp. covalently closed circular DNA (cccDNA).  For the past few decades, nucleic acid-based therapy has emerged as an attractive alternative that may result in complete clearance of HBV in infected patients.  Several genetic anti-HBV strategies have been developed.  The most studied approaches include the use of antisense oligonucleotides, ribozymes, RNA interference effectors and gene editing tools.  This review will summarize recent developments and progress made in the use of gene therapy against HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokFxCwdEXC5rVg90H21EOLACvtfcHk0ljyYS4qa3S7CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVags7g%253D&md5=b5e0a4ceeb2a8a954273d7d3e40b6a1f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3390%2Fijms160817589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160817589%26sid%3Dliteratum%253Aachs%26aulast%3DMaepa%26aufirst%3DM.%2BB.%26aulast%3DRoelofse%26aufirst%3DI.%26aulast%3DEly%26aufirst%3DA.%26aulast%3DArbuthnot%26aufirst%3DP.%26atitle%3DProgress%2520and%2520prospects%2520of%2520anti-HBV%2520gene%2520therapy%2520development%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D17589%26epage%3D17610%26doi%3D10.3390%2Fijms160817589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Goodarzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tewari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watabe, K.</span><span> </span><span class="NLM_article-title">Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3021</span><span class="NLM_x">–</span> <span class="NLM_lpage">3025</span><span class="refDoi"> DOI: 10.1099/0022-1317-71-12-3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1099%2F0022-1317-71-12-3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=2177093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlGlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1990&pages=3021-3025&author=G.+Goodarziauthor=S.+C.+Grossauthor=A.+Tewariauthor=K.+Watabe&title=Antisense+oligodeoxyribonucleotides+inhibit+the+expression+of+the+gene+for+hepatitis+B+virus+surface+antigen&doi=10.1099%2F0022-1317-71-12-3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen</span></div><div class="casAuthors">Goodarzi, Goodarz; Gross, Steven C.; Tewari, Arun; Watabe, Kounosuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3021-5</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    </div><div class="casAbstract">The effect of a series of antisense oligodeoxyribonucleotides [oligo(dN)] on the expression of the surface antigen (HBsAg) gene of human hepatitis B virus (HBV) was examd. in hepatocellular carcinoma cells contg. integrated HBV genomes.  Of a no. of antisense oligo(dN) tested, synthetic 15-mers directed at the cap site of mRNA and regions of the translational initiation site of the HBsAg gene were highly effective and inhibited viral gene expression by ≤96%.  The inhibition was specific for the HBsAg gene and appeared to be at the level of translation.  These results suggest a therapeutic potential for antisense oligo(dN) in the treatment of patients chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKna7HqQuae7Vg90H21EOLACvtfcHk0ljyYS4qa3S7CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlGlsrc%253D&md5=7acc2415580754e3f798d943581e18b6</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-71-12-3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-71-12-3021%26sid%3Dliteratum%253Aachs%26aulast%3DGoodarzi%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DS.%2BC.%26aulast%3DTewari%26aufirst%3DA.%26aulast%3DWatabe%26aufirst%3DK.%26atitle%3DAntisense%2520oligodeoxyribonucleotides%2520inhibit%2520the%2520expression%2520of%2520the%2520gene%2520for%2520hepatitis%2520B%2520virus%2520surface%2520antigen%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D1990%26volume%3D71%26spage%3D3021%26epage%3D3025%26doi%3D10.1099%2F0022-1317-71-12-3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerin, J. L.</span><span> </span><span class="NLM_article-title">Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/0166-3542(95)00050-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2F0166-3542%2895%2900050-V" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=225-242&author=B.+E.+Korbaauthor=J.+L.+Gerin&title=Antisense+oligonucleotides+are+effective+inhibitors+of+hepatitis+B+virus+replication+in+vitro&doi=10.1016%2F0166-3542%2895%2900050-V"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2895%2900050-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252895%252900050-V%26sid%3Dliteratum%253Aachs%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DGerin%26aufirst%3DJ.%2BL.%26atitle%3DAntisense%2520oligonucleotides%2520are%2520effective%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520replication%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D1995%26volume%3D28%26spage%3D225%26epage%3D242%26doi%3D10.1016%2F0166-3542%2895%2900050-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Nakazono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1297</span><span class="NLM_x">–</span> <span class="NLM_lpage">1303</span><span class="refDoi"> DOI: 10.1002/hep.510230601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1002%2Fhep.510230601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1996&pages=1297-1303&author=K.+Nakazonoauthor=Y.+Itoauthor=C.+H.+Wuauthor=G.+Y.+Wu&title=Inhibition+of+hepatitis+B+virus+replication+by+targeted+pretreatment+of+complexed+antisense+DNA+in+vitro&doi=10.1002%2Fhep.510230601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fhep.510230601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510230601%26sid%3Dliteratum%253Aachs%26aulast%3DNakazono%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DG.%2BY.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520targeted%2520pretreatment%2520of%2520complexed%2520antisense%2520DNA%2520in%2520vitro%26jtitle%3DHepatology%26date%3D1996%26volume%3D23%26spage%3D1297%26epage%3D1303%26doi%3D10.1002%2Fhep.510230601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Offensperger, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offensperger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teubner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igloi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerok, W.</span><span> </span><span class="NLM_article-title">In vivo inhibition of duck hepatitis B virus-replication and gene-expression by phosphorothioate modified antisense oligodeoxynucleotides</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1257</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=1257-1262&author=W.+B.+Offenspergerauthor=S.+Offenspergerauthor=E.+Walterauthor=K.+Teubnerauthor=G.+Igloiauthor=H.+E.+Blumauthor=W.+Gerok&title=In+vivo+inhibition+of+duck+hepatitis+B+virus-replication+and+gene-expression+by+phosphorothioate+modified+antisense+oligodeoxynucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOffensperger%26aufirst%3DW.%2BB.%26aulast%3DOffensperger%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DE.%26aulast%3DTeubner%26aufirst%3DK.%26aulast%3DIgloi%26aufirst%3DG.%26aulast%3DBlum%26aufirst%3DH.%2BE.%26aulast%3DGerok%26aufirst%3DW.%26atitle%3DIn%2520vivo%2520inhibition%2520of%2520duck%2520hepatitis%2520B%2520virus-replication%2520and%2520gene-expression%2520by%2520phosphorothioate%2520modified%2520antisense%2520oligodeoxynucleotides%26jtitle%3DEMBO%2520J.%26date%3D1993%26volume%3D12%26spage%3D1257%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span> </span><span class="NLM_article-title">Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">12436</span><span class="NLM_x">–</span> <span class="NLM_lpage">12439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=12436-12439&author=G.+Wuauthor=C.+H.+Wu&title=Specific+inhibition+of+hepatitis+B+viral+gene+expression+in+vitro+by+targeted+antisense+oligonucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DC.%2BH.%26atitle%3DSpecific%2520inhibition%2520of%2520hepatitis%2520B%2520viral%2520gene%2520expression%2520in%2520vitro%2520by%2520targeted%2520antisense%2520oligonucleotides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D12436%26epage%3D12439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Yao, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span> </span><span class="NLM_article-title">In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.1996.tb00076.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fj.1365-2893.1996.tb00076.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=8736236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADyaK28zjs1GnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=19-22&author=Z.+Q.+Yaoauthor=Y.+X.+Zhouauthor=X.+M.+Fengauthor=C.+X.+Chenauthor=J.+Guo&title=In+vivo+inhibition+of+hepatitis+B+viral+gene+expression+by+antisense+phosphorothioate+oligodeoxynucleotides+in+athymic+nude+mice&doi=10.1111%2Fj.1365-2893.1996.tb00076.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice</span></div><div class="casAuthors">Yao Z; Zhou Y; Feng X; Chen C; Guo J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-22</span>
        ISSN:<span class="NLM_cas:issn">1352-0504</span>.
    </div><div class="casAbstract">Antisense oligodeoxynucleotides strategies have been used both to study normal gene function and to block gene expression therapeutically.  We have previously shown that a number of antisense oligonucleotides against hepatitis B virus (HBV) mRNA are able to inhibit viral gene expression in vitro.  Here we report the establishment of an animal model producing HBV markers in athymic nude mice and inhibition of HBV gene expression and replication by antisense DNA in vivo. 2.2.15 cells (Hep-G2 cell line transfected with HBV genomes) were injected subcutaneously (s.c.) into athymic BALB/c nude mice at a total cell number of 0.5-1 x 10(8) per mouse.  Transplanted tumours developed about 2 weeks after inoculation.  Hepatitis B surface and e antigens (HBsAg and HBeAg), as well as HBV DNA, could be detected in the circulation of tumour-bearing mice.  Hepatitis B surface antigen and hepatitis B core antigen (HBcAg) were demonstrated in tumour cells.  After 10 days of tumour growth, antisense phosphorothioate oligonucleotide, complementary to the cap site of the SP II promoter of HBV mRNA, were injected by infiltration into or around the tumour as a daily dose of 20 micrograms per gram body weight.  Treatment for a total of 10 days resulted in an effective inhibition of viral replication and gene expression.  These results suggest therapeutic potential for antisense oligomers in the treatment of patients who are chronically infected with HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7rczBYn8SAHtlzo9xastyfW6udTcc2eZbJRAyu6X8Sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zjs1GnsA%253D%253D&md5=8f657e12f04ebf29458a224dacd9747e</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.1996.tb00076.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.1996.tb00076.x%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BX.%26aulast%3DFeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%26atitle%3DIn%2520vivo%2520inhibition%2520of%2520hepatitis%2520B%2520viral%2520gene%2520expression%2520by%2520antisense%2520phosphorothioate%2520oligodeoxynucleotides%2520in%2520athymic%2520nude%2520mice%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1996%26volume%3D3%26spage%3D19%26epage%3D22%26doi%3D10.1111%2Fj.1365-2893.1996.tb00076.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Yao, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. Q.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus in vitro by antisense oligonucleotides</span> <span class="citation_source-journal">Acta Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=35-39&author=Z.+Q.+Yaoauthor=Y.+X.+Zhouauthor=J.+Guoauthor=Z.+H.+Fengauthor=X.+M.+Fengauthor=C.+X.+Chenauthor=J.+Z.+Jiaoauthor=S.+Q.+Wang&title=Inhibition+of+hepatitis+B+virus+in+vitro+by+antisense+oligonucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%2BH.%26aulast%3DFeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BX.%26aulast%3DJiao%26aufirst%3DJ.%2BZ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%2520by%2520antisense%2520oligonucleotides%26jtitle%3DActa%2520Virol.%26date%3D1996%26volume%3D40%26spage%3D35%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Sun, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D. R.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2011.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bbrc.2011.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=430-435&author=Z.+Sunauthor=W.+Q.+Xiangauthor=Y.+J.+Guoauthor=Z.+Chenauthor=W.+Liuauthor=D.+R.+Lu&title=Inhibition+of+hepatitis+B+virus+%28HBV%29+by+LNA-mediated+nuclear+interference+with+HBV+DNA+transcription&doi=10.1016%2Fj.bbrc.2011.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DXiang%26aufirst%3DW.%2BQ.%26aulast%3DGuo%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DD.%2BR.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520by%2520LNA-mediated%2520nuclear%2520interference%2520with%2520HBV%2520DNA%2520transcription%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D409%26spage%3D430%26epage%3D435%26doi%3D10.1016%2Fj.bbrc.2011.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Noordeen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jilbert, A. R.</span><span> </span><span class="NLM_article-title">Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5306</span><span class="refDoi"> DOI: 10.1128/AAC.01005-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1128%2FAAC.01005-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5299-5306&author=F.+Noordeenauthor=A.+Vaillantauthor=A.+R.+Jilbert&title=Nucleic+acid+polymers+prevent+the+establishment+of+duck+hepatitis+B+virus+infection+in+vivo&doi=10.1128%2FAAC.01005-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1128%2FAAC.01005-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01005-13%26sid%3Dliteratum%253Aachs%26aulast%3DNoordeen%26aufirst%3DF.%26aulast%3DVaillant%26aufirst%3DA.%26aulast%3DJilbert%26aufirst%3DA.%2BR.%26atitle%3DNucleic%2520acid%2520polymers%2520prevent%2520the%2520establishment%2520of%2520duck%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5299%26epage%3D5306%26doi%3D10.1128%2FAAC.01005-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Almahtab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0156667</span><span class="refDoi"> DOI: 10.1371/journal.pone.0156667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1371%2Fjournal.pone.0156667" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0156667&author=M.+Almahtabauthor=M.+Bazinetauthor=A.+Vaillant&title=Safety+and+efficacy+of+nucleic+acid+polymers+in+monotherapy+and+combined+with+immunotherapy+in+treatment-naive+bangladeshi+patients+with+HBeAg%2B+chronic+hepatitis+B+infection&doi=10.1371%2Fjournal.pone.0156667"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0156667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0156667%26sid%3Dliteratum%253Aachs%26aulast%3DAlmahtab%26aufirst%3DM.%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520nucleic%2520acid%2520polymers%2520in%2520monotherapy%2520and%2520combined%2520with%2520immunotherapy%2520in%2520treatment-naive%2520bangladeshi%2520patients%2520with%2520HBeAg%252B%2520chronic%2520hepatitis%2520B%2520infection%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0156667%26doi%3D10.1371%2Fjournal.pone.0156667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantea, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebotarescu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojuhari, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimbei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer rep 2139 in caucasian patients with chronic HBV/HDV co-infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S257</span><span class="NLM_x">–</span> <span class="NLM_lpage">S258</span><span class="refDoi"> DOI: 10.1016/S0168-8278(15)30148-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0168-8278%2815%2930148-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25463532" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S257-S258&author=M.+Bazinetauthor=V.+Panteaauthor=V.+Cebotarescuauthor=L.+Cojuhariauthor=P.+Jimbeiauthor=A.+Vaillant&title=Significant+reduction+of+HBsAg+and+HDV+RNA+by+the+nucleic+acid+polymer+rep+2139+in+caucasian+patients+with+chronic+HBV%2FHDV+co-infection&doi=10.1016%2FS0168-8278%2815%2930148-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2815%2930148-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252815%252930148-3%26sid%3Dliteratum%253Aachs%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DPantea%26aufirst%3DV.%26aulast%3DCebotarescu%26aufirst%3DV.%26aulast%3DCojuhari%26aufirst%3DL.%26aulast%3DJimbei%26aufirst%3DP.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DSignificant%2520reduction%2520of%2520HBsAg%2520and%2520HDV%2520RNA%2520by%2520the%2520nucleic%2520acid%2520polymer%2520rep%25202139%2520in%2520caucasian%2520patients%2520with%2520chronic%2520HBV%252FHDV%2520co-infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS257%26epage%3DS258%26doi%3D10.1016%2FS0168-8278%2815%2930148-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Bazinet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantea, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cebotarescu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojuhari, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimbei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillant, A.</span><span> </span><span class="NLM_article-title">REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV/HDV co-infection</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1111%2Fjvh.08_12424" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=5-6&author=M.+Bazinetauthor=V.+Panteaauthor=V.+Cebotarescuauthor=L.+Cojuhariauthor=P.+Jimbeiauthor=A.+Vaillant&title=REP+2139+monotherapy+and+combination+therapy+with+pegylated+interferon%3A+safety+and+potent+reduction+of+HBsAg+and+HDV+RNA+in+Caucasian+patients+with+chronic+HBV%2FHDV+co-infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1111%2Fjvh.08_12424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.08_12424%26sid%3Dliteratum%253Aachs%26aulast%3DBazinet%26aufirst%3DM.%26aulast%3DPantea%26aufirst%3DV.%26aulast%3DCebotarescu%26aufirst%3DV.%26aulast%3DCojuhari%26aufirst%3DL.%26aulast%3DJimbei%26aufirst%3DP.%26aulast%3DVaillant%26aufirst%3DA.%26atitle%3DREP%25202139%2520monotherapy%2520and%2520combination%2520therapy%2520with%2520pegylated%2520interferon%253A%2520safety%2520and%2520potent%2520reduction%2520of%2520HBsAg%2520and%2520HDV%2520RNA%2520in%2520Caucasian%2520patients%2520with%2520chronic%2520HBV%252FHDV%2520co-infection%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2015%26volume%3D22%26spage%3D5%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Susman, E. D.</span><span> </span><span class="NLM_article-title">New agent shows promise in HBV/HDV co-infected patients</span> <span class="citation_source-journal">Oncol. Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1097/01.COT.0000467336.34244.7a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1097%2F01.COT.0000467336.34244.7a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=57-59&author=E.+D.+Susman&title=New+agent+shows+promise+in+HBV%2FHDV+co-infected+patients&doi=10.1097%2F01.COT.0000467336.34244.7a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1097%2F01.COT.0000467336.34244.7a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.COT.0000467336.34244.7a%26sid%3Dliteratum%253Aachs%26aulast%3DSusman%26aufirst%3DE.%2BD.%26atitle%3DNew%2520agent%2520shows%2520promise%2520in%2520HBV%252FHDV%2520co-infected%2520patients%26jtitle%3DOncol.%2520Times%26date%3D2015%26volume%3D37%26spage%3D57%26epage%3D59%26doi%3D10.1097%2F01.COT.0000467336.34244.7a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Newman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragg, G. M.</span><span> </span><span class="NLM_article-title">Natural products as sources of new drugs over the last 25 years</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1021/np068054v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np068054v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=461-477&author=D.+J.+Newmanauthor=G.+M.+Cragg&title=Natural+products+as+sources+of+new+drugs+over+the+last+25+years&doi=10.1021%2Fnp068054v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Products as Sources of New Drugs over the Last 25 Years</span></div><div class="casAuthors">Newman, David J.; Cragg, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-477</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">A review.  This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003.  In the case of all approved agents the time frame has been extended to include the 251/2 years from 01/1981 to 06/2006 for all diseases worldwide and from 1950 (earliest so far identified) to 06/2006 for all approved antitumor drugs worldwide.  We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions.  From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well.  Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 155 small mols., 73% are other than "S" (synthetic), with 47% actually being either natural products or directly derived therefrom.  In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the antiinfective area being dependent on natural products and their structures.  Although combinatorial chem. techniques have succeeded as methods of optimizing structures and have, in fact, been used in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compd. approved as a drug in this 25 plus year time frame.  We wish to draw the attention of readers to the rapidly evolving recognition that a significant no. of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpih5kusSUibVg90H21EOLACvtfcHk0liXb4igEHVd-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKrsro%253D&md5=9fc0909750367ccd3b97589aaf087cdf</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fnp068054v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp068054v%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26atitle%3DNatural%2520products%2520as%2520sources%2520of%2520new%2520drugs%2520over%2520the%2520last%252025%2520years%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2007%26volume%3D70%26spage%3D461%26epage%3D477%26doi%3D10.1021%2Fnp068054v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Matsunaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamisuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, F.</span><span> </span><span class="NLM_article-title">Isolation and structure of vanitaracin A, a novel anti-hepatitis B virus compound from Talaromyces sp</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4325</span><span class="NLM_x">–</span> <span class="NLM_lpage">4328</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2015.07.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4325-4328&author=H.+Matsunagaauthor=S.+Kamisukiauthor=M.+Kanekoauthor=Y.+Yamaguchiauthor=T.+Takeuchiauthor=K.+Watashiauthor=F.+Sugawara&title=Isolation+and+structure+of+vanitaracin+A%2C+a+novel+anti-hepatitis+B+virus+compound+from+Talaromyces+sp&doi=10.1016%2Fj.bmcl.2015.07.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.067%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DH.%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DF.%26atitle%3DIsolation%2520and%2520structure%2520of%2520vanitaracin%2520A%252C%2520a%2520novel%2520anti-hepatitis%2520B%2520virus%2520compound%2520from%2520Talaromyces%2520sp%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4325%26epage%3D4328%26doi%3D10.1016%2Fj.bmcl.2015.07.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Zembower, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korba, B. E.</span><span> </span><span class="NLM_article-title">Robustaflavone, a potential non-nucleoside anti-hepatitis B agent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1016/S0166-3542(98)00033-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS0166-3542%2898%2900033-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=81-88&author=D.+E.+Zembowerauthor=Y.+M.+Linauthor=M.+T.+Flavinauthor=F.+C.+Chenauthor=B.+E.+Korba&title=Robustaflavone%2C+a+potential+non-nucleoside+anti-hepatitis+B+agent&doi=10.1016%2FS0166-3542%2898%2900033-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2898%2900033-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252898%252900033-3%26sid%3Dliteratum%253Aachs%26aulast%3DZembower%26aufirst%3DD.%2BE.%26aulast%3DLin%26aufirst%3DY.%2BM.%26aulast%3DFlavin%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DF.%2BC.%26aulast%3DKorba%26aufirst%3DB.%2BE.%26atitle%3DRobustaflavone%252C%2520a%2520potential%2520non-nucleoside%2520anti-hepatitis%2520B%2520agent%26jtitle%3DAntiviral%2520Res.%26date%3D1998%26volume%3D39%26spage%3D81%26epage%3D88%26doi%3D10.1016%2FS0166-3542%2898%2900033-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 1: synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4647</span><span class="NLM_x">–</span> <span class="NLM_lpage">4650</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2008.07.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4647-4650&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=P.+Chengauthor=Y.+B.+Maauthor=X.+M.+Zhangauthor=F.+X.+Zhangauthor=J.+Zhouauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+1%3A+synthesis+of+alisol+A+derivatives%3A+a+new+class+of+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.bmcl.2008.07.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhang%26aufirst%3DF.%2BX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25201%253A%2520synthesis%2520of%2520alisol%2520A%2520derivatives%253A%2520a%2520new%2520class%2520of%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4647%26epage%3D4650%26doi%3D10.1016%2Fj.bmcl.2008.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">–</span> <span class="NLM_lpage">2153</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.02.122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2148-2153&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=J.+F.+Liuauthor=Y.+B.+Maauthor=R.+H.+Guoauthor=X.+M.+Zhangauthor=J.+Zhouauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+2%3A+synthesis+and+in+vitro+anti-hepatitis+B+virus+activities+of+alisol+A+derivatives&doi=10.1016%2Fj.bmcl.2009.02.122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.122%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DGuo%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25202%253A%2520synthesis%2520and%2520in%2520vitro%2520anti-hepatitis%2520B%2520virus%2520activities%2520of%2520alisol%2520A%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2148%26epage%3D2153%26doi%3D10.1016%2Fj.bmcl.2009.02.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Anti-HBV agents. part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6659</span><span class="NLM_x">–</span> <span class="NLM_lpage">6665</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.bmcl.2009.10.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6659-6665&author=Q.+Zhangauthor=Z.+Y.+Jiangauthor=J.+Luoauthor=Y.+B.+Maauthor=J.+F.+Liuauthor=R.+H.+Guoauthor=X.+M.+Zhangauthor=J.+Zhouauthor=W.+Niuauthor=F.+F.+Duauthor=L.+Liauthor=C.+Liauthor=J.+J.+Chen&title=Anti-HBV+agents.+part+3%3A+preliminary+structure-activity+relationships+of+tetra-acylalisol+A+derivatives+as+potent+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.bmcl.2009.10.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DGuo%26aufirst%3DR.%2BH.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DAnti-HBV%2520agents.%2520part%25203%253A%2520preliminary%2520structure-activity%2520relationships%2520of%2520tetra-acylalisol%2520A%2520derivatives%2520as%2520potent%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6659%26epage%3D6665%26doi%3D10.1016%2Fj.bmcl.2009.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.2174/1573406410666140902111326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.2174%2F1573406410666140902111326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25181984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=165-179&author=L.+J.+Wangauthor=H.+Chenauthor=Y.+B.+Maauthor=X.+Y.+Huangauthor=C.+A.+Gengauthor=X.+M.+Zhangauthor=J.+J.+Chen&title=Design%2C+synthesis+and+biological+evaluation+of+caudatin+analogs+as+potent+hepatitis+B+virus+inhibitors&doi=10.2174%2F1573406410666140902111326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Biological Evaluation of Caudatin Analogs as Potent Hepatitis B Virus Inhibitors</span></div><div class="casAuthors">Wang, Li-Jun; Chen, Hao; Ma, Yun-Bao; Huang, Xiao-Yan; Geng, Chang-An; Zhang, Xue-Mei; Chen, Ji-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-179</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Thirty-nine caudatin analogs were designed and synthesized.  Their anti-hepatitis B virus (HBV) activities were evaluated in vitro.  Among them, twenty-three compds. showed much better anti-HBV activity than caudatin, and eleven compds. significantly inhibited the HBV DNA replication with IC50 values < 10 μM.  Interestingly, three compds. (22, 28, 29) exhibited excellent activity against the secretion of HBsAg (IC50 = 63.02 μM, 52.81 μM, 56.08 μM), HBeAg (IC50 = 204.80 μM, 173.51 μM, 70.39 μM), along with HBV DNA replication (IC50 = 24.55 μM, 5.69 μM, 8.23 μM) with lower cytotoxicity.  The structure-activity relationships (SARs) of these caudatin analogs were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8TkKglRdNorVg90H21EOLACvtfcHk0liEfts3BBI0BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislemtLk%253D&md5=559fd8d1314421001882f1074ee241e0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.2174%2F1573406410666140902111326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406410666140902111326%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DHuang%26aufirst%3DX.%2BY.%26aulast%3DGeng%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520caudatin%2520analogs%2520as%2520potent%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D11%26spage%3D165%26epage%3D179%26doi%3D10.2174%2F1573406410666140902111326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Ashburn, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thor, K. B.</span><span> </span><span class="NLM_article-title">Drug repositioning: identifying and developing new uses for existing drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1038/nrd1468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1038%2Fnrd1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15286734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=673-683&author=T.+T.+Ashburnauthor=K.+B.+Thor&title=Drug+repositioning%3A+identifying+and+developing+new+uses+for+existing+drugs&doi=10.1038%2Fnrd1468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: identifying and developing new uses for existing drugs</span></div><div class="casAuthors">Ashburn, Ted T.; Thor, Karl B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">673-683</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results.  Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of prodn. to biotechnol. companies.  More and more companies are scanning the existing pharmacopeia for repositioning candidates, and the no. of repositioning success stories is increasing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkWl3DnePhrVg90H21EOLACvtfcHk0lhuhgk_4I-EEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtL8%253D&md5=0145c02423ab81ace6e3b3d92585cccc</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnrd1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1468%26sid%3Dliteratum%253Aachs%26aulast%3DAshburn%26aufirst%3DT.%2BT.%26aulast%3DThor%26aufirst%3DK.%2BB.%26atitle%3DDrug%2520repositioning%253A%2520identifying%2520and%2520developing%2520new%2520uses%2520for%2520existing%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D673%26epage%3D683%26doi%3D10.1038%2Fnrd1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Mu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besusso, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J.</span><span> </span><span class="NLM_article-title">A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">17330</span><span class="NLM_x">–</span> <span class="NLM_lpage">17334</span><span class="refDoi"> DOI: 10.1074/jbc.C700079200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1074%2Fjbc.C700079200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=17330-17334&author=J.+J.+Muauthor=Y.+Wangauthor=H.+Luoauthor=M.+Lengauthor=J.+Zhangauthor=T.+Yangauthor=D.+Besussoauthor=S.+Y.+Jungauthor=J.+Qin&title=A+proteomic+analysis+of+ataxia+telangiectasia-mutated+%28ATM%29%2FATM-rad3-related+%28ATR%29+substrates+identifies+the+ubiquitin-proteasome+system+as+a+regulator+for+DNA+damage+checkpoints&doi=10.1074%2Fjbc.C700079200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C700079200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C700079200%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DLeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DBesusso%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DS.%2BY.%26aulast%3DQin%26aufirst%3DJ.%26atitle%3DA%2520proteomic%2520analysis%2520of%2520ataxia%2520telangiectasia-mutated%2520%2528ATM%2529%252FATM-rad3-related%2520%2528ATR%2529%2520substrates%2520identifies%2520the%2520ubiquitin-proteasome%2520system%2520as%2520a%2520regulator%2520for%2520DNA%2520damage%2520checkpoints%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D17330%26epage%3D17334%26doi%3D10.1074%2Fjbc.C700079200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Cellular DNA repair cofactors affecting hepatitis B virus infection and replication</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5059</span><span class="NLM_x">–</span> <span class="NLM_lpage">5065</span><span class="refDoi"> DOI: 10.3748/wjg.14.5059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.14.5059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18763290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyntLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5059-5065&author=F.+Zhaoauthor=N.+B.+Houauthor=T.+Songauthor=X.+Heauthor=Z.+R.+Zhengauthor=Q.+J.+Maauthor=L.+Liauthor=Y.+H.+Zhangauthor=H.+Zhong&title=Cellular+DNA+repair+cofactors+affecting+hepatitis+B+virus+infection+and+replication&doi=10.3748%2Fwjg.14.5059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular DNA repair cofactors affecting hepatitis B virus infection and replication</span></div><div class="casAuthors">Zhao, Fan; Hou, Ning-Bo; Song, Ting; He, Xiang; Zheng, Zi-Rui; Ma, Qing-Jun; Li, Li; Zhang, Yan-Hong; Zhong, Hui</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5059-5065</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">Aim: To investigate whether hepatitis B virus (HBV) infection activates DNA damage response and DNA repair cofactors inhibit HBV infection and replication.  Methods: Human hepatocyte cell line HL7702 was studied.  Immunoblotting was performed to test the expression of ataxia telangiectasia-mutated (ATM)-Rad3-related protein (ATR), p21 and the level of phosphorylation of Chk1, p53, H2AX, ATM in HBV-infected or non-infected-cells.  Special short RNAi oligos was transfected to induce transient ATR knockdown in HL7702.  ATR-ATM chem. inhibitors caffeine (CF) and theophylline (TP), or Chk1 inhibitor 7-hydroxystaurosporine (UCN01) was studied to det. whether they suppress cellular DNA damage response and MG132 inhibits proteasome.  Results: The ATR checkpoint pathway, responding to single-strand breaks in DNA, was activated in response to HBV infection.  ATR knockdown cells decreased the HBV DNA yields, implying that HBV infection and replication could activate and exploit the activated DNA damage response.  CF/TP or UCN01 reduced the HBV DNA yield by 70% and 80%, resp.  HBV abrogated the ATR-dependent DNA damage signaling pathway by degrading p21, and introduction of the p21 protein before HBV infection reduced the HBV DNA yield.  Consistent with this result, p21 accumulation after MG132 treatment also sharply decreased the HBV DNA yield.  Conclusion: HBV infection can be treated with therapeutic approaches targeting host cell proteins by inhibiting a cellular gene required for HBV replication or by restoring a response abrogated by HBV, thus providing a potential approach to the prevention and treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodPmt1AlprrVg90H21EOLACvtfcHk0lhuhgk_4I-EEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyntLjO&md5=742b3515eab1868a297544d6686b66da</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3748%2Fwjg.14.5059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.14.5059%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DN.%2BB.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DZ.%2BR.%26aulast%3DMa%26aufirst%3DQ.%2BJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DCellular%2520DNA%2520repair%2520cofactors%2520affecting%2520hepatitis%2520B%2520virus%2520infection%2520and%2520replication%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2008%26volume%3D14%26spage%3D5059%26epage%3D5065%26doi%3D10.3748%2Fwjg.14.5059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Ataxia telangiectasia-mutated-rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6163</span><span class="NLM_x">–</span> <span class="NLM_lpage">6170</span><span class="refDoi"> DOI: 10.3748/wjg.14.6163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.14.6163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18985806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6163-6170&author=F.+Zhaoauthor=N.+B.+Houauthor=X.+L.+Yangauthor=X.+Heauthor=Y.+Liuauthor=Y.+H.+Zhangauthor=C.+W.+Weiauthor=T.+Songauthor=L.+Liauthor=Q.+J.+Maauthor=H.+Zhong&title=Ataxia+telangiectasia-mutated-rad3-related+DNA+damage+checkpoint+signaling+pathway+triggered+by+hepatitis+B+virus+infection&doi=10.3748%2Fwjg.14.6163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Ataxia telangiectasia-mutated-Rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection</span></div><div class="casAuthors">Zhao, Fan; Hou, Ning-Bo; Yang, Xiao-Li; He, Xiang; Liu, Yu; Zhang, Yan-Hong; Wei, Cong-Wen; Song, Ting; Li, Li; Ma, Qing-Jun; Zhong, Hui</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6163-6170</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">AIM: To explore whether acute cellular DNA damage response is induced upon hepatitis B virus (HBV) infection and the effects of the HBV infection.  METHODS: We incubated HL7702 hepatocytes with HBV-pos. serum, mimicking a natural HBV infection process.  We used immunoblotting to evaluate protein expression levels in HBV-infected cells or in non-infected cells; immunofluorescence to show ATR foci and Chk1 phosphorylation foci formation; flow cytometry to analyze the cell cycle and apoptosis; UV: (UV) radiation and ionizing radiation (IR)-treated cells to mimic DNA damage; and Trypan blue staining to count the viable cells.  RESULTS: We found that HBV infection induced an increased steady state of ATR protein and increased phosphorylation of multiple downstream targets including Chk1, p53 and H2AX.  In contrast to ATR and its target, the phosphorylated form of ATM at Ser-1981 and its downstream substrate Chk2 phosphorylation at Thr-68 did not visibly increase upon infection.  However, the level of Mre11 and p21 were reduced beginning at 0.5 h after HBV-pos. serum addn.  Also, HBV infection led to transient cell cycle arrest in the S and the G2 phases without accompanying increased apoptosis.  Research on cell survival changes upon radiation following HBV infection showed that survival of UV-treated host cells was greatly increased by HBV infection, owing to the reduced apoptosis.  Meanwhile, survival of IR-treated host cells was reduced by HBV infection.  CONCLUSION: HBV infection activates ATR DNA damage response to replication stress and abrogates the checkpoint signaling controlled by DNA damage response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquc0D0yKYIMbVg90H21EOLACvtfcHk0lgiEQ6k6QukYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWnsr0%253D&md5=f10035404aa37b46d087804a157417a4</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.3748%2Fwjg.14.6163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.14.6163%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DN.%2BB.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DWei%26aufirst%3DC.%2BW.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DQ.%2BJ.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DAtaxia%2520telangiectasia-mutated-rad3-related%2520DNA%2520damage%2520checkpoint%2520signaling%2520pathway%2520triggered%2520by%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2008%26volume%3D14%26spage%3D6163%26epage%3D6170%26doi%3D10.3748%2Fwjg.14.6163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Zheng, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span> </span><span class="NLM_article-title">Inhibition of HBV replication by theophylline</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2010.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2010.12.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=149-155&author=Z.+R.+Zhengauthor=J.+Y.+Liauthor=J.+Sunauthor=T.+Songauthor=C.+W.+Weiauthor=Y.+H.+Zhangauthor=G.+R.+Raoauthor=G.+M.+Chenauthor=D.+C.+Liauthor=G.+M.+Yangauthor=B.+Hanauthor=S.+Weiauthor=C.+Caoauthor=H.+Zhong&title=Inhibition+of+HBV+replication+by+theophylline&doi=10.1016%2Fj.antiviral.2010.12.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2010.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2010.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%2BR.%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DRao%26aufirst%3DG.%2BR.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DLi%26aufirst%3DD.%2BC.%26aulast%3DYang%26aufirst%3DG.%2BM.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520HBV%2520replication%2520by%2520theophylline%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D89%26spage%3D149%26epage%3D155%26doi%3D10.1016%2Fj.antiviral.2010.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Fox, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saravolatz, L. D.</span><span> </span><span class="NLM_article-title">Nitazoxanide: a new thiazolide antiparasitic agent</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span><span class="refDoi"> DOI: 10.1086/428839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1086%2F428839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=15791519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=1173-1180&author=L.+M.+Foxauthor=L.+D.+Saravolatz&title=Nitazoxanide%3A+a+new+thiazolide+antiparasitic+agent&doi=10.1086%2F428839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide: a new thiazolide antiparasitic agent</span></div><div class="casAuthors">Fox, LeAnne M.; Saravolatz, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1173-1180</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths.  It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects.  At present, there are no documented drug-drug interactions.  Nitazoxanide has been licensed for the treatment of Giardia intestinalis-induced diarrhea in patients ≥1 yr of age and Cryptosporidium-induced diarrhea in children aged 1-11 years.  At present, it is pending licensure for treatment of infection due to Cryptosporidium species in adults and for use in treating immunocompromised hosts.  It represents an important addn. to the antiparasitic arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk8xTuMMlYQrVg90H21EOLACvtfcHk0lgiEQ6k6QukYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVynsbw%253D&md5=9d1b8b6bfc962dd3ec3b3adbb13c451c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1086%2F428839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F428839%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DL.%2BM.%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26atitle%3DNitazoxanide%253A%2520a%2520new%2520thiazolide%2520antiparasitic%2520agent%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D40%26spage%3D1173%26epage%3D1180%26doi%3D10.1086%2F428839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Gilles, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, P. S.</span><span> </span><span class="NLM_article-title">Treatment of intestinal parasitic infections: a review of nitazoxanide</span> <span class="citation_source-journal">Trends Parasitol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1016/S1471-4922(01)02205-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2FS1471-4922%2801%2902205-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11854075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A280%3ADC%252BD387itVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=95-97&author=H.+M.+Gillesauthor=P.+S.+Hoffman&title=Treatment+of+intestinal+parasitic+infections%3A+a+review+of+nitazoxanide&doi=10.1016%2FS1471-4922%2801%2902205-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of intestinal parasitic infections: a review of nitazoxanide</span></div><div class="casAuthors">Gilles Herbert M; Hoffman Paul S</div><div class="citationInfo"><span class="NLM_cas:title">Trends in parasitology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">95-7</span>
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIejC39IDdKCSm0e6ZOaemfW6udTcc2ebpvk0N5Bu_nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itVarsw%253D%253D&md5=a022402051312fc038632cb60168b1a8</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2FS1471-4922%2801%2902205-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4922%252801%252902205-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilles%26aufirst%3DH.%2BM.%26aulast%3DHoffman%26aufirst%3DP.%2BS.%26atitle%3DTreatment%2520of%2520intestinal%2520parasitic%2520infections%253A%2520a%2520review%2520of%2520nitazoxanide%26jtitle%3DTrends%2520Parasitol.%26date%3D2002%26volume%3D18%26spage%3D95%26epage%3D97%26doi%3D10.1016%2FS1471-4922%2801%2902205-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeffe, E. B.</span><span> </span><span class="NLM_article-title">Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.2217/17460913.3.5.539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.2217%2F17460913.3.5.539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=18811238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFGlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=539-545&author=J.+F.+Rossignolauthor=E.+B.+Keeffe&title=Thiazolides%3A+a+new+class+of+drugs+for+the+treatment+of+chronic+hepatitis+B+and+C&doi=10.2217%2F17460913.3.5.539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C</span></div><div class="casAuthors">Rossignol, Jean-Francois; Keeffe, Emmet B.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum.  The antiviral activity of nitazoxanide was discovered by serendipity in patients with AIDS who were treated for cryptosporidial diarrhea and had HBV or HCV co-infection.  In preliminary open-label studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss or seroconversion of hepatitis B e antigen in the majority of patients, as well as hepatitis B surface antigen in approx. a quarter of patients.  In Phase II studies of patients with chronic hepatitis C genotype 4, nitazoxanide combined with peginterferon alfa-2a, with or without ribavirin, increased the sustained virol. response rate to 79-80 vs. 50% with peginterferon plus ribavirin std. of care.  Randomized, controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 and patients with chronic hepatitis B are underway, and new second generation thiazolides are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOZh4gfIQvbVg90H21EOLACvtfcHk0lgbSNloiNTQAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFGlu7bK&md5=b360c87d45283cff3fe31469847fae5a</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2217%2F17460913.3.5.539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460913.3.5.539%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26atitle%3DThiazolides%253A%2520a%2520new%2520class%2520of%2520drugs%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520and%2520C%26jtitle%3DFuture%2520Microbiol.%26date%3D2008%26volume%3D3%26spage%3D539%26epage%3D545%26doi%3D10.2217%2F17460913.3.5.539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Rossignol, J. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayoub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M. S.</span><span> </span><span class="NLM_article-title">Treatment of diarrhea caused by cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1086/321008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1086%2F321008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=11398117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Oiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2001&pages=103-106&author=J.+F.+A.+Rossignolauthor=A.+Ayoubauthor=M.+S.+Ayers&title=Treatment+of+diarrhea+caused+by+cryptosporidium+parvum%3A+a+prospective+randomized%2C+double-blind%2C+placebo-controlled+study+of+nitazoxanide&doi=10.1086%2F321008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of diarrhea caused by Cryptosporidium parvum: A prospective randomized, double-blind, placebo-controlled study of nitazoxanide</span></div><div class="casAuthors">Rossignol, Jean-Francois A.; Ayoub, Ayman; Ayers, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-106</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A prospective randomized, double-blind, placebo-controlled study was conducted in 50 adults and 50 children from the Nile delta of Egypt, to evaluate the efficacy of nitazoxanide in treating diarrhea caused by Cryptosporidium parvum.  Nitazoxanide was administered in 500-mg doses twice daily for 3 days in adults and adolescents, in 200-mg doses twice daily for 3 days in children aged 4-11 yr, and in 100-mg doses twice daily for 3 days in children aged 1-3 yr.  At 7 days after initiation of therapy, diarrhea had resolved in 39 (80%) of the 49 patients in the nitazoxanide treatment group, compared with 20 (41%) of 49 in the placebo group (P < .0001).  Diarrhea was resolved in most patients receiving nitazoxanide within 3 or 4 days of treatment initiation.  Nitazoxanide treatment reduced the duration of both diarrhea (P < .0001) and oocyst shedding (P < .0001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiYg7QprUqBrVg90H21EOLACvtfcHk0lgbSNloiNTQAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Oiu7g%253D&md5=08eb60fdda75f2a145502d06ce4707f4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1086%2F321008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F321008%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%2BA.%26aulast%3DAyoub%26aufirst%3DA.%26aulast%3DAyers%26aufirst%3DM.%2BS.%26atitle%3DTreatment%2520of%2520diarrhea%2520caused%2520by%2520cryptosporidium%2520parvum%253A%2520a%2520prospective%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520nitazoxanide%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D184%26spage%3D103%26epage%3D106%26doi%3D10.1086%2F321008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Korba, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaye, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukerjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayers, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2007.08.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=56-63&author=B.+E.+Korbaauthor=A.+B.+Monteroauthor=K.+Farrarauthor=K.+Gayeauthor=S.+Mukerjeeauthor=M.+S.+Ayersauthor=J.+F.+Rossignol&title=Nitazoxanide%2C+tizoxanide+and+other+thiazolides+are+potent+inhibitors+of+hepatitis+B+virus+and+hepatitis+C+virus+replication&doi=10.1016%2Fj.antiviral.2007.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DKorba%26aufirst%3DB.%2BE.%26aulast%3DMontero%26aufirst%3DA.%2BB.%26aulast%3DFarrar%26aufirst%3DK.%26aulast%3DGaye%26aufirst%3DK.%26aulast%3DMukerjee%26aufirst%3DS.%26aulast%3DAyers%26aufirst%3DM.%2BS.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DNitazoxanide%252C%2520tizoxanide%2520and%2520other%2520thiazolides%2520are%2520potent%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520replication%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.antiviral.2007.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Elazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrig, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puglisi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1053/j.gastro.2009.07.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2009.07.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=1827-1835&author=M.+Elazarauthor=M.+Liuauthor=S.+A.+McKennaauthor=P.+Liuauthor=E.+A.+Gehrigauthor=J.+D.+Puglisiauthor=J.+F.+Rossignolauthor=J.+S.+Glenn&title=The+anti-hepatitis+C+agent+nitazoxanide+induces+phosphorylation+of+eukaryotic+initiation+factor+2alpha+via+protein+kinase+activated+by+double-stranded+RNA+activation&doi=10.1053%2Fj.gastro.2009.07.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.07.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.07.056%26sid%3Dliteratum%253Aachs%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGehrig%26aufirst%3DE.%2BA.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520anti-hepatitis%2520C%2520agent%2520nitazoxanide%2520induces%2520phosphorylation%2520of%2520eukaryotic%2520initiation%2520factor%25202alpha%2520via%2520protein%2520kinase%2520activated%2520by%2520double-stranded%2520RNA%2520activation%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D137%26spage%3D1827%26epage%3D1835%26doi%3D10.1053%2Fj.gastro.2009.07.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Mederacke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span> </span><span class="NLM_article-title">Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?</span> <span class="citation_source-journal">Ann. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19502665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=166-168&author=I.+Mederackeauthor=H.+Wedemeyer&title=Nitazoxanide+for+the+treatment+of+chronic+hepatitis+C+new+opportunities+but+new+challenges%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?</span></div><div class="casAuthors">Mederacke, Ingmar; Wedemeyer, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-168</span>CODEN:
                <span class="NLM_cas:coden">AHNEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1665-2681</span>.
    
            (<span class="NLM_cas:orgname">Mexican Association of Hepatology</span>)
        </div><div class="casAbstract">A review.  Background & Aims: Sustained virol. response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin.  The safety and efficacy of nitazoxanide plus peginterferon alfa-2a, with or without ribavirin, were evaluated in a randomized controlled trial at 2 centers in Egypt.  Methods: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given std. of care (peginterferon alfa-2a and ribavirin for 48 wk, n = 40), nitazoxanide monotherapy for 12 wk followed by nitazoxanide plus peginterferon alfa-2a for 36 wk (n = 28), or nitazoxanide monotherapy for 12 wk followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 wk (n = 28).  Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 μg) once weekly, and wt.-based ribavirin (1000-1200 mg/day).  Results: The percentages of rapid virol. response (RVR), defined as undetectable HCV RNA at week 4 of combination therapy, and SVR were significantly higher in patients given the triple therapy compared with the std. of care (64% vs 38%, P = .048; and 79% vs 50%, P = .023; resp.).  Patients given nitazoxanide plus peginterferon alfa-2a had intermediate rates of RVR (54%) and SVR (61%).  Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving ribavirin.  Conclusions: The combination of nitazoxanide, peginterferon alfa-2a, and ribavirin increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus ribavirin, without an increase in adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Pl_KmE2xpLVg90H21EOLACvtfcHk0lhVSMaYRVAysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7jJ&md5=546e84ba509e0f715dc2fd5b77ae4137</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMederacke%26aufirst%3DI.%26aulast%3DWedemeyer%26aufirst%3DH.%26atitle%3DNitazoxanide%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520new%2520opportunities%2520but%2520new%2520challenges%253F%26jtitle%3DAnn.%2520Hepatol.%26date%3D2009%26volume%3D8%26spage%3D166%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Nitazoxanide: a first-in-class broad-spectrum antiviral agent</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1016%2Fj.antiviral.2014.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=25108173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtleisL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=94-103&author=J.+F.+Rossignol&title=Nitazoxanide%3A+a+first-in-class+broad-spectrum+antiviral+agent&doi=10.1016%2Fj.antiviral.2014.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Nitazoxanide: A first-in-class broad-spectrum antiviral agent</span></div><div class="casAuthors">Rossignol, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-103</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza.  A Phase 2b/3 clin. trial recently published in The Lancet Infectious Diseases found that oral administration of nitazoxanide 600 mg twice daily for five days reduced the duration of clin. symptoms and reduced viral shedding compared to placebo in persons with lab.-confirmed influenza.  The same study also suggested a potential benefit for subjects with influenza-like illness who did not have influenza or other documented respiratory viral infection.  From a chem. perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides.  These small-mol. drugs target host-regulated processes involved in viral replication.  Nitazoxanide is orally bioavailable and safe with extensive post-marketing experience involving more than 75 million adults and children.  A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clin. development for the treatment of influenza.  Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors.  It is synergistic with neuraminidase inhibitors, and combination therapy with oseltamivir is being studied in humans as part of ongoing Phase 3 clin. development.  Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, coronavirus, rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays.  Clin. trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C.  Ongoing and future clin. development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_XyG4B6HlO7Vg90H21EOLACvtfcHk0lhVSMaYRVAysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtleisL%252FK&md5=12dd8a143876626fc31303da2c5f24c4</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DNitazoxanide%253A%2520a%2520first-in-class%2520broad-spectrum%2520antiviral%2520agent%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D94%26epage%3D103%26doi%3D10.1016%2Fj.antiviral.2014.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Rossignol, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elfert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Gohary, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keeffe, E. B.</span><span> </span><span class="NLM_article-title">Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">856</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span><span class="refDoi"> DOI: 10.1053/j.gastro.2008.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.1053%2Fj.gastro.2008.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=856-862&author=J.+F.+Rossignolauthor=A.+Elfertauthor=Y.+El-Goharyauthor=E.+B.+Keeffe&title=Improved+virologic+response+in+chronic+hepatitis+C+genotype+4+treated+with+nitazoxanide%2C+peginterferon%2C+and+ribavirin&doi=10.1053%2Fj.gastro.2008.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26aulast%3DElfert%26aufirst%3DA.%26aulast%3DEl-Gohary%26aufirst%3DY.%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26atitle%3DImproved%2520virologic%2520response%2520in%2520chronic%2520hepatitis%2520C%2520genotype%25204%2520treated%2520with%2520nitazoxanide%252C%2520peginterferon%252C%2520and%2520ribavirin%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D136%26spage%3D856%26epage%3D862%26doi%3D10.1053%2Fj.gastro.2008.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Keeffe, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossignol, J. F.</span><span> </span><span class="NLM_article-title">Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1805</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.3748/wjg.15.1805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=10.3748%2Fwjg.15.1805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=19370775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsF2kur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1805-1808&author=E.+B.+Keeffeauthor=J.+F.+Rossignol&title=Treatment+of+chronic+viral+hepatitis+with+nitazoxanide+and+second+generation+thiazolides&doi=10.3748%2Fwjg.15.1805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides</span></div><div class="casAuthors">Keeffe, Emmet B.; Rossignol, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1805-1808</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum.  More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis C virus was recognized in in vitro systems.  These basic studies led to phase II clin. trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon, with or without ribavirin, in the treatment of chronic hepatitis C genotype 4.  The sustained virol. response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the std. of care with peginterferon plus ribavirin.  In very preliminary studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approx. a quarter of patients.  Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway, new second generation and controlled release thiazolides are being developed, and future studies of patients with chronic hepatitis B are planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqklsGnFYFTa7Vg90H21EOLACvtfcHk0li1mDB_CfF_7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsF2kur4%253D&md5=5c9d667204c617211719b7b107e3613b</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.3748%2Fwjg.15.1805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.15.1805%26sid%3Dliteratum%253Aachs%26aulast%3DKeeffe%26aufirst%3DE.%2BB.%26aulast%3DRossignol%26aufirst%3DJ.%2BF.%26atitle%3DTreatment%2520of%2520chronic%2520viral%2520hepatitis%2520with%2520nitazoxanide%2520and%2520second%2520generation%2520thiazolides%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D15%26spage%3D1805%26epage%3D1808%26doi%3D10.3748%2Fwjg.15.1805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-15%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01442%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01442" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996373d9f93291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
